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Abstract 
Chapter 1 gives background information on proteases and discusses the concept of protease 
inhibition as a therapeutic strategy for humans.  It introduces the key concept that 
conformation defines biological activity.   It also outlines how proteases almost universally 
bind their substrate/inhibitors in an extended β-strand conformation.   The use of calpain as a 
prototype protease for the testing of β-strand mimics synthesised later in the thesis is also 
discussed. 
 
Chapter 2 describes how molecular modeling was used to rationalise the structure based 
activity relationships (SAR) of known calpain inhibitors.  Molecular modeling was then used 
to successfully design a number of acyclic β-strand mimics.  The synthesis and testing of 
eight such inhibitors is described.  The most potent β-strand mimic prepared was 2.13.  This 
was determined to have an IC50 of 30 nM against calpain II. 
 
Chapter 3 outlines the history and application of ring closing metathesis (RCM) to the 
synthesis of cyclic compounds.  The attempted synthesis of an eight membered cyclic 
nitrogen to nitrogen conformationally constrained dipeptide is described.   The synthesis of a 
conformationally constrained β-amino acid calpain inhibitor (3.73) is also described. 
 
A novel calpain inhibitor motif was designed in Chapter 4.  On the basis of this an in-silico 
combinatorial library of two hundred and eighty eight possible β-strand templates was 
prepared.  Conformational analysis of this library was performed and from this a number of 
excellent β-strand templates were identified and selected for synthesis.  The preparation of 
ten β-strand templates is described.  New microwave irradiation methodology was developed 
to achieve this.  
 
 vii 
The formation of a six-membered catalyst deactivating chelate is also proposed to explain 
why some dienes fail to undergo RCM.  Two methods to circumvent the formation of such a 
chelate are outlined.  The addition of Lewis acid chloro-dicyclohexyl borane to the RCM 
reaction mixture and chain length alteration are investigated.   
 
Chapter 5 describes the design of macrocyclic β-strand mimics using induced fit molecular 
modelling.  The physicochemical properties of these were calculated in-silico.  From this 
analysis a number of Tyr-XX-Gly based and Tyr-XX-Cys based macrocyclic calpain 
inhibitors were selected for synthesis.  The preparation and testing of these are described.  In 
the Tyr-XX-Gly macrocyclic system a number of variables were investigated and numerous 
SAR implications concluded.  Aldehyde 5.14 was identified as the best electrophilic warhead 
macrocyclic calpain inhibitor with an IC50 against calpain II of 27 nM. The best non-
electrophilic warhead macrocycle (5.13) had an IC50 against calpain II of 704 nM.   
 
Chapter 6 describes synthetic optimisation for the preparation of calpain inhibitors 2.13, 
5.14 and 5.17. Multi-gram quantities of each were prepared.  Aldehydes 2.13 and 5.14 were 
evaluated as anti-cataract agents using in-vivo cataract sheep model.  Both of these β-strand 
mimics were demonstrated to retard cataract development.  Macrocycle 5.14 was found to be 
the most effective, decreasing the rate of cataract development between forty four and forty 
nine per cent relative to control. 
 
Chapter 7 outlines the attempted development of RCM methodology for the chiral synthesis 
of α-α disubstituted amino acid lactams.  In addition, methodology for the stereoselective 
incorporation of a C-N constrained β-amino acid carbocycle into a peptide or peptidomimetic 
is described. 
 viii 
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1.1: Introduction to peptidomimetics and proteases
 
Peptides and their analogues have long been used in medicinal chemistry as therapeutic 
agents against a range of pathological conditions.  However, the presence of hydrolysable 
amide bonds means that peptide drugs possess the inherent disadvantages of a short half-life, 
poor oral bioavailability and poor pharmacokinetics.  Considerable effort has been expended 
on finding peptidomimetics that possess the desired characteristics of the original peptides 
but , which are sufficiently “non-peptidic” to overcome the problems of metabolic 
degradation and poor bio-availability associated with peptides.  One area where 
peptidomimetic research has been focussed for a number of decades, and is topic of this 
thesis, is the synthesis of protease inhibitors.  
 
Proteases are globular, water soluble proteins that function as enzymes.  The widely used 
term protease is synonymous with peptidase, but for simplicity the term protease will be 
used throughout this thesis.    Proteases cleave or degrade other proteins by hydrolysing their 
component  peptide bonds.  This may appear an uninteresting reaction, but proteolytic 
enzymes are very important, accounting for  approximately two per cent of genes in humans, 
infectious organisms, and other forms of life.  Significantly, proteases regulate most 
physiological processes by controlling the activation, synthesis and turnover of proteins.  
They are consequently pivotal regulators of conception, birth, growth, maturation, ageing, 
diseases and death.  However, it is mainly due to their importance in human health and 
disease that research into proteases has attracted a very significant amount of scientific 
interest for a number of years.   
 
Proteases are categorised by the catalytic residue that effects enzymatic hydrolysis.  Six 
classes of proteases are currently recognised1; 
• Serine proteases 
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• Threonine proteases 
• Cysteine proteases 
• Aspartic proteases  
• Glutamic proteases 
• Metallo-proteases 
 
1.2: Protease inhibitors in the clinic 
 
Proteases have been the subject of intense research for a number of years and a great number 
of these studies have proposed that their inhibitors could provide successful therapeutics for a 
wide range of diseases.  Examples include, but are not limited to, cancer,2-4 parasitic, fungal 
and viral infections; (e.g. schistosomiasis,5, 6 malaria,7, 8 HIV,9-11 Hepatitis12, 13 and Herpes),14, 
15 inflammatory,16 respiratory,17, 18 immunological,19 cardiovascular20 and neurodegenerative 
disorders.21, 22  
 
The most compelling evidence of this is the number of compounds , which the 
pharmaceutical industry has either launched, or is currently conducting clinical studies upon 
(as of 2005).23  Tables 1.1 to 1.5 list by protease classification the compounds , which (as of 
2005) were known to be either in clinical trials or launched as a human drug. 
  
Table 1.1: Cysteine protease inhibitors in clinical development. 
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Table 1.2: Threonine protease inhibitors in clinical development. 
 
 
 
Table 1.3: Aspartic protease inhibitors in clinical development. 
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Table 1.4: Metalloprotease inhibitors in clinical development. 
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Table 1.5: Serine protease inhibitors in clinical development. 
 
1.3: Importance of the β-strand in protease inhibitor design 
 
With such compelling evidence for proteases being crucial mediators of mammalian 
physiology and disease, extensive research activity, particularly over the last 15 years, has 
resulted in a wealth of published information to assist in the development of new protease 
inhibitors.   
 
A key concept , which underpins much of this protease inhibitor work is that conformation 
defines biological activity.   This is not a new concept and in the area of peptidomimetic 
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research it has long been recognised that the biological function of a given peptide is 
achieved through the spatial arrangement of the peptide backbone.  An excellent example of 
this is the three-dimensional ‘bio-active’ binding pattern displayed by the macrocyclic 
antibiotic vancomycin (Figure 1.1).24  
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Figure 1.1: Chemical and crystal structure of Vancomycin. 
 
As such a key concept in the design of peptidomimetics is if a “bioactive” conformation can 
be successfully stabilised then the resulting peptidomimetic is extremely likely to possess the 
corresponding biological activity.   However, even with this knowledge, literature from the 
previous two decades suggests that de-novo peptidomimetic design for any given protease is 
extremely difficult.  The primary reason for this is simply that often the “bioactive” 
conformation is not known.   
 
This obstacle to protease inhibitor design is now much less of a problem.  The reason for this 
is that during the late 1990s a breakthrough occurred in the understanding of the 
conformation responsible for the biological activity of protease inhibitors.  As such it is now 
widely acknowledged that virtually all protease inhibitors bind to their target enzyme in an 
extended β-strand conformation.  A β-strand motif is defined by the bond angles Φ, ψ, and ω, 
(with optimum angles of -120°, 120° and 180°, respectively Figure 1.2).  In a peptide this 
affords a “zigzag” structure where the side chains are anti-parallel to one another Figure 1.3.  
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N
N
H
P2
O
H
P1
O
φ
ψ
ω
β−strand peptide backbone
Px =
side chains binding into 
Sx recognition sites in 
the target protease   
      Figure 1.2: β-strand bond angles         Figure 1.3:  Zigzag structure of the β-strand  
 
In 2005 a review25 was published in , which over one thousand five hundred three 
dimensional crystal (X-ray) and solution (NMR) protease structures from the protein data 
bank were analysed.  This analysis included substrates, products and inhibitors bound in the 
active sites of aspartic, serine, metallo, cysteine, and threonine proteases. 
 
The results of this study provided unequivocal evidence that ligand binding in the active site 
of a protease occurs when the ligand adopts an extended β-strand conformation.  Of the 1500 
or so structures studied all but six bound the peptidic and non-peptidic ligands in this 
conformation.  This is illustrated in Figures 1.4 and 1.5.  Figure 1.4 shows the overlay of  
the conformations of known inhibitors as bound to cathepsin K, a cysteine protease. Figure 
1.5 similarly shows the superimposition of known inhibitors of renin an aspartic protease.   In 
both cases it is clearly evident that all the small molecules are in the β-strand conformation.  
                                      
     Figure 1.4: Overlay of known                 Figure 1.5: Overlay of  
     inhibitors bound in cathepsin K                           known inhibitors bound in renin 
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The realisation that the β-strand motif is of fundamental importance for the binding of 
substrates and inhibitors to proteases is key to the work contained in this thesis.  Traditionally 
inhibitor design has been specific for each protease, however with this knowledge it is 
proposed that it should be possible to formulate and design generic protease inhibitor 
templates.  It is envisaged that synthesis of β-strand mimics, which act as templates, onto 
which additional recognition specific to each protease can be appended will provide a 
universal approach for the synthesis of protease inhibitors for all six classes of protease 
(Figure 1.6). 
 
 
 
Figure 1.6: Schematic universal protease inhibitor design strategy 
 
The fundamental principle underpinning this endeavour is that molecules which are pre-
organised or  “locked” into a β-strand conformation exhibit improved binding affinity, 
relative to their conformationally flexible analogues.  This is due to a reduced loss of entropy 
upon binding.26  This concept has been successfully demonstrated for an aspartic protease.27 
 
1.4: Calpain as the prototype protease for the testing of β-strand mimics 
 
In order to test the effectiveness of the β-strand mimics synthesised during this project the 
identification of a test protease was required.   At the University of Canterbury the use of a 
calpain inhibition assay to determine the IC50 of a given calpain inhibitor was well 
established.  The procedure for IC50 determination is described in appendix 1.  This provided 
a convenient and reliable method to determine how good a particular β-strand mimic was.  
Furthermore cysteine proteases have not been well studied in terms binding β-strand motifs 
and as such this is important work towards achieving this goal.  Moreover, as discussed in 
more detail later, the use of calpain as the test protease also provided opportunities for 
computational molecular modeling to be undertaken.  However, most importantly, using 
β-strand  
template 
A d d r e s s  
r e g io n  1
A d d r e s s  
r e g io n  2
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calpain as a test protease provided an opportunity to evaluate the best β-strand mimics in-vivo 
using the sheep cataract model established by our collaborators at the University of Lincoln. 
 
The calpains are a family of calcium dependent cysteine proteases that are widely expressed 
in higher organisms.  The most well characterised28 calpains are the two ubiquitously 
expressed isoforms, calpain I (µ-calpain) and calpain II (m-calpain).  The terms refer to the 
concentration of calcium required to induce their catalytic activity using in-vitro assays29 
(micromolar and millimolar respectively).   
 
As shown in Table 1.6 a number of pathologic conditions have been associated with 
disturbances of the calpain system.  These will not be described in detail here as the primary 
objective of this thesis is the synthesis of β-strand mimics.  It should however be noted that 
successful design, synthesis and conversion of a β-strand mimic into a calpain inhibitor 
provides potential opportunities to investigate the relationship between calpain over-
activation and its associated pathologies.  This point is considered in more detail in Chapter 
6 where we specifically target the development of cataract which results from the over 
activation of calpain. 
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Disease Scientific rationale/observation 
Cataract formation30 
Ca2+ influx activates calpain II, the predominant calpain in the 
lens, cleaving α and β-crystallins.  The crystallin fragments 
aggregate to form cataracts. 
Myocardinal 
infarction31-33 
Ca2+ homeostasis is lost in ischemic area, triggering 
inappropriate calpain activity.  Protein and mRNA levels of 
calpain I and calpain II increase after myocardinal infarction 
Neuronal ischemia 
(stroke)34 
Calpastatin is degraded by calpain to a membrane-bound 50 kD 
polypeptide in ischemic brain tissue.  Calpains participate in 
both apoptosis and necrosis which results in tissue damage in 
ischemic areas 
Alzheimer’s 
disease35 
There is an increased amount of calpain II in the cytoslic but not 
the membranous fraction of the brain in the neurofibrillary 
tangles of the brain 
Multiple Sclerosis36, 
37 
Levels of the 150 kD calpain specific degradation product of α-
spectrin has been shown to increase in human multiple sclerosis 
plaques (by 50%).  Degradation of a 68 kD neurofilament 
protein has been shown to be inhibited by a calpain inhibitor 
Limb-girdle 
muscular 
dystrophy38 
Associated with mutations in the gene encoding calpain III and 
probable loss of calpain III proteolytic activity 
Obsessive 
compulsive 
disorder39 
Erythrocytes from patients with OCD have significantly elevated 
calpain activities compared to normal controls. 
Gastric cancer40 This is associated with a down regulation of calpain IX 
Type 2 diabetes 
mellitus41 
Mutations in calpain X are associated with an increased 
incidence of type 2 diabetes in some populations 
Duchenne’s and 
Becker’s muscular 
dystrophies42 
Associated with the absence or deficiency of dystrophin.  This 
results in an increased Ca2+ level in muscle and inappropriate 
calpain activity 
 
Table 1.6: Pathologic conditions associated with disturbances of the calpain system 
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2.1: Current calpain inhibitors in the scientific literature 
 
The design and synthesis of calpain inhibitors is well documented in the literature1.  An 
extensive review of both calpain inhibitors previously prepared at the University of 
Canterbury and those published in the literature was conducted.  From this, a database 
capturing all the data in an easy to read and interpret format, with all data hyperlinked to 
source, was created.  A section of this database is shown in Figure 2.1.  
 
Figure 2.1: SAR database of calpain inhibitors 
Qualitative analysis of this data revealed that virtually all calpain inhibitors are peptide based.  
This is because proteases bind their substrates in a groove or cleft.  As shown in Figure 2.2 
amino acid side chains of substrates occupy enzyme sub-sites in the groove.  These are 
designated,2 with respect to the cleavable amide bond, as S3, S2, S1, S1’, S2’, S3’.  The side 
chains bind to the corresponding substrate/inhibitor residues P3, P2, P1, P1’, P2’, P3’. 
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Figure 2.2: Substrate bound into a proteases  
These peptide based calpain inhibitors can be divided into two distinct groups; 
• Irreversible inhibitors 
• Reversible inhibitors 
 
Irreversible inhibitors 
The irreversible calpain inhibitors are designed using well established mechanistic knowledge 
of cysteine proteases.  As shown in Figure 2.3 cysteine proteases hydrolyse amide bonds by 
first forming a thioacetyl intermediate which is then cleaved by an activated water molecule 
to regenerate the free thiol of the cysteine.   
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 Figure 2.3: Mechanism of a cysteine protease  
 
The mode of action of the irreversible inhibitors involves formation of a permanent covalent 
bond with the active site cysteine by virtue of the inhibitor containing a leaving group.  
Examples of these include peptide epoxide inhibitors (2.1), peptide aziridines (2.2), peptide 
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acyloxymethyl ketones (2.3), azapeptides (2.4), peptide benzotriazolooxy-methyl ketones 
(2.5) and peptide vinyl sulfones (2.6) (Figure 2.4).  
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Figure 2.4: Various irreversible calpain inhibitors 
 
Reversible inhibitors 
The vast majority of published reversible calpain inhibitors are based on generic structure 2.7.  
This generalised structure consists of three segments; 
 
• An electrophilic warhead.  This reacts with the enzyme’s active site cysteine to form a 
stable but reversible tetrahedral thiohemiacetal adduct.  Examples of groups which are 
commonly used an electrophilic warhead include, aldehyde, α-dicarbonyl, α-diketone, α-
ketoester, α-ketoamide and α-ketoacid.1, 3-15  The most potent and commonly used 
electrophilic warhead is an aldehyde, although the use of α-ketoamide is also prevalent.  
The α-ketoamide analogues tend to be slightly less potent than their direct aldehyde 
equivalents.  
 
• A dipeptide backbone.  We have shown that this must be capable of binding to the 
enzyme in a β-strand conformation.  This conformation ensures that the amino acid 
side chains (R1 and R2) are able to form the complementary (P1 and P2) interactions 
with the enzyme.  This is not reported in the literature and our group is the first to 
investigate this using molecular modeling. 
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• An additional recognition moiety.  This segment confers selectivity for calpain over 
other related enzymes.  A wide variety of groups can be employed but typically a 
rather hydrophobic aromatic group is utilised. 
N
H O
N
H
WarheadAdditional Recognition
R2
R1
2.7  
As described above computational molecular modelling by Blair Stuart and Axel Neffe, 
within our group, demonstrated that the dipeptide backbone in these inhibitors adopts a β-
strand conformation when bound to the enzyme active site.  Inhibitors of the type 2.7 were 
shown to form three critical hydrogen bonds (Gly208 and Gly271) to the enzyme (Figure 2.5).  
This was an important observation since it is in agreement with the known importance of the  
β-strand binding motif of other protease inhibitors.   
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Figure 2.5: Binding of substrates/inhibitors in calpain 
 
The work described in Chapter 2 of this thesis focusses on the chemical synthesis of calpain 
inhibitors based around the generic structure 2.7, with the objective of designing structures 
which adopt the requisite β-strand conformation.   
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2.2: Use of molecular modelling to design β-strand calpain inhibitors 
 
An understanding of binding at the molecular level is required to accurately design β-strand 
mimics which possess a high binding affinity for calpain.  The first crystal structures of 
calpain were published in 1999 and 2000.16, 17 These reveal that calpain contains six domains.  
Each domain has a distinct function and the active site is located between domains I and II 
(Figure 2.6).  
 
Figure 2.6: Calpain heterodimer.   
However, these crystal structures do not provide sufficient structural information to allow 
careful scrutiny of the substrate binding cleft.  The reason for this is that in these calcium free 
enzyme crystal structures the binding domains (domains I and II) are rotated and held slightly 
apart.  This results in the active site catalytic triad residues not being in close proximity as is 
required for catalytic activity.  As shown in Figure 2.7, the catalytic residues (cysteine and 
histidine) are separated in space by 10.5Å.   
 
This problem was resolved when Moldoveanu et al. published, in 2002, a construct of calpain 
containing only the active site domains I-II.  The structure of mini calpain I was published18 
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first, followed shortly afterwards by mini calpain II.19  In both of these structures calcium 
ions were present and over 85% of the residues form essentially the same structure as 
domains I and II do in inactive calpain II.19   
 
However, most importantly, as shown in Figure 2.7, the distance between the active site 
sulfur of cysteine 105 and the imidazole nitrogen of histidine 262 is now 3.7Ǻ.  This distance 
is the same as in the closely related cysteine protease papain.  This observation, therefore, 
indicates that these mini-calpains contain the necessary structural detail for us to use 
molecular modeling to design new β-strand mimics as calpain inhibitors. 
 
 
Figure 2.7: Calpain active site with and without Ca2+ binding 
In addition to the publication of the crystal structures, enzyme inhibition assays using these 
mini-calpains were performed.  These studies revealed that only mini calpain I had 
reasonable in-vitro catalytic activity.  This was unexpected as the X-ray structure of the 
catalytic triad was very similar in both structures.  The difference in enzymatic activity was 
rationalised by molecular modelling.  In mini calpain II a tryptophan residue blocks the active 
site, whereas in mini calpain I this is not the case.  As such mini calpain I was selected as the 
crystal structure for all molecular modeling studies reported in this thesis (Figure 2.8). 
10.5 Å 
3 .7Å 
Activated (after Ca2+ binding) Not activated 
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Figure 2.8: Comparison of the active sites of the mini calpains I and II 
 
With this information in hand the mini calpain I structure (1KXR), obtained from the protein 
data bank (pdb), was prepared for docking studies.  This required a number of steps to be 
performed: 
• water molecules and ions were deleted;  
• hydrogens atoms were added; 
• The active site Ser115 was mutated to Cys115; 
• Cys115 was deprotonated and His272 protonated to most closely match physicological 
conditions; 
• The structure was minimised using the OPLS 2001 force field with a generalised 
Born/surface area (GB/SA) water model over 500 iterations.  All residues within a 5 
Å distance of the calcium ions of the crystal structure were kept “frozen” during this 
minimization.  The RMSD of the minimised structure to the crystal structure was 0.96 
Å for the heavy atoms (C, N, O, S); 
• The docking grid was defined as the centroid of residues Cys115, Gly208, and Gly271.  
This was generated with GLIDE 3.5 using the default settings. The centre of any 
docked ligand had to be within a 12 Å box.  
 
 
Chapter 2: Design and synthesis of acyclic β-strand mimics 22 
   
The resulting structure was used in all molecular modelling experiments used in this thesis.   
The in-silico design of drugs, and protease inhibitors in general, using molecular modelling is 
well documented throughout the literature.20  Numerous commercial programs are available 
for this task.  However at the University of Canterbury all molecular was conducted using the 
Schrödinger suite 2005.   GLIDE21 was used as the docking program using the following 
parameters:  
• OPLS2001 force field, 
• Standard precision mode, 
• 90000 poses per ligand,  
• A scoring window of 5000 for keeping initial poses, 
• 10000 poses per ligand for energy minimisation, 
• Energy minimisation with a distance dependent dielectric constant of 2 and a 
maximum of 5000 conjugate gradient steps,  
• 10 poses per ligand were saved for evaluation.  
 
A number of parameters were obtained from this docking program.  The three most important 
parameters for the design of a β-strand mimic as a calpain inhibitor are: 
 
• Does the molecule bind as a β-strand mimic?  Visual and mathematical (see 
Section 4.1) examination of the molecule bound into the active site reveals whether or 
not it binds in a β-strand conformation; 
 
• Glide Score.  This numerical score is a reflection of the relative binding energy of  
each ligand to the enzyme.  A large number of parameters are used to calculate this 
score, however the number and strength of hydrogen bonds that the molecule forms 
with the enzyme active site is the largest of these components; 
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• Warhead to active site Cys105 distance.  Glide calculates the distance between the 
carbon of the electrophilic warhead group and Cys105.  Modelling known calpain 
inhibitors determined that the warhead to Cys105 distance was less than 5Ǻ for all 
potent inhibitors.  All molecules which bind with a greater distance than this were 
poor inhibitors.  As such a cut-off of 5Ǻ was used to determine if a modelled 
compound could potentially be a potent calpain inhibitor. 
 
Ligands with good initial docking scores were then subjected to re-docking using the extra 
precision docking mode in GLIDE.  The XP docking protocol provided the most accurate 
results but as this was a much slower docking protocol than the standard precision mode it 
was only used after SP docking had generated a list of promising compounds.  The XP 
docking was used to filter out “false positives” obtained from the much quicker standard 
precision docking.  The same docking parameters described above were used and same three 
scoring parameters were obtained.  
 
2.3: Patentability evaluation 
 
As the synthesis of the new β-strand mimics was based on the well studied generic structure 
2.7 an exhaustive patent search was undertaken to ensure that compounds synthesised in this 
thesis were patentable.   
 
A total of fifty four calpain inhibitor patents were obtained from a Scifinder search performed 
in early March 2004.  None of these considered the role of β-strand conformation in binding.  
As the objective of the Abell research group was to patent any new β-strand mimic calpain 
inhibitor as an anti-cataract agent four key patents were identified which were based on 
generic structure 2.7 and claimed the use of the compounds contained within as anti-cataract 
agents.  All four were published by Senju pharmaceuticals, Japan.   
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Patent 1.  Published 9.10.199922  
R1
S
O O
N
H O
N
H
R4
H
OR2 R3
2.8  
This patents the most potent inhibitors prepared by Senju.  R1 covers a very wide variety of 
moieties.  R2 and R3 are defined as both the R group of an (L)-amino acid and as a three to 
seven membered carbocycle.  R4 is the R group of an (L)-amino acid.  The warhead is 
defined as an aldehyde.  The extensive definitions of R1 essentially make it very difficult, if 
not impossible, to be outside the scope of IP coverage with an N-sulfonamide dipeptide 
aldehyde based inhibitor.  The only feasible way to be outside patent coverage would be to 
use an alternative warhead.  This motivated us to cease work on compounds of this type.   
 
• Patent 2 – Published 6.12.200123  
S
O O
N
H O
N
H
R1
N
Val
F
R2
2.9  
 
This has limited coverage compared to patent 1. It is potentially possible to break this patent 
by simply using alternative N-substituents.  However, inhibitors incorporating a hydrazone as 
a warhead are known to be  poor inhibitors.  As such it was decided that no work was to be 
performed on these types of inhibitors. 
 
• Patent 3 – Published 29.1.200424  
S
O O
N
H O
N
H
R2
O
F
R1
O
N
H
R3
2.10  
This covers a very wide range of alpha-ketoamides.  It defines a single group as the N-
substituent.  Therefore, as for patent 2, using alternative N-substituents may be sufficient to 
obtain a novel patentable inhibitor.  However, alpha-ketoamide synthesis is not trival and 
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generally alpha-ketoamides are less potent inhibitors that their coresponding aldehyde 
analogues.  Nevertheless these still represent synthetic targets of interest. 
 
• Patent 4 – Published 12.2.200425  
N
H O
N
H
R2
OR1
O
N
HO
Py ( )n
2.11  
This patent covers a handful of compounds based on a defined alpha-ketoamide.  The pyridyl 
moieties are attached by varying tether chain lengths on the N-terminus.  These compounds 
were designed to increase aqueous solubility.  Again this provides opportunities, especially 
considering that the pyridyl moieties are attached as an amide rather than as a sulfonamide.  
As such, a mix and match strategy between this patent and the first could be expected to 
provide potent and patentable inhibitors. 
 
In addition to these options a previous member of the Abell group had synthesised dialdehyde 
2.13.  This had been determined to have an IC50 of 30 nM, which was more potent than the 
best published inhibitor of type 2.7, SJA-6017 (2.12)  Furthermore molecular modelling by 
Blair Stewart indicated that this was an excellent β-strand mimic and the fact that it was not 
covered by the scope of any published patent made this a very attractive starting point for the 
synthesis of acyclic β-strand mimics.  
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2.132.12 (SJA-6017)  
As such 2.13 was used as a template to design and model a number of close analogues.  From 
this eleven were selected for synthesis and IC50 determination (Table 2.1).  Of these eight 
compounds were prepared in this thesis (Schemes 2.2 and 2.3). 
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2.4: Design, synthesis and testing of N-heterocyclic dipeptide aldehyde calpain inhibitors 
 
To minimise the number of synthetic steps required a synthetic strategy that allowed 
preparation of a range of related structures using a common intermediate was devised.  As 
shown in Scheme 2.1 the amino alcohol 2.14 provided such a key intermediate.  Commercial 
N-BOC-(L)-Val-H was coupled with (L)-leucinol using standard HATU peptide coupling 
conditions to yield N-BOC-Val-Leu-OH (2.15).  The use of HATU as a peptide coupling 
reagent ensures that the stereochemical integrity of the coupling partners is maintained.  This 
is widely acknowledged in the literature. Cleavage of the BOC protecting group was achieved 
using 4M hydrogen chloride in 1,4-dioxane. 
BOCHN CO2H BOCHN N
H
O
OH HCl.H2N N
H
O
OH
(i) (ii)
2.152.14  
Scheme 2.1. Reagents and Conditions: (i) HATU, DIPEA, (L)-leucinol, DMF, (68%); (ii) 
4M HCl in 1,4-dioxane, (100%) 
 
The 5-and 4-formyl pyrrole analogues were both prepared from commercial pyrrole-2-ethyl 
ester using the procedure published by Martyn and et al.26 (Scheme 2.2).  Formylation of 
pyrrole-2-ethyl ester afforded a mixture of 4-(2.19) and 5-(2.16) formylated pyrrole-2-ethyl 
esters in a ratio of 1:1.9.  Hydrolysis of these under basic conditions and coupling of the 
resultant acids with dipeptide alcohol 2.15 gave the required alcohols 2.18 and 2.21.  These 
were oxidised with sulfur trioxide pyridine complex in DMSO/DCM under basic conditions 
to give the desired aldehydes 2.13 and 2.22. 
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(i) (ii)
X = H, Y = CHO, 2.16
X = CHO, Y = H, 2.19
(iii)
(iv)
X = H, Y = CHO, 2.17
X = CHO, Y = H, 2.20
X = H, Y = CHO, 2.18
X = CHO, Y = H, 2.21
X = H, Y = CHO, 2.13
X = CHO, Y = H, 2.22
Scheme 2.2. Reagents and Conditions: (i) POCl3, DMF, DCE, X = H, Y = CHO (52%) and 
X = CHO, Y = H (27%) 
For X = H, Y = CHO; (ii) KOH, H2O, (96%); (iii) EDC, HOBt.H2O, DIPEA, 2.15, DCM 
(39%); (iv) SO3.Pyr, DIPEA, DMSO, DCM, (66%) 
For CHO, Y = H; (ii) KOH, H2O, (94%); (iii) EDC, HOBt.H2O, DIPEA, 2.15, DCM (24%); 
(iv) SO3.Pyr, DIPEA, DMSO, DCM, (18%) 
 
The 2-furyl and 2-(5-formyl)-furyl analogues were prepared as shown in Scheme 2.3.  
Coupling of 5-formyl-acid chloride 2.26 or 5-unsubstitued carboxylic acid 2.23 to amine 2.15 
afforded dipeptide alcohols 2.24 and 2.27 respectively.  Oxidation of each of these with 
sulfur trioxide pyridine complex in DMSO/DCM, under basic conditions, gave aldehydes 
2.25 and 2.28. 
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(i) (ii)
X= H, Y = OH, 2.23
X= CHO, Y = Cl, 2.26 X= H, 2.24
X= CHO, 2.27
X= H, 2.25
X= CHO, 2.28
 
Scheme 2.3. Reagents and Conditions:  For X = H, Y = Cl; (i) 2.15, DMAP, Et3N, DCM, 
(28%); (ii) SO3.Pyr, DIPEA, DMSO, DCM, (90%) 
For X = CHO, Y = H; (i) EDC, HOBt.H2O, DIPEA, 2.15, DCM (24%); (iv) SO3.Pyr, 
DIPEA, DMSO, DCM, (56%) 
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Summary of assay results   
 
Compounds 2.13, 2.18 and 2.21 – 2.32 were then assayed against calpain II and the results 
are presented in Table 2.1. 
 
R
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H
N
H
O
OH R
O
N
H
N
H
O
H
O
Type A Type B  
R 
substituent Type 
Compound 
Number 
Glide 
Score
Are the 3  
β-strand H-
bonds present 
Warhead 
distance 
to Cys 
(Å) 
IC50 
(nM) 
A 2.29 (M Jones) -6.60 Yes 3.94 15800 
N
H  B 
2.30 
(M Jones) -3.30 Yes 3.50 140 
 
A 2.18 -6.90 Yes 3.55 970 
N
H
H
O  B 2.13 -7.20 Yes 3.70 30 
 
A 2.21 -5.10 No 4.30 >250000 
N
H
O
H
 
B 2.22 -5.90 No >5 >250000 
 
A 2.24 -6.00 Yes 3.40 176400 
O  B 2.25 -6.50 Yes 3.70 130 
       
A 2.27 -5.90 No 3.47 119900 
O
H
O
 
B 2.28 -3.40 No 6.82 1440 
 
A 2.31 (S Mcnabb) -5.70 Yes 3.68 174000 
S  B 2.32 (S Mcnabb) -5.20 Yes 3.62 730 
 
Table 2.1: SAR of N-heterocyclic-Val-Leu-CHO calpain inhibitors  
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From Table 2.1 three SAR implications can be inferred; 
• It is vital that the inhibitors are able to adopt the β-strand conformation (Figure 2.9).  
In Table 2.1 the compounds (2.21, 2.22, 2.27 and 2.28) which are shown by 
molecular modelling to be unable to form the β-strand conformation are accordingly 
poor to very poor calpain inhibitors.   
NH
NH
H
O
O
Leu
Val
O
X
R
NH
O
NH
NH
O
O
S
Cys
Gly 271
Gly 208
115  
Figure 2.9: β-strand binding of N-heteroaromatic dipeptide aldehyde calpain inhibitors 
 
• A 5-formyl substituent on the heterocycle can either increase or decrease calpain 
inhibition.  In the case of the furyl derivates (compare 2.25 and 2.28) this substitution 
results in a ten fold decrease in protease inhibition.  This is possibly due to repulsion 
between the carbonyl of the formyl group and the oxygen of the heterocycle.  This 
results in the molecule not being able to adopt a low energy β-strand conformation 
and hence decreased calpain inhibition is observed.  In the case of the pyrrole 
derivatives (compare 2.13 and 2.30) a 3.5 fold increase in protease inhibition is 
obtained on formyl substitution.  This is predicted by the modelling scores in Table 
2.1 and is a result of the 5-formyl-pyrrole group binding in novel mode (Figure 2.10).   
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Figure 2.10: Novel binding mode of 2.13 
 
In this novel binding mode the carbonyl of the formyl group, the pyrrole NH and the carbonyl 
of the amide all contribute β-strand forming hydrogen bonds.  These atoms have replaced or 
‘mimic’ the hydrogen bonds formed by the carbonyl and the two NHs in a usual dipeptide 
backbone β-strand conformation.  Moreover, in 2.13 the hydrogen bonding atoms are 
“locked” or  conformationally constrained into a β-strand.  As such 2.13 has a lower entropy 
loss upon binding compared to other the “acyclic” β-strands mimics in Table 2.1.  This is an 
extremely important observation and throughout the reminder of this thesis the strategy of 
attempting to conformationally constrain compounds into the ‘bioactive’ β-strand 
conformation is a recurring theme. 
 
2.5: Conclusions and future work 
 
The most important conclusion derived from Chapter 2 is that all the potent inhibitors are 
able to adopt a β-strand.  A modelling protocol using a calpain construct of domains I and II 
has been developed so that the SAR of current calpain inhibitors can be rationalised.  This 
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protocol was then applied to the design of a series of acyclic N-heteroaromatic dipeptide 
aldehydes.  These new β-strand mimics were outside the scope of any current patents and the 
most potent of these was 2.13 with an IC50 against calpain II of 30 nM. 
 
The possibility to undertake further work in this area is limited.  Investigation of the novel 
binding mode of 2.13 is worthwhile to confirm that a new and  important non-peptidic β-
strand binding motif has been identified.  However apart from this section of work the area is 
extremely competitive and well patented.  Macrocyclisation as described in Chapter 4 is a 
much more worthwhile undertaking if the objective is to synthesise novel patentable β-strand 
mimics. 
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3.1: Conformational constraint of peptidomimetics 
 
Nature has found many intriguing and elegant ways to reduce the flexibility of peptides and 
proteins in order to increase both affinity and selectivity for an interacting partner molecule.  
Reduction of conformational flexibility by hydrogen bonding and formation of disulfide 
bridges are the two most well known ways to control shape.1  More sophisticated modes for 
reducing flexibility include the formation of sulfide bridges, zinc fingers, and multiple side 
chain knotting.2   
 
The principle of reducing flexibility and thereby limiting the unfavorable entropy loss upon 
binding is a widely applied principle in peptidomimetic design and drug discovery.3  The 
primary reason for this is because the correct choice of conformational constraint often 
confers both improved biological activity and enzyme/receptor selectivity.  This undertaking 
is usually quite a challenge as often the biologically active conformation of a peptide is not 
known.  However, as described in Section 1.3 it is now known that proteases almost 
universally bind their substrates in an extended β-strand conformation.  
 
As shown in Chapter 2, for the first time, molecules that adopt a β-strand conformation are 
generally excellent calpain inhibitors.  As such the next logical step in the design process was 
to prepare protease inhibitors which were “locked” by conformational constraint into the ‘bio-
active’ β-strand conformation.  We proposed to use ring closing metathesis (RCM) to 
synthesise a range of cyclic conformationally constrained β-strand templates.   
 
As shown in Figure 3.1 it was proposed that appendage of appropriate address regions to a β-
strand template, for a particular protease,  would confer specificity for that protease.  From 
analysis of the vast literature published on protease inhibitor design it is possible to identify 
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numerous groups which would potentially validate this generic protease inhibitor design 
approach.  Examples of these are shown in Figure 3.1.   
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metathesis (CM), ring-closing metathesis (RCM), ring-opening metathesis polymerization 
(ROMP) and acyclic diene metathesis polymerization (ADMET).  
 
RCM
+
ROMP
n
R1 R2+
CM R1
R2
ADMET
n
+ n
 
 Figure 3.2: Types of olefin metathesis reactions. 
 
 
3.3: Mechanism elucidation and metathesis catalyst development 
 
 
In common with most other catalytic reactions, progress in the development of metathesis has 
been directly correlated to improvements in both catalysts and mechanistic understanding. 
Early metathesis catalysts from the mid-1950s to the early 1980s were poorly defined, multi-
component homogeneous and heterogeneous systems consisting of transition metal salts 
combined with main group alkylating agents.  Some of the classic combinations included 
WCl6/Bu4Sn, WOCl4/EtAlCl2, MoO3/SiO2, and Re2O7/Al2O3 among many others.  Although 
these catalyst systems were able to metathesise olefins their synthetic utility was limited by 
the necessary harsh reaction conditions and their strongly Lewis-acidic and alkylating 
character.  These properties rendered them incompatible with most functional groups and thus 
unattractive for applications in advanced organic synthesis.  Furthermore these reactions were 
difficult to initiate and control because very little of the active species formed in the catalyst 
mixtures. 
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A major breakthrough in catalyst design and mechanistic understanding occurred in 1973.  
Researchers discovered that an unusual tantalum complex, (Me3CCH2)3Ta=CHCMe3, was the 
product (in quantitative yield) of the reaction between (Me3CCH2)3TaCl2 and two equivalents 
of neopentyllithium in pentane.  The metal in this species appeared to be in its highest 
possible oxidation state, with the carbene behaving as a dianion. Around this time researchers 
were beginning to ask questions concerning the mechanism of the olefin metathesis reaction 
and the nature of the active species in classical olefin metathesis systems.  The lack of 
definitive answers to these questions motivated extensive work to better understand olefin 
metathesis, including detailed mechanistic studies.   
 
Many mechanistic schemes were proposed over the years, but ultimately, the scheme 
developed by Chauvin was found to be the most consistent with the experimental evidence, 
and it remains the generally accepted mechanism today.6-13  As shown in Scheme 3.1, 
Chauvin proposed that olefin metathesis consists of a sequence of formal [2+2] 
cycloadditions/cycloreversions involving alkenes, metal carbenes, and metallacyclobutane 
intermediates.  It is important to note that this process is reversible and therefore an 
equilibrium mixture of olefins is obtained. As such it is necessary to shift this equilibrium in 
one direction in order to make metathesis productive in preparative terms.    
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Scheme 3.1: Mechanism of olefin metathesis. 
In the case of RCM the forward reaction is usually entropically driven.  RCM cuts one 
substrate molecule into two products thus if one of them is volatile (e.g. ethene, propene, etc.) 
the desired cycloalkene accumulates in the reaction mixture (Scheme 3.2).  Furthermore 
another important factor for productive RCM is the sensitivity of most metathesis catalysts to 
the substitution pattern of the olefin as this constitutes a kinetic obstacle for the retro-reaction. 
[M]
[M]
[M]
CH2
CH2
CH2[M]
 
Scheme 3.2: Mechanism of ring closing metathesis. 
 
3.4: The advent of well defined single-component catalysts  
 
The Chauvin mechanism was not only a breakthrough in terms of the mechanistic 
understanding of metathesis reactions but perhaps even more importantly it provided both a 
design rationale and a way to begin to understand catalyst activity.  Subsequent efforts to 
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synthesise alkylidene and metallacyclobutane complexes led to the discovery of the first of 
many single-component homogeneous catalysts for olefin metathesis during the late 1970s 
and early 1980s.  By 1980 investigations of tantalum alkylidene chemistry revealed that the 
presence of alkoxide ligands allowed tantalum species to function as metathesis catalysts for 
internal olefins.14  At about the same time, oxo-alkylidene complexes of tungsten were 
discovered,15 followed two years later by what turned out to be oxo-free cationic tungsten 
alkylidene complexes,16 both of which would metathesise olefins. These new catalysts 
included (CO)5W=CPh2,17, 18 bis(cyclopentadienyl)titanocyclobutanes,19 tris(aryloxide)tantala-
cyclo-butanes,20 and various dihalo-alkoxide-alkylidene complexes of tungsten.21-23 As well 
defined complexes, these catalysts exhibited better initiation and higher activity under milder 
conditions than ever before, thus enabling researchers to study structure-activity relationships 
and mechanism in detail. 
 
The further development of well-defined olefin metathesis catalysts was considerably aided 
when synthetic routes were perfected that produced electron-deficient imidoalkylidene 
complexes of the type (NAr)(OR')2M=CHR (M=Mo or W).  These fully functional olefin 
metathesis (pre)catalysts were the first catalysts to become widely used.  The ability to vary 
the (always sterically demanding) imido and alkoxide groups allowed a wide range of 
catalysts to be synthesised.24-26  The strongly electron-withdrawing hexafluoro-tert-butoxide 
ligand was found to result in the most rapid turnover.  The commercial availability of the 
molybdenum hexafluoro-tert-butoxide complex, which is now commonly recognised as 
Schrocks catalyst, 3.1, as well as its speed and selectivity resulted in it being explored for 
organic transformations.   
 
For a considerable period of time 3.1 was the only metathesis catalyst that allowed the 
formation of tri- and even tetrasubstituted double bonds by RCM.  Only recently was a 
ruthenium-based system developed which also allowed access to these products.27  
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An additional advantage of the molybdenum complex 3.1 resides in its tolerance towards 
certain functional groups which inhibit ruthenium-based metathesis catalysts.  Typically sulfur 
and phosphine containing compounds can be problematic.  A mismatch of the hard MoVI 
centre with soft sulfur or phosphine functionalities can explain why substrates such as 3.2, 
shown in Scheme 3.3, cyclise smoothly in the presence of 3.1 but usually fail to react in the 
presence of ruthenium catalysts.28-32    
S
S3.1
3.2  
Scheme 3.3: Functional group tolerance of 3.1 
Furthermore, catalyst 3.1 is little affected by the electronic properties of the olefinic substrates 
and reacts with both electron-rich olefins (for example, enol ethers) and electron-poor olefins 
(such as acrylates and acrylonitrile).33-38  Until very recently the ruthenium catalysts were 
mostly unreactive towards these substrates,39 but newly developed heteroleptic ruthenium 
species have largely overcome this problem. 
 
The major shortcoming  of the molybdenum catalysts, and others based on the early transition 
metals, is the high oxophilicity of the metal centre which renders them extremely sensitive to 
oxygen and moisture. As an example, the synthesis and handling of 3.1 requires an inert 
atmosphere and rigorously purified, dried, and degassed solvents/reagents.  In addition early 
metal catalysts are more fundamentally limited by moderate to poor functional group 
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tolerance.  Complex 3.1, for instance, is incompatible with aldehydes and alcohols.30  This 
problem of functional group tolerance may be overcome with protecting group strategies, but 
these are often tedious, time consuming, and synthetically inefficient.  The development of 
single-component catalysts, and in particular the Schrock type of catalysts, was a major 
advance but significant room for improvement remained. Continuing research was motivated 
by the prospect of solving the problems related to oxophilicity and functional group tolerance.  
 
First generation ruthenium catalysts 
 
The key to improved functional group tolerance in olefin metathesis was the development of a 
catalyst that reacted preferentially with olefins in the presence of heteroatomic functionalities.  
A very important conclusion derived from the early work on catalyst design was that the 
catalysts were observed to react more selectively with olefins as the metal centres were varied 
from left to right and bottom to top in the periodic table.40   This trend is illustrated for 
titanium, tungsten, molybdenum, and ruthenium in Figure 3.3. 
 
Figure 3.3: Functional group tolerance of early and late transition metal catalysts. 
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In retrospect, ruthenium based catalysts were excellent candidates as metathesis catalysts but 
these were not seriously considered for more than two decades.  This was the result of 
discouragingly low metathesis activity of ruthenium salts, as well as a limited understanding 
of how to achieve functional group tolerance. Several reports from the 1960s had, in fact, 
described the ROMP of norbornene derivatives with RuCl3(hydrate) in refluxing ethanol 
under aqueous emulsion conditions.41, 42 The polymer yields were small, but the observation 
that ROMP could take place in these protic solvents at all was an important precedent.  
 
A breakthrough occurred when 3.3 (as a mixture of cis- and trans-bis(phosphine) isomers) 
was successfully synthesised.  This was the first well-defined, metathesis-active ruthenium 
alkylidene complex.43   
Ru
P(Ph)3
P(Ph)3
Ph
Ph
Cl
Cl
3.3  
Although the initiation behaviour and functional group tolerance of 3.3 was encouraging, its 
activity was limited to the ROMP of highly strained monomers.  To extend this activity to the 
metathesis of acyclic olefins, the influence of the ligands on the catalytic activity of 5-
coordinate, 16-electron, ruthenium complexes were systematically studied.  From these 
studies it was concluded that, with regard to the anionic substituent,  chloride seemed to be 
optimal.  The effect of this rather electron-withdrawing group, however, must be 
counterbalanced by electron-donating phosphines.  Based on the trend followed by early 
transition metal catalysts, for which metathesis activity increases with more electron-
withdrawing ligands,44, 45 a variety of cationic complexes and derivatives containing less basic 
phosphines were prepared and tested.  This culminated in the discovery that the larger and 
more basic the phosphine, the higher the metathesis activity.  The tricyclohexylphosphine 
derivative (3.4) was the first ruthenium alkylidene complex active toward acyclic olefins.   
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While this catalyst is not as active as the molybdenum complex 3.1 it is more versatile due to 
its improved functional group tolerance.  For example, it was shown to cyclise dienes to five-, 
six-, and seven-membered carbocycles and heterocycles in good yields, even in the presence 
of trifluoroacetyl and tert-butoxycarbonyl, protecting groups.46  In addition, it is air-stable as a 
solid and it retains its activity even when exposed to water, alcohols, or acids.  These 
characteristics made catalyst 3.4 an ideal starting point for further catalyst optimisation. With 
a variety of complexes prepared, the fundamental reactions of ruthenium alkylidenes were 
examined. The benzylidene catalyst 3.5, was found to undergo metathesis with ethylene 
within minutes at room temperature to quantitatively form the methylidene derivative as 
shown in Scheme 3.4.  This complex was the first metathesis-active methylidene species ever 
isolated. 
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Scheme 3.4: Metathesis of ethylene with catalyst 3.5  
 
 
Catalyst 3.5 combined the bulky and strongly electron-donating P(Cy)3 ligands with the 
readily initiated benzylidene moiety and this complex is now commonly referred to as Grubbs 
first generation catalyst.    
 
Second generation ruthenium catalysts 
 
Many mechanistic studies were performed using the first generation ruthenium catalysts.  The 
key insight was that 3.5 formed a highly active mono-phosphine intermediate during the 
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catalytic cycle.  As such this intermediate became a design motif  (3.6) which was used as a 
starting point for the development of improved catalysts.  
 
RuX
R
L X
R'
(12)  
 
3.6 
Furthermore, as the decomposition of 3.5 was known to be second order and inversely 
proportional to phosphine concentration, it was important to maintain a low concentration of 
the mono-phosphine species.  As such it is important that the ancillary ligands are not too 
labile and that they sufficiently stabilised the reaction intermediates.  Any approach to 
increase the concentration of the mono-phosphine intermediate would be futile if it also 
accelerated catalyst decomposition.  It was therefore concluded that the steric and electronic 
properties of the residual neutral ligands were decisive for the performance of the catalyst.  It 
was postulated improved catalytic activity would be achieved if these ligands were even more 
basic and sterically demanding than P(Cy)3.  
 
At the time when this work was being undertaken it was already known that, compared to 
phosphines, N-heterocyclic carbene ligands were both stronger donors and much less labile.47 
The first report on their use in the context of metathesis, 48 in which both P(Cy)3 ligands of 3.5 
were replaced by N,N-disubstituted 2,3-dihydro-1H-imidazol-2-ylidene moieties 3.7, proved 
to be a rather stable complex and hence it did not exhibit an improved activity profile over 
3.5.  This result was a mechanistically reassuring discovery since the "sticky" NHC ligands 
rendered the dissociation of the ligand less likely and thus resulted in a low concentration of 
the catalytically active ruthenium template in solution and hence poorer catalytic activity. 
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Ph
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The use of a mixed-ligand complex overcame this problem.  Incorporation of one kinetically 
inert, electron-donating NHC ligand in combination with a coordinatively labile ligand 
resulted in the desired synergetic effect.  This hypothesis was independently pursued by three 
different research groups, each of which reported49-57 almost simultaneously on the 
preparation and the catalytic properties of the heteroleptic complexes shown in Figure 3.4. 
Ru
P(Cy)3Cl
Cl
N NR R
Ph
Ph
Ru
P(Cy)3Cl
Cl
N NR R
N N
Ru
P(Cy)3
Cl
Cl Ph
Ru
Cl
Cl
Cl
N NR R
Ph
Ru
CH3
Cl
3.9
3.8
3.10
3.11
R = Mesityl or CHMePh
R = Mesityl 
R = C6H11
 
Figure 3.4: Ruthenium heteroleptic complexes. 
 
These second-generation ruthenium carbene catalysts displayed performance that was 
previously only possible with the most active early metal systems.  These also possessed the 
thermal stability and the resistance toward oxygen and moisture, as well as the compatibility 
with many functional groups previously observed with the first generation of ruthenium 
catalysts.  As such these second generation catalysts were most significant because they 
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combined the best characteristics of early and late metal centres into a single species.  Until 
then it appeared that functional group tolerance was only gained at the expense of activity.  
An example of this “leap forward” in catalytic activity is evidenced with the ease with which 
the RCM of sterically demanding dienes of tri- and tetrasubstituted olefins was performed.49-55  
Similarly, electron deficient olefins which constituted problematic substrates for the first 
generation ruthenium catalysts can be ring closed using the second generation ruthenium 
catalysts.54, 58 
 
The major milestones achieved during the development of RCM methodology are illustrated 
in Figure 3.5.  The work contained in this thesis is focussed upon attempting to incorporate 
and extend RCM methodology into the synthesis of conformationally constrained β-strand 
mimics. 
.
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Figure 3.5: Major milestones achieved during the development of RCM methodology. 
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3.5: Design and synthesis of N-N conformationally constrained SJA analogues  
 
The first strategy envisaged to conformationally constrain compounds of type 2.7, into a β-
strand, using RCM was to introduce a conformational constraint between two adjacent amino 
acids to form a N-N cyclised ring of variable size (Figure 3.6).   
      
N N
R O R
SF
O
O H
O
N
H O
N
H
WarheadAdditional Recognition
R2
R1
3.12
( )n
2.7  
Figure 3.6: N-N cyclised analogue of 2.7 
The decision to design and synthesise the N-N cyclised analogues of the general structure 3.12 
was motivated by two recent publications.   
• Carbocycles of type 3.12 were shown to have a reduced conformational space that 
results in an increased affinity for biological receptors.  In addition this cyclisation 
confers dramatically improved redox stability.59-62 
 
• In 2004 researchers at Cephalon published a paper63 containing interesting SAR 
around related types of compounds as calpain I inhibitors.  Structure 3.13, with an IC50 
of 7 nM, indicated that a conformationally constrained sulfonamide could be used to 
obtain potent compounds.  Molecular modeling in our group, by Blair Stuart, indicated 
that compounds of this type bound to calpain in β-strand conformation (Figure 3.7).  
In addition, structure 3.14 with an IC50 of 50 nM indicated that if the correct 
conformational constraint was chosen the NH of the sulfonamide could be alkylated 
without significant loss of protease inhibition. 
S
N
N
H
O
O
O O
O
N
H
O
O
Ph
S
NH
N
H
O
O
O O
Ph
H
F
3.143.13  
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Figure 3.7: Superimposition of 2.12 (black) and 3.13 (CPK colours) 
 
Retrosynthetic analysis (Scheme 3.5) was used to decide on the synthetic route to compounds 
of type 3.12.  The key disconnections were that of cyclised alcohol 3.16 to diene 3.17 and the 
disconnection of diene 3.18 to its constituent carboxylic acid and amine (3.19 and 3.20). 
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Scheme 3.5: Retrosynthetic analysis of 3.15 
 
Phenylalanine was chosen as the P1 substituent and valine as P2.  The synthesis of required 
amine 3.19 is shown in Scheme 3.6.  Phenylalanine methyl ester was activated towards N-
allylation using a procedure established by Reichwein and Liskamp60.  This was achieved by 
formation of 4-nitrobenzene sulfonamide 3.21.   This was allylated using mildly basic 
conditions to yield N-allylated sulfonamide 3.22.  The N-activating sulfonamide of 3.22 was 
cleaved using thiophenol to afford required N-allyl amine 3.23. 
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HCl.H2N CO2Me
Ph
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H
CO2MeS
O
O
O2N
Ph
N CO2MeS
O
O
O2N
Ph
HCl.HN
Ph
CO2Me
(i) (ii)
3.21
(iii)
3.22 3.23  
Scheme 3.6. Reagents and Conditions: (i) 4-Nitrobenzene sulfonyl chloride, Et3N, DCM, 
(81%); (ii) K2CO3, allyl bromide, DMF, (93%); (iii) K2CO3, thiophenol, DMF, (65%) 
 
The preparation of required carboxylic acid 3.26 is shown in Scheme 3.7.  Valine methyl ester 
was coupled with 4-fluorobenzene sulfonyl chloride to yield sulfonamide 3.24.  This was 
allylated using potassium carbonate as the base and the ester hydrolysed to form desired N-
allyl carboxylic acid 3.26. 
HCl.H2N CO2Me N
H
CO2MeS
O
O
F
N CO2MeS
O
O
F NS
O
O
F CO2H(i) (ii)
3.24
(iii)
3.25 3.26  
Scheme 3.7. Reagents and Conditions: (i) 4-Fluorobenzene sulfonyl chloride, DIPEA, DCM 
(92%); (ii) K2CO3, allyl bromide, DMF, (89%); (iii) NaOH, THF, H2O, MeOH, (95%) 
 
As shown in Scheme 3.8 coupling of N-allyl amine 3.23 and N-allyl carboxylic acid 3.26 was 
attempted using a wide variety of peptide coupling reagents.  All these failed.  In addition the 
acid chloride and acid fluoride of 3.26 were prepared, but these both failed to form desired di-
peptide 3.27 on reaction with amine 3.23.  As such this synthetic route was abandoned. 
 
An alternative route to the target compound was devised when previously prepared N-allyl 
carboxylic acid 3.26 was coupled with allyl amine to yield diene 3.28 (Scheme 3.8).  This was 
subjected to Grubbs second generation catalyst under a variety of  reaction conditions but no 
ring closed product was obtained.  Only starting diene 3.28 was recovered in quantitative 
yield..  As such this synthesis was also not pursued further. 
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R = Phe-OMe, 3.27
R = H, 3.28
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Scheme 3.8. Reagents and Conditions: For R = Phe-OMe: (i) HATU, DIPEA, 3.23, DMF; or 
HATU, DIPEA, 3.23, THF; or HATU, DIPEA, 3.23, (1/1) DMF/DCM; or EDC, HOAT, 
DIPEA, 3.23, DMF; or  PyAOP, DIPEA, 3.23, DMF; or PyBroP, DIPEA, 3.23, DMF; or a) 
Cyanuric fluoride, Pyr, DCM; b) 3.23, DCM; or a) (COCl)2, DMF, DCM b) 3.23, DCM (all 
0%).  For R = H: (i) HATU, HOAt, DIPEA, allyl amine, DMF, (73%); b) 10 mol% 3.9, 
DCM, rt; or 10 mol% 3.9; benzene, reflux; or 10 mol% 3.9; 1,1,2-TCE, reflux; or 3x 10 mol% 
3.9; 1,1,2-TCE, microwave (all 0%) 
 
The reason for the failure of diene 3.28 to undergo RCM is postulated to be due to the diene 
forming a stable six membered catalyst deactivating chelate with Grubbs second generation 
catalyst (Figure 3.8) (discussed in further detail in Section 4.16). 
Ru
N
H
R
O
O
Ru
NH
R
O
Ru
NH
R
O
Ru
NH
RX
Chelation deactivates 
catalyst to RCM  
Figure 3.8: Chelate formation from 3.28 and Grubbs second generation catalyst 
 
The synthetic route, therefore, had to be modified to negate RCM failure due to chelation and 
an inability to couple N-allyl amine 3.23 with N-allyl carboxylic acid 3.26.  As discussed 
further in Section 4.16 the chelate is particularly strongly bound when a proton is located on 
the amide.  However, as it was not possible to couple an N-allyl amine the allyl group had to 
be introduced after peptide coupling.  As shown in Scheme 3.9 this was achieved using P4-
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phosphazene.  Methyl ester 3.24 was hydrolysed with sodium hydroxide and resultant 
carboxylic acid 3.30 was coupled with phenylalanine methyl ester to afford di-peptide 3.31.  
A double allylation was achieved using allyl bromide and P4-phosphazene to yield diene 3.32.  
RCM was accomplished using Grubbs second generation catalyst in refluxing 1,1,2-TCE in 
60% isolated yield.  Reduction of tetrahydro-diazocinone methyl ester 3.33 with DIBAL-H 
resulted in a complex mixture of inseparable products.  As such this synthetic sequence was 
abandoned. 
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3.30 3.31
3.323.333.34
X
Scheme 3.9. Reagents and Conditions: (i) LiOH.H2O, MeOH, H2O, (100%); (ii) HATU, 
HOAt, DIPEA, Phe-OMe, DMF, (86%); (iii) P4-Phosphazene, allyl bromide, THF, (51%); 
(iv) 3x 10 mol%, 1,1,2-TCE, microwave, (60%) (v) DIBAL-H, DCM (0%) 
 
As shown in Scheme 3.10 tetrahydro-diazocinone methyl ester 3.39 was prepared using the 
same synthetic methodology as that used in Scheme 3.9.  The only difference was the 
incorporation of valine as the P2 residue.  This was introduced in order to obtain directly 
comparable SAR with acyclic analogue 2.12.  However, reduction of methyl ester 3.39 with 
lithium aluminium hydride also resulted in complete decomposition.  Moreover around the 
same period of time advances in molecular modelling suggested that this class of potential 
inhibitors would provide poor β-strand mimics and as such the synthesis of these types of 
compounds was terminated.   
 
Despite this setback the synthetic methodology devised in Schemes 3.9 and 3.10 presented an 
opportunity to develop methodology for the facile variation of ring size.  The important 
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observation was that the proton of the sulfonamide was more acidic than that of the amide.  It 
was envisaged that a selective allylation could be achieved using a mild base.  As shown in 
Scheme 3.10 dipeptide 3.37 was allylated with both allyl bromide and 4-bromo-but-1-ene, 
using potassium carbonate as base, to yield mono-allylated dipeptides 3.41 and 3.42.  No 
further work was performed on these types of compounds as they were rated as low priority 
after the successful synthesis of the β-strand macrocycles (see Chapters 4 and 5).  However 
allylation of the amide proton of 3.41 and 3.42 using P4-phosphazene base and either allyl 
bromide or 4-bromo-but-1-ene respectively would yield nine and ten membered rings after 
RCM.   
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(vi) (v)
3.393.40
 
Scheme 3.10. Reagents and Conditions: (i) HATU, DIPEA, Leu-OMe, DMF, (93%); (ii) 2M 
HCl, Et2O, (100%); (iii) 4-Fluorobenzene sulfonyl chloride, DIPEA, DCM (24%);  
For n = 1, R = CH2CHCH2: (iv) P4-phosphazene, allyl bromide, THF (37%); (v) 3x 10 
mol%, 3.9, 10 mol% (Cy)2BCl, 1,1,2-TCE, microwave, (60%); (vi) LiAlH4, THF, (0%) 
For n = 1, R = H: (iv) K2CO3, allyl bromide, DMF, (78%); For n = 2, R = H: (iv) K2CO3, 4-
bromo-1-butene, DMF, (74%) 
 
3.6: Design and synthesis of β-amino acid C-N carbocycles  
 
Previous work in our laboratory systematically replaced the leucine and valine α-amino acids 
in 2.12 with  β-amino acids.64  However, all the compounds prepared in this series proved to 
have low activity.  From this work it was concluded that incorporation of β-amino acids into a 
calpain inhibitor was detrimental to inhibitory activity.   
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However, as β-amino acids are known to increase the biostability of peptide-based drugs65 it 
was postulated that, if it was possible to conformationally constrain β-amino acid compounds 
into a β-strand then this might provide an approach for the design and synthesis of 
metabolically stable β-strand mimics.  As such general structure 3.43 was selected as a 
synthetic target. 
N
R O
N
H
H
O
R
3.43
( )n
 
Molecular modelling (Figure 3.9) of 3.43 where n is 1 and the R substituent is a 4-
fluorobenzene sulfonamide indicated a β-strand conformation may be obtained.  It was not a 
perfect β-strand mimic but it was a good starting point for RCM studies in these types of 
compounds.  Furthermore molecular modelling indicated that the aldehyde was located in 
close proximity to the catalytic cysteine residue.  
.  
Figure 3.9: Superimposition of 2.12 (Black) and 3.43 R = 4-F-phenyl sulfonamide and n = 1 
(CPK colours) 
 
One of the objectives of the synthesis was to develop versatile synthetic methodology that 
would allow a variety N-substituted carbocycles to be prepared.  Retrosynthetic analysis 
(Scheme 3.11) of 3.43 incorporating the easily cleaved N-BOC protecting group was 
performed.  A further consideration factored into the retrosynthesis was that it was considered 
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prudent to synthesise the conformational constraint first in order to establish that ring closure 
using RCM could be achieved.   
BOCN
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3.44 3.45 3.46 3.47
3.483.49
 Scheme 3.11: Retrosynthetic analysis of 3.44 
 
As shown in Scheme 3.12 valine was chosen as the P2 residue as this generally results in the 
most potent calpain inhibition.66  As per the retrosynthetic analysis (Scheme 3.11), N-BOC-
Val-H was converted to N-BOC-β-Val-OMe (3.50) using Arndt-Eistert homologation 
conditions.67  Allylation was achieved, albeit it in low yield, to afford 3.51.  However, N-
allylation of this was not possible using allyl bromide and sodium hydride as the base.  It was 
decided that this failure, combined with the low yield and problematic purification of 3.51, 
required the design of an improved synthetic route. 
BOCHN CO2H BOCHN CO2Me
BOCHN
CO2Me
BOCN
CO2Me
(i), (ii) (iii) (iv)
3.513.50 3.52
x
 
Scheme 3.12. Reagents and Conditions: (i) ClCO2Et, Et3N, THF; (ii) CH2N2, AgOBn, Et3N, 
MeOH, (65% over 2 steps); (iii) LDA, LiCl, allyl bromide, THF -78oC, (16%) (iv) NaH, allyl 
bromide, THF, (0%) 
 
The new methodology had to provide both ease of N-allylation and C-allylation.  It was 
postulated that the NH proton of 3.50 may have contributed to the side products obtained 
when this was C-allylated using LDA and allyl bromide.  As such it was hypothesised the use 
of a 4-nitrobenzene sulfonamide would not only activate the nitrogen towards allylation but 
N-allylation would also remove the proton from the sulfonamide.  As such it was envisaged 
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that using this strategy, cleaner higher yielding C-allylation would be achieved.  This 
methodology was therefore incorporated into a revised synthetic strategy.  
As shown in Scheme 3.13 the BOC protecting group of N-BOC-β-valine (3.50), prepared 
earlier (see Scheme 3.12), was cleaved using a 10% solution of TFA in DCM to afford amine 
3.53.  Sulfonamide 3.54 was prepared using standard sulfonyl chloride coupling conditions.  
This was allylated with allyl bromide using potassium carbonate as the base to give N-allyl-β-
amino acid 3.55.  However, C-allylation using either LDA or LiHMDS as base resulted in 
complete decomposition.  This synthetic route was therefore abandoned. 
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Scheme 3.13. Reagents and Conditions: (i) 20% TFA, DCM, (100%); (ii) 4-Nitrobenzene 
sulfonyl chloride, Et3N, DCM, (30%); (iii) K2CO3, allyl bromide, DMF, (100%); (iv) LDA, 
LiCl,  allyl bromide, THF; or LiHMDS, allyl bromide, THF, (both 0%) 
 
As valine was proving difficult to work with due to problems with chromatographic 
purification, particularly given the complex mixture of products obtained, the amino acid was 
changed to phenylalanine.   
 
As shown in Scheme 3.14 synthesis of carbocycle 3.62 was successfully achieved using 
phenylalanine as the amino acid and 4-fluorobenzene sulfonyl chloride as an N-activating 
group.  BOC protected phenylalanine was converted to β-amino acid methyl ester 3.57 using 
Arndt-Eistert homologation conditions.67  Stereoselective allylation was achieved, albeit in 
low yield to afford 3.58.  This reaction was performed on a ten gram scale to ensure that 
sufficient material was obtained to continue the synthesis.  The BOC protecting group was 
cleaved using TFA in DCM to give the TFA salt of amine 3.59.  Treatment of this under 
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standard sulfonyl chloride coupling conditions with 4-flourobenzene sulfonyl chloride  
afforded sulfonamide 3.60.  This was allylated using mildly basic conditions to afford diene 
3.61.  This was ring closed using Grubbs second generation catalyst in DCM at room 
temperature to give cyclised product 3.62 in 81% isolated yield.  However, under basic 
hydrolysis conditions 3.62 decomposed.   
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Scheme 3.14. Reagents and Conditions: (i) a) ClCO2Et, Et3N, THF; b) CH2N2, AgOBn, Et3N, 
MeOH, (62% over 2 steps); (ii) LDA, LiCl, allyl bromide, THF -78oC, (26%) (iii) 10% TFA, 
DCM (100%); (iv) 4-Fluorobenzene sulfonyl chloride, Et3N, DCM, (100%); (v) K2CO3, allyl 
bromide, DMF, (82%); (vi) 10 mol% 3.9, DCM (81%); (vii) LiOH.H2O, MeOH, H2O, THF, 
(0%) 
 
In order to circumnavigate the base sensitivity of cyclised ester 3.62, an alternative order of 
synthetic steps was attempted in which hydrolysis of methyl ester 3.60 was performed much 
earlier in the synthetic sequence (Scheme 3.15).  Resultant carboxylic acid 3.64 was coupled 
with (L)-leucinol using standard peptide coupling procedures to form dipeptide 3.65.  
However, allylation under standard mild base conditions, developed earlier in this section, 
resulted in triolefinic product 3.66.  This was an unexpected and unexplained product, 
however NMR and mass spectrometry characterisation confirmed this to be the structure. 
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Scheme 3.15. Reagents and Conditions: (i) LiOH, MeOH, H2O, THF, (46%); (ii) EDC, 
HOAt, DIPEA, (L)-leucinol, DMF, (61%); (iii) K2CO3, allyl bromide, THF, (84%), (iv) LDA, 
LiCl, allyl bromide, THF -78oC 
 
Required aldehyde, 3.73, was successfully prepared using the synthetic sequence shown in 
Scheme 3.16.  Arndt-Eistert homologation of N-CBZ-Phe-H afforded β-amino acid 3.67.  
Stereoselective C-allylation using LDA as base gave olefin 3.68 which was N-allylated using 
P4-phosphazene base to give diene 3.69.  Treatment with Grubbs second generation catalyst 
then gave 3.70.  Hydrolysis of the methyl ester with sodium hydroxide, followed by peptide 
coupling of carboxylic acid 3.71 with (L)-leucinol afforded dipeptide alcohol 3.72.  Oxidation 
with sulfur trioxide pyridine complex in DMSO/DCM produced required aldehyde 3.73. 
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Scheme 3.16. Reagents and Conditions: (i) ClCO2Et, Et3N, THF; (ii) CH2N2, AgOBn, Et3N, 
MeOH, (48% over 2 steps); (iii) LDA, LiCl, allyl bromide, THF, (65%); (iv) P4-Phosphazene, 
allyl bromide, THF, (87%); (v) 10 mol% 3.9, DCM, (82%); (vi) NaOH, THF, H2O, (100%); 
(vii) EDC, HOAt, DIPEA, (L)-leucinol, DMF, (58%); (viii) SO3.Pyr, DIPEA, DMSO, DCM, 
(61%) 
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In order to obtain meaningful SAR the direct acyclic analogue of 3.73 was synthesised.  As 
shown in Scheme 3.17 this was achieved using standard peptide chemistry.  Methyl ester 3.67 
was hydrolysed and resultant carboxylic acid 3.74 coupled with (L)-leucinol to give dipeptide 
alcohol 3.75.  Oxidisation with sulfur trioxide pyridine complex in DMSO/DCM gave 
aldehyde 3.76. 
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Scheme 3.17. Reagents and Conditions: (i) NaOH, THF, H2O, MeOH, (94%); (ii) EDC, 
HOAt, DIPEA, (L)-leucinol, DMF, (30%); (iii) SO3.Pyr, DIPEA, DMSO, DCM, (52%) 
 
Compounds 3.72, 3.73, 3.75 and 3.76 were then assayed against calpain II and the results are 
given in Table 3.1.   
Compound Glide Score
Number of β-
strand hydrogen 
bonds to enzyme 
Warhead 
distance to 
Cys (Å) 
IC50 
(nM) 
CBZHN
O
N
H
OH
Ph
3.75
 
-7.3 0 3.8 228000 
CBZN
PhO
N
H
OH
3.72
 
-5.4 0 6.7 179000 
CBZHN
O
N
H
H
Ph
O
3.76  
-6.4 0 7.2 4230 
CBZN
PhO
N
H
H
O
3.73
 
-6.6 0 6.6 3150 
 
Table 3.1: SAR of β-amino acid C-N carbocycles 
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These results suggest that incorporation of β-phenylalanine at P2 in the acyclic series results 
in only moderate calpain inhibition (see compounds 3.75 and 3.76).  This result is rationalised 
by molecular modelling.  Inclusion of a β-amino acid into the peptide backbone results in the 
loss of β-strand conformation and thus the loss of β-strand hydrogen bonds in the enzyme 
active site.   
 
In addition, from Table 3.1 it can also be inferred that cyclic inhibitor 3.73 is not in the ‘bio-
active’ conformation.  This conclusion is reached from the inhibition results of 3.73 and 3.76.  
The IC50 values for these two analogues suggest that they are equipotent.  As molecular 
modelling clearly shows that the acyclic analogue is not able to bind in a β-strand 
conformation then as the cyclic analogue is equipotent this also must not be able to bind in a 
β-strand conformation.  Moreover the corresponding alcohols (3.72 and 3.75) possess 
negligible calpain inhibition thus further supporting the hypothesis that neither of these types 
of compounds are able to exist in a β-strand conformation. 
 
3.7: Conclusions and future work 
 
The synthesis of an eight membered cyclic nitrogen to nitrogen analogue of SJA-6017 (2.12) 
was attempted.  Cyclisation was achieved by allylating both nitrogen protons of a suitably 
protected 2.12 analogue and performing RCM on this diene.  However, the cyclic methyl 
esters 3.33 and 3.39 were unexpectedly very sensitive to reducing reagents and as such the 
synthesis of a N-N cyclised calpain inhibitor was not possible.   
 
Synthetic methodology was developed to allow the facile synthesis of the nine and ten 
membered ring analogues of cyclic methyl esters 3.33 and 3.39.  This could be worth pursuing 
with the objective of preparing a publication outlining the use of a sulfonamide as an approach 
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to achieve selective allylation and thus methodology to prepare different ring sized N-N 
cyclised dipeptides. 
 
The synthesis of conformationally constrained β-amino acid calpain inhibitor 3.73 was 
successfully achieved.  This proved to be a moderate calpain inhibitor with an IC50 of 3.15 
µM.  It is equipotent to its direct acyclic analogue (3.76) which was also successfully 
prepared.   
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4.1: Use of macrocyclisation to constraint a peptidomimetic in a β-strand conformation 
 
Chapter 2 described the successful design and synthesis of acyclic compounds which 
molecular modeling showed were able to adopt a β-strand conformation.   Chapter 3 
described the use of RCM to synthesise cyclic dipeptides with the objective of 
conformationally constraining these into a β-strand conformation.  However, the carbon to 
nitrogen conformationally constrained dipeptide (3.70) was a poor calpain inhibitor while 
molecular modeling suggested 3.35 was a poor β-strand mimetic.  Furthermore previous work 
in our laboratory, where a carbon to carbon conformational constraint1 as in 4.0 was 
synthesised, proved to be a very poor calpain inhibitor.  As such it was concluded that these 
were not β-strand mimics.   
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O H
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The cyclic compounds described above (3.35, 3.70 and 4.0) were designed on the basis of the 
generic calpain inhibitor template (2.7), see Section 2.1.  These findings provided very clear 
evidence that if a successful cyclic β-strand mimic was to be designed using a conformational 
constraint strategy, then more was required than simply constructing conformational 
constraints of generic dipeptide motif 2.7.  This chapter describes the design and 
implementation of a carbon to carbon macrocyclisation strategy to conformationally constrain 
tripeptides into a β-strand conformation.  As such a new generic structure was adopted as the 
design template (4.1).   
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There were two main reasons why this new template was chosen. 
• As the conformational constraint is incorporated as a carbon to carbon backbone 
cyclisation, the template is capable of forming the three key β-strand hydrogen bonds 
to the protease (to Gly208 and Gly271 in the case of calpain).  See Section 2.1. 
 
• The central amino acid (R) in 4.1 ensures that it is still capable of forming the 
complementary P2/S2 enzyme/substrate interaction.  
 
Macrocyclisation was also an attractive strategy for two other reasons; 
• Macrocyclic compounds with amide bonds have been demonstrated to possess higher 
resistance to proteolytic cleavage relative to their acyclic analogues.2 
 
• Macrocyclic compounds often exhibit improved cell permeability compared to their 
acyclic counterparts.3, 4 
 
4.2: Generation of an in-silico library of macrocyclic β-strand templates 
 
A retrosynthetic analysis of macrocyclic β-strand template 4.1 using RCM the key cyclisation 
step was performed (Scheme 4.1).  To use RCM chemistry 4.1 must be disconnected to a 
diene precursor (4.3), which in turn is disconnected to two side chain derivatised amino acids 
(4.4 and 4.5).   
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Scheme 4.1 Retrosynthetic analysis of 4.1 
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Based on this general retrosynthetic scheme it was necessary to employ a protecting group 
strategy.  A key requirement of the synthetic route was the ability to vary the N-substituent of 
the macrocycle easily.  An advanced intermediate, with an easily cleaved amine protecting 
group, was required to minimise the number of synthetic steps.  Furthermore, an aldehyde 
was chosen as the warhead for these initial studies.  The strategy was to determine the 
optimum β-strand macrocyclic mimic using an aldehyde and to subsequently append different 
warheads.   
 
A generic synthesis of the macrocyclic templates is shown in Scheme 4.2.  A BOC protected 
amino acid with an olefin in the side chain (4.6) is coupled with an amino acid methyl ester to 
give a dipeptide (4.7).  This is hydrolysed to carboxylic acid 4.8 and coupled with a second 
amino acid containing an olefin in the side chain with the C-terminus protected as a methyl 
ester to give diene 4.9.  RCM of this affords orthogonally protected macrocycle 4.10. 
BOCHN CO2H BOCHN N
H
O R
CO2Me
BOCHN
N
H
O R
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Scheme 4.2. Reagents and Conditions:  (i) HATU, DIPEA, H2N-AA-OMe, DMF; (ii) NaOH, 
THF, H2O, MeOH; (iii) HATU, DIPEA, H2N-AA(allyl)-OMe, DMF; (iv) 3.9, solvent. 
 
With this proposed general synthetic route in hand an in-silico combinatorial library of 
potential macrocycles was prepared.  This was composed of an 18 X 16 array of derivatised 
amino acids synthesised with either N or C protection containing an allyl group in the side 
chain.  An excel spreadsheet was constructed containing all possible macrocyclic compounds 
which could be prepared from the eighteen N-BOC-allyl amino acids and the sixteen allyl 
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amino acid methyl esters (Figure 4.3) using combinatorial chemistry methodology.  Sections 
of the excel spreadsheet are shown in Figures 4.1 and 4.2. 
 
Figure 4.1: In-silico β-strand combinatorial library 
 
Figure 4.2: Virtual library of a 18 X 16 array (288 compounds) 
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Figure 4.3: Side chain allylated amino acids composing the in-silico library 
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4.3: Conformational analysis of the in-silico library 
 
Boltzmann weighted conformational analysis was used to determine if a particular 
macrocycle could adopt the β-strand conformation.  Conformational searches were conducted 
using the Monte Carlo multiple minimum (MCMM) method.  These were run with a 
generalised Born/surface area (GB/SA) water model using the OPLS2001 force field.  
Settings of 1000 steps for the conformational search and up to 500 iterations for the 
minimisation of each generated structure were used.  The default Polak-Ribiere conjugate 
gradient method was used for all minimisations and this was stopped when the default 
gradient convergence threshold of D = 0.05 kJ/(mol*Å) was reached.   
 
The conformation of a specific conformer was determined using a numerical method to 
assign this as either β-strand, β-twist or β-turn.  As shown in Figure 4.4 the distance between 
the NH of the first amino acid and the carbonyl of the central amino acid was used.   
N
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Figure 4.4: Measurement used to define a β-strand or β-turn conformation 
 
An optimal β-strand had a distance of approximately 2.5Ǻ and a clear β-turn occurred when 
the distance was greater than 3.7Ǻ.  As such the definitions used in this thesis are;  
• β-strand is < 3.1Ǻ 
• β-twist (an intermediate case between β-strand and β-turn conformation) is 3.11 to 
3.69Ǻ. 
• β-turn conformation >3.7Ǻ. 
An example of the implementation of this methodology is shown in Figure 4.4b. 
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Figure 4.4b: Distance measured in order to assign a structure as either a β-strand or β-turn  
 
An ensemble of low energy conformers for each structure was generated using a 12kJ/mol/Ǻ 
window.  A Boltzmann weighted conformational analysis was then performed on this 
ensemble, and a weighted percentage of the three different conformations was calculated.  An 
example of this is shown in Table 4.1 with the three far right columns (orange highlighted) 
indicating the percentage of each conformation for a particular macrocycle; 
 
Table 4.1: Conformational analysis using Boltzmann weighted distribution 
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This analysis generated a number of macrocyclic structures which appeared to be moderate to 
excellent β-strand mimics.  The best of these, as discussed below, were selected for synthesis. 
 
4.4: Synthesis of  17-membered Tyr-aa-Gly based macrocycles 
 
As described in Sections 4.2 and 4.3 conformational analysis was used to prioritise the 
macrocycles for synthesis.  The prototype macrocyclic system targeted to validate the 
retrosynthetic strategy in Scheme 4.2 was the Tyr-aa-Gly system of variable ring size (n = 1 
to 3) (4.11).   
BOCHN
N
H
O R
O
O
N
H
CO2Me
4.11
( )n
 
These were attractive targets primarily for two reasons; 
• The ring size could be easily varied by using the appropriate C-allylated amino acid, 
namely, (S)-vinyl-Gly-OMe, (S)-allyl-Gly-OMe or (S)-homo-allyl-Gly-OMe,  
• All three ring sizes (16-18) were predicted by molecular modelling to exist 
predominantly as a β-strand. 
 
The synthesis of the seventeen membered ring macrocycle is shown in Scheme 4.3.  
Commercial N-BOC-O-allyl-Tyr-H was coupled with Val-OMe using standard HATU 
peptide coupling conditions to yield dipeptide 4.12.  The ester was hydrolysed with sodium 
hydroxide and resultant carboxylic acid 4.13 was coupled with (S)-allyl-Gly-OMe to afford 
diene 4.15.  The (S)-allyl-Gly-OMe (4.14) was obtained from an acid catalysed esterification 
reaction of (S)-allyl-Gly based on a published literature procedure.5  RCM was performed 
under a variety of conditions (discussed in Section 4.5) to prepare the ring closed product as 
a mixture of geometric isomers (4.16 and 4.17, discussed in Section 4.6).  Hydrogenation at 
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atmospheric pressure and room temperature, with palladium on carbon, afforded orthogonally 
protected macrocycle 4.18 in quantitative yield. 
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Scheme 4.3. Reagents and Conditions: (i) HATU, DIPEA, Val-OMe, DMF, (86%); (ii) 
NaOH, THF, H2O, MeOH, (97%); (iii) SOCl2, MeOH, (100%); (iv) HATU, DIPEA, (s)-allyl-
Gly-OMe (4.14), DMF, (83%); (v) 10 mol% 3.9, DCM, rt, (0%); or 10 mol% 3.9, DCM, 
reflux, (0%); or 3 x 10 mol% 3.9, 1,1,2-TCE, reflux, (12%, 4.16 and 31%, 4.17); or 3 x 10 
mol% 3.9, 1,1,2-TCE, microwave, (68%, 4.17); (vi) H2, 20 mol% Pd/C, MeOH, EtOAc, 
(100%) 
 
4.5: Microwave assisted RCM 
 
RCM reactions are generally carried out at room temperature or slightly elevated 
temperatures (e.g. refluxing dichloromethane).  However, in cases where cyclisation does not 
proceed moderately elevated temperatures are often required.  The macrocyclisation of diene 
4.15 required an elevated temperature (refluxing 1,1,2-trichloroethane) for several hours to 
obtain its maximum yield.  However, it was postulated that the use of microwave irradiation 
might prove useful to accelerate the reaction rate since Grubbs second generation catalyst 
decomposes at elevated temperature.   
 
Since its widespread introduction during the late 1990s the use of microwave irradiation as a 
non-conventional energy source has been applied to numerous chemical reactions.6-8  
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Microwave heating has also been demonstrated to expedite metal-catalysed organic synthesis.  
Palladium catalysed transformations are the most extensively studied,9-11 but molybdenum,12, 
13 and very recently ruthenium14-16 have also been the focus of research.  The use of 
microwave irradiation in the field of RCM is very much in its infancy.  This was the subject 
of a review published by our laboratory in 2005.17  To the best of our knowledge this was the 
first review of microwave irradiation in the field of RCM chemistry.   
 
With this knowledge in hand microwave irradiation to promote RCM appeared to hold 
significant potential.  This was applied to the synthesis of our target macrocycles (Scheme 
4.3).  The use of microwave irradiation in the RCM reaction of diene 4.15 resulted in both an 
increased yield (50% increase relative to the thermal reaction) and a shorter reaction time 
(one hour instead of the eighteen hours for thermal reflux).   
 
The reason for this reaction rate acceleration, and improved yield, is postulated to be 
primarily due to the fact that microwave heating transfers heat directly into the reaction, 
rather than via the vessel walls.  A thermally unstable such as Grubbs second generation 
catalyst would be expected to be more stable in the reaction media relative to the hot vessel 
walls.  This is in agreement with previous studies which have demonstrated that the use of 
microwave irradiation in the area of RCM results in both an increase in reaction rate and a 
decrease in the rate of catalyst decomposition.17   
 
The microwave irradiation reaction conditions developed in Scheme 4.3 were adopted as the 
optimal conditions for all subsequent macrocyclic RCM reactions discussed in this thesis.  A 
further extension of these conditions was later developed whereby 10 mol% of a Lewis acid 
(chloro-dicyclohexyl borane) was used as an additive to increase the yield of RCM reactions 
(see Section 4.19). 
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4.6: Effect of microwave irradiation on the E/Z isomer ratios  
 
As described throughout this Chapter, macrocyclisation using RCM results in an E/Z mixture 
of product macrocycles.  The geometric isomers 4.16 and 4.17 obtained in Scheme 4.3 were 
separated and the configuration of each geometric isomer assigned on the basis of nOe.  The 
key difference between the two isomers was that an nOe was observed between the α-Gly 
proton and one of methylene protons adjacent to the tyrosine oxygen in only one isomer.  In 
the Z-isomer the Boltzmann weighted distance between these two protons was calculated, 
using Macromodel 9.0, to be 4.9Ǻ, and in the E-isomer it was calculated to be 6.1Ǻ (Figure 
4.5).  Accordingly the assignments were made on this basis.   
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Figure 4.5: Assignment of geometric isomers from Scheme 4.3 
 
A summary of the ratio of geometric isomers obtained in the cyclisation of 4.15 under both 
thermal and microwave heating is shown in Table 5.2.   
Heating meth eld (%) E
Therm
Microwave 68 0:100  
 
Table 5.2: Geometric isomer ratios using thermal and microwave heating 
 
Molecular modelling indicates that the E-isomer is of lower energy and as such this is 
presumed to be the thermodynamic product.  Using thermal heating a 2.5:1 ratio of geometric 
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isomers was obtained and the thermodynamic E-isomer predominated.  This is in agreement 
with the literature18 where Grubbs second generation catalyst is known to favour the 
thermodynamic product.  However, the use of microwave irradiation exclusively gave the 
kinetic product (Z-isomer).  To the best of our knowledge this is the first reported example of 
this microwave effect in the area of RCM.  The reason for this is postulated to be because 
microwave heating increases the reaction such that the kinetic product is exclusively favoured 
over the thermodynamic product. 
 
The chromatographic separation of geometric isomers 4.16 and 4.17 is the only example of 
such a separation in this thesis.  In all other RCM macrocyclisations the geometric isomers 
were inseparable using flash chromatography.  As such the ratio of the isomers was 
quantified by NMR but as they were inseparable, and were used as such, it is not possible to 
assign which is the predominant isomer. 
 
4.7: Synthesis of 16-membered ring Tyr-Val-Gly macrocycle 
 
The synthesis of the sixteen membered ring Tyr-Val-Gly macrocycle required the preparation 
of (S)-vinyl-Gly-OMe (4.27).  This was first attempted using literature precedence19 starting 
from commercially available (L)-methionine (Scheme 4.4).  The amino acid was condensed 
with phthalic anhydride using microwave irradiation to give carboxylic acid 4.19.  This was 
esterified with saturated methanolic hydrogen chloride to give N-phthaloyl-methionine 
methyl ester 4.20.  Oxidation with sodium metaperiodate afforded sulfoxide 4.21 as a 1:1 
mixture of diastereoisomers.  However, in my hands, the reported20 photolysis failed to yield 
desired product 4.22.  In addition, thermal elimination did not yield the desired product.   
This reaction sequence was therefore abandoned. 
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Scheme 4.4. Reagents and Conditions: (i) Phthalic anhydride, H2O, microwave, (100%); (ii) 
HCl(g), MeOH, (100%); (iii) NaIO4, MeOH, H2O, (94%); (iv) 1600W photolysis, MeCN, 
(0%); or Xylene, reflux, (0%) 
 
The required (S)-vinyl-Gly-OMe 4.27 was successful synthesised as shown in Scheme 4.5.  
Commercially available Met-OMe was orthogonally protected to give N-CBZ amino acid 
4.23.  Oxidation with sodium metaperiodate gave sulfoxide 4.24 as a 1:1 mixture of 
diastereoisomers.  This was thermally eliminated under vacuum following a literature 
procedure,21 and the distillate treated with 6M aqueous hydrochloric acid, at reflux, to give 
vinyl amino acid 4.26.  Acid catalysed esterification furnished the hydrogen chloride salt of 
amine 4.27.  Peptide coupling of this to previously prepared dipeptide carboxylic acid 4.13, 
using HATU methodology gave diene 4.28.  This was ring closed using microwave 
irradiation to yield macrocycle 4.29 as a 1:3.8 mixture of geometric isomers by NMR.  These 
isomers were not separable and were subjected to hydrogenation at atmospheric pressure and 
room temperature to give the di-protected saturated macrocycle 4.30. 
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Scheme 4.5. Reagents and Conditions: (i) Benzyl chloroformate, NaHCO3, EtOAc, H2O, 
(98%); (ii) NaIO4, H2O, MeOH, (100%); (iii) thermal elimination (kugelrohr), (20%); (iv) 
6M HCl(aq), (71%); (v) SOCl2, MeOH, (100%); (vi) HATU, DIPEA, 4.13, DMF, (76%); (vii)  
or 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (32%); (viii) H2, 20 mol% Pd/C, MeOH, EtOAc, 
(52%) 
 
4.8: Attempted synthesis of 18-membered ring Tyr-Leu-Gly macrocycle of using homo-
allyl glycine 
 
The synthesis of the eighteen membered ring analogue of 4.18 and 4.30 using the established 
synthetic methodology described in Schemes 4.3 and 4.5 required the preparation of (S)-
homo-allyl-Gly-OMe.  As shown in Scheme 4.6 this was attempted using transition metal 
coordination chemistry following literature procedures.22 
 
Commercially available N-BOC-(L)-proline was coupled with 2-aminobenzophenone using 
HATU to give 4.31.  The BOC protecting group was cleaved using TFA in DCM and 
subsequent salt exchange achieved by neutralisation, organic extraction and treatment with 
ethereal hydrogen chloride gave the hydrochloride salt of amine 4.32.  This was N-benzylated 
using benzyl bromide to afford 4.33.  Preparation of the Gly-Ni(II)-BPB complex 4.34 was 
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achieved by reacting 4.33 with nickel (II) nitrate hexahydrate and glycine under basic 
conditions.  However, allylation of this using potassium hydroxide as base under reaction 
conditions developed by Gu et al23 afforded a complex mixture of products.  NMR and MS 
analysis of the crude product indicated the desired compound was present but its purification 
and isolation was very problematic.  This result motivated development of alternative 
methodology for the synthesis of macrocycle 4.42 (Scheme 4.7).  The reaction sequence in 
Scheme 4.6 was not pursued further. 
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Scheme 4.6. Reagents and Conditions: (i) HATU, DIPEA, 2-aminobenzophenone, DMF, 
(69%); (ii) a) 10% TFA, DCM, b) HCl, Et2O (100%); (iii) benzyl bromide, Et3N, THF, 
(72%); (iv) KOH, Ni(NO3)2.6H2O, glycine, MeOH, (42%); (v) NaOH, 4-bromo-but-1-ene, 
DMF, (0%) 
 
4.9: Synthesis of 18-membered ring Tyr-Leu-Gly macrocycle 
 
As shown in Scheme 4.7 macrocycle 4.42 was prepared using slightly different methodology 
to that shown in Schemes 4.3 and 4.5.  As the synthesis of (S)-homo-allyl-Gly-OMe was 
problematic instead of varying the chain length of the amine to vary the macrocyclic ring 
size, an alternative strategy of changing the length of the allyl chain on the tyrosine oxygen 
was used.   
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N-BOC-O-homo-allyl-Tyr-OMe 4.36 was prepared by allylation of commercial N-BOC-Tyr-
OMe with 4-bromo-but-1-ene.  This allowed the larger homologue of the 17-membered 
macrocycle 4.18 to be synthesised using (S)-allyl-Gly-OMe, thus negating the requirement to 
synthesise (S)-homo-allyl-Gly-OMe.  Base hydrolysis of methyl ester 4.36, followed by a 
HATU peptide coupling with Leu-OMe, gave dipeptide 4.38.  Sodium hydroxide hydrolysis 
gave carboxylic acid 4.39 which was coupled with (S)-allyl-Gly-OMe, using standard HATU 
reaction conditions, to give diene 4.40.  RCM was achieved using Grubbs second generation 
catalyst, microwave irradiation and a Lewis acid additive (chloro-dicyclohexylborne) to 
afford unsaturated macrocycle 4.41 in quantitative yield as a 1:1.9 mixture (by NMR) of 
geometric isomers.  These were not separated and the mixture was hydrogenated under 
standard conditions to yield the saturated orthogonally protected macrocycle 4.42 in moderate 
yield. 
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Scheme 4.7. Reagents and Conditions: (i) K2CO3, 4-bromo-but-1-ene, DMF, (27%); (ii) 
NaOH, THF, H2O, MeOH, (85%); (iii) HATU, DIPEA, Leu-OMe, DMF, (64%); (iv) NaOH, 
THF, H2O, MeOH, (96%); (v) HATU, DIPEA, (s)-allyl-Gly-OMe, DMF, (84%); (vi) 3 x 10 
mol% 3.9, 10 mol% chlorodicyclohexylborane, 1,1,2-TCE, microwave, (100%); (vii) H2, 20 
mol% Pd/C, MeOH, EtOAc, (26%) 
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4.10: Synthesis of 17-membered ring Tyr-Leu-Gly, Tyr-Phe-Gly, Tyr-cyclohexane-Gly 
macrocycles 
 
As shown in Scheme 4.8 a range of macrocycles 4.49, 4.54 and 4.58 were prepared with (L)-
leucine, (L)-phenylalanine and cyclohexane in the P2 position to investigate the effect of 
changing the P2 amino acid.  Leu-OMe and Phe-OMe were commercially available, however 
1-amino-cyclohexane-1-methyl ester (4.44) was prepared from its corresponding amino acid 
(4.43) using acid catalysed esterification following a literature precedence.24  Each of these 
methyl esters was coupled to commercially available N-BOC-Tyr-O-Allyl-H, using HATU 
peptide coupling methodology, to give dipeptides 4.45, 4.50 and 4.55.  Each of these was 
hydrolysed under basic conditions, and the resultant carboxylic acids 4.46, 4.51 and 4.56 
coupled with (S)-allyl-Gly-OMe to give their respective dienes (4.47, 4.52 and 4.57).  These 
three dienes were ring closed using Grubbs second generation catalyst and microwave 
irradiation.  To the RCM reactions of the leucine and cyclohexane dienes (4.47 and 4.57) 10 
mol% of Lewis acid chloro-dicyclohexylborane was also added.  This was not added to the 
phenylalanine RCM reaction as the Lewis acid methodology was not established at that time.  
These RCM reactions afforded the three unsaturated macrocycles 4.48, 4.53 and 4.58 as 
mixtures of geometric isomers.  For R = Leu, 1:9 ratio, R = Phe, 1:6.25 ratio and R = Cy, 
1:6.5 ratio.  The leucine and phenylalanine macrocycles (4.48 and 4.53) were then 
hydrogenated under standard conditions to yield saturated macrocycles 4.49 and 4.54.  
Cyclohexane macrocycle 4.58 was not hydrogenated as molecular modelling indicated this 
was a very poor β-strand mimetic and as such no further work was performed on this 
macrocycle. 
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Scheme 4.8. Reagents and Conditions: For R = Leu (ii) HATU, DIPEA, Leu-OMe, DMF, 
(80%); (iii) NaOH, THF, H2O, MeOH, (97%); (iv) HATU, DIPEA, (s)-allyl-Gly-OMe, DMF, 
(97%); (v) 3 x 10 mol% 3.9, 10 mol% chloro-dicyclohexyl borane, 1,1,2-TCE, microwave, 
(91%); (vi) H2, 20 mol% Pd/C, MeOH, EtOAc, (98%). 
For R = Phe (ii) HATU, DIPEA, Phe-OMe, DMF, (81%); (iii) NaOH, THF, H2O, MeOH, 
(93%); (iv) HATU, DIPEA, (s)-allyl-Gly-OMe, DMF, (65%); (v) 3 x 10 mol% 3.9, 1,1,2-
TCE, microwave, (51%); (vi) H2, 20 mol% Pd/C, MeOH, EtOAc, (25%). 
For R = Cy (i) SOCl2, MeOH, (100%); (ii) HATU, DIPEA, 4.44 , DMF, (59%); (iii) NaOH, 
THF, H2O, MeOH, (98%); (iv) HATU, DIPEA, (s)-allyl-Gly-OMe, DMF, (76%); (v) 3 x 10 
mol% 3.9, 10 mol% chloro-dicyclohexyl borane, 1,1,2-TCE, microwave, (31%).  
 
4.11: Synthesis of 17-membered ring Tyr-Val-β-Gly macrocycle 
 
Molecular modelling studies using the induced fit protocol (see Section 5.1) indicated that 
although the macrocycles created in the in-silico library (see Section 4.2) were excellent β-
strand mimics in each case the distance between the electrophilic warhead and the active site 
cysteine was slightly longer than that of the acyclic β-strand calpain inhibitors described in 
Chapter 2.  As such it was postulated that the use of a β-amino acid warhead would reduce 
this distance as the extra methylene group would extend the aldehyde slightly further away 
from the β-strand backbone.  It was anticipated that this would in turn impart better calpain 
inhibition to the macrocycle.  As shown in Scheme 4.9 the synthesis of such a macrocycle 
(4.61) was achieved starting with commercially available (S)-3-amino-hex-5-enoic acid.  This 
was esterified using methanolic hydrogen chloride to give the C-protected β-amino acid 4.59.  
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HATU mediated peptide coupling with previously prepared carboxylic acid 4.13 gave diene 
4.60 which was cyclised to give 4.61 as a mixture of geometric isomers (1:9.1) on treatment 
with Grubbs second generation catalyst and microwave irradiation.  Hydrogenation under 
standard conditions gave the required saturated orthogonally protected β-amino acid 
macrocycle 4.62. 
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Scheme 4.9. Reagents and Conditions: (i) SOCl2, MeOH, (86%); (ii) HATU, DIPEA, 4.13, 
DMF, (83%); (iii) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (66%); (iv) H2, 20 mol% Pd/C, 
MeOH, (84%). 
 
4.12: Synthesis of 19-membered ring Tyr-Val-Cys-macrocycle 
 
As shown in Schemes 4.10 – 4.13 a series of P1 analogues of 4.18 (compounds 4.66, 4.71, 
4.75, and 4.80) were selected for synthesis based on their excellent β-strand scores from in-
silico conformational analysis (Section 4.3).   
 
Scheme 4.10 details the synthesis of macrocycle 4.67 which incorporates cysteine at the P1 
position.   The synthesis of allyl cysteine was achieved following literature procedures.25  
Commercially available N-BOC-Cys-OMe was allylated with allyl bromide using 
triethylamine as a mild base to give orthogonally protected allyl cysteine 4.63 which was 
treated with a saturated ethereal hydrogen chloride solution to give the hydrogen chloride salt 
of amine 4.64.  Coupling with previously prepared carboxylic acid 4.13, using HATU peptide 
coupling methodology, furnished diene 4.65.  Ring closure was achieved using Grubbs 
second generation catalyst and microwave irradiation to afford unsaturated macrocycle 4.66 
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as a 1:1.7 mixture of geometric isomers.  The saturated macrocycle 4.67 was obtained by 
hydrogenation of 4.66 at atmospheric pressure and room temperature. 
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Scheme 4.10. Reagents and Conditions: (i) Et3N, allyl bromide, DCM, (55%); (ii) HCl(g), 
Et2O, (100%); (iii) HATU, DIPEA, 4.13, DMF, (97%); (iv) 3 x 10 mol% 3.9, 1,1,2-TCE, 
microwave, (72%); (v) H2, 20 mol% Pd/C, MeOH, EtOAc (44%). 
 
4.13: Synthesis of 19-membered ring Tyr-Val-Ser-macrocycle 
 
Scheme 4.11 describes the synthesis of macrocycle 4.72 which contains serine at the P1 
position.   Allylation of commercially available N-BOC-Ser-OMe proved to be more 
problematic than allylation of the direct cysteine analogue (4.63).  Attempted base mediated 
allylation, using either sodium hydride or triethylamine as the base, with allyl bromide 
resulted in no reaction and only starting material was recovered in quantitative yield.  
However, allylated serine (4.68) was successfully obtained under neutral conditions using a 
literature procedure.26  First the mixed anhydride of allyl alcohol and ethyl chloroformate was 
prepared (allyl ethyl carbonate) and this was reacted with N-BOC-Ser-OMe, 
triphenylphosphine and allyl palladium (II) chloride dimer, via a П-allylpalladium complex 
intermediate, to give orthogonally protected allyl serine 4.68.    The N-BOC protecting group 
was cleaved using a 4M solution of hydrogen chloride in 1,4-dioxane to give the hydrogen 
chloride salt of amine 4.69.  This was coupled with previously synthesised carboxylic acid 
4.13 using HATU mediated peptide coupling to give diene 4.70.  RCM using Grubbs second 
generation catalyst and microwave irradiation gave unsaturated macrocycle 4.71 as a 1:4.7 
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mixture of geometric isomers.  Hydrogenation of this using palladium on carbon catalyst 
gave saturated macrocycle 4.72. 
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Scheme 4.11. Reagents and Conditions: (i) NaH, allyl bromide, DMF (0%); or Et3N, allyl 
bromide, DCM (0%); or a) allyl alcohol, ethyl chloroformate, Et3N, Et2O b) allyl palladium 
chloride, PPh3, THF (21%); (ii) 4M HCl, Dioxan, (87%); (iii) HATU, DIPEA, 4.13, DMF, 
(62%); (iv) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (23%); (v) H2, 20 mol% Pd/C, MeOH, 
EtOAc (100%). 
 
4.14: Attempted synthesis of  23-membered ring Tyr-Val-Tyr-macrocycle 
 
An attempted route to the synthesis of the P1 tyrosine analogue of 4.18 is shown in Scheme 
4.12.  The required O-allyl-(L)-Tyr-OMe (4.73) was prepared from commercially available 
N-BOC-O-allyl-(L)-Tyr-H using an acidic methanolic solution to achieve a simultaneous N-
BOC cleavage and esterification reaction in one pot.  Treatment of the resultant 
hydrochloride salt of amine 4.73 with carboxylic acid 4.13 and HATU gave diene 4.74.  
RCM of this diene using using Grubbs second generation catalyst and microwave irradiation 
did not yield any ring closed product.  Only starting material was recovered and as such the 
reaction sequence was abandoned. 
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Scheme 4.12. Reagents and Conditions: (i) SOCl2, MeOH, (96%); (ii) HATU, DIPEA, 4.13, 
DMF, (17%); (iii) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (0%). 
 
4.15: Attempted synthesis of  21-membered ring Tyr-Val-Gln-macrocycle 
 
An attempted route to the synthesis of the P1 glutamine analogue of 4.18 is shown in Scheme 
4.13.   Commercially available Glu-OMe was N-BOC protected using BOC anhydride and 
triethylamine to afford orthogonally protected amino acid 4.76 using an established  
procedure.27  The side chain acid of this was coupled with allyl amine and HATU to give the 
required diprotected allyl Gln 4.77.  The N-BOC protecting group was cleaved using 
saturated ethereal hydrogen chloride to give the hydrogen chloride salt of amine 4.78.  This 
was reacted with dipeptide carboxylic acid 4.13 and HATU to yield diene 4.79.  However, 
ring closure of this diene using Grubbs second generation catalyst and microwave irradiation 
did not yield the desired macrocycle.  As discussed in Sections 4.16 and 4.20 this is 
postulated to be due to the formation of a catalyst deactivating chelate.  No further work was 
performed on this macrocyclic system. 
. 
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Scheme 4.13. Reagents and Conditions: (i) (BOC)2O, Et3N, Dioxan, H2O, (97%); (ii) HATU, 
DIPEA, allyl amine, DMF, (14%); (iii) HCl(g), Et2O, (100%); (iv) HATU, DIPEA, 4.13, 
DMF, (38%); (v) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (0%). 
 
 
4.16: Effect of substrate chelation on RCM 
 
A number of dienes both within this thesis and the Abell research group in general have 
failed to ring close when subjected to RCM.  Analysis of these dienes reveals a common 
theme (Figure 4.6).   
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Figure 4.6: Dienes which fail to cyclise using RCM 
Generally dienes that contain either an allyl amide or allyl ester result in either low yields of 
ring closed product or no ring closed product at all.  This observation leads us to propose that 
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dienes of this type form a stable, catalyst deactivating, six membered chelate during the RCM 
catalytic cycle (Figure 4.7) for which there is some precedence. 
Ru
X
R
O
O
Ru
X
R
O
Ru
X
R
O
Ru
X
R
X
Chelation deactivates 
catalyst to RCM  
Figure 4.7: Proposed catalyst deactivating chelate 
The chelation of oxygen functionalities to ruthenium during metathesis was recognised very 
early by both Grubbs et al.28 and Schrock et a.l29 during the development of RCM 
methodology.  However, such chelates are not well documented in the literature.  Often, as 
discussed in Section 7.1, the failure of RCM in substrates of this type is assigned to the fact 
that these dienes adopt a conformation not conducive to cyclisation, i.e. an extended 
conformation across the C1-N1 amide bond with respect to the rest of the molecule (Figure 
7.1).  It is proposed in this thesis that this is not the primary reason why such dienes fail to 
undergo RCM.  Instead it is suggested that the reason why such substrates fail to ring close is 
the result of chelate formation.   
 
This thesis also proposes that there is a growing body of evidence related to the existence of 
such chelates, and that these are indeed catalyst deactivating chelates.  There are three 
particularly pertinent examples of published work which support this hypothesis; 
 
1. As shown in Scheme 4.14 Hoveyda et al30, 31 serendipitously isolated a stable, 
catalytically active species (4.83) from the attempted ring opening metathesis, cross 
metathesis reaction of 2-isopropoxystyrene (4.82) with octadiene (4.81) in the 
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presence of Grubbs first generation catalyst (3.5).  Complex 4.83 was active in 
metathesis reactions and was of sufficient stability to be recovered efficiently by 
chromatography.  This clearly demonstrates the potential of intramolecular chelating 
effects to interfere dramatically with a metathesis reaction. 
 
OPh O Ru
P(Cy)3
O
Cl
Cl
+
5 mol% 3.5
4.81 4.82 4.83  
Scheme 4.14: Isolation of 4.83 
2. This chelation principle was extended to prepare, by ligand exchange, the 
chromatographically stable Grubbs second generation catalyst analogue 4.84.32, 33 
This work proves that Grubbs second generation catalyst (3.9) is also capable of 
participating in a chelation reaction. 
Ru
NN MesMes
O
Cl
Cl
4.84  
3. Chelate formation has been used in cross metathesis to successfully to obtain 
chemoselectivity (Scheme 4.15).34, 35  The cross metathesis of an hydroxy-olefin 4.85 
and an acetoxy-olefin 4.86 with acrolein 4.87 under identical conditions yielded 
different products.  Alcohol 4.85 was functionalised twice to afford 4.88 whereas 4.86 
yielded only the product of a single cross coupling 4.89.  
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Scheme 4.15: Chemo-selective cross metathesis 
 
It was proposed35 that selectivity could arise through either deactivation of one of the carbon- 
carbon double bonds by the electron-withdrawing acetoxy group or, as work within our 
laboratory in the field of RCM would suggest, through the formation of an unreactive six-
membered catalyst deactivating chelate (Figure 4.8).  This complex results in selective cross 
metathesis of the homo-allylic unit in 4.86 only.  This is because any chelate derived from 
this would require seven-membered ring formation.  As such this would be expected to be 
much less stable than the six membered ring chelate from the allylic moiety.  In the case of 
hydroxy substrate 4.85 no such stable ring chelates are possible, and thus unselective CM is 
observed. 
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O O
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OO Ru
OO Ru
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Chelation deactivates 
catalyst to RCM
 
Figure 4.8: CM chemoselectivity from chelate formation. 
4.17: Design and synthesis of a model system to understand chelation effects in RCM 
As described in Section 4.16 allyl amides or allyl esters are problematic RCM substrates as 
they form catalyst deactivating chelates.  As such a test system to establish if the heteroatom 
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(i.e the nitrogen or oxygen in the amide or ester) is the key constituent of a substrate that  
forms a catalyst deactivating chelate was devised.  As shown in Scheme 4.16 the two amide 
dienes 4.91 and 4.93 were prepared by HATU mediated peptide coupling of 5-hexenoic 
acid/allyl amine and 4-pentenoic acid/homo-allyl amine, respectively.  
HCl.H2N N
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NH2
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N
H
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N
H
O
N
H
O
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O
N
H
O
N
H
O
(i) (ii)
4.90
X
(ii)
(iii) (iv) X
(iv)
4.91
4.92
4.98
4.93
4.94  
 
Scheme 4.16. Reagents and Conditions: (i) HATU, DIPEA, 4-pentenoic acid, DMF, (78%); 
(ii) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (0%); (iii) HATU, DIPEA, 5-hexenoic acid, 
DMF, (75%); (iv) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (0%). 
 
The RCM substrates (4.91 and 4.93) are both capable of forming six membered chelates.  
However, the six membered chelate formed by 4.93 results from the allyl amide moiety and 
as such is a chelate containing an heteroatom whereas the six membered chelate formed by 
4.91 results from the allyl moiety and as such the chelate contains no heteroatom (Figure 4.9) 
O
Ru
NH
N
H
O
N
H
O
O
Ru
NH
4.91
4.93  
Figure 4.9: Chelates formed by amides 4.91 and 4.93 
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If the presence of the heteroatom was of primary importance to forming the stable catalyst 
deactivating chelate then 4.91 would be expected to ring close whereas 4.93 would not.  
However, as shown in Scheme 4.16 neither of these substrates yielded ring closed product 
and instead an intermolecular CM reaction occurred.  This reaction was characterised by LC-
MS analysis and presumably the cross metathesis reaction involved the olefins that do not 
participate in six membered ring chelation.  This test system therefore suggests that the 
ability to form a six membered chelate is the dominant effect rather than the presence of a 
heteroatom in the chain that forms the chelate.  This knowledge was then used to improve the 
yields of the macrocycles as discussed in Section 4.19.   
 
4.18: Strategies to avoid catalyst deactivation from substrate chelation 
 
With this chelation hypothesis in hand it was deemed necessary to either design new 
synthetic strategies or develop methodology, which would avoid or destabilise chelate 
formation.  The two strategies devised were the use of a Lewis acid to make the chelate more 
labile (Section 4.19) and the redesign of a synthetic route to ensure there are no dienes which 
are capable of chelation formation (Section 4.20). 
 
4.19: Use of a Lewis acid as an additive in RCM reactions 
 
If chelate formation is a problem a classical method to circumvent such an issue is to add a 
Lewis acid to destabilise the chelate.  As such it was postulated that if a Lewis acid was 
added to the RCM reaction media then this should destabilise the catalyst deactivating chelate 
and thus facilitate productive RCM.  However, one major concern was that the additive must 
also be compatible with the RCM catalyst and that it must also undergo kinetically labile 
coordination with the carbonyl group.  During early metathesis methodology development 
Furstner et al36 demonstrated that strong Lewis acids such as TiCl4 or SnCl4 decomposed 
metathesis catalysts, whereas Ti(OiPr)4 was used successfully to increase RCM reaction 
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yields.  Furthermore, Vedrenne et al37 studied a number of Lewis acids to improve the yields 
of CM reactions, where one of the partners was an allylic carbamate or amide.  From this 
study, it was determined that boron-based Lewis acids were better candidates for promoting 
metathesis reactions than titanium-based Lewis acids.  In addition, chloro-dicyclohexyl 
borane was the best of the boron-based Lewis acids studied and as such this was adopted as 
the Lewis acid additive in our work.   
 
This strategy was investigated using five different dienes.  As shown in Table 4.3 in all five 
reactions where chloro-dicyclohexyl borane was added an increase in yield was observed.   
 
Furthermore, the stoichiometry of Lewis acid required to obtain the maximum increase in 
yield (compound 6.4) agreed with those previously published37 in the CM area.  Optimum 
yields were obtained using a sub equimolar quantity of the Lewis acid.   
 
Moreover, the concept that addition of  a Lewis acid to a diene which fails to ring close under 
microwave irradiation conditions would then facilitate this to do so was validated by another 
member of the group.  Compound MKL 2.4 was isolated, albeit in low yield, when Lewis 
acid was added.  Without addition of Lewis acid no ring closed product was obtained. 
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Compound Compound number Reaction conditions 
Yield 
(%) 
3 X 10 mol% 3.9, 
µ-wave 29 
3 X 10 mol% 3.9, 
10 mol% (Cy)2BCl, 
µ-wave 
65 N
H
N
H
O
O
O
N
H
CO2MeS
O
O
F
 
6.4 
3 X 10 mol% 3.9, 
100 mol% (Cy)2BCl, 
µ-wave 
38 
 
3 X 10 mol% 3.9, 
µ-wave 43 BOCHN
N
H
O
O
O
N
H
CO2Me
 
4.47 
3 X 10 mol% 3.9, 
10 mol% (Cy)2BCl, 
µ-wave 
91 
 
3 X 10 mol% 3.9, 
µ-wave N/A BOCHN
N
H
O
O
O
N
H
CO2Me
 
4.40 
3 X 10 mol% 3.9, 
10 mol% (Cy)2BCl, 
µ-wave 
100 
 
3 X 10 mol% 3.9, 
µ-wave 42 
BOCHN
N
H
O
O
N
H
CO2Me
O O
S
 
MKL 2.7 
3 X 10 mol% 3.9, 
10 mol% (Cy)2BCl, 
µ-wave 
50 
 
3 X 10 mol% 3.9, 
µ-wave 0 
CBZHN
N
H
O
O
N
H
CO2Me
O N
H  
MKL 2.4 
3 X 10 mol% 3.9, 
10 mol% (Cy)2BCl, 
µ-wave 
14 
 
Table 4.3: Effect of Lewis acid additive on the yield of RCM 
 
4.20: Chain length alteration to avoid catalyst deactivation from substrate chelation 
 
As described in Section 4.18 a strategy to circumnavigate the formation of a catalyst 
deactivating chelate is to ensure that the synthetic route avoids the formation of a stable 
chelate.  An example of the modification of a synthetic route to avoid possible chelate 
formation is shown in Figure 4.10.  As previously described, diene 4.96 did not undergo 
RCM.  This was postulated to be because diene 4.96 forms a stable catalyst deactivating 
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chelate.  A strategy envisaged to circumnavigate this problem was to change the chain length 
of each olefin (i.e 4.95 compared to 4.96) so that chelate formation is no longer possible.  
RCM of 4.95 would yield the same macrocyclic product (after subsequent hydrogenation).  
However, synthesis of this exact example was not performed as it required significant 
synthetic effort to prepare the required precursors to 4.95.   
BOCHN
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N
H
O
CO2MeBOCHN
N
H
O
O
N
H
N
H
O
CO2Me
Instead of
4.95 4.96  
Figure 4.10: Avoidance of chelation by changing chain length 
 
In order to validate the concept illustrated in Figure 4.10 the higher homologue of 4.80 was 
prepared (Scheme 4.17).  As described in Scheme 4.13, the precursor diene to 4.80 (4.79) 
failed to ring close because it forms a stable chelate.  As shown in Figure 4.11 chelate 
formation can be avoided by incorporation of an extra methylene group.  The only difference 
between diene 4.79 and diene 4.101 is that 4.101 contains an extra methylene group so that 
4.101 can no longer form a six membered chelate.   
BOCHN
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O
N
H
CO2Me
O NHO
BOCHN
N
H
O
O
N
H
CO2Me
O NHO
Instead of
4.101 4.79  
Figure 4.11: Avoidance of chelation by changing chain length 
 
Before diene 4.101 could be synthesised the preparation of but-3-enylamine (4.98) was first 
required.  This was successfully achieved using two different methods.  In method one, allyl 
cyanide was reduced with a combination of lithium aluminium hydride and aluminium 
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trichloride to give amine 4.98 as the hydrochloride salt after work-up and subsequent 
treatment with ethereal hydrogen chloride.  Although successful this was deemed to be 
potentially problematic on a large scale due to the toxicity of allyl cyanide.  In addition, the 
aqueous work-up/isolation of 4.98 was not trivial.  As such a second method was used, based 
on literature procedures,38 to prepare large quantities of 4.98.  Potassium phthalimide, 
prepared from phthalimide using potassium hydroxide, was allylated with 4-bromo-1-butene 
to afford isoindole 4.97 which gave 4.98 on treatment of this with hydrazine.  However, 
attempted coupling of 4.98 with commercially available N-BOC-Glu-OMe and HATU gave 
returned starting material only after aqueous work-up.  However, EDC peptide coupling gave 
required amide 4.99, albeit it in relatively low yield.  Amine 4.100 was obtained by using 
acidic methanol to cleave the N-BOC protecting group of 4.99.  This was coupled to 
carboxylic acid 4.13 using standard EDC peptide coupling conditions to afford diene 4.101.  
This was ring closed using Grubbs second generation catalyst and microwave irradiation to 
yield macrocycle 4.102 as a 1:2 mixture (by NMR) of geometric isomers.  Modelling of this 
macrocycle indicated that this would not be a good β-strand mimic and as such no further 
synthesis was performed on this macrocycle.  However, this reaction sequence validated the 
concept that changing the chain length of the olefin avoids chelate formation and allows 
productive RCM to be achieved. 
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Scheme 4.17. Reagents and Conditions: (i) LiAlH4, AlCl3, Et2O, (54%); (ii) a) KOH, EtOH; 
b) 4-bromo-1-butene, DMF (96% over 2 steps); (iii) Hydrazine monohydrate, EtOH, (37%); 
(iv) HATU, DIPEA, N-BOC-Glu-OMe, DMF (0%); or EDC, HOBt.H2O, DIPEA, N-BOC-
Glu-OMe, DMF, (18%); (v) SOCl2, MeOH, (100%); (vi) EDC, HOBt.H2O, DIPEA, 4.13, 
DMF, (54%); (vii) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (17%). 
 
4.21: Conclusions and further work 
 
Novel calpain inhibitor motif 4.1 was devised.  This motif was designed to conformationally 
constrain a tripeptide into a β-strand conformation whilst allowing it to form three critical β-
strand hydrogen bonds to the enzyme.  Retrosynthetic analysis of this template was 
undertaken and an in-silico combinatorial library of two hundred and eighty eight possible β-
strand templates was prepared.  Conformational analysis of this library was performed and 
from this a number of excellent β-strand templates were identified. 
 
The synthesis of ten β-strand templates, chosen on the basis of their excellent percentage β-
strand scores, was successfully achieved.  However, the synthesis of two templates (4.75 and 
4.80) using ring closing metathesis failed.  The reason for this is postulated to be due to the 
formation of a six membered catalyst deactivating chelate. 
 
New microwave irradiation methodology was developed for the ring closure of tripeptide 
dienes using RCM chemistry.  Moreover the use of microwave irradiation resulted in an 
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interesting observation.  In the only example where the chromatographic separation of 
geometric isomers (4.16 and 4.17) from the RCM reaction was possible, microwave 
irradiation resulted in the exclusive formation of the kinetic isomer.  This is of particular note 
as Grubbs second generation is known to favour the thermodynamic product under non-
microwave irradiation conditions.  To the best of our knowledge this is the first reported 
example of such an effect.  This certainly warrants further studies. 
  
Two methods were identified to overcome the formation of a postulated six-membered 
catalyst deactivating chelate.  Addition of Lewis acid chloro-dicyclohexyl borane to the RCM 
reaction media to destabilise the chelate and changing the chain length of the olefins to avoid 
chelate formation were both successful.  In particular the use of a Lewis acid was extremely 
effective.  In all cases where comparable data was obtained this resulted in an increase yield 
of ring closed product. 
 
A vast amount of further work could be undertaken in this area.  There are still a large 
number of novel β-strand templates, which were identified by conformational analysis and 
which could be synthesised using the synthetic methodologies developed in this Chapter. 
   
Furthermore, factors that govern the geometric isomer ratio from the RCM reaction remain 
unknown.  Studies to determine exactly what influences this ratio would be of interest to the 
wider synthetic chemistry community.  
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5.1: Use macrocyclic calpain inhibitors as anti-cataract agents 
 
Chapter 4 described the synthesis of a range of macrocyclic β-strand mimics.  With these in 
hand, the focus of the research was changed from the synthesis of β-strand mimics to the 
elaboration of these into a range of macrocyclic calpain inhibitors, which could potentially be 
used as anti-cataract agents.  This chapter describes the synthesis of a range of macrocyclic 
calpain inhibitors with the objective of identifying a potential human anti-cataract therapeutic.   
 
As described in Section 1.4 calpain over-activation is thought to be involved in a number of 
human diseases of which cataract formation, and progression, is one example.  There are a 
number of mechanisms by which cataracts are thought to be formed and subsequently 
develop.  Calpain II mediated proteolysis is one which is currently receiving considerable 
attention in the literature.1-4  As such the scientific rationale upon which our group embarked 
on designing and synthesising  an anti-cataract agent is depicted schematically in Figure 5.4. 
 
 
Figure 5.4: Schematic diagram to illustrate the role of calpain in cataract development 
The hypothesis is that an “insult” to the eye, which can originate from many possible sources 
such as old age, diabetes, U.V. radiation and genetic factors amongst many others, results in 
increased levels of calcium in the eye.  This increased calcium concentration activates lens 
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calpain (under homeostatic control this lens calpain is present in its inactive form).  This 
calpain “over-activation”, in turn leads to the proteolysis of crystallins.   
There are four major families of crystallins, referred to as the alpha, beta, gamma and delta 
crystallins.  In the lens of the eye, crystallins are water-soluble structural proteins and, under 
normal conditions, these crystallins are transparent and show a high degree of regular packing.  
However, proteolysis results in changes to the crystallin structure, which in turn leads to 
insolubilisation and aggregation.  It is this insolubilisation that results in light scattering and 
the condition known as cataract.  It is postulated that administration of a calpain inhibitor 
would reverse this over-activation of calpain, and hence stop the proteolysis of the crystallins, 
thus preventing or slowing down cataract formation/development. 
There is significant evidence that such an approach could result in an effective anti-cataract 
drug.  Over the past two decades, several published studies have suggested that calpain II is 
involved in animal cataract. Early investigations established that calpain II proteolysed 
crystallins and that calpain inhibitors could prevent the progression of rodent cataract induced 
by Ca2+ mediated activation of calpain II.1, 5, 6  Taken together with more recent studies,7, 8 it 
is now generally accepted that calpain II plays a major role in rodent lens opacification.  
Furthermore, several studies have shown calpain II to be the major calpain activated in 
murine diabetic cataractogenesis.7, 9  In addition, calpain II has recently been shown to induce 
cataractogenesis and cleave crystallins in the lenses of a variety of other mammalian species, 
namely, mice and guinea pigs,10, 11 calves,12 monkeys and rabbits.13  
 
Calpain II in human lenses has been shown to be the major calpain in the epithelial cells of 
human lenses showing age-related cortical cataract.14   Furthermore, using cultured human 
lenses, it has been shown that an increase in Ca2+ levels in these lenses, within physiological 
limits, results in cortical opacification accompanied by a significant loss of crystallins from 
the soluble fraction of these lenses.2  Moreover, analysis of the insoluble fraction from these 
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lenses reveals high levels of proteolysed vimentin. This cytoskeletal protein is a lens substrate 
of calpain II and the proteolysis of it is taken as a biomarker of enzyme activation.8  Taken 
overall, these results strongly suggest that calpain II plays at least a role in some human 
cataract. 
 
5.2: Use of molecular modelling to design macrocyclic calpain inhibitors
 
As eluded to in many sections of this thesis the chemical structure of a calpain inhibitor 
consists of three distinct segments (Figure 5.1). 
 
1. A central β-strand backbone or template which is capable of forming the required 
hydrogen bonds to the enzyme. 
2. Two address regions specific for calpain recognition.  A wide variety of groups can be 
employed as address region 1 but usually a rather hydrophobic aromatic group is used.  
Typically address region 2 is an electrophilic centre which undergoes nucleophilic 
attack by the cysteine sulfur.  The most commonly utilised functional group is an 
aldehyde.             
 
 
Figure 5.1: Generic calpain inhibitor 
 
The macrocyclic β-strand templates, of generic structure 4.1, outlined in Chapter 4 were 
designed using these principles.  The challenge in this chapter was to design additional 
recognition and warhead moieties, using molecular modelling, in order to confer potent 
calpain inhibition to the macrocyclic β-strand templates synthesised in Chapter 4.   
β-strand  
template 
A d d r e s s  
r e g io n  1
A d d r e s s  
r e g io n  2
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N
H O
N
H O
R
N
H
Warhead
Additional Recognition
4.1   
The SP/XP docking protocol, described in Section 2.2, used to model the dipeptides 
synthesised in Chapter 2 is not suitable for modelling the macrocycles contained in the 
virtual library.  The reason for this is that the tripeptide macrocycles extend further into the 
calpain binding pocket than the dipeptides do.  As such the macrocycles interact with 
residues in the P3/4 binding pocket of the enzyme.  As shown in Figure 5.2 using the “rigid” 
SP/XP protocol,  the Lys347 residue blocks the binding pocket around the P3/4 binding region. 
The result of this is that docking macrocycles using the SP/XP protocol results in these being 
predicted to be extremely poor calpain inhibitors.  The reason for this is that the N-substituent 
of the macrocycle sterically clashes with Lys347.   
 
It is, however, well known that the active site geometry of a protein complex depends heavily 
upon conformational changes induced by the bound ligand.  For this reason Schrödinger’s 
induced fit protocol was used to dock the macrocycles. 
 
 
Figure 5.2: Comparison of SP/XP docking and induced fit docking 
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The induced fit docking protocol solved the steric clash problem encountered during rigid 
docking by employing a combination of Glide and Prime to exhaustively consider possible 
binding modes and the associated conformational changes within the enzyme active site.  As  
described in Section 4.3 MacroModel 9.0 was used to run conformational searches on the 
macrocycles in order to generate an ensemble of low energy conformers.  The lowest energy 
β-strand conformer was then used as the starting conformation for the induced fit docking.    
 
Induced fit docking was performed using noncharged amino acids Cys115 and His272.  The 
centroid of Cys115, Gly208, Gly271, Glu349, and Asn253 was chosen for the docking grid 
generation, as this defines the centre of the active site; the induced fit protocol selects the size 
of the box by default. 
 
The starting conformer was then docked into the enzyme using Glide.  A reduced van der 
Waals radii of the ligand and protein atoms (0.5) was used in order to generate a diverse 
ensemble of ligand poses.  The side chain of Lys347 was removed for the docking and the 
twenty best poses of this initial docking were kept.   
 
For each ligand pose all residues of the protein within a 5Å distance to the ligand pose were 
reoriented with PRIME 1.2, including Lys347, to accommodate the ligand. These residues, and 
the ligand, were then minimised.  The ligands were re-docked (with a van der Waals radius of 
0.8) to the newly generated protein structure if this was within 30 kcal/mol of the lowest 
energy protein structure.  For each of these protein structures, one ligand pose was kept for 
evaluation. 
 
Figure 5.3 illustrates the power of the combination of induced fit docking and the use of 
RCM to prepare macrocycles that are conformationally constrained into a β-strand 
conformation.  This shows the superimposition of the enzyme bound structure of 2.12 and 
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one of the best (280 nM against calpain II) macrocyclic constraints (5.10).  From this it is 
clear that the backbone of the macrocycle is forced to adopt the ‘bio-active’ β-strand 
conformation exactly mimicking that of 2.12.   
 
5.10 
5.10 
2.12 
2.12 
Figure 5.3: Superimposition of 2.12 and 5.10 when bound in the enzyme 
 
 
5.3: Physicochemical analysis of the in-silico library 
 
The successful design of a calpain inhibitor as an anti-cataract agent not only requires the 
inhibitor to be an excellent β-strand mimic, but it must also be able to diffuse to the site of 
action (the lens) in sufficient concentration.  As such it was also necessary to consider the 
physicochemical properties of the calpain inhibitor.   
 
The two most important physicochemical properties for eye drugs are aqueous solubility and 
LogP.  The latter is defined as the partition coefficient between water and n-octanol.  Within 
our research group there were two potential administration routes for any anti-cataract agent 
available to us; 
• Topical administration (as either an eye drop or paste) 
• Intravitreal injection  
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Topical administration  
Topical drug delivery is the most common treatment for diseases of the anterior segment of 
the eye.  However, this administration route is often severely limited by the low permeability 
of the cornea, rapid clearance by tear drainage, and absorption into the conjunctiva.  Hence, 
the bioavailability of topically administered drugs is very low.15  Drug transport processes, 
and methods to improve bioavailability, have been studied extensively over the past 
decades.16-18   A mathematical model of solute transient diffusion across the cornea to the 
anterior chamber of the eye for topical drug delivery was reported in 2004.15  As shown in 
Figure 5.5 the Cmax (the maximum solute concentration in the anterior chamber), tmax (the 
time needed to reach Cmax), and Ma (the fractional amount of solute diffusing into the 
chamber) are related to LogP. 
 
 
Figure 5.5: mathematical model to describe the interationships between LogP 
and Cmax, tmax and Ma
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From Figure 5.5 it can be seen that a LogP of between one and fifty is required to achieve 
greater than one per cent cornea permeability within two hours.  It is also well recognised that 
aqueous solubility, in a given series of very closely related compounds, is generally inversely 
proportional to LogP.  It was decided that all topical agents synthesised should have a LogP 
between one and three (red and green lines in Figure 5.5).  While compounds with a LogP 
greater than three are likely to possess good cornea permeability they are also extremely 
likely to have negligible aqueous solubility.  As such LogP criteria were used in selecting 
which macrocycles to synthesise.  Partition coefficients were calculated (cLogP) using a 
physicochemical property calculator at www.logp.com.   
 
A number of moieties were proposed, from molecular modeling, to be suitable address 
regions and as such cLogP determination was required on a large number of compounds.  For 
example, if ten address regions were of interest, and one hundred macrocycles were also of 
interest, a total of one thousand cLogP calculations were required.  To make this process 
more efficient an approximate cLogP was calculated using a fragment based approach.  The 
cLogP of the macrocyclic aldehyde, amine (5.1) was calculated and then the appropriate 
value for the address region was either added or subtracted (Table 5.1). 
 
Address 
moiety 
Fragment 
cLogP  Address moiety 
Fragment 
cLogP 
S
O
O
Me
 
-1.10  S
O
O
N
N
Ph
 
+3.14 
N
H O  
-0.97  
S  
+1.32 
F
S
O
O
 
-0.88  
O
O
Ph  
+0.68 
 
N
H
N
HO
O
O
NH2 CHO
5.1
 
 
 
                                                                        Table 5.1: Fragment based cLogP        
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Intravitreal administration 
 
 
As described in the previous topical administration Section only a tiny percentage of the 
drug applied topically on the surface of the eye reaches the internal ocular tissues.  
Intravitreal injection provides a direct approach for administration of eye drugs to avoid this 
problem.  An intravitreal injection involves the direct injection of a drug solution into the 
vitreous humor of the eye (Figure 5.6). Recently, intravitreal injection of polymeric delivery 
systems for ganciclovir have been used for the treatment of cytomegalovirus retinitis in 
patients with acquired immunodeficiency syndrome.19-22  Furthermore, a variety of  steroids 
and antibiotics have long been applied clinically by intravitreal injection.23   
 
 
Figure 5.6: The human eye 
We considered that the major obstacle for the successful implementation of an intravitreal 
administration strategy was the very low aqueous solubility of our inhibitors.  However, it 
was postulated that some of the macrocycles in the in-silico library which had very low 
cLogP’s would also possess at least moderate aqueous solubility.  As such it was believed 
that intravitreal injection would provide a route of administration for potent compounds 
which had low cLogP’s and hence were not suitable for topical administration (see Chapter 
6).  
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5.4: Synthesis of 17-membered ring Tyr-xx-Gly macrocyclic calpain inhibitors 
 
As shown in Schemes 5.1 and 5.2 a range of macrocycles incorporating different amino acids 
in the P2 position were synthesised.  The aldehyde of both the  N-CBZ and N-4-fluoro-
benzene sulfonamide of each P2 variant were prepared.  Scheme 5.1 shows the initial method 
developed by Matthew Jones in our group to achieve this.  Orthogonally protected 
macrocycle 4.18 was hydrolysed using sodium hydroxide to give carboxylic acid 5.2.  BOC 
cleavage using 1M aqueous hydrochloric acid gave the fully deprotected amino acid 
macrocycle 5.3.  The benzyloxycarbonyl group was introduced using benzylchloroformate 
and weakly basic aqueous reaction conditions to give N-CBZ carboxylic acid macrocycle 5.4.  
The mixed anhydride of this with ethyl chloroformate was prepared using standard 
procedures, and subsequent sodium borohydride reduction afforded alcohol 5.5.  A sulfur 
trioxide/pyridine oxidation gave the required N-CBZ P2 valine macrocyclic aldehyde 5.6.  
The overall yield from the orthogonally protected macrocycle 4.18 was only 0.8%. 
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H
O
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O
N
H
OH
(i)
(iii)
(ii)
4.18 5.35.2
(iv)(v)
5.4
5.55.6
Scheme 5.1. Reagents and Conditions: (i) NaOH, THF, H2O, (93%); (ii) 1M HCl(aq), (100%); 
(iii) benzyl chloroformate, saturated NaHCO3(aq), (34%); (iv) a) ethyl chloroformate, Et3N, 
THF; b) NaBH4, THF, (13%); (v) SO3.Pyr, DIPEA, DMSO, DCM, (21%) 
 
This thesis describes the development and use of an alternative higher yielding synthetic 
route for the preparation of analogues of 5.6 (Scheme 5.2).  The overall yield from the 
orthogonally protected macrocycle for the synthesis of the direct leucine analogue of 5.6 
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using this methodology was 15%.  This is almost a twenty fold improvement compared to the 
0.8% achieved using the method in Scheme 5.1.  
 
The synthetic methodology used to prepare the P2 variants of 5.6 is shown in Scheme 5.2.  
The N-BOC protecting group was cleaved using a solution of 4M hydrogen chloride, in 1,4-
dioxane, to give the hydrogen chloride salts of macrocyclic amines 5.7, 5.11 and 5.18.  These 
were then coupled to either 4-fluorobenzenesulfonyl chloride or benzyl chloroformate using 
standard reaction conditions.  The macrocyclic methyl esters (5.8, 5.12, 5.15 and 5.19) were 
then reduced to the corresponding aldehyde.  This was achieved either directly (5.8 and 5.19) 
using DIBAL-H or by a two step process (5.12 and 5.15) whereby the ester was reduced 
using lithium aluminium hydride to an alcohol which was then reoxidised to the aldehyde 
using a sulfur trioxide pyridine complex.  Reduction of phenylalanine methyl ester 5.19, with 
DIBAL-H, gave a complex mixture of products by proton NMR.  Aldehyde 5.21 was 
successfully synthesised by Joanna Duncan and as such is not discussed further in this thesis. 
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4.18, R = (L) Val 
4.49, R= (L) Leu
4.54, R = (L) Phe 
5.8, R= (L) Val, X = SO2, Y = 4-F-Ph
5.12, R = (L) Leu, X = C(O), Y = OCH2Ph
5.15, R= (L) Leu, X = SO2, Y = 4-F-Ph
5.19, R = (L) Phe, X = SO2 ,Y = 4-F-Ph
5.7, R = (L) Val
5.11, R= (L) Leu
5.18, R = (L) Phe
5.9, R= (L) Val, X = SO2 ,Y = 4-F-Ph
5.13, R = (L) Leu, X = C(O), Y = OCH2Ph
5.16, R= (L) Leu, X = SO2 ,Y = 4-F-Ph
5.20, R = (L) Phe, X = SO2 ,Y = 4-F-Ph
(iv)
5.10, R= (L) Val, X = SO2 ,Y = 4-F-Ph
5.14, R = (L) Leu, X = C(O), Y = OCH2Ph
5.17, R= (L) Leu, X = SO2 ,Y = 4-F-Ph
5.21, R = (L) Phe, X = SO2 ,Y = 4-F-Ph
Scheme 5.2. Reagents and Conditions: (i) 4M HCl, 1,4-dioxane, (all 100%);  
For R= Val, X = SO2, Y = 4-F-Ph; (ii) 4-fluorobenzenesulfonyl chloride, DIPEA, DMF, 
(36%), (iii) DIBAL-H, DCM, (4% 5.9 and 17% 5.10) 
For R=Leu, X = C(O), Y = OCH2Ph; (ii) benzyl chloroformate, DIPEA, DMF, (43%); (iii) 
LiAlH4, THF, (83%); (iv) SO3.Pyr, DIPEA, DMSO, DCM, (42%);  
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For R=Leu, X = SO2, Y = 4-F-Ph; (ii) 4-fluorobenzenesulfonyl chloride, DIPEA, DMF, 
(7%); (iii) LiAlH4, THF, (87%); (iv) SO3.Pyr, DIPEA, DMSO, DCM, (69%); 
For R=Phe, X = SO2, Y = 4-F-Ph; (ii) 4-fluorobenzenesulfonyl chloride, DIPEA, DMF, 
(18%), (iii) DIBAL-H, DCM, (0%) 
 
5.5: Synthesis of 16 and 18-membered Tyr-xx-Gly macrocyclic calpain inhibitors  
 
As shown in Scheme 5.3 the synthesis of the Tyr-xx-Gly based sixteen and eighteen 
membered macrocyclic calpain inhibitors was achieved.  The sixteen membered macrocyclic 
N-4-fluorobenzene sulfonamide (5.25) was synthesised from orthogonally protected 
macrocycle 4.30.  The N-BOC protecting group of 4.30 was cleaved with 4M hydrogen 
chloride in 1,4-dioxane to give the hydrogen chloride salt of amine 5.22.  The sulfonamide 
5.23 was prepared by coupling amine 5.22 to 4-fluorobenzenesulfonyl chloride under 
standard conditions.  Reduction of methyl ester 5.23 with DIBAL-H gave a mixture of both 
the alcohol 5.24 and the desired aldehyde 5.25.  These were separated by flash 
chromatography.  The eighteen membered N-CBZ macrocycle (5.29) was synthesised from 
orthogonally protected macrocycle 4.42.  The N-BOC protecting group of 4.42 was removed 
by treatment with 4M hydrogen chloride in 1,4-dioxane.  The resultant hydrogen chloride salt 
of amine 5.26 was reacted with benzylchloroformate to give N-CBZ macrocycle 5.27.  
Reduction with lithium aluminium hydride gave alcohol 5.28 and subsequent oxidation, with 
sulfur trioxide pyridine complex gave aldehyde 5.29. 
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4.42, R= (L) Leu, n = 3
5.23, R = (L) Val, n = 1, 
X = SO2, Y = 4-F-Ph
5.27, R = (L) Leu, n = 3, 
X = C(O), Y = OCH2Ph 
5.22, R = (L) Val, n =1
5.26, R= (L) Leu, n = 3
(iii)(iv)
5.24, R = (L) Val, n = 1, 
X = SO2, Y = 4-F-Ph 
5.28, R = (L) Leu, n = 3, 
X = C(O), Y = OCH2Ph
5.25, R = (L) Val, n = 1, 
X = SO2, Y = 4-F-Ph 
5.29, R = (L) Leu, n = 3, 
X = C(O), Y = OCH2Ph
( )n
( )n( )n
 
Scheme 5.3. Reagents and Conditions: For R = Val, n = 1; (i) 4M HCl, 1,4-dioxane, (100%); 
(ii) 4-fluorobenzenesulfonyl chloride, DIPEA, DMF, (16%); (iii) DIBAL-H, DCM, (7% 5.24 
and 5% 5.25); For R = Leu, n = 3; (i) 4M HCl, 1,4-dioxane (100%); (ii) benzyl 
chloroformate,  DIPEA, DMF, (69%); (iii) LiAlH4, THF, (72%); (iv) SO3.Pyr, DIPEA, 
DMSO, DCM, (82%) 
 
5.6: Synthesis of various N-substituted 17-membered Tyr-xx-Gly macrocycles 
 
The synthesis of further address region analogues of 5.6 in order to generate SAR for the 
address region of the macrocycles was carried out by Matthew Jones (Scheme 5.4). 
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5.30, X = C(O), Y = 
5.32, X = SO2' Y = 
5.2
5.31, X = C(O), Y = 
5.33, X = SO2' Y = 
Scheme 5.4. Reagents and Conditions: For X = C(O) and Y = 2-pyrrole (i) EDC, 
HOBt.H2O, DIPEA, Pyrrole-2-carboxylic acid, DMF, (21%); (ii) DIBAL-H, DCM, (33%). 
For X = SO2 and Y = 4-(phenyldiazo) benzene (i) 4-azabenzenephenyl sulfonyl chloride, 
DIPEA, DMF, (30%); (ii) DIBAL-H, DCM, (6%) 
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5.7: Synthesis of unsaturated 17-membered Tyr-Val-Gly macrocycle 
 
The synthesis of an unsaturated calpain inhibitor is shown in Scheme 5.5.  Compound 5.36 
was selected for synthesis to investigate the effect on calpain inhibition of incorporating a 
double bond into a macrocyclic calpain inhibitor.  The N-BOC protecting group of 
orthogonally protected macrocycle 4.16 was cleaved on treatment with 4M hydrogen chloride 
in 1,4-dioxane to give the hydrogen chloride salt of amine 5.34.  N-4-fluorobenzene 
sulfonamide 5.35 was prepared by reaction of amine 5.34.  Reduction of ester 5.35 with 
DIBAL-H gave aldehyde 5.36. 
HCl.H2N N
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Scheme 5.5. Reagents and Conditions: (i) 4M HCl, 1,4-dioxane, (100%); (ii) 4-fluoro-
benzenesulfonyl chloride, DIPEA, DMF, (33%); (iii) DIBAL-H, DCM, (18%) 
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5.8: Synthesis of 17-membered ring Tyr-Val-Gly β-amino acid macrocycle 
 
As shown in Scheme 5.6 the synthesis a β-amino acid warhead macrocycle was achieved in 
our lab by Matthew Jones.  The N-BOC protecting group of orthogonally protected 
macrocycle 4.62 was cleaved on treatment with saturated ethereal hydrogen chloride.  The 
hydrogen chloride salt of amine 5.37 was coupled with pyrrole-2-carboxylic acid and methyl 
ester 5.38 was reduced using DIBAL-H to give aldehyde 5.39.  
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4.62 5.37
(iii)
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Scheme 5.6. Reagents and Conditions: (i) HCl(g), Et2O, (100%); (ii) EDC, HOBt.H2O, 
DIPEA, Pyrrole-2-carboxylic acid, DMF, (21%); (iii) DIBAL-H, DCM, (2%) 
 
5.9: Synthesis of 19-membered ring Tyr-Val-Cys macrocyclic calpain inhibitors
 
Molecular modelling indicates that cysteine P1 substituted Tyr-xx-Cys macrocycles are 
excellent β-strand mimics (see Chapter 4).  As such macrocycle 4.67 was elaborated into a 
number of calpain inhibitors (Scheme 5.7).  The N-BOC protecting group of orthogonally 
protected macrocycle 4.67 was cleaved with a solution of 4M hydrogen chloride in 1,4-
dioxane to give the hydrogen chloride salt of amine 5.42.  The preparation of the N-CBZ  
analogue is described in this thesis whilst the N-4-fluorobenzene sulfonamide analogue was 
prepared by another member of the group (Matthew Jones).  The N-CBZ methyl ester (5.45) 
was prepared by reacting amine 5.42 with benzyloxycarbonyl chloroformate.  Reduction of 
methyl ester 5.45 with DIBAL-H gave aldehyde 5.46. 
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X = SO2, Y = 4-F-Ph, 5.43
X = C(O), Y = OCH2Ph, 5.45
(iii)
X = SO2, Y = 4-F-Ph, W = CHO, 5.44
X = C(O), Y = OCH2Ph, W = CHO, 5.46  
Scheme 5.7. Reagents and Conditions: For X = SO2, Y = 4-F-Ph (i) 4M HCl, 1,4-dioxane, 
(100%); (ii) 4-fluorobenzenesulfonyl chloride, DIPEA, DMF, (17%); (iii) DIBAL-H, DCM, 
(12%).  For X = C(O), Y = OCH2Ph (i) 4M HCl, 1,4-dioxane, (100%); (ii) benzyl 
chloroformate, DIPEA, DMF, (18%); (iii) DIBAL-H, DCM, (17%) 
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5.10: Calpain inhibition results of the macrocyclic β-strand mimics  
 
A summary of calpain inhibition assay results for the Tyr-xx-Gly series of macrocyclic β-
strand mimics is shown in Table 5.2.  See appendix 1 for details of the calpain inhibition 
assay. 
N
H
N
H
O
O
O
N
H
W
A
A
R
Y
( )n  
Y R W n A Cpmd # 
Induced 
fit Glide 
Score 
% conformation 
(Boltzmann weighted)    
β-strand  β-twist 
Warhead 
distance to 
Cys (Å) 
IC50 
(nM) cLogP 
Val CH2OH 0 CH2 5.24 -8.80 99.54 0.41 >>5 6490 -0.86 
Val CH2OH 1 CH2 5.9 -9.80 99.60 0 4.80 1090 -0.61 
Leu CH2OH 1 CH2 5.16 -10.4 100 0 3.80 930 -0.53 
Val CHO 0 CH2 5.25 -10.2 100 0 3.20 3710 -0.68 
Val CHO 1 CH2 5.10 -9.37 81.16 9.36 4.33 280 -0.20 
Val CHO 1 CH 5.36 -7.72 32.60 6.02 >5 2860 -0.75 
S
O
O
F
 
Leu CHO 1 CH2 5.17 -9.58 76.05 23.95 4.06 45 -0.37 
 
Leu CH2OH 1 CH2 5.13 -10.2 100 0 4.30 704 1.27 
Leu CH2OH 2 CH2 5.28 -8.90 89.42 5.12 4.30 1100 1.47 
Val CHO 1 CH2 5.6 9.09 50.62 57.86 3.63 85 1.33 
Leu CHO 1 CH2 5.14 -8.60 50.62 47.86 3.70 27 1.59 
O
O
Ph
 
Leu CHO 2 CH2 5.29 -10.3 89.88 9.54 3.50 180 1.80 
 
Val CHO 1 CH2 5.31 -8.42 78.82 8.52 3.89 690 0.40 
N
H O  
Val CH2CHO 1 CH2 5.39 -9.50 81.55 7.38 3.90 75230 1.91 
 
Val CHO 1 CH2 5.40 -9.50 86.48 1.43 3.50 949 1.70 
MeSO2 Val CH2CHO 1 CH2 5.41 -9.00 95.41 0.17 >>5 112800 -0.73 
 
NN S
O
OPh
 
Val CHO 1 CH2 5.33 -6.22 84.49 4.55 4.07 1530 3.28 
 
Table 5.2: Calpain inhibition assay results for the Tyr-xx-Gly series  
 
From the assay results reported in Table 5.2 a number of SAR conclusions can be drawn; 
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Effect of P2 amino acid on calpain inhibition 
 
Leucine is the best P2 substituent.  In all cases where the direct valine and leucine analogues 
were prepared, leucine results in more potent calpain inhibition than valine.  Examples 
include the direct analogues N-CBZ leucine aldehyde 5.14 (27 nM) / N-CBZ valine aldehyde 
5.6 (85 nM) and N-4-F-benzene sulfonamide leucine aldehyde 5.17 (45 nM) / N-4-F-benzene 
sulfonamide valine aldehyde 5.10 (280 nM). 
 
There is no single molecular modelling parameter that can accurately rationalise this effect.  
It is simply not possible to predict the most potent calpain inhibitor within a series of very 
closely related analogues.  It is instead a complex relationship between percentage β-strand 
conformation, warhead distance from the active site Cys and induced fit docking score.  For 
example comparing aldehydes 5.10 (280 nM) and 5.17 (45 nM) there is approximately a six 
fold difference in calpain inhibition.  Molecular modelling data shows that 5.17 has the better 
induced fit docking score (-9.58 and -9.37 respectively) and warhead distance to Cys105 (4.06 
Å compared to 4.33 Å) but a lower percentage of β-strand conformation (76.05% to 81.16%).   
 
Effect of removing the electrophilic warhead 
 
If an excellent β-strand mimic is obtained which possesses high binding affinity for calpain 
an electrophilic warhead group is not required for potent inhibition.  Alcohols 5.9 (1090 nM), 
5.13 (704 nM) and 5.16 (930 nM) are all potent calpain inhibitors with no reactive 
electrophilic warhead.  The best compound (5.13) is to the best of our knowledge the most 
potent non-warhead active site binding calpain inhibitor known. 
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Effect of macrocyclic ring size on calpain inhibition 
 
A seventeen membered macrocycle is optimal for calpain inhibition in the Tyr-xx-Gly 
macrocyclic series.  This is concluded from SAR studies across four compounds.  The 
seventeen membered N-4-fluorobenzenesulfonamide macrocyclic aldehyde 5.10 (280 nM) is 
over thirteen fold potent than the direct sixteen membered analogue 5.25 (3710 nM).  The 
seventeen membered N-CBZ macrocyclic aldehyde 5.14 (27 nM) is approximately 6.5 fold 
more potent as a calpain inhibitor than the direct eighteen membered analogue 5.19 (180 nM). 
 
These findings are also confirmed by the alcohols of the macrocycles.  These show the same 
results.  The seventeen membered ring alcohol 5.13 (704 nM) is better than the eighteen 
membered ring alcohol 5.28 (1100 nM) which is in turn better than the sixteen membered 
ring alcohol 5.24 (6490 nM). 
 
Effect of address region on calpain inhibition 
 
The incorporation of different address region moieties onto the same macrocyclic β-strand 
template has a very significant effect on calpain inhibition.  For example there is a six fold 
decrease in calpain inhibition by changing the N-substituent from N-4-fluorobenzene 
sulfonamide 5.10 (280 nM) to 4-(phenyldiazo) benzene sulfonamide 5.33 (1530 nM).  The 
effect is rationalised using molecular modelling.  Aldehyde 5.10 has a much higher induced 
fit docking score than 5.33 (-9.37 and -6.22 respectively) 
 
It can also be concluded that benzyloxycarbonyl is an excellent address moiety for calpain 
inhibition.  Incorporation of this affords the most potent calpain inhibitor 5.14 (27 nM).  
Molecular modelling indicates that this is because N-CBZ confers the best balance of 
percentage β-strand conformation, warhead to Cys105 distance and induced fit docking score. 
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Effect of incorporating unsaturation on calpain inhibition 
 
Retention of the E double bond from the RCM reaction is detrimental for calpain inhibition.  
The unsaturated macrocycle  5.36 (2860 nM) is ten fold less potent than the direct saturated 
analogue 5.10 (280 nM).  Molecular modelling clearly indicates that 5.36 does not exist in a 
high percentage β-strand conformation compared to 5.10 (32.60% compared to 81.16%).  In 
addition, the electrophilic warhead of unsaturated macrocycle 5.36 is much further away from 
the active site cysteine (> 5 Å) than the electrophilic warhead is in 5.10. 
  
Effect of using a β-amino acid warhead
 
 
The use a β-amino acid warhead eliminates virtually all calpain inhibitory activity.  The IC50 
values of the β-amino acid analogues 5.39 (75230 nM) and 5.41 (112800 nM) are over two 
orders of magnitude greater than those of the corresponding α-amino acid analogues 5.31 
(690 nM) and 5.40 (949 nM).   
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Calpain inhibition results of the Tyr-Val-Cys based macrocycles 
 
A summary of calpain inhibition assay results for the Tyr-Val-Cys series of macrocyclic β-
strand mimics is shown in Table 5.3.  See appendix 1 for details of the calpain inhibition 
assay. 
N
H
N
H
O
O
O
N
H
S
Y H
O
 
 
Y Compound  Number 
Induced fit 
Glide Score
% conformation 
(Boltzmann 
weighted) 
β-strand  β-twist 
Warhead 
distance to 
Cys (Å) 
IC50 
(nM) cLogP 
S
O
O
F
 
5.44 -7.50 97.85 1.90 4.00 2400 0.39 
 
O
O
Ph
 
5.46 -10.1 93.96 3.88 4.70 295 1.89 
 
Table 5.3: Effect of P1 residue on calpain inhibition 
 
The P1 cysteine based macrocycles 5.44 and 5.46 are both β-strand mimetics as they possess 
moderate to excellent calpain inhibition (2400 nM and 285nM respectively).  They are 
however less potent than their direct P1 glycine analogues (5.10, 280 nM and 5.6, 85 nM).   
 
The inhibitory activity of the Tyr-Val-Cys based macrocycles are influenced to a greater 
extent by the N-substituent.  Changing from N-CBZ (5.6, 85 nM) to N-4-fluorobenzene 
sulfonamide (5.10, 280 nM) in the P1 glycine series results in approximately a three fold 
decrease in activity whereas in the P1 cysteine series the same substitution (5.46, 295 nM and 
5.44, 2400 nM) results in an eight fold decrease in activity.  This substituent effect can be 
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explained using the induced fit docking scores.  In the P1 cysteine series molecular modelling 
indicates that N-CBZ macrocycle 5.46 (-10.1) is a much better calpain binder than N-4-
fluorobenzene sulfonamide macrocycle 5.44 (-7.50).  The difference in their induced fit 
docking scores is 2.6.  In the P1 glycine series the difference in the induced fit docking score 
for the N-CBZ (5.6, -9.09) and the N-4-fluorobenzene sulfonamide (5.10, -9.37) analogues is 
only 0.32. 
 
5.11: Conclusions and future work 
 
A number of calpain inhibitors in two different macrocyclic series were designed using 
induced fit molecular modelling and in-silico physicochemical calculations.  Nineteen of 
these were synthesised and tested.  Overall from this work it is concluded that Tyr-xx-Gly 
based macrocycles are better calpain inhibitors than Tyr-xx-Cys based macrocycles. 
 
In the Tyr-xx-Gly macrocyclic system a number of variables were investigated.  The ring size 
was varied from sixteen to eighteen and it was found that a seventeen membered ring was 
optimal for calpain inhibition.   
 
The central amino acid of the macrocyclic system was systematically varied and leucine was 
discovered to result in the best inhibition.   
 
A number of address regions were investigated.  Benzyloxycarbonyl was found to result in 
the most potent calpain inhibition with the best macrocyclic inhibitor (5.14) having an IC50 
against calpain II of 27 nM.   
 
The effects of incorporating unsaturation in the macrocycle and using a β-amino acid 
aldehyde were also investigated.  Both of these approaches were detrimental to calpain 
inhibition with incorporation of a β-amino acid aldehyde being particularly bad. 
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One of the most promising findings from this chapter is that macrocyclic inhibitors which are 
‘pre-organised’ into the ‘bio-active’ β-strand conformation do not require an electrophilic 
warhead for potent inhibition.   The best non-electrophilic warhead macrocycle (5.13) had an 
IC50 against calpain II of 704 nM.  This finding should motivate extensive further work in 
this area. 
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6.1: Ovine in-vivo cataract model 
 
This chapter describes the in-vivo evaluation studies performed on three of the best β-strand 
mimics identified in Chapters 2 and 5.  It also describes the synthetic optimisation which was 
required in order to successfully carry out a multi-gram synthesis of each of these. 
 
As described in Chapter 1, calpain over activation is thought to be involved in a number of 
human diseases of which cataract formation is one such example.  In order to develop a 
calpain inhibitor as a human drug, animal trials first need to be conducted in order to 
demonstrate that the proposed drug is both safe and efficacious.  Our collaborators at Lincoln 
University, New Zealand have developed an animal model for cataract.  They have 
established a flock of sheep which develop hereditary cataracts.  This was achieved by mating 
a cataractous Romney ram with normal-eyed, unrelated Coopworth ewes.1    
 
Our colleagues at Lincoln University have published1 a number of findings which suggest that 
calpain over-activation is involved in ovine cataract formation and development;  
 
• three calpain isoforms are present in young lamb lenses.  
• lens calcium concentration increases in the early stages of ovine cataract formation 
and this is ten fold higher in lambs with mature cataract than in lambs with normal 
lenses.  
• calpain activity decreases as the cataracts develop 
 
The presence of calpain and calcium elevation during ovine cataract formation strongly 
suggests that proteolysis plays a key role in opacification of ovine lens.  As such this animal 
model of cataract provides an excellent in-vivo model in which to establish efficacy of the best 
calpain inhibitors described in Chapters 2 and 5 as anti-cataract agents.  In order that 
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quantification of the in-vivo efficacy results could be achieved two scoring systems for 
cataractogenesis were devised; a one to six scale and a one to seven scale.   
 
One to six scale 
Cataract development in the ovine lens is divided into three main stages, and each of these 
into two sub stages (Figure 6.1); 
• Early cataracts (stages 1 to 2) consist of discrete anterior and posterior cortical 
opacities, usually centered at the lens suture lines.  
• mid-stage (stages 3 to 4) cataracts form spoke-like patterns radiating to the peripheral 
cortex and epithelial layer.  
• mature cataract involves the whole lens (stages 5 to 6).  
 
(1) Small opacity detected at either the anterior or posterior suture line. (2) Small opacities detected at both 
suture lines. (3) Opacification at sutures and mild cortical involvement. (4) Moderate to severe cortical 
involvement. (5) Immature cataract involving the whole lens. (6) Mature cataract. 
Figure 6.1: One to six cataract scoring system 
One to seven scale 
The one to seven cataract scale was developed in order to increase the sensitivity of the scale 
around the midpoint of cataract development.  Essentially stage four of the one to six scale has 
been split into two (Figure 6.2).  
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(1) Anterior suture lines (2) Anterior & posterior suture lines (3) 0-33% cortical nuclear involvement (4) 33-66% 
cortical nuclear involvement (5) Greater than 66% cortical nuclear involvement (6) Total immature cataract (7) 
Total mature cataract  
Figure 6.2: One to seven cataract scoring system 
 
6.2: Synthetic optimisation of 5.17 (Cat-812) 
 
In order to evaluate the efficacy of our calpain inhibitors as anti-cataract agents in the in-vivo 
sheep model two potential administration routes were identified, intravitreal injection and 
topical administration (see Section 5.3).  Compound 5.17 was identified as an intravitreal 
candidate.  This had a cLogP of -0.37 and an IC50 value of 45 nM against calpain II. 
 
Multi-gram quantities of 5.17 were required for an in-vivo sheep trial.  However, as shown in 
Scheme 6.1, the original synthetic route to 5.17 had an overall yield of 0.37%.   Three 
synthetic steps contributed to the low yield.  RCM afforded only a moderate yield of ring 
closed product (29%), formation of the sulfonamide was extremely low yielding (7%) and 
DIBAL reduction of the ester was poor (25%).  As the two lowest yielding transformations 
were the final two steps of the synthesis this initial synthetic route was not suitable for the 
preparation of multi-gram quantities of 5.17.  
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Scheme 6.1. Reagents and Conditions: (i) HATU, DIPEA, Leu-OMe, DMF, (80%); (ii) 
NaOH, THF, H2O, MeOH, (97%); (iii) SOCl2, MeOH, (100%); (iv) HATU, DIPEA, (s)-allyl-
Gly-OMe, DMF, (97%); (v) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (29%); (vi) H2, 20 
mol% Pd/C, MeOH, EtOAc, (98%); (vii) 4M HCl, 1,4-dioxane, (100%); (viii) 4-
fluorobenzene sulfonyl chloride, DIPEA, DMF, (7%); (ix) DIBAL, DCM, (25%);  Overall 
yield – 0.37% 
 
As shown in Scheme 6.2 the overall yield of the synthetic route to 5.17 was improved from 
0.37% to 16%.  This was achieved by optimising two synthetic transformations and changing 
the order of the synthetic steps.   
 
The yield of the sulfonamide formation reaction was improved by moving this step to earlier 
in the synthesis (from 7% to 65%).  The yield of the RCM reaction was increased from 29% 
to 65% by adding 10 mol% of Lewis acid chloro-dicyclohexyl borane to the microwave 
irradiated reaction media (described in Section 4.19).  The aldehyde was obtained by a 
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reduction, oxidisation protocol.  Although this required an extra step it increased the yield of 
the ester to aldehyde transformation from 25% to 59%. 
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Scheme 6.2. Reagents and Conditions: (i) HATU, DIPEA, Leu-OMe, DMF, (80%); (ii) 4M 
HCl, 1,4-dioxane, (100%); (iii) 4-fluorobenzene sulfonyl chloride, DIPEA, DCM, (65%); (iv) 
NaOH, THF, H2O, MeOH, (95%); (v) SOCl2, MeOH, (100%); (vi) HATU, DIPEA, (s)-allyl-
Gly-OMe, DMF, (89%); (vii) 3 x 10 mol% 3.9, 10 mol% chloro-dicyclohexyl borane, 1,1,2-
TCE, microwave, (65%); (viii) H2, 20 mol% Pd/C, MeOH, EtOAc, (93%); (ix) LiAlH4, THF, 
(86%) (x) SO3.Pyr, DIPEA, DMSO, DCM (69%);  Overall yield – 16% 
 
6.3: Synthesis of 2.13 (CAT-0059) for in-vivo evaluation 
 
As described in Section 5.2 the optimal route of administration for a human cataract drug is 
topical drug delivery.  Compound 2.13 was identified as our best acyclic topical candidate 
with an IC50 of 30 nM and the required balance of physicochemical properties.  It had a cLogP 
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of 0.90 and moderate aqueous solubility of 0.1 mg/ml.   As shown in Scheme 6.3 no 
optimisation of the synthetic route was required as it was already designed as a divergent 
synthesis (Chapter 2).                                       
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Scheme 6.3. Reagents and Conditions: (i) POCl3, DMF, DCE, (52%); (ii) KOH, H2O, (96%); 
(iii) HATU, DIPEA, (L)-leucinol, DMF, (68%); (iv) 4M HCl in 1,4-dioxane, (100%); (v) 
EDC, HOBt.H2O, DIPEA, 2.15, DCM (39%); or HATU, DIPEA, 2.15, DMF (27%); (vi) 
SO3.Pyr, DIPEA, DMSO, DCM, (66%) 
6.4: Results of intravitreal trial of 2.13 (Cat 0059) 
Prior to commencing a full scale in-vivo sheep trial it was deemed prudent to ensure that 
compounds administered by intravitreal injection diffused to the site of action (the lens).  To 
investigate this our collaborators at Lincoln University administered an intravitreal injection 
of 2.13 to five sheep.  These were sacrificed at  1, 6, 24, 72 and 168 hours.  HPLC and LCMS 
analysis of  the vitreous humor, aqueous humor and lens was performed to detect whether or 
not 2.13 was present.  Results of this analysis are shown in Table 6.1  
                          Time (h) 
          Tissue 1 6 24 72 168 
2.13 detected in vitreous humor Yes Yes No No No 
2.13 detected in aqueous humor No No No No No 
2.13 detected in the lens No No No No No 
 
Table 6.1: Detection of 2.13 after intravirtreal injection 
The results in Table 6.1 clearly demonstrate that intravitreal injection is not a suitable method 
of drug delivery for compound 2.13.  The drug was only detected in the vitreous humour 
during the course of the experiment 2.13 and it was not detected, at any time, either in the 
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aqueous humor or at the site of action (the lens).  Furthermore 2.13 was cleared entirely from 
the vitreous humor between six and twenty four hours.    For these reasons intravitreal 
injection was rejected as a route of administration for our calpain inhibitors as anti-cataract 
agents. 
 
6.5: In-vivo sheep trial results of 2.13 (CAT-0059) 
 
Two separate in-vivo trials were conducted by the Lincoln University cataract group using 
2.13.  In October 2004 a ten week trial using an eye drop formulation of 2.13 comprised of the 
following composition (see appendix 2) was conducted; 
• 0.1% (w/w) compound 2.13 
• 14% EtOH 
• 0.9% sodium chloride 
• 0.3% hydroxypropyl methyl cellulose 
• 0.05% disodium EDTA 
• 0.01% benzalkonium chloride 
• 84.65% MilliQ purified water 
 
The calpain inhibitor was applied to the left eye of cataract lambs, leaving the right eye as an 
untreated control.  The progression of cataracts in both eyes was determined by a veterinary 
ophthalmologist using a slit-lamp microscope.  Each eye was assigned a cataract score (see 
Section 6.2).  The cataract scores were taken two weeks before the start of the evaluation (t= -
14) and three times during the eleven weeks of treatment (t = 10, 37, 67 days).   The mean 
score after each examination is shown in Figure 6.4.   
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Figure 6.4. A plot of mean cataract scores for untreated and treated eyes 
 
The cataract scores of the treated and untreated eyes were the same over the first thirty seven 
days of the treatment period.  At the end of the treatment period, the eyes treated showed a 
higher cataract score than the untreated eye (P < 0.05) thus it was concluded that 2.13 did not 
retard cataract development under these conditions. 
 
The reason for this failure was thought to be due to insufficient diffusion of 2.13 through the 
cornea into the anterior of the eye.  The use of ethanol in the eye drop formulation resulted in 
an eye drop which had extremely low surface tension.  This resulted in the majority of the eye 
drop immediately being washed off the surface of the eye. 
  
As such another trial was undertaken in October 2005 using 2.13 formulated into an ointment.  
It was anticipated that an ointment would remain on the surface of the eye for a longer period 
of time compared to an eye drop.  Importantly, the ointment preparation enabled a ten fold 
higher concentration of 2.13 to be used relative to the eye drop.  It was hypothesised that both 
the increased concentration of 2.13 and the fact that the ointment was much more viscous 
would result in an increased concentration of 2.13 residing on the eye for a longer period of 
time.  In turn it was expected that this would allow more time for diffusion across the cornea 
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and thus this would result in a very significant increase in the concentration of 2.13 in the 
anterior of the eye.  The formulation was prepared (see appendix 2) using the following 
composition (w/w): 
• 1%  compound 2.13  
• 25% cetyl stearyl alcohol 
• 35% lanolin 
• 39% paraffin oil. 
 
The trial began on 16/11/05 and continued until 26/2/06. Twenty-four two to three month old 
lambs were selected for the trial based on their cataract score on 28/10/06.  Their cataract 
scores ranged from one to four with means of 1.92 for the left eye and 1.96 for the right.  The 
left eye of each sheep was treated twice daily with twenty five milligrams of ointment 
containing 0.25 milligrams of 2.13.   
 
During the trial the cataracts progressed rapidly and by 22/2/06 over half had mature cataracts 
(Table 6.2).   This data is also shown graphically in Figure 6.5.   
 
Date Number Left Eye Right Eye Left Std Dev Right Std 
Dev 
28-Oct 24 1.92 1.96 0.58 0.69 
29-Nov 24 3.17 3.71 1.58 1.85 
Dec-07 24 3.42 3.75 1.61 1.73 
Dec-21 22* 4.41 4.45 1.82 2.09 
Jan-09 24 4.79 4.79 1.93 2.00 
Jan-20 23 5.43 5.13 1.93 1.91 
Feb-22 22 5.95 5.86 1.56 1.67 
 
*
 
 two animals could not be scored because of eye infection  
 
Table 6.2: Results of 2.13 ointment in-vivo cataract sheep trial. 
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Figure 6.5: Results of 2.13 ointment in-vivo cataract sheep trial. 
 
After one month the treated left eyes showed an average cataract score of 3.17 and the control 
right eyes showed an average cataract score of 3.71.  This was significant in a paired t-test at p 
< 0.05 indicating successful retardation of cataract development. 
 
This result is very promising in the context of developing a human cataract drug.  Human 
cataracts typically develop much slower than those within the sheep trial.  It is postulated that 
the statistically significant delay of cataract development for one month in the in-vivo sheep 
cataract model would translate into a much longer period of time in humans.    
 
In the developed world cataract is readily treated by surgery.  However, there are frequently 
long waiting lists for cataract operations and during this time the individual usually receives 
no treatment and as such cataract development progresses unabated.  The results from this 
trial suggest that development of a compound, such as 2.13,  which might slow down the rate 
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of cataract development for a number of months or even years would greatly improve the 
quality of life for individuals awaiting cataract surgery.  
Furthermore, from this in-vivo trial it can also be concluded that correct formulation of the 
drug is imperative for successful treatment.  Use of 2.13 as an anti-cataract agent in the form 
of an eye drop was totally unsuccessful whereas use of 2.13 as an ointment resulted in a 
statistically significant reduction in the rate of cataract formation.  This ointment formulation 
of 2.13 shows promise as a potential treatment for cataract. 
6.6: Synthetic optimisation of 5.14 (CAT-811) 
 
As described in Section 5.2 the optimal route of administration for our inhibitors is topical 
drug delivery.  The macrocyclic inhibitors were designed using LogP calculations to optimise 
cornea penetration.  As such a macrocyclic inhibitor was required for in-vivo evaluation which 
was both potent and with a LogP in the target range of one to three.  Compound 5.14 was 
chosen with a cLogP of 1.59 and an IC50 value of 27 nM against calpain II.  This was 
formulated into an ointment (see appendix 2), suitable for intraocular application, with a 
optimised formulation comprised of (w/w): 
• 1%  compound 5.14  
• 25% cetyl stearyl alcohol 
• 35% lanolin 
• 39% paraffin oil 
 
The experimental procedure for the preparation of ointment of 5.14 required the aldehyde to 
first be dissolved in cetyl stearyl alcohol.  Mass spectrometry analysis of this initial solution 
indicated that 5.14 was in equilibrium with its hemi-acetal 5.14b (Scheme 6.4). 
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Scheme 6.4: Hemi-acetal equilibrium of 5.14 
 
This observation is critical to the interpretation of the in-vivo trial results.  Formation of hemi-
acetal 5.14b results in an increase in the clogP of 5.14 (from 1.59 to 5.48 and 5.61 
respectively).  As discussed in Section 5.3 logP is directly related to cornea permeability.  
From Figure 5.5 it is seen that the increase in logP, upon formation of the hemi-acetal, is 
predicted to result in a three fold increase in the percentage of compound which reaches the 
anterior side of the eye.  This is a significant advantage for cataract treatment and as such this 
represents a pseudo pro-drug approach  
 
The use of 5.14 in this formulation required the synthesis of multi-gram quantities of 5.14.  As 
shown in Scheme 6.5 the initial synthetic route of 5.14 had an overall yield of 2.0%.   
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Scheme 6.5. Reagents and Conditions: (i) HATU, DIPEA, Leu-OMe, DMF, (80%); (ii) 
NaOH, THF, H2O, MeOH, (97%); (iii) SOCl2, MeOH, (100%); (iv) HATU, DIPEA, (s)-allyl-
Gly-OMe, DMF, (97%); (v) 3 x 10 mol% 3.9, 1,1,2-TCE, microwave, (29%); (vi) H2, 20 
mol% Pd/C, MeOH, EtOAc, (98%); (vii) 4M HCl, 1,4-dioxane, (100%); (viii) benzyl 
chloroformate, DIPEA, DMF, (43%); (ix) DIBAL, DCM, (22%);  Overall yield – 2.0% 
 
The low overall yield is the result of a nine step, almost linear, synthetic route with three low 
to moderate yielding steps (RCM, N-CBZ formation and reduction of the ester to the 
aldehyde). The order of the synthetic steps could not be changed as hydrogenation of the 
double bond in 4.48 was required.  Reaction conditions which would also cleave a N-CBZ 
functionality.  As such the synthetic optimisation strategy was to improve the yield of the 
individual steps.   
 
As shown in Scheme 6.6 the RCM reaction yield was improved from 29% to 91% by addition 
of 10 mol% of chloro-dicyclohexyl borane to the microwave irradiated RCM reaction media.  
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The ester reduction to aldehyde was also improved from 22% (using DIBAL) to 35% using a 
lithium aluminium hydride reduction, sulfur trioxide oxidation sequence.  Combined the 
improvement of yield in these two steps increased the overall yield five fold (10% compared 
to 2%).  This sequence then allowed preparation of  two grams of 5.14. 
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Scheme 6.6. Reagents and Conditions: (i) HATU, DIPEA, Leu-OMe, DMF, (80%); (ii) 
NaOH, THF, H2O, MeOH, (97%); (iii) SOCl2, MeOH, (100%); (iv) HATU, DIPEA, (s)-allyl-
Gly-OMe, DMF, (97%); (v) 3 x 10 mol% 3.9, 10 mol% chloro-dicyclohexyl borane, 1,1,2-
TCE, microwave, (91%); (vi) H2, 20 mol% Pd/C, MeOH, EtOAc, (98%); (vii) 4M HCl, 1,4-
dioxane, (100%); (viii) benzyl chloroformate, DIPEA, DMF, (43%); (ix) LiAlH4, THF, 
(83%); (x) SO3.Pyr, DIPEA, DMSO, DCM, (42%); Overall yield – 10% 
 
6.7: In-vivo sheep trial results of 5.14 (CAT-811) 
 
The protocol used for this trial was the same as for the 2.13 ointment trial.  The trial began on 
16/12/05 and continued to 28/3/06.  Twenty-four three to four month old lambs were selected 
for the trial based on their cataract score on 7/12/05.  Their initial scores ranged from 1 to 2 
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with means of 1.50 for the left eye and 1.54 for the right.  Two lambs died during the trial and 
a further two were sacrificed in an attempt to measure levels of 5.14 in the eyes.  The left eye 
of each sheep was treated twice daily with twenty five milligrams of ointment containing 0.25 
milligrams of 5.14.  (Table 6.3 and Figure 6.6). 
Date Number Left Eye Right Eye Left Std Dev Right Std Dev 
Oct-28 24 0.71 0.61 0.62 0.58 
Dec-07 24 1.5 1.54 0.51 0.59 
Dec-21 23 1.57 1.55 0.66 0.67 
Jan-09 23 2.17 1.96 1.15 0.82 
Jan-20 23 2.26 2.26 1.14 1.1 
Feb-22 22 2.68 2.5 0.95 0.67 
Mar-20 20 3.2 3.05 1.44 1 
 
Table 6.3: Results of 5.14 ointment in-vivo cataract sheep trial. 
 
Figure 6.3: Results of 5.14 ointment in-vivo cataract sheep trial. 
 
A key finding from the trial is that progression of cataracts in both eyes was very slow and by 
the last measurement, after 143 days, none of the sheep had progressed to mature cataracts 
and only two eyes had total immature cataracts.  These are unprecedented results as no 
chemical compound has ever been used to so dramatically reduce the rate of cataract 
development. 
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The fact that there was no significant difference between the eyes at any point in the trial can 
be explained by cross over of drug between the eyes.  This is a recognised but poorly 
understood phenomenon.  To support this hypothesis it should be noted that our collaborators 
have previously demonstrated1 that between twenty and forty per cent of 2.13 was detected in 
the untreated eye of the cataract sheep flock from a previous in-vivo efficacy trial.  Moreover, 
there is literature precedence to explain such an observation.  The application of glaucoma 
drug timolol maleate to albino rabbits resulted in lowering of intraocular pressure in the 
contralateral eye by 20-40% relative to the treated eye.2  Further work is required to establish 
the mechanism of, and quantify, cross over of 5.14 between the eyes 
 
In order to understand this data the rate of progression of cataracts in this trial was evaluated 
The progression of cataract was compared with data from other trials.  Four comparable data 
sets were identified; 
• control animals from a trial undertaken with SJA 6017 in 2000  
• the untreated right eye from the SJA 6017 trial in 2000  
• the untreated right eye from two trials in 2004.   
The weekly rate of cataract score progression for all five groups of animals was calculated 
(Table 6.4).  This data is also represented graphically in Figure 6.7.  
Group Number of animals 
Rate of cataract score 
progression (per week) 
Untreated eye (5.14 trial) 20 0.1064 
Untreated eye  (Control animals) 9 0.1890 
Untreated eye (SJA 2000 trial) 14 0.2093 
Untreated eye  (first 2004 trial) 9 0.1953 
Right eye (second 2004 trial) 12 0.2037 
 
Table 6.4: Daily rate of cataract score progression 
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Figure 6.7: Weekly rate of cataract score progression 
 
Sheep treated with 5.14 had a weekly cataract score progression of 0.1064 and those not 
treated with 5.14 had weekly cataract progression scores of between 0.1890 and 0.2093.  
From the data it is clear that the rate of cataract formation in animals treated with 5.14 was 
markedly decreased.   
 
The data obtained from the in-vivo trial indicates that 5.14 is efficacious.  Administration of 
5.14 slowed the rate of cataract formation between forty four and forty nine per cent relative 
to control animals.  The next in-vivo trial to commence in September 2006 will re-investigate 
the use of 5.14 as an anti-cataract agent.  This trial will be constructed as a double blind 
placebo controlled drug efficacy study.  Two groups of lambs will be treated with drug or 
placebo respectively.  Neither our collaborators or the veterinary ophthalmologist will be 
aware of which group are being administered the drug and which are receiving placebo.  Data 
from this work will be used to confirm whether or not 5.14 has the potential to be developed 
as an anti-cataract drug. 
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6.8: Conclusions and further work 
 
The synthetic routes to three calpain inhibitors (2.13, 5.14 and 5.17) were optimised and used 
to synthesise multi-gram quantities of each.  Two of these (2.13 and 5.14) were evaluated as 
anti-cataract agents in-vivo using the cataract sheep model.  Both of these β-strand mimics 
were demonstrated to retard cataract development.  Macrocycle 5.14 was found to be the most 
effective, decreasing the rate of cataract development between forty four and forty nine per 
cent relative to control. 
 
Intravitreal injection was determined to be an inappropriate route of administration for our 
calpain inhibitors.  This was concluded from a study where compound 2.13 was injected into 
five sheep and ex-vivo LCMS and HPLC analysis showed that 2.13 did not to diffuse to the 
site of action (the lens).   
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7.1: Synthesis of α-α conformationally constrained peptidomimetic lactams 
 
A key concept in peptidomimetic research (see Section 3.1) is that conformation defines 
biological activity.  Lactam rings have found extensive use in the medicinal and 
pharmaceutical industry as a means of conformational constraint.1-3  Given the success of our 
RCM methodology we chose to investigate the synthesis of peptide-based lactams using 
RCM.  A 1996 paper by Grubbs et al.4 demonstrates this approach with the synthesis of 
racemic glycine based lactams such as 7.1 (Scheme 7.1).  
 
BOCHN
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N CO2Me
Ru
P(Cy)3
P(Cy)3
Ph
Ph
Cl
Cl
N
BOCHN
O
CO2Me(3.4)
7.1  
Scheme 7.1. Reagents and Conditions: (i) 5 mol% 3.4, CHCl3, 52% 
 
The creation and implementation of a synthetic strategy which would provide a 
stereoselective route to novel α-α disubstituted seven-membered lactams of general type 7.2 
was sought in our laboratory.  As shown in Scheme 7.2 retrosynthetic analysis was performed 
to aid synthetic route design.   
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Scheme 7.2. Retrosynthesis of lactam 7.2 
 
Work on this type of compound was commenced by Dr J. Gardiner.  As shown in Scheme 
7.3, diene 7.6 was successfully prepared but RCM failed. 
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Scheme 7.3. Reagents and Conditions: (i) 10 mol% 3.5,  range of conditions (DCM, rt; or 
benzene, rt; or benzene, reflux), (all 0%) 
 
The reason for the failure of RCM was thought to be due to diene 7.6 adopting an extended 
conformation, with the terminal olefin trans to the C1-N1 amide bond (Figure 7.1).  As such 
it was hypothesised that the olefins were too distant to undergo RCM  
 
Figure 7.1: Trans relationship of a diene across the C1-N1 amide bond 
Replacement of the amide proton with 2,4-dimethoxybenzene has been used successfully5 in 
the Abell group to favour a cis relationship of olefins across a C1-N1 amide to promote RCM.  
As such it was postulated that substitution of the allyl amide nitrogen in 7.6 would favour a 
cis relationship of olefins across the C1-N1 bond and thus this would allow productive RCM. 
 
The first attempted synthesis of a N-substituted diene was performed using a synthetic 
strategy that was well established in the Abell group (Scheme 7.4).6-10  The sodium salt of 
(L)-phenylalanine was condensed with benzaldehyde with azetropic removal of water to give 
Chapter 7: Application of ring closing metathesis to the synthesis of peptidomimetics 152 
  
 
Schiff base 7.8.  Acylation of this with benzoyl chloride gave pure trans-5-oxazolidinone 7.9.  
The assignment of trans configuration to 7.9 was based on literature NMR data.10  
Stereoselective allylation of 7.9 with allyl bromide, followed by hydrolysis under basic 
conditions gave carboxylic acid 7.11.  Attempted coupling of N-allyl amine 7.13 to carboxylic 
acid 7.11, under a wide variety of conditions, gave side product oxazol-5-one 7.12 
exclusively.  
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Scheme 7.4. Reagents and Conditions: (i) NaOH(aq); (ii) PhCHO, DCM, reflux (95%, (over 2 
steps)); (iii) PhCOCl, DCM, 0oC (35%); (iv) LiHMDS, allyl bromide, THF, -78oC (81%); (v) 
NaOH, MeOH, H2O (100%); (vi) a) Cyanuric fluoride, Pyr, DCM; b) 7.13, DCM; or HATU, 
DIPEA, 7.13, DMF; or HATU, DIPEA, 7.13, THF; or EDC, HOAT, DIPEA, 7.13, DMF; or 
HATU, HOAT, DIPEA, 7.13, DMF or  PyAOP, DIPEA, 7.13, DMF; or PyBroP, DIPEA, 
7.13, DCM (all 0% for desired coupling, 0-100% of 7.12); (vii) Allylamine, THF, (73%) 
 
Scheme 7.5 shows a possible mechanism for the intramolecular cyclisation of 7.11 to give 
oxazol-5-one 7.12.  Cyclisation occurs by carbonyl nucleophilic attack at the electrophilic 
centre (X is either an HOAT ester or F).  Literature supports this mechanism.11  
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Scheme 7.5: Mechanism for the intramolecular cyclisation 
 
With oxazol-5-one 7.12 in hand, and as an alternative synthesis to prepare diene 7.6, the anion 
of allyl amine was used successfully to ring open oxazol-5-one 7.12 (Scheme 7.6).  Ring 
opening of oxazol-5-one 7.12 was also attempted using the anion of N-allyl amine 7.13.  
However, only starting material was recovered in quantitative yield.  The reason for this is 
postulated to be that the amine is simply too sterically hindered to react. 
N
H
O
Ph
Ph
O
N
HN
O
O
Ph
Ph
(i)
7.6
7.12
 
Scheme 7.6. Reagents and Conditions: (i) nBuLi, THF, -78oC, allyl amine, (96%) or N-allyl-
Gly-OEt (0%).  
 
The failure of diene 7.6 to cyclise using Grubbs first generation catalyst was reported by Dr J 
Gardiner.  This thesis now reports the cyclisation of diene 7.6 using Grubbs second generation 
catalyst in refluxing benzene (Scheme 7.7).  This unexpectedly resulted in a ring contraction 
reaction and formation of six membered lactam ring 7.14.    
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Scheme 7.7. Reagents and Conditions:(i)10 mol% 3.9, benzene, reflux, o.n (32%) 
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Data presented in Section 4.16 suggest that failure of 7.6 to undergo RCM to form the seven 
membered ring is probably due to the formation of a stable catalyst de-activating six-
membered chelate rather than the previous postulated steric reasons.  Chelation can also be 
used to account for the formation of the ring contracted product.   
 
Ring contraction is postulated to be due to a ruthenium catalysed double bond migration (7.6 
to 7.15) followed by RCM (7.15 to 7.14).  This is unusual as under normal circumstances 
RCM reactions are faster than the competing double bond migration reaction.   
 
In this thesis it is proposed that dienes such as 7.6 form a six membered catalyst deactivating 
chelate with Grubbs second generation catalyst (Scheme 7.8 and discussed in much more 
detail in Section 4.16).  This chelate prevents productive RCM and as such the “slow” (as 
compared to usual RCM reactions) ruthenium catalysed double bond migration occurs 
exclusively.  Double bond migrated diene 7.15 no longer forms a six-membered catalyst 
deactivating chelate and as such RCM to form the six membered lactam occurs quickly.   
 
It would be worthwhile to repeat this reaction using the combined microwave 
irradiation/Lewis acid RCM reaction conditions (see Section 4.16) to determine if this would 
result in the formation of the desired seven membered lactam.  
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Scheme 7.8: Catalyst deactivation and subsequent RCM ring contraction reaction 
 
This ring contraction reaction motivated further synthetic effort to prepare an N-amide 
substituted analogue of diene 7.6.  This was of interest as it was still thought that an N-amide 
substituent would facilitate productive RCM. 
 
As formation of oxazolone 7.12 (Scheme 7.4) resulted from nucleophilic attack by the oxygen 
of the benzoyl group, an alternative nitrogen protecting group was required.  As shown in 
Scheme 7.9 benzyloxycarbonyl was employed as the nitrogen protecting group.   
 
Diastereomerically pure cis-5-oxazolidinone 7.16 was prepared using a literature procedure12  
and assignment of cis to 7.16 was confirmed by comparison to literature NMR data.12  
Stereoselective allylation with allyl bromide afforded disubstituted oxazolidinone 7.17 and 
hydrolysis under basic conditions gave carboxylic acid 7.18.  Coupling of N-allyl amine 7.13 
was achieved using PyAOP as the coupling reagent.  However, ring closed product 7.20 was 
not obtained from RCM of diene 7.19.  Starting material was recovered in quantitative yield.  
This is postulated to be because diene 7.19 can still form the six membered catalyst 
deactivating chelate. 
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Scheme 7.9. Reagents and Conditions: (i) Benzaldehyde dimethylacetyl, BF3.OEt2, 4 Å 
sieves, ether, (31%); (ii) LiHMDS, allyl bromide, THF, -78oC, (50%); (iii) NaOH, THF, H2O, 
MeOH, (94%); (iv) PyAOP, DIPEA, 7.13, DMF, (18%); (v) 10 mol% 3.9, benzene, reflux, 
o.n (0%) 
 
7.2: Synthesis of C-N conformationally constrained β-amino acid lactams  
 
Recently β-amino acid containing peptides and peptidomimetics have generated considerable 
interest.  In our laboratory the incorporation of β-amino acids into cyclic lactams has been 
extensively studied.  We have developed methodology13 to synthesise compounds of general 
type 7.21. These can either be unsubstituted or substituted at the R2 position.  Compounds 
7.22 and 7.23, representative examples of this class, have been prepared by our group.    
NH
O
CBNZHN
Ph
NH
O
R2
PHN
R1
NH
O
CBNZHN
Ph7.22 7.237.21  
 
The objective of work contained in this thesis was to develop methodology to allow 
incorporation of 7.21 based motifs into peptides and peptidomimetics.   
 
The synthesis of cyclic lactam 7.29, shown in Scheme 7.10, provides an example of this 
methodology. The first step required conversion of N-CBZ protected phenylalanine into its 
corresponding β-amino acid methyl ester (7.25) under standard Arndt-Eistert homologation 
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conditions.14  The enolate of methyl ester 7.25, generated using LDA, was allylated with allyl 
bromide to give 7.26 stereospecifically.   Hydrolysis of methyl ester 7.26,  and coupling of 
resultant carboxylic acid 7.27 with amine 7.13 gave diene 7.28.  RCM was achieved using 
Grubbs second generation catalyst in refluxing benzene to give lactam 7.29. 
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Scheme 7.10. Reagents and Conditions: (i) ClCO2Et, Et3N, THF; (ii) CH2N2, AgOBn, Et3N, 
MeOH, (48% over 2 steps); (iii) LDA, LiCl, allyl bromide, THF, (65%); (iv) NaOH, THF, 
MeOH, H2O, (83%); (v) PyAOP, N-allyl-gly-OEt 7.13, DIPEA, DMF, (29%); (vi) 10 mol% 
3.9, benzene, reflux, (22%) 
 
 
7.3: Conclusions and future work 
 
Methodology for the chiral synthesis of α-α disubstituted amino acid dienes such as 7.19 has 
been developed.  However, RCM of diene 7.19 remained elusive.  Further work in this area is 
needed to optimise the RCM reaction conditions for these types of substrates.  The use of the 
combined microwave irradiation/Lewis acid reaction conditions developed in Chapter 4 
could potentially be used to ring close diene 7.19.   
 
A rare ring contraction RCM reaction was observed when diene 7.6 was subjected to Grubbs 
second generation catalyst.  Instead of obtaining a seven membered lactam, six membered 
lactam 7.14 was obtained.  This thesis proposes that this is due to the allyl amide functionality 
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forming a stable six membered catalyst deactivating chelate.  This observation certainly 
warrants further investigation. 
 
Methodology was developed for the stereoselective incorporation of a C-N constrained β-
amino acid carbocycle, such as 7.29, into a peptide or peptidomimetic.  The application of this 
methodology to the synthesis of conformationally constrained calpain inhibitors is described 
in Section 3.6 of this thesis.  
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8.1 General Methods and Experimental Procedures 
 
Melting Points 
 
All melting points were obtained on an Electrothermal apparatus and are uncalibrated. 
 
Nuclear Magnetic Resonance 
 
Proton NMR spectra were obtained on a Varian Inova spectrometer operating at either 
300 MHz or 500 MHz.  Carbon NMR spectra were obtained on a Varian Unity 300 
spectrometer, operating at 75 MHz with a delay of (D1) of 1s.  All spectra were obtained 
at 23o C unless specified.  Chemical shifts are reported in parts per million (ppm) on the  
δ scale.  Solvents used in NMR analysis (reference peak listed) included CDCl3 (CHCl3 
at δH 7.26 ppm, CDCl3 at δC 77.0 ppm); CD3OD (CHD2OD at δH 3.31 ppm, CD3OD at δC 
49.05 ppm); (CD3)2SO ((CHD2)2SO at δH 2.50 ppm, (CD3)2SO at δC 49.43 ppm).  
 
All proton assignments were made on the basis of two-dimensional NMR experiments 
including COSY, HSQC, HMBC and nOe.  All were obtained on the Varian Inova 
spectrometer operating at 500 MHz.  The HSQC and HMBC experiments were all 
obtained with a delay of (D1) of 1s. 
 
Infrared Spectroscopy 
 
Infrared spectra were obtained using a Shimadzu 9201PC series FTIR interfaced with an 
Intel 486 PC operating Shimadzu’s HyperIR software.  Spectra were obtained using solid 
KBr (diffuse reflectance). 
 
Small Molecule Mass Spectrometry 
 
Electron impact (EI) mass spectra were detected on a Kratos MS80 RFA mass 
spectrometer operating at 4000V (accelerating potential) and 70 eV (ionization energy).  
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The source temperature was 200-250o C.  Electrospray ionization (ESI) mass spectra 
were detected on a micromass LCT TOF mass spectrometer, with a probe voltage of 
3200V, temperature of 150o C and a source temperature of  80o C.  Direct ionization used 
10µL of a 10µg mL-1 solution, using a carrier solvent of 50% acetonitrile/water at a flow 
rate of 20µL min-1.  Ionization was assisted by the addition of 0.5% formic acid. 
 
Microanalysis 
 
Microanyalysis was performed at the University of Otago Microanalytical Laboratory.  
All reported values are within ±0.4% of the calculated value. 
 
Reagents, Solvents and Laboratory Methodology 
 
Oven-dried glassware was used in all reactions performed under an inert atmosphere 
(either dry nitrogen or argon).  All starting materials and reagents were obtained 
commercially unless otherwise stated.   
 
Concentration in-vacuo refers to the removal of solvents “under reduced pressure” by 
rotary evaporation (low vacuum pump) followed by application of high vacuum (oil 
pump) for a minimum of thirty minutes.   
 
Analytical thin layer chromatography (TLC) was performed on plastic-backed Merck 
Kieselgel KG60F254 silica plates.  Visualisation was achieved using short wave ultraviolet 
light and KMNO4 or phosphomolybdate dip.  Flash chromatography was performed using 
230-400 mesh Merck Silica gel 60 either under a positive pressure of dry nitrogen or 
using the Buchi sepacore flash chromatography system. 
 
THF and diethyl ether were distilled from sodium benzophenone ketyl under an inert 
atmosphere immediately prior to use.  Dichloromethane, 1,2-dichloroethane, benzene, 
toluene, triethylamine and 1,1,2-trichloroethane were distilled from calcium hydride 
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under an inert atmosphere.  Anhydrous DMF obtained from commercial sources.  
Petroleum ether refers to the fraction collected between 50-70o C.  
 
General Procedures 
All general experimental procedures afforded a single stereoisomer as drawn unless noted 
otherwise. 
 
General procedure A1: HATU mediated peptide coupling 
 
The acid, amine (2 equiv) and HATU (1.1 equiv) were dissolved in anhydrous DMF (0.10–0.50M relative 
to acid).  DIPEA was added (4 equiv) and the reaction mixture stirred at rt for 18 h.  This was partitioned 
between ethyl acetate and 1M HCl(aq).  The organic phase was then washed sequentially with 1M HCl(aq) 
and brine before being dried (MgSO4), filtered and concentrated in-vacuo. See individual experiments for 
details. 
 
General procedure A2: HATU mediated peptide coupling 
 
The acid, amine (1.1 equiv) and HATU (1.1 equiv) were dissolved in anhydrous DMF (0.10–0.50M 
relative to acid).  DIPEA was added (4 equiv) and the reaction mixture stirred at rt for 18 h.  This was 
partitioned between ethyl acetate and 1M HCl(aq).  The organic phase was washed sequentially with 1M 
HCl(aq) and brine before being dried (MgSO4), filtered and concentrated in-vacuo. See individual 
experiments for details. 
 
General procedure A3: HATU mediated peptide coupling 
 
The acid, amine (2 equiv), HATU (1.1 equiv) and HOAt (1.1 equiv) were dissolved in anhydrous DMF 
(0.10–0.50M relative to acid).  DIPEA (4 equiv) was added and the reaction mixture stirred at rt for 18 h.  
This was partitioned between ethyl acetate and 1M HCl(aq).  The organic phase was washed sequentially 
with 1M HCl(aq) and brine before being dried (MgSO4), filtered and concentrated in-vacuo. See individual 
experiments for details. 
 
General procedure B1: EDC mediated peptide coupling 
 
The acid, EDC (1.1 equiv), HOBt.H2O (1.1 eq) and amine (1.5 equiv) were dissolved in anhydrous DMF 
(0.10–0.50M relative to acid).  DIPEA was added (4.75 equiv) and the reaction mixture stirred at rt for 18 h.  
This was partitioned between ethyl acetate and 1M HCl(aq).  The organic phase was washed sequentially 
with 1M HCl(aq) and brine before being dried (MgSO4), filtered and concentrated in-vacuo. See individual 
experiments for details. 
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General procedure B2: EDC mediated peptide coupling 
 
The acid, EDC (1.2 equiv), HOBt.H2O (1.2 eq) and amine (1.1 equiv) were dissolved in anhydrous DMF 
(0.10–0.50M relative to acid).  DIPEA was added (4 equiv) and the reaction mixture stirred at rt for 18 h.  
This was partitioned between ethyl acetate and 1M HCl(aq).  The organic phase was washed sequentially 
with 1M HCl(aq) and brine before being dried (MgSO4), filtered and concentrated in-vacuo. See individual 
experiments for details. 
General procedure B3: EDC mediated peptide coupling 
 
The acid, EDC (1.3 equiv), HOBt.H2O (1.5 eq) and amine (1.1 equiv) were dissolved in anhydrous DCM 
(0.10–0.50M relative to acid).  DIPEA was added (2.5 equiv) and the reaction mixture stirred at rt for 18 h.  
More DCM was added and this was partitioned with 3M HCl(aq).  The organic phase was washed 
sequentially with 3M HCl(aq), water and brine before being dried (MgSO4), filtered and concentrated in-
vacuo. See individual experiments for details. 
 
General procedure C1: Ester hydrolysis with base 
 
The ester was dissolved in THF and to this NaOH (1.5 equiv) pre-dissolved in water was added (THF:H2O 
ratio - 3.5:1).  The minimum amount of methanol was added to obtain a homogenous solution and stirring 
was continued at rt for 18 h.  The reaction mixture was concentrated in-vacuo, the residue partitioned 
between EtOAc and 1M HCl(aq), and the aqueous phase extracted twice more with EtOAc.  The combined 
organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in-vacuo.  See 
individual experiments for details. 
 
General procedure C2: Ester hydrolysis with base 
 
The ester was dissolved in a 3:1 mixture of methanol and water (0.1M).  LiOH (5 equiv) was added and the 
mixture stirred at rt for 18 h.  The reaction mixture was concentrated in-vacuo and  the residue partitioned 
between EtOAc and 1M HCl(aq).  The aqueous phase was extracted twice more with EtOAc and the 
combined organic extracts washed with brine, dried (MgSO4), filtered and concentrated in-vacuo.  See 
individual experiments for details. 
 
General procedure D1: Ring closing metathesis at room temperature 
 
The diene was dissolved in anhydrous DCM (0.01M) under an atmosphere of argon.  Grubbs second 
generation catalyst (0.10 equiv) was added and the mixture stirred at rt for eighteen h before being 
concentrated in-vacuo. See individual experiments for details. 
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General procedure D2: Ring closing metathesis using thermal heating 
 
The diene was dissolved in anhydrous 1,1,2-trichloroethane (0.01M) under an atmosphere of argon.  
Grubbs second generation catalyst (0.10 equiv) was added.  The mixture was heated at reflux for one hour.  
Two further additions of Grubbs second generation catalyst (0.10 equiv) were added and after each the 
reaction mixture was subjected to one h and eighteen h of reflux respectively.  This was then cooled and 
concentrated in-vacuo. See individual experiments for details. 
 
General procedure E1: Ring closing metathesis using microwave heating 
 
The diene was dissolved in anhydrous 1,1,2-trichloroethane (0.01M) under an atmosphere of argon.  
Grubbs second generation catalyst (0.10 equiv) was added.  The mixture was heated at reflux in the 
microwave (1200 W) for 20 min.  Two further additions of Grubbs second generation catalyst (0.10 equiv) 
were added and after each the reaction mixture was subjected to a further 20 min heating in the microwave. 
This was then cooled and concentrated in-vacuo.  See individual experiments for details. 
 
General procedure E2: Ring closing metathesis using microwave heating and 
chloro-dicyclohexyl borane additive 
 
The diene was dissolved in anhydrous 1,1,2-trichloroethane (0.01M) under an atmosphere of argon.  To this 
were added 1M chloro-dicyclohexyl borane in hexanes (0.10 equiv) and Grubbs second generation catalyst 
(0.10 equiv).  The mixture was heated at reflux in the microwave (1200 W) for 20 min.  Two further 
additions of Grubbs second generation catalyst (0.10 equiv) were added and after each the reaction mixture 
was subjected to a further 20 min heating in the microwave. The mixture was then cooled and concentrated 
in-vacuo.  See individual experiments for details. 
 
General procedure F1: Esterification with thionyl chloride and methanol 
 
The carboxylic acid was suspended in methanol. The mixture was cooled in ice and 10% (v/v) thionyl 
chloride was added portionwise.  The solution was stirred in ice for one h and then at rt for 18 h before 
being concentrated in-vacuo. See individual experiments for details. 
 
General procedure F2: Esterification with thionyl chloride and methanol 
 
The carboxylic acid was suspended in methanol. This was cooled in ice and 20% (v/v) thionyl chloride was 
added portionwise.  The solution was stirred in ice for one h and then at rt for 18 h before being 
concentrated in-vacuo. See individual experiments for details. 
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General procedure G1: Hydrogenation of a carbon-carbon double bond 
 
The olefin was dissolved in methanol and 20% (w/w) of 10% palladium on carbon catalyst was added.  The 
mixture was subjected to hydrogenation at rt and atmospheric pressure for 18 h. The mixture was filtered 
through celite and concentrated in-vacuo.  See individual experiments for details. 
 
General procedure G2: Hydrogenation of a carbon-carbon double bond 
 
The olefin was dissolved in a 1:1 mixture of methanol/ethyl acetate and 20% (w/w) of 10% palladium on 
carbon catalyst was added.  The mixture was subjected to hydrogenation at rt and atmospheric pressure for 
18 h. The mixture was filtered through celite and concentrated in-vacuo.  See individual experiments for 
details. 
 
General procedure G3: Hydrogenation of a carbon-carbon double bond 
 
The olefin was dissolved in a 1:1 mixture of methanol and DCM and 20% (w/w) of 10% palladium on 
carbon catalyst was added.  The mixture was subjected to hydrogenation at rt and atmospheric pressure for 
18 h. The mixture was filtered through celite and concentrated in-vacuo.  See individual experiments for 
details. 
 
General procedure H1: N-CBZ protection of an amino acid  
 
The amine was dissolved in anhydrous DMF.  Benzyl chloroformate (1.5 equiv) and DIPEA (4 equiv) were 
added, and the mixture stirred at rt for 18 h.  The reaction mixture was partitioned between chloroform and 
1M HCl(aq).  The aqueous phase was separated and extracted three times with chloroform.  The combined 
organic extracts were dried (MgSO4), filtered and concentrated in-vacuo.  See individual experiments for 
details. 
 
General procedure H2: N-CBZ protection of an amino acid  
 
The amine was dissolved in anhydrous DMF.  Benzyl chloroformate (1.5 equiv) and DIPEA (4 equiv) were 
added and the mixture stirred at rt for 18 h.  The reaction mixture was partitioned between ethyl acetate and 
1M HCl(aq), the aqueous phase was separated and extracted three more times with ethyl acetate.  The 
combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in-vacuo.  See 
individual experiments for details. 
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General procedure I1: N-BOC cleavage  
 
The N-BOC protected compound in 4M HCl in 1,4-dioxane was stirred at rt for 18 h.  The solution was 
then concentrated in-vacuo.  See individual experiments for details. 
 
General procedure I2: N-BOC cleavage  
 
The N-BOC protected compound in 10% TFA, DCM (v/v) was stirred at rt for 18 h.  The solution was then 
concentrated in-vacuo.  See individual experiments for details. 
General procedure I3: N-BOC cleavage  
 
The N-BOC protected compound in 2M HCl in diethyl ether was stirred at rt for 18 h.  The solution was 
then concentrated in-vacuo.  See individual experiments for details.  
 
General procedure I4: N-BOC cleavage  
 
The N-BOC protected compound in diethyl ether was cooled in ice and saturated with gaseous hydrogen 
chloride.  This was warmed to rt, stirred for 18 h and concentrated in-vacuo.  See individual experiments 
for details. 
 
General procedure I5: N-BOC cleavage  
 
The N-BOC protected compound dissolved/suspended in methanol was cooled in ice and 10% (v/v) thionyl 
chloride was added portionwise.  The solution was stirred in ice for one h and then at rt for 18 h before 
being concentrated in-vacuo. See individual experiments for details. 
 
General procedure J: One pot esterification and N-BOC cleavage 
 
A suspension of N-BOC carboxylic acid in methanol was cooled in ice and 20% (v/v) thionyl chloride was 
added portionwise.  The solution was stirred in ice for one h and then at rt for 18 h before being 
concentrated in-vacuo. See individual experiments for details. 
 
General procedure K: N-BOC protection of an amino acid 
 
The amino acid was dissolved in a 1/1 biphasic mixture of water and 1,4-dioxane.  To this were added 
triethylamine (2.8 equiv) and di-tert-butyl dicarbonate (1.2 equiv).  The mixture was stirred at rt for 
eighteen h before being concentrated in vacuo.  The residue was partitioned between ethyl acetate and 10% 
(w/w) citric acid(aq).  The aqueous phase was re-extracted twice more with ethyl acetate and the combined 
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organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in vacuo.  See individual 
experiments for details. 
 
General procedure L: Sulfur trioxide/pyridine complex oxidation of an alcohol. 
 
A solution of the alcohol in a 2:1 mixture of DMSO and DCM (0.10M) was cooled in ice and DIPEA (4 
equiv) was added.  To this a solution of SO3.Pyr complex dissolved in DMSO was added.  The mixture was 
stirred in ice for one h (or until TLC indicated complete consumption of the starting alcohol).  The reaction 
mixture was diluted with ethyl acetate and partitioned with 1M HCl(aq).  The organic phase was washed 
with saturated NaHCO3(aq) and brine before being dried (MgSO4), filtered and concentrated in vacuo.  See 
individual experiments for details. 
 
General procedure M1: Sulfonyl chloride coupling to an amine. 
 
The amine was dissolved in anhydrous DCM (0.1M) under an atmosphere of argon.  To this were added 
anhydrous triethylamine (4 equiv) and the sulfonyl chloride (1.1 equiv).  The mixture was stirred at rt for 
eighteen h.  The reaction mixture was diluted with further DCM and partitioned with 1M HCl(aq).  The 
organic phase was washed twice more with 1M HCl(aq), twice with 50% NaHCO3(aq) and once with brine 
before being dried (MgSO4), filtered and concentrated in vacuo.  See individual experiments for details. 
 
General procedure M2: Sulfonyl chloride coupling to an amine. 
 
To a solution of the amine in anhydrous DCM (0.1M) under an atmosphere of argon, were added DIPEA 
(2.2 equiv) and sulfonyl chloride (1.1 equiv).  The mixture was stirred at rt for eighteen h before  
concentrated in vacuo.  The residue was partitioned between ethyl acetate and 1M HCl(aq) and the organic 
phase washed sequentially with 1M HCl(aq) and brine, dried (MgSO4), filtered and concentrated in vacuo.  
See individual experiments for details. 
 
General procedure M3: Sulfonyl chloride coupling to an amine. 
 
To a solution of the amine in anhydrous DMF (0.1M) under an atmosphere of argon, were added DIPEA 
(2.2 equiv) and sulfonyl chloride (1.1 equiv).  The mixture was stirred at rt for eighteen h.  The reaction 
mixture was diluted with ethyl acetate and partitioned with 1M HCl(aq). The organic phase was washed 
again with 1M HCl(aq) and then with brine, dried (MgSO4), filtered and concentrated in vacuo.  See 
individual experiments for details. 
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General procedure O1: N-allylation. 
 
To a solution of the amine in anhydrous DMF (0.2M) under an atmosphere of argon, were added potassium 
carbonate (2 equiv) and allyl bromide (1.2 equiv).  The mixture was stirred at rt for eighteen h before being 
diluted with ethyl acetate and partitioned with 1M HCl(aq).  The aqueous phase was extracted twice more 
with ethyl acetate.  The combined organic extracts were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo.  See individual experiments for details. 
   
General procedure O2: N-allylation. 
 
To a solution of the amine in anhydrous DMF (0.2M) under an atmosphere of argon, were added potassium 
carbonate (2 equiv) and allyl bromide (4 equiv).  The mixture was stirred at rt for eighteen h before being 
diluted with ethyl acetate and partitioned with 1M HCl(aq).  The aqueous phase was extracted twice more 
with ethyl acetate.  The combined organic extracts were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo.  See individual experiments for details. 
 
General procedure O3: N-allylation. 
 
The sulfonamide/amide was dissolved in anhydrous THF (0.1M) under an atmosphere of argon.  The 
solution was cooled to -78oC and P4-phosphazene (2 equiv per NH) was added.  The mixture was stirred at 
-78oC for one h and then allyl bromide (2 equiv per NH) was added.  The mixture was stirred at -78oC for a 
further two h and then at rt for eighteen h before being concentrated in vacuo.  The residue was partitioned 
between ethyl acetate and 1M HCl(aq).  The organic phase was washed sequentially with 1M HCl(aq) and 
brine before being dried (MgSO4), filtered and concentrated in vacuo.  See individual experiments for 
details. 
 
General procedure P: Arndt-Eistert homologation. 
 
The N-protected α-amino acid was dissolved in anhydrous THF, under an atmosphere of argon and this was 
cooled to -25oC.  Triethylamine (1 equiv) and ethyl chloroformate (1 equiv) were added and the mixture 
was stirred at -25oC for twenty min.  The mixture was warmed in ice and ethereal diazomethane (~1.2 
equiv) was added dropwise over ten min.  This was stirred in ice for two h and then at rt for a further 
sixteen h.  Glacial acetic acid was added to quench the reaction followed by 1M NaOH(aq) to adjust the 
solution to pH 8.  Ethyl acetate and water were added and the mixture allowed to partition.  The aqueous 
phase was separated and extracted again with ethyl acetate.  The combined organic extracts were washed 
sequentially with saturated NH4Cl(aq) and brine, before being dried (MgSO4), filtered and concentrated in 
vacuo.  The resultant diazoketone was used without purification.  A suspension the diazoketone in super-
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dry methanol (0.25M), under an atmosphere of argon, was cooled to -25oC and a solution of silver benzoate 
(0.11 equiv) in triethylamine (2.9 equiv) was added.  The mixture was stirred at -25oC for fifteen min and 
then at rt for eighteen h before being concentrated in vacuo.  The residue was partitioned between ethyl 
acetate and saturated NaHCO3(aq).  The organic phase was washed sequentially with saturated NH4Cl(aq) and 
brine before being dried (MgSO4), filtered and concentrated in vacuo.  See individual experiments for 
details. 
 
General procedure Q: C-allylation. 
 
A solution of diisopropylamine (2.2 equiv) and LiCl (3 equiv) in anhydrous THF (0.1M) under an 
atmosphere of argon, was cooled to -78oC.  nBuLi (2.2 equiv) was added and the mixture was stirred at -
78oC for thirty min.  A solution of the N-protected β-amino acid (1 equiv) in THF (1M) and allyl bromide 
(4 equiv) were added.  Stirring was continued at -78oC for one h and then at rt for a further seventeen h 
before being concentrated in vacuo.  The residue was partitioned between ethyl acetate and saturated 
NH4Cl(aq), the organic phase washed with saturated NaHCO3(aq) and brine before being dried (MgSO4), 
filtered and concentrated in vacuo.  See individual experiments for details. 
 
General procedure R: DIBAL-H reduction of methyl ester to aldehyde. 
 
A solution of the ester in anhydrous DCM (0.01M), under an atmosphere of argon, was cooled to -78 ˚C. 
DIBAL-H (5.5 equiv) was added dropwise.  The mixture was stirred at -78 ˚C for three h and super-dry 
methanol (1:1 ratio with DCM initially added), precooled to -78 ˚C, was added dropwise and the mixture 
stirred at -78 ˚C for a further twenty five min.  The cooling bath was removed and 1M HCl(aq) added.  The 
organic layer was separated from the resulting white precipitate, diluted with ethyl acetate and allowed to 
partition.  The organic phase was washed sequentially with 1M HCl(aq), saturated NaHCO3(aq) and brine 
before being dried (MgSO4), filtered and concentrated in vacuo.  See individual experiments for details. 
 
General procedure S: Lithium aluminium hydride reduction of methyl ester to 
alcohol. 
A solution of the methyl ester dissolved in anhydrous THF (0.1M), under an atmosphere of argon, was 
cooled in ice. 1M LiAlH4 in either diethyl ether or THF was added (1.1 equiv).  The mixture was stirred in 
ice for one h and then at rt for a further seventeen h.  Methanol was added to quench the reaction and the 
mixture was stirred at rt for ten min before being concentrated in-vacuo.  The residue was partitioned 
between EtOAc and 1M KHSO4(aq).  The aqueous phase was extracted twice more with chloroform and 
each organic extract was washed with brine before being combined, dried (MgSO4), filtered and 
concentrated in-vacuo.  See individual experiments for details.  
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5-Formyl-1H-pyrrole-2-carboxylic acid [1-((S)-(S)-1-formyl-3-methyl-butylcarbamoyl)-2-methylpropyl]-
amide (2.13) 
N
H
H
O
O
N
H
N
H
O
H
O
 
Alcohol 2.18 (0.600g, 1.78 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a yellow solid, 0.394g, 
66%.  Rf = 0.38 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 11.71 (1H, bs, NH Pyrrole), 9.61 (1H, s, CHO), 9.59 (1H, s, CHO), 7.55 
(1H, d J=6.7Hz, NH Leu), 7.35 (1H, d J=8.4Hz, NH Val), 6.96 (1H, d J=2.7Hz, Ar-H), 6.79 (1H, d J=2.7Hz, Ar-
H), 4.79 (1H, dd, J=8.4Hz, J=8.4Hz, CHCH(CH3)2), 4.44-4.58 (1H, m, CHCH2CH(CH3)2), 2.07-2.19 (1H, m, 
CHCH(CH3)2), 1.60-1.69 (2H, m, CHCH2CH(CH3)2), 1.33-1.48 (1H, m, CHCH2CH(CH3)2), 1.07 (3H, d J=6.6 
Hz, CHCH(CH3)2), 1.02 (3H, d, J=6.6 Hz, CHCH(CH3)2), 0.85 (3H, d J=6.1 Hz, CHCH2CH(CH3)2), 0.82 (3H, d 
J=6.1 Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 199.4, 180.5, 172.1, 160.0, 134.2 , 132.0, 121.0, 111.4, 58.9, 57.5, 37.3, 
31.0, 24.6, 22.8, 21.7, 19.2, 18.8   
 
HRMS (ES) 336.1925 (MH+). C17H25N3O4 requires 336.1923 
 
Microanalysis. C, 58.99; H, 7.28; N, 12.07.  C17H25N3O4 requires C, 59.29; H, 7.61; N, 12.20 
 
[(S)-1-((S)-1-Hydroxymethyl-3-methyl-butylcarbamoyl)-2-methylpropyl]carbamic acid tert-butyl ester 
(2.14) 
BOCHN
N
H
O
OH
 
N-BOC-Val-H (9.26g, 42.7 mmol) was reacted with (L)-leucinol using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 9.18g, 68%.  Rf = 0.24 (2/1 (EtOAc / (50/70) Pet ether)). 
mp 54-56 ºC  
 
1H NMR ppm (500 MHz in CDCl3)  6.24 (1H, d J=7.9Hz, NH Leu), 5.10 (1H, d J=7.32Hz, NH Val), 3.99–4.06 
(1H, m, CHCH2CH(CH3)2), 3.80 (1H, dd J=7.3Hz, J=7.3Hz, CHCH(CH3)2), 3.65 (1H, dd J=3.2Hz, J=11.1Hz, 
CH2OH), 3.50 (1H, dd J=5.6Hz, J=11.1Hz, CH2OH), 2.06-2.16 (1H, m, CHCH(CH3)2), 1.58-1.62 (1H, m, 
CHCH2CH(CH3)2), 1.43 (9H, s, C(CH3)3), 0.88-0.97 (12H, m, CHCH2CH(CH3)2 and CHCH(CH3)2) 
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13C NMR ppm (75 MHz in CD3OD) 172.9, 163.3, 79.2, 64.3, 60.7, 49.3, 39.8, 30.4, 27.4, 24.4, 22.6, 21.0, 18.5, 
17.3 
 
HRMS (ES) 317.2249 (MH+). C16H32N2O4 requires 317.2240 
 
(S)-2-Amino-N-((S)-1-hydroxymethyl-3-methylbutyl)-3-methylbutyramide (2.15) 
HCl.H2N N
H
O
OH
 
N-BOC protected compound 2.14 (7.00g, 22.2 mmol) was reacted using General Procedure I1 to afford a white 
solid, 5.59g, 100%. 
mp 64-66 ºC 
 
1H NMR ppm (500 MHz in (CD3)2SO) 8.13 (2H, bs, NH2) 4.72-4.77 (1H, m, CHCH2CH(CH3)2), 3.79-3.87 (1H, 
m, CHCH(CH3)2) 3.52-3.56 (1H, m, CH2OH), 3.26 (1H, dd J=6.0Hz, J=16.0Hz, CH2OH), 2.02-2.08 (1H, m, 
CHCH(CH3)2), 1.60-1.68 (1H, m, CHCH2CH(CH3)2), 1.30-1.33 (2H, m, CHCH2CH(CH3)2), 0.85-0.94 (12H, m, 
CHCH2CH(CH3)2 and CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in (CD3)2SO) 167.1, 63.4, 57.3, 49.2, 29.7, 23.9, 23.3, 21.9, 18.2, 17.9.  
 
HRMS (ES) 217.1910 (MH+). C11H24N2O2 requires 217.1916  
 
5-Formyl-1H-pyrrole-2-carboxylic acid ethyl ester (2.16) and 4-Formyl-1H-pyrrole-2-carboxylic acid ethyl 
ester (2.19) 
N
H
CO2Et
H
O
N
H
CO2Et
O
H
2.16 2.19  
Phosphorus oxychloride (7.36 mL, 79.0 mmol) was added dropwise over fifteen min to DMF (1 equiv) in ice 
under an atmosphere of argon.  A solution of  pyrrole-2-carboxylic ethyl ester (0.91 equiv) in DCE (18 mL) was 
added dropwise at in ice over one h.  This was then heated at reflux for fifteen min, cooled in ice and a solution 
of sodium acetate tri-hydrate (5.00 equiv) in water (80 mL) was added.  This was refluxed for fifteen min, cooled 
and diethyl ether (150 mL) was added.  The mixture was partitioned and the aqueous phase was extracted twice 
more with diethyl ether.  The combined organic extracts were washed sequentially with saturated NaHCO3(aq) 
and brine, dried (MgSO4), filtered and concentrated in vacuo.  The crude material was purified by flash 
chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 5-formyl product as a yellow 
solid, 6.25g, 52%.  Rf = 0.46 (1/1 (EtOAc / (50/70) Pet ether)) and 4-formyl product as a brown solid, 3.24g, 
27%.  Rf = 0.29 (1/1 (EtOAc / (50/70) Pet ether)). 
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5-Formyl-1H-pyrrole-2-carboxylic acid ethyl ester (2.16) Lit1 
mp 71-73oc.  
 
1H NMR ppm (500 MHz in CDCl3) 9.95 (1H, bs, NH), 9.66 (1H, s, CHO), 6.92-6.94 (2H, m, Ar-H), 4.38 (2H, q 
J=7.1Hz, CO2CH2CH3), 1.38 (3H, t J=7.1Hz, CO2CH2CH3) 
 
LRMS (ES) 168.1 (MH+). C8H9NO3 requires 168.1  
 
4-Formyl-1H-pyrrole-2-carboxylic acid ethyl ester (2.19) Lit2 
mp 102-104oc. Lit2 104-106oc. 
 
1H NMR ppm (500 MHz in CDCl3) 10.32 (1H, bs, NH), 9.84 (1H, s, CHO), 7.58 (1H, d J=1.5Hz, Ar-H), 7.32 
(1H, d J=1.5Hz, Ar-H), 4.35 (2H, q J=7.1Hz, J=7.1Hz, J=7.2Hz, CO2CH2CH3), 1.37 (3H, t, J=7.1Hz, J=7.1Hz, 
CO2CH2CH3) 
 
LRMS (ES) 168.1 (MH+). C8H9NO3 requires 168.1 
 
5-Formyl-1H-pyrrole-2-carboxylic acid (2.17) Lit1 
N
H
H
O
CO2H
 
To a suspension of ethyl ester 2.16 (6.30g, 37.7 mmol) in water (190 mL) potassium hydroxide (4 equiv) was 
added.  This was stirred at 40oC for two h, cooled, acidified to pH 1 using cHCl and EtOAc (200 mL) added.  
This was partitioned and the aqueous phase extracted twice more with EtOAc.  The combined organic extracts 
were dried (MgSO4), filtered and concentrated in vacuo to afford a yellow solid, 5.03g, 96%.     
mp 200-203oc. 
 
1H NMR ppm (500 MHz in (CD3)2SO) 13.09 (1H, bs, CO2H), 12.88 (1H, bs, NH), 9.68 (1H, s, CHO), 6.94 (1H, 
d J=3.7Hz, Ar-H), 6.83 (1H, d J=3.7Hz, Ar-H)) 
 
13C NMR ppm (75 MHz in (CD3)2SO). 176.1, 156.2, 130.0, 123.8, 111.2, 110.2  
  
LRMS (ES) 140.0 (MH+). C6H5NO3 requires 140.0  
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5-Formyl-1H-pyrrole-2-carboxylic acid {1-[(S)-1-((S)-hydroxymethyl)-3-methylbutylcarbamoyl]-2-methyl-
propyl}amide (2.18) 
N
H
H
O
O
N
H
N
H
O
OH
 
Carboxylic acid 2.17 (0.321g, 2.31 mmol) was reacted with amine 2.15 using General Procedure B3.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a yellow solid, 0.304g, 39%.  Rf = 0.22 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 9.58 (1H, s, CHO), 6.99 (1H, d J=4.0Hz, Ar-H), 6.95 (1H, d J=4.0Hz, Ar-
H), 4.28 (1H, d J=8.3 Hz, CHCH(CH3)2), 3.95-4.02 (1H, m, CHCH2CH(CH3)2), 3.47 (1H, dd J=5.4Hz, 
J=10.9Hz, CH2OH), 3.43 (1H, dd J=5.6Hz, J=10.9, CH2OH), 2.08-2.17 (1H, m, CHCH(CH3)2), 1.58-1.69 (1H, 
m, CHCH2CH(CH3)2), 1.31-1.34 (2H, m, CHCH2CH(CH3)2), 0.99 (3H, d J=6.7 Hz, CHCH(CH3)2), 0.98 (3H, d 
J=6.7 Hz, CHCH(CH3)2), 0.88 (3H, d J=6.7Hz, CHCH2CH(CH3)2), 0.84 (3H, d J=6.7 Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CD3OD). 180.9, 172.1, 134.6, 119.2, 112.5, 112.0, 64.2, 59.5, 49.4, 39.7, 30.4, 24.5, 
22.4, 20.9, 18.5, 17.8   
 
HRMS (ES) 338.2080 (MH+). C17H27N3O4 requires 338.2086 
 
Microanalysis. C, 59.89; H, 8.44; N, 13.70.  C17H27N3O4 requires C, 60.35; H, 8.86; N, 13.20 
 
5-Formyl-1H-pyrrole-2-carboxylic acid [1-((S)-(S)-1-formyl-3-methylbutylcarbamoyl)-2-methylpropyl]-
amide (2.13) 
N
H
H
O
O
N
H
N
H
O
H
O
 
Alcohol 2.18 (0.600g, 1.78 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a yellow solid, 0.394g, 
66%.  Rf = 0.38 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 11.71 (1H, bs, NH Pyrrole), 9.61 (1H, s, CHO), 9.59 (1H, s, CHO), 7.55 
(1H, d J=6.7Hz, NH Leu), 7.35 (1H, d J=8.4Hz, NH Val), 6.96 (1H, d J=2.7Hz, Ar-H), 6.79 (1H, d J=2.7Hz, Ar-
H), 4.79 (1H, dd, J=8.4Hz, J=8.4Hz, CHCH(CH3)2), 4.44-4.58 (1H, m, CHCH2CH(CH3)2), 2.07-2.19 (1H, m, 
CHCH(CH3)2), 1.60-1.69 (2H, m, CHCH2CH(CH3)2), 1.33-1.48 (1H, m, CHCH2CH(CH3)2), 1.07 (3H, d J=6.6 
Hz, CHCH(CH3)2), 1.02 (3H, d, J=6.6 Hz, CHCH(CH3)2), 0.85 (3H, d J=6.1 Hz, CHCH2CH(CH3)2), 0.82 (3H, d 
J=6.1 Hz, CHCH2CH(CH3)2) 
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13C NMR ppm (75 MHz in CDCl3). 199.4, 180.5, 172.1, 160.0, 134.2 , 132.0, 121.0, 111.4, 58.9, 57.5, 37.3, 
31.0, 24.6, 22.8, 21.7, 19.2, 18.8   
 
HRMS (ES) 336.1925 (MH+). C17H25N3O4 requires 336.1923  
 
Microanalysis. C, 58.99; H, 7.28; N, 12.07.  C17H25N3O4 requires C, 59.29; H, 7.61; N, 12.20 
 
4-Formyl-1H-pyrrole-2-carboxylic acid (2.20) Lit2 
N
H
CO2H
O
H
 
To a suspension of ethyl ester 2.19 (3.20g, 19.1 mmol) in water (100 mL) was added potassium hydroxide (4 
equiv).  This was stirred at 40oC for two h, cooled, acidified to pH 1 using cHCl and EtOAc added (200 mL).  
This was partitioned and the aqueous phase extracted twice more with EtOAc.  The combined organic extracts 
were dried (MgSO4), filtered and concentrated in vacuo to afford a brown solid, 2.50g, 94%.     
 
1H NMR ppm (500 MHz in (CD3)2SO) 12.85 (1H, bs, CO2H), 12.53 (1H, s, NH), 9.74 (1H, s, CHO), 7.77 (1H, d 
J=1.5Hz, Ar-H), 7.07 (1H, d J=1.5Hz, Ar-H) 
 
13C NMR ppm (75 MHz in (CD3)2SO). 185.8, 161.5, 130.8, 126.5, 125.6, 112.5  
  
LRMS (ES) 140.0 (MH+). C6H5NO3 requires 140.0  
 
4-Formyl-1H-pyrrole-2-carboxylic acid {1-[(S)-1-((S)-hydroxymethyl)-3-methylbutylcarbamoyl]-2-methyl-
propyl}amide (2.21) 
N
H
O
N
H
N
H
O
OH
O
H
 
Carboxylic acid 2.20 (0.175g, 1.26 mmol) was reacted with amine 2.15 using General Procedure B3.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a brown solid, 0.102g, 24%.  Rf = 0.18 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 11.49 (1H, bs, NH Pyrrole), 9.80 (1H, s, CHO), 7.57-7.70 (4H, m, Ar-H and 
NH Leu and NH Val), 4.56 (1H, dd J=8.8Hz, J=8.8Hz,  CHCH(CH3)2), 4.07-4.16 (1H, m, CHCH2CH(CH3)2), 
3.75 (1H, dd J=3.3Hz, J=11.2Hz, CH2OH), 3.63 (1H, dd J=5.6Hz, J=11.2Hz, CH2OH), 2.11-2.19 (1H, m, 
CHCH(CH3)2,), 1.52-1.68 (1H, m, CHCH2CH(CH3)2), 1.26-1.44 (2H, m, CHCH2CH(CH3)2), 1.01 (3H, d 
J=6.7Hz, CHCH(CH3)2), 0.97 (3H, d J=6.7 Hz, CHCH(CH3)2), 0.82 (3H, d J=6.5Hz, CHCH2CH(CH3)2), 0.77 
(3H, d J=6.5Hz, CHCH2CH(CH3)2) 
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13C NMR ppm (75 MHz in CDCl3). 172.4, 160.9, 130.1, 128.1, 127.0, 109.2, 65.7, 59.4, 50.1, 39.7, 31.2, 24.8, 
22.7, 22.2, 19.2, 18.8  
 
HRMS (ES) 338.2079 (MH+). C17H27N3O4 requires 338.2086 
 
4-Formyl-1H-pyrrole-2-carboxylic acid [1-((S)-(S)-1-formyl-3-methylbutylcarbamoyl)-2-methylpropyl]-
amide (2.22) 
N
H
O
N
H
N
H
O
H
O
O
H
 
Alcohol 2.21 (0.100g, 0.296 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a yellow solid, 0.0179g, 
18%.  Rf = 0.26 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 10.01 (1H, bs, NH Pyrrole), 9.85 (1H, s, CHO), 9.84 (1H, s, CHO), 7.59-
7.61 (2H, m, NH Leu and NH Val), 7.56-7.59 (2H, m, Ar-H), 4.28-4.43 (2H, m, CHCH(CH3)2 and 
CHCH2CH(CH3)2), 2.03-2.22 (1H, m, CHCH(CH3)2), 1.35-1.43 (3H, m CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 1.01 (3H, d J=6.5Hz, CHCH(CH3)2), 0.98 (3H, d J=6.5 Hz, CHCH(CH3)2), 0.84 (3H, d 
J=6.4Hz, CHCH2CH(CH3)2), 0.79 (3H, d J=6.4Hz, CHCH2CH(CH3)2) 
 
HRMS (ES) 336.1918 (MH+). C17H25N3O4 requires 336.1923 
 
Furan-2-carboxylic acid [(S)-1-((S)-1-hydroxymethyl-3-methylbutylcarbamoyl)-2-methylpropyl]amide 
(2.24) 
O
O
N
H
N
H
O
OH
 
Amino alcohol 2.15 (1.00g, 3.96 mmol) was dissolved in anhydrous DCM (30 mL) under at atmosphere of 
argon.  To this DMAP (1.1 equiv) and triethylamine (3 equiv) were added.  This was cooled in ice and 2-furoyl 
chloride added (1 equiv).  This was stirred in ice for two h and then at rt for eighteen h.  The reaction mixture 
was diluted with DCM, partitioned with 1M HCl(aq) and the organic phase dried (MgSO4), filtered and 
concentrated in vacuo.  The crude material was purified by flash chromatography on silica using a gradient of 
EtOAc and (50/70) pet ether to yield a white solid, 0.344g, 28%.  Rf = 0.11 (1/1 (EtOAc / (50/70) Pet ether)). 
mp 38-4in ice. 
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1H NMR ppm (500 MHz in CD3OD) 7.66 (1H, dd J=1.2Hz, J=2.1Hz, Ar-H), 7.13 (1H, dd J=2.1Hz, J=3.4Hz, 
Ar-H), 6.57 (1H, dd J=1.2Hz, J=3.4Hz, Ar-H), 4.29 (1H, d J=7.9Hz, CHCH(CH3)2), 3.97-4.01 (1H, m, 
CHCH2CH(CH3)2), 3.51 (1H, dd J=5.3Hz, J=10.8Hz, CH2OH), 3.46 (1H, dd J=5.6Hz, J=10.8Hz, CH2OH), 2.10-
2.19 (1H, m, CHCH(CH3)2), 1.58-1.67 (1H, m, CHCH2CH(CH3)2), 1.31-1.42 (2H, m, CHCH2CH(CH3)2), 1.00 
(3H, d J=6.8 Hz, CHCH(CH3)2), 0.98 (3H, d J=6.8 Hz, CHCH(CH3)2), 0.87 (3H, d J=6.7 Hz, CHCH2CH(CH3)2), 
0.85 (3H, d J=6.7Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CD3OD). 172.0, 159.0, 147.2, 145.1, 114.4, 111.8, 64.3, 59.0, 49.5, 39.7, 30.8, 24.6, 
22.5, 21.1, 18.6, 17.8  
 
HRMS (ES) 311.1793 (MH+). C16H26N2O4 requires 311.1971  
 
FTIR CM-1 (KBr) 3277, 2958, 1633, 1593, 1519, 758 
 
Microanalysis. C, 61.83; H, 8.93; N, 8.84.  C16H26N2O4 requires C, 61.91; H, 8.44; N, 9.03 
 
Furan-2-carboxylic acid [(S)-1-((S)-1-formyl-3-methylbutylcarbamoyl)-2-methylpropyl]amide (2.25) 
O
O
N
H
N
H
O
H
O
 
Alcohol 2.24 (0.340g, 1.10 mmol) was oxidised using General Procedure L to afford a white solid, 0.304g, 90%.   
mp 42-44oc. 
 
1H NMR ppm (500 MHz in CDCl3) 9.52 (1H, s, CHO), 7.59 (1H, d J=7.4Hz, NH Leu), 7.39 (1H, bs, Ar-H), 
7.15 (1H, d J=9.1Hz, NH Val), 7.07 (1H, dd J=0.8Hz, J=3.2Hz, Ar-H), 6.42 (1H, dd J=1.4Hz, J=3.2Hz, Ar-H), 
4.68 (1H, dd J=7.4Hz, J=9.1Hz, CHCH(CH3)2), 4.38-4.42 (1H, m, CHCH2CH(CH3)2), 2.15-2.23 (1H, m, 
CHCH(CH3)2), 1.55-1.61 (2H, m, CHCH2CH(CH3)2), 1.35-1.44 (1H, m, CHCH2CH(CH3)2), 1.04 (3H, d 
J=6.7Hz, CHCH(CH3)2), 1.00 (3H, d J=6.7 Hz, CHCH(CH3)2), 0.83 (3H, d J=5.5 Hz, CHCH2CH(CH3)2), 0.80 
(3H, d J=5.5Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 199.6, 171.6, 158.2, 147.2, 144.4, 114.7, 112.0, 57.7, 57.2, 37.1, 31.6, 24.6, 
22.8,21.7, 19.2, 18.2  
 
HRMS (ES) 309.1820 (MH+). C16H24N2O4 requires 309.1814  
 
FTIR CM-1(KBr) 3287, 2961, 1738, 1645, 1519, 758 
 
Microanalysis. C, 58.50; H, 7.73; N, 8.47.  C16H26N2O4 requires C, 58.88; H, 8.03; N, 8.58 
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5-Formylfuran-2-carboxylic acid {1-[(S)-1-((S)-hydroxymethyl)-3-methylbutylcarbamoyl]-2-methyl-
propyl}amide (2.27) 
O
H
O
O
N
H
N
H
O
OH
 
 
5-Formyl-furyl-2-carboxylic acid (0.554g, 3.96 mmol) was reacted with amine 2.15 using General Procedure B2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a white solid, 0.321g, 24%.  Rf = 0.43 (2/1 (EtOAc / (50/70) Pet ether)). 
mp 46-48oc. 
 
1H NMR ppm (500 MHz in CDCl3) 9.75 (1H, s, CHO), 7.25-7.29 (2H, m, Ar-H), 7.26 (1H, d J=6.4Hz NH Val), 
6.21 (1H, d J=8.0Hz, NH Leu), 4.38-4.41 (1H, m, CHCH(CH3)2), 4.05-4.10 (1H, m, CHCH2CH(CH3)2), 3.71 
(1H, dd J=3.4Hz, J=11.0Hz, CH2OH), 3.60 (1H, dd J=5.5Hz, J=11.0Hz, CH2OH), 2.17-2.26 (1H, m, 
CHCH(CH3)2), 1.51-1.60 (1H, m, CHCH2CH(CH3)2), 1.37-1.43 (2H, m, CHCH2CH(CH3)2), 0.97 (3H, d 
J=7.2Hz, CHCH(CH3)2), 0.96 (3H, d J=7.2 Hz, CHCH(CH3)2), 0.81 (3H, d J=5.7Hz, CHCH2CH(CH3)2), 0.80 
(3H, d J=5.7 Hz, CHCH2CH(CH3)2)  
 
13C NMR ppm (75 MHz in CDCl3) 178.5, 170.9, 170.8, 157.3, 152.5, 150.6, 115.9, 65.1, 58.8, 49.9, 39.8, 31.5, 
24.8, 22.8, 22.3, 19.2, 18.5 
 
HRMS (ES) 339.1906 (MH+). C17H26N2O5 requires 339.1920  
 
FTIR CM-1 (KBr) 2962, 2353, 1688, 1655, 1543 
 
Microanalysis. C, 60.58; H, 7.57; N, 8.09.  C17H26N2O5 requires C, 60.34; H, 7.74; N, 8.28 
 
5-Formylfuran-2-carboxylic acid [1-((S)-(S)-1-formyl-3-methylbutylcarbamoyl)-2-methylpropyl] amide 
(2.28) 
O
H
O
O
N
H
N
H
O
H
O
 
Alcohol 2.27 (0.180g, 0.532 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white solid, 0.100g, 
56%.  Rf = 0.42 (2/1 (EtOAc / (50/70) Pet ether)). 
mp 39-41oc. 
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1H NMR ppm (500 MHz in CDCl3) 9.73 (1H, s, Ar-CHO), 9.59 (1H, s, Leu-CHO), 7.35 (1H, d J=8.8Hz, NH 
Val), 7.30 (1H, d J=3.6Hz, Ar-H), 7.26 (1H, d J=3.6Hz, Ar-H), 6.85 (1H, d J=7.1Hz, NH Leu), 4.54-4.60 (2H, 
m, CHCH(CH3)2 and CHCH2CH(CH3)2), 2.20-2.28 (1H, m, CHCH(CH3)2), 1.66-1.72 (2H, m, 
CHCH2CH(CH3)2), 1.40-1.47 (1H, m, CHCH2CH(CH3)2), 1.06 (3H, d J=6.9 Hz, CHCH(CH3)2), 1.04 (3H, d 
J=6.9 Hz, CHCH(CH3)2), 0.93 (3H, d J= 5.6 Hz, CHCH2CH(CH3)2 ), 0.92 (3H, d J=5.6 Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 199.6, 178.5, 171.2, 157.4, 152.6, 150.5, 121.1, 116.0, 58.4, 57.4, 37.3, 31.4, 
24.7, 22.9, 21.8, 19.3, 18.4 
 
HRMS (ES) 337.1761 (MH+). C17H24N2O5 requires 337.1763 
 
FTIR CM-1 (KBr) 3279, 2959, 1734, 1687, 1651, 1539, 1494 
 
Microanalysis. C, 60.37; H, 7.35; N, 8.09.  C17H26N2O5 requires C, 60.70; H, 7.19; N, 8.33 
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(S)-2-(4-Nitrobenzenesulfonylamino)-3-phenylpropionic acid methyl ester (3.21) Lit1 
N
H
CO2MeS
O
O
O2N
Ph  
Phe-OMe (3.34g, 15.3 mmol) was reacted with 4-nitrobenzene sulfonyl chloride using General Procedure M1 to 
afford a white solid, 4.57g, 81%. 
 
1H NMR ppm (500 MHz in CDCl3) 8.22 (2H, d J=8.7Hz, Ar-H (4-NO2 Ph)), 7.84 (2H, d J=8.7Hz, Ar-H (4-NO2 
Ph)), 7.21-7.23 (3H, m, Ar-H (Phe)), 7.05 (2H, dd J=2.6Hz, J=5.9Hz, Ar-H (Phe)), 5.28 (1H, d J=9.3Hz, NH), 
4.26 (1H, ddd J=5.5Hz, J=7.0Hz, J=9.3Hz, CHCO2CH3), 3.62 (3H, s, CO2CH3), 3.12 (1H, dd J=5.5Hz, 
J=13.9Hz, CHCH2Ph), 2.98 (1H, dd J=7.0Hz, J=13.9Hz, CHCH2Ph) 
 
LRMS (ES) 365.1 (MH+). C16H16N2O6S requires 365.1  
 
 (S)-2-[Allyl-(4-nitrobenzenesulfonyl)-amino]-3-phenylpropionic acid methyl ester (3.22) Lit1 
N CO2MeS
O
O
O2N
Ph  
Sulfonamide 3.21 (4.50g, 12.4 mmol) was reacted with allyl bromide using General Procedure O1 to afford an 
orange oil, 4.68g, 93%. 
 
1H NMR ppm (500 MHz in CDCl3) 8.22 (2H, d J=8.9Hz, Ar-H (4-NO2 Ph)), 7.76 (2H, d J=8.9Hz, Ar-H (4-NO2 
Ph)), 7.30-7.34 (3H, m, Ar-H (Phe)), 7.23 (2H, dd J=1.9Hz, J=7.2Hz, Ar-H (Phe)), 5.69 (1H, dddd J=6.5Hz, 
J=6.5Hz, J=10.2Hz, J=15.1Hz, NCH2CHCH2), 5.15-5.27 (2H, m, NCH2CHCH2), 4.94 (1H, dd J=6.5Hz, 
J=8.8Hz, CHCO2CH3), 4.01 (1H, dd J=6.5Hz, J=16.3Hz, NCH2CHCH2), 3.89 (1H, dd J=6.5Hz, J=16.3Hz, 
NCH2CHCH2), 3.64 (3H, s, CO2CH3), 3.42 (1H, dd J=6.5Hz, J=14.4Hz, CHCH2Ph), 3.04 (1H, dd J=8.8Hz, 
J=14.4Hz, CHCH2Ph) 
 
LRMS (ES) 405.1 (MH+). C19H20N2O6S requires 405.1  
 
(S)-2-Allylamino-3-phenylpropionic acid methyl ester (3.23) Lit1 
HCl.HN CO2Me
Ph  
Methyl ester 3.22 (4.60g, 11.4 mmol) was dissolved in anhydrous DMF (30 mL).  To this potassium carbonate (3 
equiv) and thiophenol (1.2 equiv) were added.  This was stirred at rt for one h.  Diethyl ether (100 mL) and water 
(75 mL) were added.  This was partitioned and the aqueous phase extracted twice more with diethyl ether.  The 
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combined organic extracts were washed three times with 50% NaHCO3(aq) and brine before being dried (MgSO4), 
filtered and concentrated in vacuo.  The crude material was purified by flash chromatography on silica using a 
gradient of EtOAc and (50/70) pet ether.  To the combined product fractions 2M hydrogen chloride in diethyl 
ether (40 mL) was added.  This was concentrated in vacuo to afford a pale yellow solid, 1.89g, 65%.  Rf = 0.22 
(1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (300 MHz in CDCl3) 7.16-7.30 (5H, m, Ar-H), 5.80 (1H, tdd J=6.0Hz, J=6.0Hz, J=10.2Hz, 
J=16.3Hz, NHCH2CHCH2), 5.04-5.14 (2H, m, NHCH2CHCH2), 3.63 (3H, s, CO2CH3), 3.55 (1H, dd J=6.8Hz, 
J=6.8Hz, CHCO2CH3), 3.26 (1H, dd J=6.8Hz, J=14.0Hz, CHCH2Ph), 3.10 (1H, dd J=6.8Hz, J=14.0Hz, 
CHCH2Ph), 2.95 (2H, d J=6.0Hz, NCH2CHCH2) 
  
LRMS (ES) 220.1 (MH+). C13H17NO2 requires 220.1  
 
(S)-2-(4-Fluorobenzenesulfonylamino)-3-methylbutyric acid methyl ester (3.24) Lit2 
N
H
CO2MeS
O
O
F
 
Val-OMe (2.00g, 11.9 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure M2 
to afford a white solid, 3.18g, 92%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.82-7.86 (2H, m, Ar-H), 7.13-7.19 (2H, m, Ar-H), 5.14 (1H, d J=10.1Hz, 
NH), 3.74 (1H, dd J=5.1Hz, J=10.1Hz, CHCO2CH3), 3.48 (3H, s, CO2CH3), 2.00-2.09 (1H, m, CHCH(CH3)3), 
0.95 (3H, d J=6.8Hz, CHCH(CH3)3), 0.87 (3H, d J=6.8Hz, CHCH(CH3)3) 
 
LRMS (ES) 290.1 (MH+). C12H16FNO4S requires 290.1  
 
(S)-2-[Allyl-(4-fluorobenzenesulfonyl)amino]-3-methylbutyric acid methyl ester (3.25) 
N CO2MeS
O
O
F
 
Sulfonamide 3.24 (1.00g, 3.46 mmol) was allylated using General Procedure O2 to afford a yellow oil, 1.01g, 
89%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.81-7.85 (2H, m, Ar-H), 7.12-7.17 (2H, m, Ar-H), 5.80 (1H, dddd J=5.3Hz, 
J=7.7Hz, J=10.1Hz, J=17.6Hz, NCH2CHCH2), 5.05-5.20 (2H, m, NCH2CHCH2), 4.11 (1H, d J=10.6Hz, 
CHCO2CH3), 4.03 (1H, dd J=7.7Hz, J=16.4Hz, NCH2CHCH2), 3.88 (1H, dd J=5.3Hz, J=16.4Hz, NCH2CHCH2), 
3.44 (3H, s, CHCO2CH3), 2.09-2.17 (1H, m, CHCH(CH3)3), 1.01 (3H, d J=6.6Hz, CHCH(CH3)3), 0.90 (3H, d 
J=6.6Hz, CHCH(CH3)3) 
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LRMS (ES) 330.1 (MH+). C15H20FNO4S requires 330.1  
 
(S)-2-[Allyl-(4-fluorobenzenesulfonyl)amino]-3-methylbutyric acid (3.26) 
NS
O
O
F CO2H
 
Methyl ester 3.25 (1.01g, 3.07 mmol) was hydrolysed using General procedure C1 to afford a white solid, 
0.919g, 95% 
 
1H NMR ppm (500 MHz in CDCl3) 7.83-7.86 (2H, m, Ar-H), 7.11-7.16 (2H, m, Ar-H), 5.81 (1H, dddd J=5.7Hz, 
J=7.3Hz, J=10.1Hz, J=17.3Hz, NCH2CHCH2), 5.07-5.21 (2H, m, NCH2CHCH2), 4.13 (1H, d J=10.4Hz, 
CHCO2CH3), 3.97 (1H, dd J=7.3Hz, J=16.4Hz, NCH2CHCH2), 3.91 (1H, dd J=5.7Hz, J=16.4Hz, NCH2CHCH2), 
2.08-2.18 (1H, m, CHCH(CH3)3), 0.98 (3H, d J=6.6Hz, CHCH(CH3)3), 0.98 (3H, d J=6.6 Hz, CHCH(CH3)3) 
 
LRMS (ES) 316.1 (MH+). C14H18FNO4S requires 316.1  
 
(S)-N-Allyl-2-[allyl-(4-fluoro-benzenesulfonyl)amino]-3-methylbutyramide (3.28) 
NS
O
O
F
N
H
O
 
Carboxylic acid 3.26 (0.184g, 0.583 mmol) was reacted with allyl amine using General Procedure A3.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 0.151g, 73%.  Rf = 0.38 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.82-7.86 (2H, m, Ar-H), 7.15-7.19 (2H, m, Ar-H), 6.24 (1H, bs, NH), 5.74-
5.83 (2H, m, SO2NCH2CHCH2 and C(O)NHCH2CHCH2), 5.08-5.24 (4H, m, SO2NCH2CHCH2 and 
C(O)NHCH2CHCH2), 4.10-4.13 (1H, m, C(O)NHCH2CHCH2), 3.87-3.93 (1H, m, C(O)NHCH2CHCH2), 3.80-
3.85 (2H, m, SO2NCH2CHCH2), 3.69 (1H, d J=10.9Hz, CHCO2CH3), 3.49 (3H, s, CO2CH3), 2.19-2.28 (1H, m, 
CHCH(CH3)3), 0.89 (3H, d J=6.4Hz, CHCH(CH3)3), 0.59 (3H, d J=6.4Hz, CHCH(CH3)3) 
 
HRMS (ES) 355.1501 (MH+). C17H23FN2O3S requires 355.1491  
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(S)-2-(4-Fluorobenzenesulfonylamino)-3-methylbutyric acid (3.30) Lit2 
N
H
S
O
O
F CO2H
 
Methyl ester 3.24 (1.62g, 5.60 mmol) was hydrolysed using General Procedure C2 to afford a white solid, 1.54g, 
100%. 
 
1H NMR ppm (500 MHz in CDCl3) 9.15 (1H, bs, CO2H), 7.83-7.86 (2H, m, Ar-H), 7.13-7.18 (2H, m, Ar-H), 
5.25 (1H, d J=9.9Hz, NH), 3.77-3.80 (1H, m, CHCO2CH3), 2.08-2.15 (1H, m, CHCH(CH3)3), 0.97 (3H, d 
J=6.8Hz, CHCH(CH3)3), 0.88 (3H, d J=6.8Hz, CHCH(CH3)3)   
  
LRMS (ES) 276.1 (MH+). C11H14FNO4S requires 276.1  
 
(S)-2-[(S)-2-(4-Fluorobenzenesulfonylamino)-3-methylbutyrylamino]-3-phenylpropionic acid methyl ester 
(3.31) 
N
H
S
O
O
F
N
H
O
Ph
CO2Me
 
Carboxylic acid 3.30 (0.500g, 1.82 mmol) was reacted with Phe-OMe using General Procedure A3.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 0.704g, 86%.  Rf = 0.27 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.86-7.90 (2H, m, Ar-H (4-F-Ph)), 7.26-7.30 (3H, m, Ar-H (Phe)), 7.14-7.19 
(2H, m, Ar-H (4-F-Ph)), 6.95 (2H, dd J=1.9Hz, J=7.3Hz, Ar-H (Phe)), 6.10 (1H, d J=7.6Hz, NH Phe), 5.40 (1H, 
d J=8.6Hz, NH Val), 4.68 (1H, ddd J=5.9Hz, J=5.9Hz, J=7.6Hz, CHCH2Ph), 3.69 (3H, s, CO2CH3), 3.53 (1H, dd 
J=4.8Hz, J=8.6Hz, CHCH(CH3)3), 2.98 (1H, dd J=5.9Hz, J=14.0Hz, CHCH2Ph), 2.92 (1H, dd J=5.9Hz, 
J=14.0Hz, CHCH2Ph), 1.96-2.05 (1H, m, CHCH(CH3)3), 0.88 (3H, d J=6.8Hz, CHCH(CH3)3), 0.78 (3H, d 
J=6.8Hz, CHCH(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3) 171.3, 169.7, 135.3, 130.1, 130.0, 129.0, 128.7, 127.3, 116.3, 116.0, 61.6, 
53.3, 52.4, 37.7, 31.7, 19.0, 16.9  
 
LRMS (ES) 437.1 (MH+). C21H25FN2O5S requires 437.1 
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(S)-2-(Allyl-{(S)-2-[allyl-(4-fluorobenzenesulfonyl)amino]-3-methylbutyryl}amino)-3-phenylpropionic acid 
methyl ester (3.32) 
NS
O
O
F
N
Ph
CO2Me
O
 
Dipeptide 3.31 (0.500g, 1.09 mmol) was allylated using General Procedure O3.  The crude material was purified 
by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white solid, 0.300g, 
51%.  Rf = 0.37 (1/7 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.80-7.86 (2H, m, Ar-H (4-F-Ph)), 7.24-7.39 (5H, m, Ar-H (Phe) and Ar-H 
(4-F-Ph)), 7.11-7.17 (2H, m, Ar-H (Phe)), 5.48-5.68 (2H, m, SO2NCH2CHCH2 and C(O)NCH2CHCH2), 5.06-
5.29 (4H, m, SO2NCH2CHCH2 and C(O)NCH2CHCH2), 4.93 (1H, dd J=1.7Hz, J=10.1Hz, SO2NCH2CHCH2), 
4.60 (1H, dd J=1.9, J=10.4Hz, SO2NCH2CHCH2), 4.52-4.57 (1H, m, CHCH2Ph), 4.00-4.15 (2H, m, 
C(O)NCH2CHCH2 and CHCH(CH3)3), 3.94 (1H, dd J=3.5Hz, J=16.0Hz, C(O)NCH2CHCH2), 3.68 (3H, s, 
CO2CH3), 3.55 (1H, dd J=3.9Hz, J=13.5Hz, CHCH2Ph), 3.09 (1H, dd J=9.4Hz, J=13.5Hz, CHCH2Ph), 2.34-2.39 
(1H, m, CHCH(CH3)3), 0.92 (3H, d J=6.3Hz, CHCH(CH3)3), 0.89 (3H, d J=6.3Hz, CHCH(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3) 170.6, 170.4, 166.5, 163.1, 137.7, 136.6, 136.6, 134.6, 133.6, 130.4, 130.3, 
129.1, 128.4, 126.6, 119.0, 117.3, 116.0, 115.7, 60.7, 60.7, 52.0, 51.4, 46.8, 34.9, 28.8, 19.5, 19.4  
 
HRMS (ES) 517.2179 (MH+). C27H33FN2O5S requires 517.2172  
 
(S)-2-[(Z)-(S)-4-(4-Fluorobenzenesulfonyl)-3-isopropyl-2-oxo-3,4,5,8-tetrahydro-2H-[1,4]-diazocin-1-yl]-3-
phenylpropionic acid methyl ester (3.33) 
N N
O
CO2Me
Ph
SF
O
O
 
Diene 3.32 (0.100g, 0.189 mmol) was ring closed using General Procedure E1.  The crude material was purified 
by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a brown solid, 
0.0568g, 60%.  Rf = 0.16 (1/3 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.80-7.85 (2H, m, Ar-H (4-F-Ph)), 7.27 (2H, dd J=7.3Hz, J=7.3Hz, Ar-H 
(Phe)), 7.12-7.22 (5H, m, Ar-H (4-F-Ph) and Ar-H (Phe)), 5.80 (1H, ddd J=4.8Hz, J=4.8Hz, J=9.8Hz, 
SO2NCH2CHCHCH2N), 5.41-5.47 (1H, m, SO2NCH2CHCHCH2N), 4.32-4.37 (2H, m, CHCH2Ph and 
CHCH(CH3)3), 4.22 (1H, dd J=4.8Hz, J=17.3Hz, SO2NCH2CHCHCH2N), 3.99 (1H, dd J=5.9Hz, J=16.2Hz, 
SO2NCH2CHCHCH2N), 3.74 (1H, dd J=4.8Hz, J=17.3Hz, SO2NCH2CHCHCH2N), 3.66 (3H, s, CO2CH3), 3.33 
(1H, dd J=5.2Hz, J=14.2Hz, CHCH2Ph), 3.26 (1H, dd J=8.4Hz, J=16.2Hz, SO2NCH2CHCHCH2N), 3.09 (1H, dd 
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J=10.2Hz, J=14.2Hz, CHCH2Ph), 2.09-2.18 (1H, m, CHCH(CH3)3), 0.82 (3H, d J=6.6Hz, CHCH(CH3)3), 0.79 
(3H, d J=6.6Hz, CHCH(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3) 170.5, 168.8, 166.6, 163.2, 137.4, 136.3, 132.5, 130.0, 129.9, 129.2, 128.5, 
127.1, 126.6, 116.2, 115.9, 67.3, 63.3, 52.0, 44.2 43.3, 35.0, 30.1, 20.1, 17.0 
  
HRMS (ES) 489.1862 (MH+). C25H29FN2O5S requires 489.1859  
 
(S)-2-((S)-2-tert-Butoxycarbonylamino-3-methylbutyrylamino)-4-methylpentanoic acid methyl ester (3.35) 
Lit3 
BOCHN
N
H
O
CO2Me
 
N-BOC-Val-H (3.67g, 17.0 mmol) was reacted with Leu-OMe using General Procedure A1.  The crude material 
was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white 
solid, 5.44g, 93%.  Rf = 0.39 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 6.59 (1H, d J=7.0 Hz, NH Val), 5.17 (1H, d J=8.1 Hz, NH Leu), 4.53-4.62 
(1H, m, CHCH2CH(CH3)2), 3.92 (1H, dd J=6.6Hz, J=7.0Hz, CHCH(CH3)2), 3.68 (1H, s, CO2CH3), 1.91-2.20 
(1H, m, CHCH(CH3)2), 1.47-1.70 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.40 (1H, s, C(CH3)3), 
0.86-0.94 (12H, m, CHCH2CH(CH3)2 and CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 173.1, 171.4, 163.3, 59.9, 52.2, 50.6, 41.4, 31.8, 30.8, 28.2, 24.7, 22.8, 19.2, 
17.8 
  
LRMS (ES) 345.2 (MH+). C17H32N2O5 requires 345.2  
 
(S)-2-((S)-2-Amino-3-methylbutyrylamino)-4-methylpentanoic acid methyl ester hydrogen chloride salt 
(3.36) Lit3 
HCl.H2N N
H
O
CO2Me
 
N-BOC protected compound 3.35 (0.980g, 2.85 mmol) was reacted using General Procedure I3 to afford a white 
solid, 0.799g, 100%. 
 
1H NMR ppm (500 MHz in CDCl3) 8.26 (3H, bs, NH2 and NH Leu), 4.35-4.40 (1H, m, CHCH2CH(CH3)2), 4.11-
4.29 (1H, m, CHCH(CH3)2), 3.72 (3H, s, CO2CH3), 2.15-2.24 (1H, m, CHCH(CH3)2), 1.47-1.62 (3H, m, 
CHCH2CH(CH3)2)and CHCH2CH(CH3)2),  0.92-0.97 (12H, m CHCH2CH(CH3)2 and CHCH(CH3)2) 
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LRMS (ES) 245.2 (MH+). C12H24N2O3 requires 245.2  
 
(S)-2-[(S)-2-(4-Fluorobenzenesulfonylamino)-3-methylbutyrylamino]-4-methylpentanoic acid methyl ester 
(3.37) Lit2 
N
H
N
H
O
CO2Me
S
O
O
F
 
Amine 3.36 (0.800g, 2.85 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M2.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a white solid, 0.270g, 24%.  Rf = 0.26 (1/3 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.83-7.89 (2H, m, Ar-H), 7.10-7.16 (2H, m, Ar-H), 6.16 (1H, d J=8.1Hz, 
NH Val), 5.63 (1H, d J=8.8Hz, NH Leu), 4.35-4.44 (1H, m, CHCH2CH(CH3)2), 4.11 (1H, dd J=7.1Hz, J=8.1Hz, 
CHCH(CH3)2), 3.69 (3H, s, CO2CH3), 1.99-2.08 (1H, m, CHCH(CH3)2), 1.41-1.54 (1H, m,  CHCH2CH(CH3)2), 
1.21-1.37 (2H, m, CHCH2CH(CH3)2), 0.94 (3H, d J=6.8 Hz, CHCH(CH3)2), 0.84 (3H, d J=6.8 Hz, 
CHCH(CH3)2), 0.84 (3H, d, J=6.5 Hz, CHCH2CH(CH3)2), 0.80 (3H, d J=6.5 Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 172.8, 170.1, 165.9, 163.9, 135.8, 130.0, 129.9, 116.1, 115.9, 61.4, 52.2, 
50.6, 41.1, 31.8, 24.4, 22.4, 21.5, 19.0, 17.0  
 
LRMS (ES) 403.2 (MH+). C18H27FN2O5S requires 403.2  
 
(S)-2-(Allyl-{(S)-2-[allyl-(4-fluorobenzenesulfonyl)amino]-3-methylbutyryl}amino)-4-methylpentanoic acid 
methyl ester (3.38) 
N CO2Me
O
NSF
O
O
 
Dipeptide 3.37 (0.671g, 1.67 mmol) was allylated using General Procedure O3.  The crude material was purified 
by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless oil 
0.301g, 37%.  Rf = 0.52 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.78-7.88 (2H, m, Ar-H), 7.11-7.18 (2H, m, Ar-H), 5.89 (1H, dddd, 
J=5.6Hz, J=7.3Hz, J=10.1Hz, J=15.8Hz, CHNCH2CHCH2), 5.59-5.68 (1H, m, SO2NCH2CHCH2), 4.85-5.41 
(2H, m, SO2NCH2CHCH2 and CHNCH2CHCH2, 4.67 (1H, dd, J=6.1Hz, J=8.5Hz, CHCH2CH(CH3)2), 4.62 (1H, 
d J=10.5Hz, CHCH(CH3)2), 4.40 (1H, dd, J=7.4Hz, J=16.6Hz, CHNCH2CHCH2), 4.18 (1H, dd, J=8.0Hz, 
J=16.4Hz, SO2NCH2CHCH2), 3.96 (2H, m, CHNCH2CHCH2 and SO2NCH2CHCH2) 3.66 (3H, s, CO2CH3), 
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2.23-2.39 (1H, m, CHCH(CH3)2), 1.87-1.96 (1H, m, CHCH2CH(CH3)2), 1.48-1.67 (2H, m, CHCH2CH(CH3)2), 
0.87-0.93 (12H, m, CHCH2CH(CH3)2 and CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 171.8, 171.1, 166.6, 163.3, 134.8, 134.4, 130.5, 130.4, 118.7, 117.4, 116.1, 
115.8, 60.6, 55.9, 52.0, 49.6, 47.0, 37.6, 29.1, 24.9, 22.8, 22.0, 19.7, 19.2  
 
HRMS (ES) 483.2320 (MH+). C24H35FN2O5S requires 483.2329  
 
(S)-2-[(Z)-(S)-4-(4-Fluorobenzenesulfonyl)-3-isopropyl-2-oxo-3,4,5,8-tetrahydro-2H-[1,4]diazocin-1-yl]-4-
methylpentanoic acid methyl ester (3.39) 
N N
O
SF
O
O
CO2Me
 
Diene 3.38 (0.100g, 0.189 mmol) was ring closed using General Procedure E1.  The crude material was purified 
by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a brown solid, 
0.0568g, 60%.  Rf = 0.16 (1/3 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.80-7.88 (2H, m, Ar-H), 7.11-7.17 (2H, m, Ar-H), 5.88 (1H, td, J=4.3Hz, 
J=7.3z, J=10.1z,SO2CH2CHCHCH2), 5.75 (1H, m, SO2CH2CHCHCH2), 4.83 (1H, dd J=5.8Hz, J=8.5Hz, 
CHCH2CH(CH3)2), 4.31-4.40 (2H, m, CHCH(CH3)2 and SO2CH2CHCHCH2) 4.26 (1H, dd, J=7.0Hz, J=16.0Hz, 
SO2CH2CHCHCH2), 3.82 (1H, dd J=4.3Hz, J=16.0Hz, SO2CH2CHCHCH2), 3.68 (1H, dd J=7.9z, J=15.5Hz, 
SO2CH2CHCHCH2), 3.65 (3H, s, CHCO2CH3), 2.17-2.29 (1H, m, CHCH(CH3)2), 1.71-1.81 (1H, m, 
CHCH2CH(CH3)2), 1.43-1.56 (2H, m, CHCH2CH(CH3)2), 0.92 (3H, d J=6.7Hz, CHCH2CH(CH3)2), 0.89 (6H, m, 
CHCH2CH(CH3)2and CHCH(CH3)2), 0.79 (3H, d J=6.7Hz, CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 171.9, 169.3, 166.5, 163.2, 136.1, 131.5, 130.1, 130.0, 128.7, 116.1, 115.9, 
67.9, 57.1, 51.9, 43.2, 41.6,38.2, 29.7, 24.7, 22.8, 21.8, 20.5, 18.2  
 
HRMS (ES) 455.2016 (MH+). C22H31FN2O5S requires 455.2016  
 
(S)-2-{(S)-2-[Allyl-(4-fluorobenzenesulfonyl)amino]-3-methyl-butyrylamino}-4-methyl-pentanoic acid 
methyl ester (3.41) 
N
N
H
O
CO2Me
S
O
O
F
 
Sulfonamide 3.37 (1.00g, 2.48 mmol) was dissolved in anhydrous DMF (20 mL) under an atmosphere of argon.  
To this potassium carbonate (2 equiv) and allyl bromide (4 equiv) were added.  This was stirred at rt  for eighteen 
h before being diluted with EtOAc and partitioned with 1M HCl(aq).  The aqueous phase was extracted twice 
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more with EtOAc.  The combined organic extracts were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to afford a colourless oil, 0.857g, 78%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.78-7.91 (2H, m, Ar-H), 7.12-7.17 (2H, m, Ar-H), 6.51 (1H, d J=7.5Hz, 
NH), 5.74 (1H, tdd J=6.7Hz, J=6.7Hz, J=10.1Hz, J=16.8Hz, NHCH2CHCH2), 5.03-5.23 (2H, m, 
NHCH2CHCH2), 4.41-4.50 (1H, m, CHCH2CH(CH3)2), 4.06 (1H, dd J=6.7Hz, J=16.1Hz, NHCH2CHCH2), 3.89 
(1H, dd, J=6.7Hz, J=16.1Hz, NHCH2CHCH2), 3.76 (1H, d J=10.9Hz, CHCH(CH3)2), 3.71 (3H, s, CHCO2CH3), 
2.14-2.25 (1H, m,  CHCH(CH3)2), 1.56-1.68 (2H, m, CHCH2CH(CH3)2), 1.46-1.54 (1H, m, CHCH2CH(CH3)2), 
0.92 (3H, d J=6.0 Hz, CHCH2CH(CH3)2), 0.91 (3H, d J=6.0Hz, CHCH2CH(CH3)2), 0.87 (3H, d J=6.7Hz, 
CHCH(CH3)2), 0.58 (3H, d J=6.7Hz, CHCH(CH3)2) 
 
HRMS (ES) 443.2108 (MH+). C21H31FN2O5S requires 443.2016 
 
(S)-2-{(S)-2-[But-3-enyl-(4-fluorobenzenesulfonyl)amino]-3-methylbutyrylamino}-4-methyl pentanoic acid 
methyl ester (3.42) 
N
N
H
O
CO2Me
S
O
O
F
 
Sulfonamide 3.37 (1.00g, 2.48 mmol) was dissolved in anhydrous DMF (20 mL) under an atmosphere of argon.  
To this potassium carbonate (2 equiv) and 4-bromo-1-butene (4 equiv) were added.  This was stirred at rt for 
eighteen h before being diluted with EtOAc and partitioned with 1M HCl(aq).  The aqueous phase was extracted 
twice more with EtOAc.  The combined organic extracts were washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo to afford a colourless oil, 0.839g, 74%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.82-7.86 (2H, m, Ar-H), 7.13-7.19 (2H, m, Ar-H), 6.69 (1H, d J=7.1Hz, 
NH Leu), 5.64-5.73 (1H, m, CH2CH2CHCH2), 4.96-5.06 (2H, m, CH2CH2CHCH2), 4.46-4.51 (1H, m, 
CHCH2CH(CH3)2), 3.69-3.73 (4H, m, CO2CH3 and CHCH(CH3)2), 3.40-3.48 (1H, m, CH2CH2CHCH2), 3.14-
3.21 (1H, m, CH2CH2CHCH2), 2.29-2.45 (2H, m, CH2CH2CHCH2), 2.14-2.22 (1H, m, CHCH(CH3)2), 1.52-1.73 
(3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.92-0.96 (6H, m, CHCH2CH(CH3)2), 0.88 (3H, d J=6.3Hz, 
CHCH(CH3)2), 0.49 (3H, d J=6.3Hz, CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 173.0, 169.8, 134.6, 129.8, 129.7, 117.0, 116.4, 116.1, 65.7, 52.2, 50.8, 44.5, 
40.8, 34.5, 26.8, 24.6, 22.7, 21.6, 19.7, 18.9 
 
HRMS (ES) 457.2183 (MH+). C22H33FN2O5S requires 457.2172 
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(R)-3-tert-Butoxycarbonylamino-4-methylpentanoic acid methyl ester (3.50) Lit4 
BOCHN
CO2Me
 
N-BOC-Val-H (5.00g, 43.0 mmol) was homologated using General Procedure P.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless 
oil, 6.86g, 65%.  Rf = 0.47 (1/9 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 4.86 (1H, d J=8.7Hz, NH), 3.74-3.79 (1H, m, CHCH(CH3)2), 3.64 (3H, s, 
CO2CH3), 2.53 (1H, dd J=5.0Hz, J=15.2Hz, CH2CO2CH3), 2.47 (1H, dd J=6.9Hz, J=15.2Hz, CH2CO2CH3), 
1.77-1.85 (1H, m, CHCH(CH3)2) , 1.40 (9H, s, C(CH3)3), 0.88 (6H, d J=6.8Hz, CHCH(CH3)2) 
 
LRMS (ES) 246.2 (MH+). C12H23NO4 requires 246.2 
 
 (S)-2-((S)-1-tert-Butoxycarbonylamino-2-methylpropyl)pent-4-enoic acid methyl ester (3.51) 
BOCHN
CO2Me
 
β-amino acid 3.50 (0.575g, 2.34 mmol) was allylated using General Procedure Q.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless 
oil, 0.107g, 16%.  Rf = 0.22 (1/9 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 5.76 (1H, dddd J=7.1Hz, J=7.1Hz, J=10.1Hz, J=17.1Hz, CH2CHCH2), 5.30 
(1H, d J=10.3Hz, NH), 5.01-5.11 (2H, m, CH2CHCH2), 3.64 (3H, s, CO2CH3), 3.47 (1H, ddd J=4.0Hz, J=8.8Hz, 
J=10.3Hz, CHCH(CH3)2), 2.73 (1H, ddd J=4.0Hz, J=6.5Hz, J=8.5Hz, CHCO2CH3), 2.34-2.40 (1H, m, 
CH2CHCH2), 2.24-2.30 (1H, m, CH2CHCH2), 1.56 (1H, m, CHCH(CH3)2), 1.41 (9H, s, C(CH3)3), 0.94 (3H, d 
J=6.7Hz, CHCH(CH3)2), 0.92 (3H, d J=6.7Hz, CHCH(CH3)2) 
 
LRMS (ES) 286.2 (MH+). C15H27NO4 requires 286.2  
 
(R)-3-Amino-4-methylpentanoic acid methyl ester trifluoroacetic acid salt (3.53) Lit2 
CO2Me
TFA.H2N
 
N-BOC protected compound 3.50 (0.200g, 0.815 mmol) was reacted using General Procedure I2 to afford a 
yellow oil, 0.211g, 100% 
 
1H NMR ppm (500 MHz in CDCl3) 7.51 (2H, bs, NH2), 3.75 (3H, s, CO2CH3), 3.39-3.51 (1H, m, CHCH(CH3)2), 
2.76 (1H, dd J=3.7Hz, J=17.9Hz, CH2CO2CH3), 2.70 (1H, dd J=9.3Hz, J=17.9Hz, CH2CO2CH3), 1.97-2.10 (1H, 
m, CHCH(CH3)2), 1.05 (3H, d J=6.9Hz, CHCH(CH3)2), 1.01 (3H, d J=6.9Hz, CHCH(CH3)2) 
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LRMS (ES) 146.1 (MH+). C7H15NO2 requires 146.1  
 
(R)-4-Methyl-3-(4-nitrobenzenesulfonylamino)pentanoic acid methyl ester (3.54) 
CO2Me
N
H
SO2N
O
O
 
Amine 3.53 (0.210g, 0.815 mmol) was reacted with 4-nitrobenzene sulfonyl chloride using General Procedure 
M1.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a yellow oil, 0.0806g, 30%.  Rf = 0.28 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (300 MHz in CDCl3) 8.35 (2H, d J=8.8Hz, Ar-H), 8.06 (2H, d J=8.8Hz, Ar-H), 5.44 (1H, d 
J=9.0Hz, NH), 3.59 (3H, s, CO2CH3), 3.40-3.44 (1H, m, CHCH(CH3)3), 2.48 (1H, dd J=5.2Hz, J=15.8Hz, 
CH2CO2CH3), 2.37 (1H, dd J=5.2Hz, J=15.8Hz, CH2CO2CH3), 1.78-1.89 (1H, m, CHCH(CH3)3), 0.84 (3H, d 
J=6.7Hz, CHCH(CH3)3), 0.83 (3H, d J=6.7 Hz, CHCH(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3). 171.8, 128.2, 124.2, 56.8, 51.9, 36.2, 31.9, 18.8, 18.6 
  
LRMS (ES) 331.1 (MH+). C13H18N2O6S requires 331.1  
 
(R)-3-[Allyl-(4-nitrobenzenesulfonyl)amino]-4-methylpentanoic acid methyl ester (3.55) 
CO2Me
NSO2N
O
O
 
Sulfonamide 3.54 (0.136g, 0.412 mmol) was allylated using General Procedure O2 to afford a yellow oil, 0.152g, 
100%. 
 
1H NMR ppm (500 MHz in CDCl3) 8.31 (2H, d J=8.9Hz, Ar-H), 8.04 (2H, d J=8.9Hz, Ar-H), 5.71-5.82 (1H, m, 
CH2CHCH2), 5.11-5.26 (2H, m, CH2CHCH2), 4.05 (1H, ddd J=6.4Hz, J=6.4Hz, J=10.0Hz, CHCH(CH3)2), 3.88 
(1H, dd J=6.8Hz, J=16.1Hz, CH2CHCH2), 3.81 (1H, dd J=7.1Hz, J=16.1Hz, CH2CHCH2), 3.57 (3H, s, 
CO2CH3), 2.58 (1H, dd, J=6.4Hz, J=15.8Hz, CH2CO2CH3), 2.37 (1H, dd J=6.4Hz, J=15.8Hz, CH2CO2CH3), 
1.81-1.91 (1H, m, CHCH(CH3)2), 0.91 (3H, d J=7.1Hz, CHCH(CH3)2), 0.88 (3H, d J=7.1 Hz, CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 171.5, 146.7, 134.4, 128.8, 124.0, 118.8, 62.3, 51.9, 47.8, 37.7, 32.1, 20.5, 
19.5  
 
HRMS (ES) 371.1291 (MH+). C16H22N2O6S requires 371.1277  
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(S)-3-tertButoxycarbonylamino-4-phenylbutyric acid methyl ester (3.57) Lit5 
BOCHN
Ph
CO2Me
 
N-BOC-Phe-H (8.00g, 32.1 mmol) was homologated using General Procedure P.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a yellow oil, 
5.84g, 62%.  Rf = 0.39 (1/5 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (300 MHz in CDCl3) 7.21-7.33 (5H, m, Ar-H), 5.13 (1H, d J=6.2Hz, NH), 4.17-4.20 (1H, m, 
CHCH2CO2CH3), 3.71 (3H, s, CO2CH3), 2.97 (1H, dd J=5.9Hz, J=12.7Hz, CHCH2Ph), 2.84 (1H, dd J=7.6Hz, 
J=12.7Hz, CHCH2Ph), 2.50 (1H, dd J=5.3Hz, J=15.3Hz, CHCH2CO2CH3), 2.48 (1H, dd J=5.3Hz, J=15.3Hz 
CHCH2CO2CH3), 1.44 (9H, s, (CH3)3) 
 
LRMS (ES) 294.2 (MH+). C16H23NO4 requires 294.2  
 
(S)-2-((S)-1-tert-Butoxycarbonylamino-2-phenylethyl)pent-4-enoic acid methyl ester (3.58) 
BOCHN
Ph
CO2Me
 
β-amino acid 3.57 (0.500g, 1.70 mmol) was allylated using General Procedure Q.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a yellow oil, 
0.148g, 26%.  Rf = 0.47 (1/5 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.22-7.33 (5H, m, Ar-H), 5.70 (1H, dddd, 1H, J=7.0Hz, J=7.0Hz, J=10.1Hz, 
J=17.1Hz, CH2CHCH2), 5.53 (1H, d J=9.7Hz, NH), 4.96-5.10 (2H, m, CH2CHCH2), 4.02-4.12 (1H, m, 
CHCH2Ph), 3.76 (3H, s, CO2CH3), 2.86-2.92 (1H, m, CHCO2CH3), 2.60-2.70 (2H, m, CHCH2Ph), 2.42-2.48 
(1H, m, CH2CHCH2), 2.32 (1H, ddd J=6.8Hz, J=7.0Hz, J=13.7Hz, CH2CHCH2), 1.43 (9H, s, (CH3)3) 
 
LRMS (ES) 334.2 (MH+). C19H27NO4 requires 334.2  
 
(S)-2-((S)-1-Amino-2-phenylethyl)-pent-4-enoic acid methyl ester trifluoroacetic acid salt (3.59) 
Ph
CO2Me
TFA.H2N
 
 
N-BOC protected compound 3.58 (0.148g, 0.444 mmol) was reacted using General Procedure I2 to afford a 
yellow oil, 0.154g, 100% 
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1H NMR ppm (500 MHz in CDCl3) 7.58 (2H, bs, NH2), 7.33-7.40 (3H, m, Ar-H), 7.16 (2H, m, Ar-H), 5.60 (1H, 
tdd J=7.0Hz, J=9.8Hz, J=16.9Hz, CH2CHCH2), 5.13-5.17 (2H, m, CH2CHCH2), 3.79 (3H, s, CO2CH3), 3.75-
3.78 (1H, m, CHCH2Ph), 3.08 (1H, dd J=7.2Hz, J=14.1Hz, CHCH2Ph), 2.98 (1H, dd J=8.0Hz, J=14.1Hz, 
CHCH2Ph), 2.81 (1H, tdd J=4.7Hz, J=7.0Hz, J=7.0Hz, CHCO2CH3), 2.55 (2H, dd J=7.0Hz J=7.0Hz, 
CH2CHCH2) 
 
LRMS (ES) 234.2 (MH+). C14H19NO2 requires 324.1  
 
(S)-2-[(S)-1-(4-Fluoro-benzenesulfonylamino)-2-phenylethyl]pent-4-enoic acid methyl ester (3.60) 
Ph
CO2Me
N
H
S
O
O
F
 
Amine 3.59 (0.154g, 0.444 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M1.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a white solid, 0.174g, 100%.  Rf = 0.32 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.77-7.79 (2H, m, Ar-H (4-F-Ph)), 7.20-7.24 (3H, m, Ar-H (Phe)), 7.11-7.16 
(2H, m, Ar-H (4-F-Ph)), 7.02 (2H, dd J=1.0Hz, J=6.9Hz, Ar-H (Phe)), 5.67 (1H, d J=9.0Hz, NH), 5.51-5.59 (1H, 
m, CH2CHCH2), 4.91-5.01 (2H, m, CH2CHCH2), 3.68-3.73 (4H, m, CHCH2Ph and CO2CH3), 2.77 (1H, dd 
J=5.8Hz, J=13.8Hz, CHCH2Ph), 2.56-2.67 (2H, m, CHCH2Ph and CHCO2CH3), 2.34 (1H, m, CH2CHCH2), 2.17 
(1H, m, CH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3). 174.5, 134.1, 129.5, 129.4, 129.1, 128.6, 126.8, 117.5, 116.3, 116.0, 56.1, 
51.8, 46.2, 40.9, 33.7  
  
LRMS (ES) 392.2 (MH+). C20H22FNO4S requires 392.1  
 
(S)-2-{(S)-1-[Allyl-(4-fluorobenzenesulfonyl)amino]-2-phenylethyl}pent-4-enoic acid methyl ester (3.61) 
Ph
NS
O
O
F
CO2Me
 
Sulfonamide 3.60 (0.200g, 0.511 mmol) was allylated using General Procedure O2.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white solid, 
0.180g, 82%.  Rf = 0.27 (1/7 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.42-7.48 (2H, m, Ar-H (4-F-Ph)), 7.25-7.35 (5H, m, Ar-H (Phe)), 6.97-7.03 
(2H, m, Ar-H (4-F-Ph)), 5.76 (1H, dddd, 1H, J=2.2Hz, J=4.5Hz, J=9.8Hz, J=12.8Hz, NCH2CHCH2), 5.49-5.58 
(1H, m, CHCH2CHCH2), 5.06-5.39 (4H, m, NCH2CHCH2 and CHCH2CHCH2), 4.58-4.63 (1H, m, CHCH2Ph), 
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3.74-3.87 (2H, m, NCH2CHCH2), 3.68 (3H, s, CO2CH3), 3.11 (1H, dd J=6.6Hz, J=13.9Hz, CHCH2Ph), 3.04 
(1H, dd J=7.6Hz, J=13.9Hz, CHCH2Ph), 2.87-2.94 (1H, m, CHCO2CH3), 2.40-2.48 (2H, m, CH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3) 173.2, 130.5, 134.8, 134.2, 130.4, 129.4, 128.6, 126.7, 118.0, 117.5, 115.8, 
115.5, 62.1, 51.7, 49.9, 37.5, 34.5  
 
HRMS (ES) 432.1658 (MH+). C23H26FNO4S requires 432.1645  
 
(2S,3S)-2-Benzyl-1-(4-fluorobenzenesulfonyl)-2,3,4,7-tetrahydro-1H-azepine-3-carboxylic acid methyl 
ester (3.62) 
N
Ph
CO2MeSF
O
O
 
Diene 3.61 (0.174g, 0.403 mmol) was reacted with Grubbs second generation catalyst using General Procedure 
D1.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a brown solid, 0.132g, 81%.  Rf = 0.19 (1/5 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.36-7.40 (2H, m, Ar-H (4-F-Ph)), 7.19-7.22 (3H, m, Ar-H (Phe)), 7.04 (2H, 
dd J=1.3Hz, J=6.7Hz, Ar-H (Phe)), 6.86-6.92 (2H, m, Ar-H (4-F-Ph)), 5.73-5.85 (2H, m, NCH2CHCHCH2 and 
NCH2CHCHCH2), 4.93-4.97 (1H, m, CHCH2Ph), 4.14 (1H, ddd J=2.1Hz, J=4.6Hz, J=6.1Hz, NCH2CHCHCH2), 
3.83-3.89 (1H, m, NCH2CHCHCH2), 3.69 (3H, s, CO2CH3), 3.08-3.12 (1H, m, CHCHCO2CH3), 2.88-2.92 (2H, 
m, CHCH2Ph), 2.56-2.60 (2H, m, NCH2CHCHCH2)  
 
13C NMR ppm (75 MHz in CDCl3). 173.2, 138.0, 134.9, 134.2, 130.5, 130.4, 129.4, 128.6, 126.7, 118.0, 117.5, 
115.8, 115.5, 62.1, 51.7, 49.9, 48.5, 37.5, 34.5  
 
HRMS (ES) 404.1320 (MH+). C21H22FNO4S requires 404.1332  
 
(S)-2-[(S)-1-(4-Fluorobenzenesulfonylamino)-2-phenylethyl]pent-4-enoic acid (3.64) 
Ph
N
H
S
O
O
F
CO2H
 
 
Methyl ester 3.60 (0.200g, 0.511 mmol) was hydrolysed using General Procedure C2 to afford a yellow solid, 
0.0887g, 46%. 
 
1H NMR ppm (300 MHz in CDCl3) 7.74-7.82 (2H, m, Ar-H (4-F-Ph)), 7.03-7.25 (7H, m, Ar-H (4-F-Ph) and Ar-
H (Phe)), 5.81 (1H, d J=9.4Hz, NH), 5.52-5.67 (1H, m, CH2CHCH2), 4.92-5.03 (2H, m, CH2CHCH2), 3.68-3.78 
(1H, m, CHCH2Ph), 2.75-2.81 (2H, m, CHCH2Ph), 2.65 (1H, ddd J=3.1Hz, J=7.1Hz, J=7.1Hz, CHCO2CH3), 
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2.45 (1H, ddd J=7.0Hz, J=7.1Hz, J=14.2Hz, CH2CHCH2), 2.26 (1H, ddd J=7.1Hz, J=7.2Hz, J=14.2Hz, 
CH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3). 178.7, 166.5, 163.2, 137.1, 136.7, 134.1, 129.6, 129.4, 129.1, 128.7, 128.4, 
126.9, 117.8, 116.4, 116.1, 55.9, 46.2, 40.5, 33.2 
  
LRMS (ES) 378.1 (MH+). C19H20FNO4S requires 378.1  
 
(S)-2-[(S)-1-(4-Fluorobenzenesulfonylamino)-2-phenylethyl]pent-4-enoic acid ((S)-1-hydroxymethyl-3-
methylbutyl)amide (3.65) 
Ph
N
H
S
O
O
F
O
N
H
OH
 
Carboxylic acid 3.64 (0.180g, 0.477 mmol) was reacted with (L)-leucinol using General Procedure B3.  The 
crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to 
yield a yellow solid, 0.125g, 61%.  Rf = 0.20 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 7.62-7.67 (2H, m, Ar-H (4-F-Ph), 7.06-7.10 (3H, m, Ar-H (4-F-Ph) and Ar-
H (Phe)), 6.96-7.03 (4H, m, Ar-H (Phe)), 5.59-5.70 (1H, m, CH2CHCH2), 4.89-4.98 (2H, m, CH2CHCH2), 3.94-
4.02 (1H, m, CHCHCH2(CH3)2), 3.68 (1H, ddd J=6.3Hz, J=6.6Hz, J=9.8Hz, CHCH2Ph), 3.45-3.49 (2H, m, 
CHCH2OH), 2.82 (1H, dd J=6.6Hz, J=14.0Hz, CHCH2Ph), 2.75 (1H, dd J=6.3Hz, J=14.0Hz, CHCH2Ph), 2.51-
2.62 (1H, m, CHCH2CHCH2), 2.17-2.39 (2H, m, CHCH2CHCH2), 1.58-1.65 (1H, m, CHCHCH2(CH3)2), 1.24-
1.38 (2H,m, CHCHCH2(CH3)2), 0.89 (3H, d J=6.6Hz, CHCHCH2(CH3)2), 0.86 (3H, d J=6.6Hz, 
CHCHCH2(CH3)2
 
HRMS (ES) 477.2221 (MH+). C25H33FN2O4S requires 477.2223  
 
(S)-2-{(S)-1-[Allyl-(4-fluorobenzenesulfonyl)amino]-2-phenylethyl}pent-4-enoic acid allyl ester (3.66) 
Ph
NS
O
O
F
O
O
 
 
Sulfonamide 3.65 (0.120g, 0.280 mmol) was allylated using General Procedure O2.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white solid, 
0.110g, 84%.  Rf = 0.51 (1/9 (EtOAc / (50/70) Pet ether)). 
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1H NMR ppm (500 MHz in CDCl3) 7.40-7.46 (2H, m, Ar-H (4-F-Ph)), 7.26-7.30 (3H, m, Ar-H (Phe)), 7.20-7.22 
(2H, m, Ar-H (4-F-Ph)), 6.93-6.98 (2H, m, Ar-H (Phe)), 5.87-5.96 (1H, m, OCH2CHCH2), 5.73 (1H, dddd 
J=6.9Hz, J=6.9Hz, J=10.0Hz, J=13.7Hz, NCH2CHCH2), 5.51 (1H, tdd, J=6.4Hz, J=6.4Hz, J=9.7Hz, J=13.1Hz, 
CHCH2CHCH2), 5.02-5.35 (6H, m, OCH2CHCH2 and NCH2CHCH2 and CHCH2CHCH2), 4.49-4.60 (3H, m, 
OCH2CHCH2 and CHCH2Ph), 3.81 (1H, dd, J=6.9Hz, J=16.1Hz, NCH2CHCH2), 3.73 (1H, dd J=6.9Hz, 
J=16.1Hz, NCH2CHCH2), 3.07 (1H, dd J=5.6Hz, J=14.4Hz, CHCH2Ph), 3.01 (1H, dd J=8.5Hz, J=14.4Hz, 
CHCH2Ph), 2.84-2.90 (1H, m, CHCH2CHCH2), 2.18-2.29 (2H, m, CHCH2CHCH2) 
 
HRMS (ES) 458.1792 (MH+). C25H28FNO4S requires 458.1801 
 
(S)-3-Benzyloxycarbonylamino-4-phenylbutyric acid methyl ester (3.67) Lit6 
N
H
Ph
CO2Me
O
O
Ph
 
N-CBZ-Phe-H (5.00g, 16.7 mmol) was homologated using General Procedure P.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless 
oil, 2.62g, 48%.  Rf = 0.48 (1/3 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.08-7.34 (10H, m, Ar-H), 5.41 (1H, d J=8.6Hz, NH), 5.05 (2H, s, 
OCH2Ph), 4.15-4.28 (1H, m, CHCH2Ph), 3.63 (3H, s, CO2CH3), 2.94 (1H, dd J=6.5Hz, J=13.6Hz, CHCH2Ph), 
2.81 (1H, dd J=7.6Hz, J=13.6Hz, CHCH2Ph), 2.49 (2H, dd J=5.3Hz, J=5.3Hz, CH2CO2CH3)  
 
13C NMR ppm (75 MHz in CDCl3). 172.0, 155.7, 137.5, 136.5, 135.7, 133.2, 129.3, 128.5, 128.5, 128.1, 128.0, 
126.7, 66.6, 51.7, 49.4, 40.2, 37.4 
  
LRMS (ES) 328.1 (MH+). C19H21NO4 requires 328.2 
 
(S)-2-((S)-1-tert-Butoxycarbonylamino-2-phenylethyl)pent-4-enoic acid methyl ester (3.68) 
N
H
Ph
CO2Me
O
O
Ph
 
β-amino acid 3.67 (1.00g, 3.05 mmol) was allylated using General Procedure Q.  The crude material was purified 
by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield an orange solid, 
0.730g, 65%.  Rf = 0.42 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.18-7.40 (10H, m, Ar-H), 5.84 (1H, d J=9.6Hz, NH), 5.62-5.72 (1H, m, 
CHCH2CHCH2), 4.94-5.17 (2H, m, CHCH2CHCH2), 4.06-4.17 (1H, m, CHCH2Ph), 3.71 (3H, s, CO2CH3), 2.92 
(1H, dd J=6.3Hz, J=13.6Hz, CHCH2Ph), 2.70 (1H, dd J=8.5Hz, J=13.6Hz, CHCH2Ph), 2.60-2.66 (1H, m, 
CHCH2CHCH2), 2.38-2.47 (1H, m, CHCH2CHCH2), 2.30 (1H, ddd J=6.9Hz, J=6.9Hz, J=13.8Hz, CHCO2CH3) 
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13C NMR ppm (75 MHz in CDCl3). 174.7, 155.9, 137.4, 136.6, 134.3, 129.2, 128.4,  127.9, 127.9, 126.5, 117.4, 
66.5, 53.1, 51.6, 46.4, 40.5, 34.3  
 
LRMS (ES) 368.2 (MH+). C22H25NO4 requires 368.2  
 
(S)-2-((S)-1-Benzyloxycarbonylamino-2-phenylethyl)pent-4-enoic acid methyl ester (3.69) 
N
Ph
CO2Me
O
O
Ph
 
β-amino acid 3.68 (0.960g, 2.61 mmol) was allylated using General Procedure O3.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white solid, 
0.926g, 87%.  Rf = 0.22 (1/7 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.02-7.37 (10H, m, Ar-H), 5.68-5.82 (2H, m OCH2CHCH2 and 
CHOCH2CHCH2, 5.01-5.16 (6H, m, OCH2CHCH2 and CHCH2CHCH2 and OCH2Ph), 3.84-3.90 (1H, m, 
CHCH2Ph), 3.56 (3H, s, CO2CH3), 3.35-3.46 (2H, m, NCH2CHCH2), 2.87-2.95 (2H, m, CHCH2Ph), 2.38-2.45 
(3H, m, CHCH2CHCH2 and CHCH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3). 174.7, 155.9, 137.4, 136.6, 134.3, 129.2, 128.4, 127.9, 126.5, 117.4, 66.5, 
53.1, 51.6, 46.4, 40.5, 34.3  
 
LRMS (ES) 408.2 (MH+). C25H29NO4 requires 408.2 
 
(2S,3S)-2-Benzyl-2,3,4,7-tetrahydro-azepine-1,3-dicarboxylic acid 1-benzyl ester-3-methyl ester (3.70) 
N
Ph
CO2Me
O
O
Ph
 
Diene 3.69 (0.930g, 2.28 mmol) was reacted with Grubbs second generation catalyst using General Procedure 
D1.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a brown solid, 0.710g, 82%.  Rf = 0.29 (1/5 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.13-7.33 (10H, m, Ar-H), 5.71-5.80 (2H, m, NCH2CHCHCH2 and 
NCH2CHCHCH2), 5.26-5.33 (1H, m, CHCH2Ph), 5.10 (2H, s, OCH2Ph), 4.45-4.51 (1H, m, NCH2CHCHCH2), 
4.24-4.31 (1H, m, NCH2CHCHCH2), 3.71-3.77 (1H, m, CHCO2CH3), 3.64 (3H, s, CO2CH3), 3.01-3.04 (1H, m, 
CHCH2Ph), 2.89-2.95 (1H, m, CHCH2Ph), 2.53-2.67 (2H, m, NCH2CHCHCH2)  
  
HRMS (ES) 380.1871 (MH+). C23H25NO4 requires 380.1862  
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 (2S,3S)-2-Benzyl-2,3,4,7-tetrahydro-azepine-1,3-dicarboxylic acid-1-benzyl ester (3.71) 
N
Ph
CO2H
O
O
Ph
 
Methyl ester 3.70 (0.710g, 1.87 mmol) was hydrolysed using General Procedure C1 to afford an orange solid, 
0.683g, 100%. 
 
1H NMR ppm (300 MHz in CDCl3) 7.02-7.46 (10H, m, Ar-H), 5.63-5.88 (2H, m, NCH2CHCHCH2 and 
NCH2CHCHCH2) 5.28-5.33 (1H, m, CHCH2Ph), 5.10 (2H, s, OCH2Ph), 4.45-4.52 (1H, m, NCH2CHCHCH2), 
4.20-4.29 (1H, m, NCH2CHCHCH2), 3.71-3.79 (1H, m, CHCO2H), 3.06-3.12 (1H, m, CHCH2Ph), 2.92-3.00 
(1H, m, CHCH2Ph), 2.57-2.64 (2H, m, NCH2CHCHCH2) 
 
13C NMR ppm (75 MHz in CDCl3). 180.5, 137.6, 129.4, 129.3, 128.6, 128.5, 128.4, 127.9, 126.5, 127.8, 127.5, 
67.3, 56.5, 47.6,  47.1, 41.4, 32.9, 26.5  
 
LRMS (ES) 366.1 (MH+). C22H23NO4 requires 366.2  
 
(2S,3S)-2-Benzyl-3-((S)-1-hydroxymethyl-3-methylbutylcarbamoyl)-2,3,4,7-tetra-hydroazepine-1-
carboxylic acid benzyl ester (3.72) 
N
Ph
N
H
OH
O
O
O
Ph
 
Carboxylic acid 3.71 (0.650g, 1.78 mmol) was reacted with (L)-leucinol using General Procedure B3.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a yellow solid, 0.481g, 58%.  Rf = 0.43 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.18-7.37 (10H, m, Ar-H), 6.30 (1H, bs, NH), 5.63-5.78 (2H, m, 
NCH2CHCHCH2 and NCH2CHCHCH2), 5.02 (2H, s, OCH2Ph), 4.93-4.97 (1H, m, CHCH2Ph), 4.57-4.61 (1H, 
m, CHCHC(O), 4.23-4.29 (1H, m, NCH2CHCHCH2), 4.01-4.07 (1H, m, CHCH2CH(CH3)2), 3.64-3.72 (2H, m, 
NCH2CHCHCH2 and CH2OH), 3.48-3.52 (1H,m, CH2OH), 2.88-3.05 (2H, m CHCH2Ph), 2.68-2.74 (1H, m, 
NCH2CHCHCH2), 2.36-2.43 (1H, m, NCH2CHCHCH2), 1.62-1.69 (1H, m, CHCH2CH(CH3)2), 1.36-1.52 (2H, 
m, CHCH2CH(CH3)2), 0.88-0.92 (6H, m, CHCH2CH(CH3)2) 
 
HRMS (ES) 465.2756 (MH+). C28H36N2O4 requires 465.2753  
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(2S,3S)-2-Benzyl-3-((S)-1-formyl-3-methylbutylcarbamoyl)-2,3,4,7-tetrahydroazepine-1-carboxylic acid 
benzyl ester (3.73) 
N
Ph
N
H
H
O
O
O
O
Ph
 
Alcohol 3.72 (0.520g, 1.11 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless oil, 0.314g, 
61%.  Rf = 0.33 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in (CD3)2SO).  Compound 3.73 exists as a 1:1 mixture of rotamers.  9.44 and 9.40 (1H, 
s, CHO), 8.38 and 8.28 (1H, d, J=7.0Hz, NH), 7.09-7.38 (10H, m, Ar-H), 5.70-5.85 (2H, m, NCH2CHCHCH2 
and NCH2CHCHCH2), 5.03 (1H, d J=13.1Hz, OCH2Ph), 5.02 (1H, d J=13.1Hz, OCH2Ph), 4.91-4.98 (1H, m, 
CHCH2Ph), 4.28-4.36 and 4.20-4.26 (1H, m, NCH2CHCHCH2), 4.06-4.19 (1H, m, CHCH2CH(CH3)2), 3.72-3.94 
(1H, m, NCH2CHCHCH2), 2.93-3.17 (2H, m CHCHO and CHCH2Ph), 2.55-2.83 (2H, m, CHCH2Ph and 
NCH2CHCHCH2), 2.24-2.39 (1H, m, NCH2CHCHCH2), 1.59-1.73 (1H, m, CHCH2CH(CH3)2), 1.40-1.59 (2H, 
m, CHCH2CH(CH3)2), 0.84-0.91 (6H, m, CHCH2CH(CH3)2) 
 
HRMS (ES) 463.2602 (MH+). C28H34N2O4 requires 463.2597  
 
(S)-3-Benzyloxycarbonylamino-4-phenylbutyric acid (3.74) Lit6 
N
H
Ph
CO2HO
O
Ph
 
Methyl ester 3.67 (2.00g, 6.11 mmol) was hydrolysed using general procedure C1 to afford a white solid, 1.80g, 
94%. 
 
1H NMR ppm (500 MHz in CDCl3) 9.29 (1H, bs, CO2H), 7.07-7.39 (10H, m, Ar-H (CBZ) and Ar-H (Phe)), 5.32 
(1H, d J=8.4Hz, NH), 5.07 (2H, s, OCH2Ph), 4.16-4.31 (1H, m, CHCH2Ph), 2.96 (1H, dd J=6.4Hz, J=13.5Hz, 
CHCH2Ph), 2.87 (1H, dd J=7.9Hz, J=13.5Hz, CHCH2Ph), 2.59 (1H, dd J=5.0Hz, J=16.3Hz CH2CO2H), 2.53 
(1H, dd  J=5.1Hz, J=16.3Hz, CH2CO2H) 
 
LRMS (ES) 314.1 (MH+). C18H19NO4 requires 314.1 
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(S)-1-Benzyl-2-((S)-1-hydroxymethyl-3-methylbutylcarbamoyl)ethyl]carbamic acid benzyl ester (3.75) 
N
H
Ph
O
N
H
OH
O
O
Ph
 
Carboxylic acid 3.74 (1.80g, 5.74 mmol) was reacted with (L)-leucinol using General Procedure B3.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a yellow solid, 0.711g, 30%.  Rf = 0.29 (3/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 7.17-7.32 (10H, m, Ar-H (CBZ) and Ar-H (Phe)), 4.99 (1H, d J=12.7Hz 
OCH2Ph), 4.93 (1H, d J=12.7Hz OCH2Ph), 4.12-4.19 (1H, m, CHCH2Ph), 3.90-3.98 (1H, m, CHCH2CH(CH3)2), 
3.42 (1H, dd J=5.5Hz, J=11.0Hz, CH2OH), 3.39 (1H, dd J=5.5Hz, J=11.0Hz, CH2OH), 2.84 (1H, dd J=5.9Hz, 
J=13.5Hz, CHCH2Ph), 2.77 (1H, dd J=8.2Hz, J=13.5Hz, CHCH2Ph), 2.34-2.44 (2H, m, CHCH2C(O)), 1.58-1.66 
(1H, m, CHCH2CH(CH3)2), 1.33-1.36 (2H, m, CHCH2CH(CH3)2), 0.88 (3H, d J=6.7Hz, CHCH2CH(CH3)2), 0.86 
(3H, d J=6.7Hz, CHCH2CH(CH3)2)   
 
13C NMR ppm (75 MHz in CD3OD) 171.8, 156.7, 138.2, 137.0, 129.2, 128.6, 128.1, 128.0, 127.5, 127.3, 126.1, 
65.9, 64.3, 50.4, 49.4, 49.3, 40.8, 40.4, 39.7, 24.6, 22.5, 20.9  
 
HRMS (ES) 413.2439 (MH+). C17H27N2O2 requires 413.2440  
 
[(S)-1-Benzyl-2-((S)-1-formyl-3-methylbutylcarbamoyl)ethyl]carbamic acid benzyl ester (3.76) 
N
H
Ph
O
N
H
H
O
O
O
Ph
 
 
Alcohol 3.75 (0.150g, 0.364 mmol) was oxidised using General Procedure L to afford a white solid, 0.0776g, 
52%.   
 
1H NMR ppm (500 MHz in CDCl3)  9.55 (1H, s, CHO), 7.13-7.29 (10H, m, Ar-H (CBZ) and Ar-H (Phe)), 6.05 
(1H, d J=4.9Hz, NH Leu), 5.68 (1H, d J=6.7Hz, NH Phe), 5.07 (2H, s, OCH2Ph), 4.47-4.51 (1H, m, 
CHCH2CH(CH3)2), 4.13-4.20 (1H, m, CHCH2Ph), 3.01 (1H, dd J=6.4Hz, J=12.8, CHCH2Ph), 2.85 (1H, dd 
J=8.0Hz, J=12.8Hz, CHCH2Ph), 2.33-2.45 (2H, m, CHCH2C(O)), 1.57-1.64 (2H, m, CHCH2CH(CH3)2), 1.30-
1.35 (1H, m, CHCH2CH(CH3)2), 0.93-0.96 (6H, m, CHCH2CH(CH3)2)  
 
13C NMR ppm (75 MHz in CDCl3) 199.1, 171.1, 155.9, 137.7, 136.4, 129.3, 128.6, 128.5, 128.0, 127.9, 126.7, 
66.6, 57.2, 50.2, 40.2, 38.8, 37.7, 24.8, 23.0, 21.8  
 
HRMS (ES) 411.2289 (MH+). C24H30N2O4 requires 411.2284  
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(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tert-butoxycarbonylaminopropionylamino]-3-methylbutyric acid methyl 
ester (4.12) 
BOCHN
N
H
O
O
CO2Me
 
 
N-BOC-O-allyl-Tyr-H (5.00g, 16.3 mmol) was reacted with Val-OMe using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 6.08g, 69%.  Rf = 0.29 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 in CDCl3) 7.09 (2H, d J=6.5Hz, Ar-H), 6.80 (2H, d J=6.5Hz, Ar-H), 6.47 (1H, bs, NH Val), 
5.97-6.05 (1H, m, OCH2CHCH2), 5.01-5.40 (2H, m, OCH2CHCH2), 5.12 (1H, bs, NH Tyr), 4.47-4.49 (2H, m, 
OCH2CHCH2), 4.37-4.46 (1H, m, CHCH2Ph), 4.30-4.34 (1H, m, CHCH(CH3)2), 3.66 (3H, s, CO2CH3), 3.01-
3.04 (2H, m, CHCH2Ph), 2.04-2.11 (1H, m, CHCH(CH3)2), 1.39 (9H, s, C(CH3)3), 0.85 (3H, d J=6.8Hz, 
CHCH(CH3)2), 0.82 (3H, d J=6.8Hz, CHCH(CH3)2)  
 
13C NMR ppm (75 MHz in CDCl3) 174.7, 171.9, 157.5, 133.2, 130.3, 128.6, 117.6, 114.8, 68.7, 57.2, 37.0, 31.0, 
28.2, 18.8, 17.6 
 
HRMS (ES) 435.2501 (MH+). C23H34N2O6 requires 435.2495 
 
(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-methylbutyric acid (4.13) 
BOCHN
N
H
O
O
CO2H
 
 
Dipeptide 4.12 (4.90g, 11.3 mmol) was dissolved in THF (70 mL) and hydrolysed using General procedure C1.  
This afforded a white solid, 4.60g, 97%. 
 
1H NMR ppm (500 in CDCl3) 7.11 (2H, d J=8.3Hz, Ar-H), 6.83 (2H, d J=8.3Hz, Ar-H), 6.64 (1H, d J=8.2Hz, 
NH Val), 5.98-6.07 (1H, m, OCH2CHCH2), 5.00-5.39 (2H, m, OCH2CHCH2), 5.19 (1H, bs, NH Tyr), 4.51 (3H, 
m, CHCH2Ph and OCH2CHCH2), 4.36-4.40 (1H, m, CHCH(CH3)2), 2.97-3.02 (2H, m, CHCH2Ph), 2.16-2.23 
(1H, m, CHCH(CH3)2), 1.40 (9H, s, C(CH3)3), 0.88-0.93 (6H, m, CHCH(CH3)2) 
 
 
LRMS (ES) 421.3 (MH+). C22H32N2O6 requires 421.2 
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(S)-2-Amino-pent-4-enoic acid methyl ester (4.14) Lit1 
HCl.H2N CO2Me
 
 
(s)-allyl-Gly-H (5.00g, 43.4 mmol) was suspended in Methanol (100 mL). This was esterified using General 
procedure F1 to afford a white solid. 7.19g, 100%.  
 
1H NMR ppm (500 MHz in CD3OD) 5.78 (1H, dddd J=7.1Hz, J=7.2Hz, J=7.2Hz, J=10.0Hz, CH2CHCH2), 5.25-
5.31 (2H, m, CH2CHCH2), 4.16 (1H, dd J=6.2Hz, J=6.2Hz, CHCO2CH3), 3.84 (3H, s, CHCO2CH3), 2.69 (2H, 
m, CH2CHCH2) 
 
13C NMR ppm (75 MHz in CD3OD) 169.1, 130.3, 120.3, 52.3, 52.1, 34.4   
 
LRMS (ES) (MH+). C6H11NO2 requires 130.1  
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-methylbutyryl-
amino}-pent-4-enoic acid methyl ester (4.15) 
 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Dipeptide 4.13 (1.00g, 2.38 mmol) was reacted with amine 4.14 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 1.05g, 83%.  Rf = 0.48 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 in CDCl3) 7.09 (2H, d J=8.6Hz, Ar-H), 6.82 (2H, d J=8.6Hz, Ar-H), 6.61 (1H, d J=8.4Hz, 
NH Val), 6.56 (1H, d J=6.8Hz, NH Gly), 6.03 (1H, tdd J=5.3Hz, J=10.6Hz, J=17.2Hz, OCH2CHCH2), 5.62-5.71 
(1H, m, CHCH2CHCH2), 5.10-5.41 (4H, m, OCH2CHCH2 and CHCH2CHCH2), 5.05 (1H, d J=5.5Hz, NH Tyr), 
4.58-4.62 (1H, m, CHCH2CHCH2), 4.48-4.50 (2H, m, OCH2CHCH2), 4.30-4.33 (1H, m, CHCH2Ph), 4.25 (1H, 
dd J=6.5Hz, J=8.4Hz, CHCH(CH3)2), 3.73 (3H, s, CO2CH3), 2.96-3.05 (2H, m, CHCH2Ph), 2.46-2.59 (2H, m, 
CHCH2CHCH2), 2.07-2.14 (1H, m, CHCH(CH3)2), 1.39 (9H, s, C(CH3)3), 0.90 ( 3H, d, J=6.8 Hz, 
CHCH(CH3)2), 0.86 (3H, d, J=6.8 Hz, CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 171.7, 171.4, 170.4, 157.6, 133.2, 132.2, 130.0, 128.6, 119.3, 117.6, 114.9, 
68.7, 58.4, 52.3, 51.7, 36.2, 30.7, 28.2, 19.0 
 
HRMS (ES) 532.3010 (MH+). C28H42N3O7 requires 532.3023 
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(E)-(7S,10S,13S)-13-tertButoxycarbonylamino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (4.16) 
BOCHN
N
H
O
O
O
N
H
CO2Me BOCHN N
H
O
O
O
N
H
CO2Me
4.16 4.17  
 
Diene 4.15 (1.80g, 3.39 mmol) was reacted with Grubbs second generation catalyst using General procedure D2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield the E-isomer as a brown solid, 0.205g, 12%.  Rf = 0.24 (1/1 (EtOAc / (50/70) Pet ether)) and the Z-
isomer as a brown solid, 0.528g, 31%.  Rf = 0.22 (1/1 (EtOAc / (50/70) Pet ether)). 
 
E-Isomer 
 
1H NMR ppm (500 in CDCl3) 7.05 (2H, d J=8.6Hz, Ar-H), 6.75 (2H, d J=8.6Hz, Ar-H), 5.74-5.75 (2H, m, NH 
Val and NH Gly), 5.43-5.56 (2H, m, OCH2CHCHCH2 and OCH2CHCHCH2), 5.32 (1H, d J=8.7Hz, NH Tyr), 
4.76 (1H, ddd J=3.4Hz, J=9.2Hz, J=10.1Hz, CHCO2CH3), 4.58-4.64 (2H, m, OCH2CHCHCH2), 4.21 (1H, ddd 
J=5.2Hz, J=8.7Hz, J=11.6Hz, CHCH2Ph), 3.99 (1H, dd J=4.8Hz, J=7.5Hz, CHCH(CH3)2), 3.75 (3H, s, 
CHCO2CH3), 3.13 (1H, dd J=5.2Hz, J=12.5Hz, CHCH2Ph), 2.66-2.75 (2H, m, CHCH2Ph and 
OCH2CHCHCH2), 2.26-2.32 (1H, m, OCH2CHCHCH2), 2.07-2.14 (1H, m, CHCH(CH3)2), 1.45 (9H, s, 
C(CH3)3), 0.81-0.83 (6H, m, CHCH(CH3)2) 
 
HRMS (ES) 504.2718 (MH+). C26H37N3O7 requires 504.2710 
 
Z-Isomer 
 
1H NMR ppm (500 in CDCl3) 7.06 (2H, d J=7.9Hz, Ar-H), 6.74 (2H, d J=7.9Hz, Ar-H), 6.14 (1H, d J=8.7Hz, 
NH Gly), 5.94 (1H, d J=7.7Hz, NH Val), 5.44-5.55 (2H, m, OCH2CHCHCH2 and OCH2CHCHCH2), 4.75 (1H, 
dt J=3.3Hz, J=10.6Hz, CHCO2CH3), 4.55-4.65 (2H, m, OCH2CHCHCH2), 4.24 (1H, ddd J=5.0Hz, J=8.3Hz, 
J=12.6Hz, CHCH2Ph), 4.07 (1H, dd J=5.2Hz, J=7.7Hz, CHCH(CH3)2), 3.73 (3H, s, CHCO2CH3), 3.10 (1H, dd 
J=5.0Hz, J=12.8Hz, CHCH2Ph), 2.66-2.73 (2H, m, CHCH2Ph and OCH2CHCHCH2), 2.25-2.32 (1H, m, 
OCH2CHCHCH2), 2.04-2.09 (1H, m, CHCH(CH3)2), 1.44 (9H, s, C(CH3)3), 0.81 (6H, d J=6.8Hz, CHCH(CH3)2) 
 
HRMS (ES) 504.2718 (MH+). C26H37N3O7 requires 504.2710 
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(Z)-(7S,10S,13S)-13-tertButoxycarbonylamino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (4.17) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Diene 4.15 (3.50g, 6.58 mmol) was reacted with Grubbs second generation catalyst using General Procedure E1.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 2.25g, 31%.  Rf = 0.22 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 in CDCl3) 7.06 (2H, d J=7.9Hz, Ar-H), 6.74 (2H, d J=7.9Hz, Ar-H), 6.14 (1H, d J=8.7Hz, 
NH Gly), 5.94 (1H, d J=7.7Hz, NH Val), 5.44-5.55 (2H, m, OCH2CHCHCH2 and OCH2CHCHCH2), 4.75 (1H, 
dt J=3.3Hz, J=10.6Hz, CHCO2CH3), 4.55-4.65 (2H, m, OCH2CHCHCH2), 4.24 (1H, ddd J=5.0Hz, J=8.3Hz, 
J=12.6Hz, CHCH2Ph), 4.07 (1H, dd J=5.2Hz, J=7.7Hz, CHCH(CH3)2), 3.73 (3H, s, CHCO2CH3), 3.10 (1H, dd 
J=5.0Hz, J=12.8Hz, CHCH2Ph), 2.66-2.73 (2H, m, CHCH2Ph and OCH2CHCHCH2), 2.25-2.32 (1H, m, 
OCH2CHCHCH2), 2.04-2.09 (1H, m, CHCH(CH3)2), 1.44 (9H, s, C(CH3)3), 0.81 (6H, d J=6.8Hz, CHCH(CH3)2) 
 
HRMS (ES) 504.2711 (MH+). C26H37N3O7 requires 504.2710 
 
(7S,10S,13S)-13-tertButoxycarbonylamino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (4.18) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
A mixture of the unsaturated macrocycles 4.16 and 4.17 (1.36g, 2.70 mmol) was hydrogenated in 50 mL of 
methanol using General Procedure G1 to afford a brown solid, 1.36g, 100% 
 
1H NMR ppm (500 MHz in CDCl3) 7.05 (2H, d J=8.0Hz, Ar-H), 6.78 (2H, d J=8.0Hz, Ar-H), 6.23 (1H, d 
J=7.1Hz, NH Val), 5.90 (1H, d J=8.2Hz, NH Gly), 5.29 (1H, d J=8.6Hz, NH Tyr), 4.56 (1H, dt J=3.9Hz, 
J=8.2Hz, CHCO2CH3), 4.21-4.30 (2H, m, CHCH2Ph, OCH2CH2CH2CH2) 4.09-4.13 (1H, m, 
OCH2CH2CH2CH2), 3.84-3.86 (1H, m, CHCH(CH3)2), 3.72 (3H, s, CHCO2CH3), 3.10 (1H, dd J=5.4Hz, 
J=12.2Hz, CHCH2Ph), 2.67 (1H, dd J=12.2Hz, J=12.2Hz, CHCH2Ph), 1.95-2.02 (1H, m, CHCH(CH3)2), 1.86-
1.92 (1H, m, OCH2CH2CH2CH2), 1.80 (1H, m, OCH2CH2CH2CH2), 1.49-1.57 (2H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2), 1.44 (9H, s, C(CH3)3), 1.25-1.35 (2H, m, OCH2CH2CH2CH2), 0.87 (3H, d J=6.6 Hz, 
CHCH(CH3)2), 0.81 (3H, d J=6.6Hz, CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 172.7, 170.3, 169.8, 156.9, 155.1, 130.0, 128.4, 115.9, 79.6, 66.8, 57.6, 56.8, 
52.3, 51.0, 38.4, 32.3, 31.7, 28.2, 21.7, 18.2, 18.1 
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HRMS (ES) 506.2871 (MH+). C26H40N3O7 requires 506.2866 
 
(S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-4-methylsulfanyl-butyric acid (4.19) Lit2 
N
S
CH3
CO2H
O
O
 
(L)-Methionine (5.00g, 3.35 mmol) and phthalic anhydride (4.96g, 1 equiv) were suspended in water (7 mL).  
This was heated in the microwave (800W) for six min in an open round bottomed flask to allow evaporation of 
the water.  A yellow gum was obtained, 9.36g, 100%. 
 
1H NMR ppm (500 MHz in CDCl3) 8.81 (1H, bs, CO2H), 7.85 (2H, d J=5.6Hz, Ar-H), 7.73 (2H, d J=5.6Hz, Ar-
H), 5.16 (1H, dd J=4.5Hz, J=8.9Hz, CHCO2H), 2.44-2.60 (4H, m, CHCH2CH2S and CHCH2CH2S), 2.07 (3H, s, 
SCH3) 
 
13C NMR ppm (75 MHz in CDCl3) 174.6, 167.6, 134.3, 131.6, 123.6, 50.6, 30.7, 27.7, 15.2 
 
LRMS (ES) 280.1 (MH+). C13H13NO4S requires 280.1 
 
(S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-4-methylsulfanyl-butyric acid methyl ester (4.20) Lit2 
N
S
CH3
O
O
CO2Me
 
 
Carboxylic acid 4.19 (9.36g, 33.5 mmol) was suspended in methanol (150 mL).  This was cooled in ice and 
saturated with hydrogen chloride gas.  This was warmed to rt and stirred for eighteen h.  The reaction mixture 
was concentrated in vacuo and the crude material purified by flash chromatography on silica using a gradient of 
EtOAc and (50/70) pet ether to afford a colourless oil, 9.83g, 100%.  Rf = 0.31 (1/3 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.88 (2H, d J=5.5Hz, Ar-H), 7.77 (2H, d J=5.5Hz, Ar-H), 5.09-5.12 (1H, m, 
CHCO2CH3), 3.75 (3H, s, CHCO2CH3), 2.47-2.61 (4H, m, CHCH2CH2S and CHCH2CH2S), 2.09 (3H, s, SCH3) 
 
13C NMR ppm (75 MHz in CDCl3) 169.5, 167.4, 134.2, 131.7, 123.5, 52.8, 50.7, 30.7, 28.0, 15.2 
 
LRMS (ES) 294.1 (MH+). C14H15NO4S requires 294.1 
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(S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-4-methanesulfinylbutyric acid methyl ester (4.21) Lit2 
N
S
CH3
O
O
O
CO2Me
 
 
Sulphide 4.20 (1.40g, 4.78 mmol) was dissolved in methanol (30 mL).  This was cooled in ice and a solution of 
sodium metaperiodate (1.07g, 1.05 equiv) in water (12 mL) was added dropwise over ten min.  This was stirred  
in ice for one h and then at rt for a further two h.  The resultant white precipitate was removed by filtration under 
vacuum, the residue washed with methanol and the filtrate concentrated in vacuo to yield 4.21 as a 1:1 mixture of 
diastereoisomers.  This was obtained as a colourless oil, 1.39g, 94%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.84-7.86 (2H, m, Ar-H), 7.74-7.76 (2H, m, Ar-H), 4.93-4.97 (1H, m, 
CHCO2CH3), 3.76 (3H, s, CHCO2CH3), 2.60-2.88 (4H, m, CHCH2CH2S and CHCH2CH2S) 2.53-2.54 (3H, m, 
SCH3) 
 
LRMS (ES) 310.1 (MH+). C14H15NO5S requires 310.1 
 
(S)-2-Benzyloxycarbonylamino-4-methylsulfanylbutyric acid methyl ester (4.23) Lit3 
 
N
H
S
CO2Me
CH3
O
O
Ph
 
(L)-methionine (3.70g, 18.5 mmol) was dissolved in a biphasic mixture of EtOAc (75 mL) and water (75 mL).  
This was cooled in ice and sodium hydrogen bicarbonate (7.78g, 5 equiv) and benzyl chloroformate (2.98 mL, 
1.1 equiv) were added.  This was stirred in ice for one h and then at rt for a further eighteen h before the mixture 
was allowed to partition.  The organic phase was washed sequentially with 1M HCl(aq), saturated aqueous sodium 
hydrogen bicarbonate and brine before being dried (MgSO4), filtered and concentrated in vacuo to afford a 
yellow oil, 5.40g, 98%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.29 (5H, m, Ar-H), 5.79 (1H, d J=7.9Hz, NH), 5.08 (2H, s, CH2Ph), 4.43-
4.47 (1H, m, CHCO2CH3), 3.70 (3H, s, CHCO2CH3), 2.49 (2H, dd, J=7.4Hz, J=7.4Hz, CHCH2CH2S), 2.11 (1H, 
ddd J=7.2Hz, J=12.8Hz, J=14.4Hz, CHCH2CH2S), 2.04 (3H, s, SCH3), 1.93 (1H, ddd, J=7.1Hz, J=7.1Hz, 
J=14.4Hz, CHCH2CH2S) 
 
LRMS (ES) 298.1 (MH+). C14H19NO4S requires 298.1 
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(S)-2-Benzyloxycarbonylamino-4-methanesulfinylbutyric acid methyl ester (4.24) Lit3 
N
H
S
CO2Me
CH3O
O
O
Ph
 
Sulphide 4.23 (5.40g, 18.2 mmol) was dissolved in methanol (60 mL).  This was cooled in ice and a solution of 
sodium metaperiodate (4.08g, 1.05 equiv) in water (25 mL) was added dropwise over ten min.  This was stirred  
in ice for one h and then at rt for a further two h.  The resultant white precipitate was removed by filtration under 
vacuum, the residue washed with methanol and the filtrate concentrated in vacuo.  The resultant colourless oil 
was partitioned between DCM and water.  The aqueous phase was extracted twice more with DCM, methanol 
added to the combined organic extracts to obtain an homogenous solution and this was dried (MgSO4), filtered 
and concentrated in vacuo to afford a yellow oil, 5.69g, 100%. This was obtained as a 1:1 mixture of 
diastereoisomers.   
 
1H NMR ppm (500 MHz in CDCl3) 7.30-7.35 (5H, m, Ar-H), 6.00-6.08 (1H, m, NH), 5.10 (2H, s, CH2Ph), 4.44-
4.50 (1H, m, CHCO2CH3), 3.75 (3H, s, CHCO2CH3), 2.67-2.77 (2H, m, CHCH2CH2S), 2.53-2.54 (3H, m, 
SCH3), 2.32-2.40 (1H, m, CHCH2CH2S), 2.09-2.19 (1H, m, CHCH2CH2S) 
 
13C NMR ppm (75 MHz in CDCl3) 172.6, 156.0, 136.2, 128.6, 128.4, 128.3, 128.1, 128.0, 69.9, 53.5, 53.0, 52.4, 
31.6, 29.8, 15.3 
 
LRMS (ES) 314.1 (MH+). C14H19NO5S requires 314.1 
 
(S)-2-Benzyloxycarbonylamino-but-3-enoic acid methyl ester (4.25) Lit3 
 
N
H
CO2MeO
O
Ph
 
Sulfoxide 4.24 (5.69g, 18.2 mmol) was placed in a round bottomed flask in a kugelrohr.  This was directly 
connected to a low vacuum diaphragm pump and heated/distilled at 140oC.  The distillate was purified by flash 
chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless oil, 0.905g, 20%.  
Rf = 0.24 (1/7 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.31-7.35 (5H, m, Ar-H), 5.86-5.93 (1H, m, CHCH2), 5.61 (1H, d J=6.3Hz, 
NH), 5.01-5.39 (2H, m, CHCH2), 5.11 (2H, s, CH2Ph), 4.91-4.96 (1H, m, CHCO2CH3) , 3.74 (3H, s, 
CHCO2CH3) 
 
13C NMR ppm (75 MHz in CDCl3) 170.9, 155.5, 136.1, 132.2, 128.5, 128.2, 128.1, 127.5, 126.9, 117.7, 67.1, 
56.1, 52.7  
 
LRMS (ES) 250.1 (MH+). C13H16NO4 requires 250.1 
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(S)-2-Benzyloxycarbonylamino-but-3-enoic acid methyl ester (4.26) Lit4 
NH2 CO2H
 
Olefin 4.25 (0.905g, 3.61 mmol) was suspended in 6M HCl(aq)(20 mL)  This was heated at reflux for two h, 
cooled and partitioned with DCM.  The aqueous phase was washed again with DCM before being concentrated 
in vacuo to afford a white solid.  This was recrystallised from acetone to afford a white solid, 0.350g, 71% 
 
1H NMR ppm (500 MHz in (CD3)2SO) 8.32 (2H, bs, NH2), 6.02-6.11 (1H, m, CHCH2), 5.50-5.75 (2H, m, 
CHCH2), 4.68-4.73 (1H, m, CHCO2H)  
 
(S)-2-Amino-but-3-enoic acid methyl ester hydrochloride (4.27) Lit4 
HCl.H2N CO2Me
 
Amino acid 4.26 (0.350g, 2.56 mmol) was dissolved in methanol (10 mL) and esterified using General Procedure 
F2 to afford a white solid, 0.388g, (100%) 
 
1H NMR ppm (500 MHz in CDCl3) 8.70 (2H, bs, NH2), 6.06-6.13 (1H, m, CHCH2), 5.52-5.73 (2H, m, CHCH2), 
4.79-4.82 (1H, m, CHCO2CH3), 3.83 (3H, s, CHCO2CH3) 
 
(S)-2-((S)-2-{(S)-3-(4-Allyloxyphenyl)-2-[(tertbutoxyhydroxymethyl)amino]propionylamino}-3-methyl-
butyrylamino)but-3-enoic acid methyl ester (4.28) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Dipeptide 4.13 (1.03g, 2.45 mmol) was reacted with amine 4.27 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 0.964g, 76%.  Rf = 0.46 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.08 (2H, d J=8.2Hz, Ar-H), 6.82 (2H, d J=8.2Hz, Ar-H), 6.62 (1H, d 
J=7.5Hz, NH), 6.53 (1H, d J=8.5Hz, NH), 6.42 (1H, d J=8.3Hz, NH), 6.07 (1H, tdd J=5.3Hz, J=10.6Hz, 
J=17.2Hz, OCH2CHCH2), 5.90-5.97 (1H, m, CHCHCHCH2), 5.05-5.42 (4H, m, OCH2CHCH2 and CHCHCH2), 
4.95-5.00 (1H, m, CHCO2CH3), 4.49-4.51 (2H, m, OCH2CHCH2), 4.25-4.38 (2H, m, CHCH2Ph and 
CHCH(CH3)2), 3.74 (3H, s, CHCO2CH3), 3.01-3.05 (2H, m, CHCH2Ph), 2.04-2.11 (1H, m, CHCH(CH3)2), 1.45 
(9H, s, C(CH3)3),  0.89 (3H, d J=7.1Hz, CHCH(CH3)2), 0.87 (3H, d J=7.1Hz, CHCH(CH3)2) 
 
HRMS (ES) 518.2878 (MH+). C27H39N3O7 requires 518.2866 
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(E/Z)-(6S,9S,12S)-12-tertButoxycarbonylamino-9-isopropyl-8,11-dioxo-2-oxa-7,10-diazabicyclo-
[12.2.2]octadeca-1(17),4,14(18),15-tetraene-6-carboxylic acid methyl ester (4.29) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Diene 4.28 (0.830g, 1.60 mmol) was reacted with Grubbs second generation catalyst using General Procedure 
E1.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a brown solid, 0.251g, 32%.  A 1:3.8 ratio of geometric isomers was obtained.  Rf = 0.32 and 
0.35 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H-NMR for major isomer from mixture (500 MHz in CDCl3) 6.95 (2H, d J=8.1Hz, Ar-H), 6.78 (2H, d J=8.1Hz, 
Ar-H), 5.84 (1H, d J=8.0Hz, NH Tyr), 5.38-5.47 (2H, m, OCH2CHCHCH and OCH2CHCHCH), 4.91-4.94 (1H, 
m, CHCO2CH3), 4.61-4.73 (2H, m, OCH2CHCHCH), 4.04-4.13 (2H, m, CHCH2Ph and CHCH(CH3)2), 3.78 
(3H, s, CHCO2CH3), 3.03 (1H, dd J=5.1Hz, J=12.5Hz, CHCH2Ph), 2.68 (1H, dd J=12.5Hz, J=12.5Hz, 
CHCH2Ph), 1.92-1.97 (1H, m, CHCH(CH3)2), 1.45 (9H, s, C(CH3)3), 0.81-0.85 (6H, m, CHCH(CH3)2) 
 
Selected 1H-NMR for minor isomer from mixture: 7.19 (2H, d J=8.3Hz, Ar-H), 4.22-4.30 (2H, m, CHCH2Ph and 
CHCH(CH3)2), 3.74 (3H, s, CHCO2CH3) 
 
HRMS (ES) 490.2546 (MH+). C25H35N3O7 requires 490.2553 
 
(6S,9S,12S)-12-tert-Butoxycarbonylamino-9-isopropyl-8,11-dioxo-2-oxa-7,10-diazabicyclo-[12.2.2]-
octadeca-1(17),14(18),15-triene-6-carboxylic acid methyl ester (4.30) 
 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
The unsaturated macrocycle 4.29 (0.251g, 0.513 mmol) was hydrogenated in 20 mL of methanol using General 
Procedure G1 to afford a brown solid, 0.131g, 52%. 
 
1H NMR ppm (500 MHz in CDCl3) 6.96 (2H, d J=8.2Hz, Ar-H), 6.71 (2H, d J=8.2Hz, Ar-H), 6.15 (1H, d 
J=7.1Hz, NH Val), 5.93 (1H, d J=8.2Hz, NH Gly), 5.28 (1H, d J=8.6Hz, NH Tyr), 4.53-4.55 (1H, m, 
CHCO2CH3), 4.23-4.31 (1H, m, OCH2CH2CH2CH) 4.05-4.22 (2H, m, CHCH2Ph and OCH2CH2CH2CH), 3.82-
3.84 (1H, m, CHCH(CH3)2), 3.76 (3H, s, CHCO2CH3), 3.12 (1H, dd J=5.2Hz, J=12.5Hz, CHCH2Ph), 2.62 (1H, 
dd J=12.5Hz, J=12.5Hz, CHCH2Ph), 2.02-2.08 (1H, m, CHCH(CH3)2), 1.86-1.92 (1H, m, OCH2CH2CH2CH), 
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1.80 (1H, m, OCH2CH2CH2CH), 1.49-1.57 (2H, m, OCH2CH2CH2CH and OCH2CH2CH2CH), 1.47 (9H, s, 
C(CH3)3), 0.89 (3H, d J=6.8Hz, CHCH(CH3)2), 0.86 (3H, d J=6.8Hz, CHCH(CH3)2) 
HRMS (ES) 492.2700 (MH+). C25H37N3O7 requires 492.2710 
 
(S)-2-(2-Benzoylphenylcarbamoyl)pyrrolidine-1-carboxylic acid tertbutyl ester (4.31) Lit5 
N
O
N
H
PhO
BOC  
 
N-BOC-Pro-H (5.00g, 23.2 mmol) was reacted with 2-aminobenzophenone using General Procedure A1.  The 
crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to 
yield a white solid, 6.30g, 69%.  Rf = 0.38 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) (Compound exists as a mixture of rotamers) 11.35 and 11.28 (1H, bs, NH), 
8.66-8.72 and 8.26-8.28 (1H, bm, Ar-H), 7.69 (2H, d J=7.1Hz, Ar-H), 7.55-7.58 (3H, m, Ar-H), 7.47 (2H, dd 
J=6.9Hz, J=6.9Hz, Ar-H), 7.06-7.13 (1H, m, Ar-H), 4.42-4.49 and 4.29 (1H, m and dd J=3.6Hz, J=6.1Hz, 
CHCH2CH2CH2N), 3.71-3.80 (1H, bm, CHCH2CH2CH2N), 3.60 and 3.44-3.50 (1H, dd and m, J=1.8Hz, 
J=6.0Hz, CHCH2CH2CH2N), 3.09 and 2.55 (1H, dd and dd J=7.0Hz, J=12.4Hz and J=6.3Hz, J=13.7Hz, 
CHCH2CH2CH2N), 2.26-2.34 and 2.20-2.22 (1H, m and m, CHCH2CH2CH2NH), 2.12-2.18 and 1.91 (2H, m and 
ddd J=6.6Hz, J=6.6Hz, J=11.7Hz, CHCH2CH2CH2N) 1.42 and 1.30 (9H, s and s, C(CH3)3) 
 
LRMS (ES) 395.2 (MH+). C23H26N2O4 requires 395.2  
 
(S)-Pyrrolidine-2-carboxylic acid (2-benzoylphenyl)amide hydrochloride (4.32) Lit5 
N
H O
N
H
PhO
HCl.
 
N-BOC protected compound 4.31 (6.30g, 16.0 mmol) was reacted using General Procedure I2.  This was 
partitioned between EtOAc and 1M NaOH(aq).  The aqueous phase was extracted twice more with EtOAc.  To the 
combined organic extracts 2M HCl in diethyl ether was added (20 mL).  This was dried (MgSO4), filtered and 
concentrated in vacuo to afford a yellow solid, 5.28g, 100%. 
 
1H NMR ppm (500 MHz in CDCl3) 11.61 (1H, bs, NHPh), 8.44 (1H, d J=8.7Hz, Ar-H), 7.72 (2H, dd J=0.8Hz, 
J=7.4Hz, Ar-H), 7.58 (1H, dd J=7.4Hz, J=7.4Hz, Ar-H), 7.45-7.52 (4H, m, Ar-H), 7.10 (1H, dd J=7.4Hz, 
J=7.4Hz, Ar-H), 5.54 (1H, bs, CHCH2CH2CH2NH), 4.18 (1H, dd J=5.8Hz, J=8.7Hz, CHCH2CH2CH2NH), 3.13-
3.22 (2H, m, CHCH2CH2CH2NH), 2.28 (1H, dddd J=8.0Hz, J=8.0Hz, J=8.7Hz, J=16.0Hz, CHCH2CH2CH2NH), 
1.95 (1H, dddd J=5.8Hz, J=7.5Hz, J=7.5Hz, J=16.0Hz, CHCH2CH2CH2NH), 1.77-1.86 (2H, m, 
CHCH2CH2CH2NH) 
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LRMS (ES) 295.1 (MH+). C18H18N2O2 requires 295.1  
 
(S)-1-Benzyl-pyrrolidine-2-carboxylic acid (2-benzoylphenyl)amide (4.33) Lit5 
N
O
N
H
PhO
Ph  
Amine 4.32 (4.90g, 16.6 mmol) was dissolved in anhydrous THF (25 mL) under an atmosphere of argon.  This 
was cooled in ice.  Triethylamine (5.57 mL, 2.4 equiv) and benzyl bromide (4.75 mL, 2.4 equiv) were added.  
This was stirred in ice for one h and then at rt for eighteen h before being concentrated in vacuo.  The residue 
was partitioned between EtOAc and water.  The organic phase was washed with water and then brine, dried 
(MgSO4), filtered and concentrated in vacuo.  The crude material was purified by flash chromatography on silica 
using a gradient of EtOAc and (50/70) pet ether to yield a yellow solid, 4.10g, 72%.  Rf = 0.32 (1/4 (EtOAc / 
(50/70) Pet ether)).  
 
1H NMR ppm (500 MHz in CDCl3) 11.53 (1H, bs, NH), 8.57 (1H, d J=8.4Hz, Ar-H), 7.78 (2H, d J=8.4Hz, Ar-
H), 7.60 (1H, dd J=7.5Hz, J=7.5Hz, Ar-H), 7.48-7.55 (4H, m, Ar-H), 7.37 (2H, dd J=2.7Hz, J=6.2Hz, Ar-H), 
7.07-7.14 (4H, m, Ar-H), 3.92 (1H, d J=12.9Hz, NCH2Ph), 3.59 (1H, d J=12.9Hz, NCH2Ph), 3.31 (1H, dd 
J=4.8Hz, J=10.1Hz, CHCH2CH2CH2NH), 3.21 (1H, ddd J=2.1Hz, J=6.7Hz, J=9.7Hz, CHCH2CH2CH2NH), 2.40 
(1H, ddd J=6.8Hz, J=9.6Hz, J=9.7Hz, CHCH2CH2CH2NH), 2.21-2.29 (1H, m, CHCH2CH2CH2NH), 1.96 (1H, 
ddd J=4.8Hz, J=8.0Hz, J=12.7Hz, CHCH2CH2CH2NH), 1.69-1.86 (2H, m, CHCH2CH2CH2NH) 
 
13C NMR ppm (75 MHz in CDCl3) 198.0, 174.6, 139.1, 138.5, 138.1, 133.3, 132.5, 130.1, 129.1, 128.3, 128.1, 
127.0, 125.3, 122.2, 121.5, 68.2, 59.8, 53.8, 31.0, 24.1  
 
LRMS (ES) 384.9 (MH+). C25H24N2O2 requires 385.2  
 
Glycine-nickel-(II)-(N-benzylprolyl)amino]benzophenone (4.34) Lit5 
 
N
OO
Ni
O
N N
H
H
 
Benzyl proline benzophenone 4.33 (4.30g, 11.2 mmol), glycine (4.20g, 5 equiv) and nickel nitrate hexahydrate 
(6.50g, 2 equiv) were suspended in methanol (60 mL).  The mixture was heated to 60oC and a solution of 
potassium hydroxide (4.39g, 7 equiv) in water (50 mL) was added and heating continued at 60oC for one h.  
After cooling the mixture was neutralised to pH 7 using glacial acetic acid, more water (150 mL) was added and 
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stirred continued at rt for a further eighteen h  The red precipitate was collected using suction filteration.  The 
crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to 
yield a yellow solid, 4.10g, 72%.  Rf = 0.32 (1/4 (EtOAc / (50/70) Pet ether)).  
 
1H NMR ppm (500 MHz in CDCl3) 8.29 (1H, dd, J=3.8Hz, J=8.5, Ar-H), 8.07 (2H, dd, J=3.8Hz, J=6.3Hz, Ar-
H), 7.48-7.56 (3H, m, Ar-H), 7.43 (2H, dd J=5.5Hz,  J=9.3Hz, Ar-H), 7.31 (1H, dd J= 6.7, J=11.6Hz, Ar-H), 
7.25-7.27 (1H, m, Ar-H), 7.18-7.24 (1H, m, Ar-H), 7.08-7.13 (1H, m, Ar-H), 6.95-7.02 (1H, m, Ar-H), 6.80 
(1H, dd J=3.8Hz, J=8.5Hz, Ar-H), 6.70 (1H, dd J=6.7Hz, J=11.6Hz, Ar-H), 4.49 (1H, d J=12.7Hz, NCH2Ph), 
3.78 (1H, d J=3.7Hz,NCH2C(O)), 3.64-3.73 (3H, m, CHCH2CH2CH2N and NCH2C(O) and NCH2Ph), 3.47 (1H, 
ddd, J= 4.6Hz, J=4.6Hz, J=10.6Hz, CHCH2CH2CH2N), 3.28-3.41 (1H, m, CHCH2CH2CH2N), 2.52-2.63 (1H, m, 
CHCH2CH2CH2N), 2.36-2.49 (1H, m, CHCH2CH2CH2N), 2.02-2.20 (2H, m, CHCH2CH2CH2N) 
 
(S)-3-(4-But-3-enyloxyphenyl)-2-tertbutoxycarbonylaminopropionic acid methyl ester (4.36) 
BOCHN
O
CO2Me
 
N-BOC-Tyr-OMe (10.0g, 33.9 mmol) was dissolved in DMF (40 mL).  To this potassium carbonate (5.62g, 1.2 
equiv) and 4-bromo-1-butene (4.13 mL, 1.2 equiv) were added.  The mixture was stirred at rt for eighteen h 
before being diluted with EtOAc (120 mL) and partitioned with 1M HCl(aq).  The organic phase was washed with 
1M HCl(aq) and then with brine before being dried (MgSO4), filtered and concentrated in vacuo.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 3.20g, 27%.  Rf = 0.82 (1/2 (EtOAc / (50/70) Pet ether)).  
 
1H NMR ppm (500 MHz in CDCl3) 7.01 (2H, d J=6.3Hz, Ar-H), 6.82 (2H, d, J=6.3Hz, Ar-H), 5.85-5.94 (1H, m, 
OCH2CH2CHCH2), 5.06-5.31 (2H, m, OCH2CH2CHCH2), 4.95 (1H, d J=6.1Hz, NH), 4.48-4.58 (1H, m, 
CHCO2CH3), 3.98 (2H, t, J=6.4Hz, J=6.7Hz, J=6.7Hz, OCH2CH2CHCH2), 3.70 (3H, s, CHCO2CH3), 3.04 (1H, 
dd J=6.0Hz, J=13.9Hz, CHCH2Ph), 2.98 (1H, dd J=5.0Hz, J=13.9Hz, CHCH2Ph), 2.53 (2H, dt, J=3.2Hz, 
J=6.4Hz, J=8.2Hz, OCH2CH2CHCH2), 1.41 (9H, s, C(CH3)3) 
 
HRMS (ES) 350.1975 (MH+). C19H27NO5 requires 350.1967 
 
(S)-3-(4-But-3-enyloxyphenyl)-2-tertbutoxycarbonylamino-propionic acid (4.37) 
BOCHN
O
CO2H
 
Methyl ester 4.36 (3.20g, 9.16 mmol) was dissolved in THF (30 mL) and hydrolysed using General procedure 
C1.  This afforded a white solid, 2.60g, 85% 
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1H NMR ppm (500 MHz in CD3OD) 7.11 (2H, d J=7.3Hz, Ar-H), 6.78 (2H, d J=7.3Hz, Ar-H), 5.91 (1H, ddt 
J=2.0Hz, J=6.7Hz, J=17.0Hz, OCH2CH2CHCH2), 5.05-5.16 (2H, m, OCH2CH2CHCH2), 4.16-4.19 (1H, m, 
CHCO2H), 3.97 (2H, t J=6.3Hz, OCH2CH2CHCH2), 3.09 (1H, dd J=3.9Hz, J=13.7Hz, CHCH2Ph), 2.84 (1H, dd 
J=7.6Hz, J=13.9Hz, CHCH2Ph), 2.48-2.51 (2H, m, OCH2CH2CHCH2), 1.38 (9H, s, C(CH3)3) 
 
LRMS (ES) 358.2 (MNa+). C18H25NO5Na requires 358.2 
 
(S)-2-[(S)-3-(4-But-3-enyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-4-ethyl-pentanoic acid 
methyl ester (4.38) 
 
BOCHN
O
N
H
O
CO2Me
 
Carboxylic acid 4.37 (2.60g, 7.75 mmol) was reacted with Leu-OMe using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 2.30g, 64%.  Rf = 0.34 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.11 (2H, d J=8.5Hz, Ar-H), 6.82 (2H, d J=8.5Hz, Ar-H), 6.24 (1H, d 
J=7.5Hz, NH Leu), 5.85-5.94 (1H, m, OCH2CH2CHCH2), 5.08-5.17 (2H, m, OCH2CH2CHCH2), 5.01 (1H, bs, 
NH Tyr), 4.54-4.58 (1H, m, CHCH2CH(CH3)2), 4.27-4.32 (1H, m, CHCH2Ph), 3.98 (2H, dt J=2.3Hz, J=6.7Hz, 
OCH2CH2CHCH2), 3.69 (3H, s, CO2CH3), 2.95-3.05 (2H, m, CHCH2Ph), 2.51-2.55 (2H, m, OCH2CH2CHCH2), 
1.53-1.60 (2H, m, CHCH2CH(CH3)2), 1.44-1.49 (1H, m, CHCH2CH(CH3)2), 1.42 (9H, s, C(CH3)3), 0.88-0.91 
(6H, m, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 172.8, 171.0, 157.8, 134.4, 130.3, 130.2, 128.4, 116.9, 114.6, 67.1, 55.7, 
52.2, 50.6, 41.5, 37.1, 33.6, 28.2, 24.6, 22.7, 21.8 
 
HRMS (ES) 463.2809 (MH+). C25H38N2O6 requires 463.2808 
 
(S)-2-[(S)-3-(4-But-3-enyloxy-phenyl)-2-tertbutoxycarbonylaminopropionylamino]-4-methylpentanoic acid 
(4.39) 
BOCHN
O
N
H
O
CO2H
 
Dipeptide 4.38 (2.30g, 4.97 mmol) was dissolved in THF (30 mL) and hydrolysed using General procedure C1.  
This afforded a white solid, 2.14g, 96%. 
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1H NMR ppm (500 MHz in CDCl3) 9.41 (1H, bs, CO2H), 7.09 (2H, d J=8.1Hz, Ar-H), 6.80 (2H, d J=8.1Hz, Ar-
H), 6.70 (1H, d J=7.7Hz, NH Leu), 5.84-5.92 (1H, m, OCH2CH2CHCH2), 5.29 (1H, bs, NH Tyr), 5.07-5.16 (2H, 
m, OCH2CH2CHCH2), 4.54-4.57 (1H, m, CHCH2CH(CH3)2), 4.36-4.37 (1H, m, CHCH2Ph), 3.95 (2H, t 
J=6.5Hz, J=6.5Hz, OCH2CH2CHCH2), 2.93-3.02 (2H, m, CHCH2Ph), 2.49-2.51 (2H, m, OCH2CH2CHCH2) 
1.50-1.69 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.38 (9H, s, C(CH3)3), 0.90-0.92 (6H, m, 
CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 175.9, 171.6, 157.8, 134.4, 130.3, 130.2, 128.4, 116.9, 114.6, 67.1, 55.6, 
50.8, 41.1, 37.7, 37.1, 30.6, 28.2, 24.6, 22.8, 21.8 
 
LRMS (ES) 449.6 (MH+). C24H36N2O6 requires 449.3 
 
(S)-2-{(S)-2-[(S)-3-(4-But-3-enyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-4-methylpentan-
oylamino}-pent-4-enoic acid methyl ester (4.40) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Carboxylic acid 4.39 (2.14g, 4.77 mmol) was reacted with amine 4.14 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 2.24g, 84%.  Rf = 0.32 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.09 (2H, d J=8.4Hz, Ar-H), 6.93 (1H, d J=7.7Hz, NH Gly), 6.80 (2H, d 
J=8.4Hz, Ar-H), 6.71 (1H, d J=7.3Hz, NH Leu), 5.89 (1H, tdd J=6.7Hz, J=10.1Hz, J=17.0Hz, 
OCH2CH2CHCH2), 5.68-5.72 (1H, m, CHCH2CHCH2), 5.09-5.22 (4H, m, OCH2CH2CHCH2 and 
CHCH2CHCH2), 4.54-4.60 (1H, m, CHCO2CH3), 4.50 (1H, ddd J=6.0Hz, J=6.0Hz, J=7.3Hz, 
CHCH2CH(CH3)2), 4.36-4.38 (1H, m, CHCH2Ph), 3.96 (2H, t J=6.7Hz, OCH2CH2CHCH2), 3.73 (3H, s, 
CHCO2CH3), 2.99 (1H, dd J=6.0Hz, J=14.0Hz, CHCH2Ph), 2.93 (1H, dd J=6.9Hz, J=14.0Hz, CHCH2Ph), 2.45-
2.58 (4H, m, CHCH2CHCH2 and OCH2CH2CHCH2, 1.54-1.66 (2H, m, CHCH2CH(CH3)2), 1.43-1.48 (1H, m, 
CHCH2CH(CH3)2), 1.39 (9H, s, C(CH3)3), 0.86 (3H, d J=6.3Hz, CHCH2CH(CH3)2), 0.86 (3H, d J=6.3Hz, 
CHCH2CH(CH3)2)  
 
13C NMR ppm (75 MHz in CDCl3) 171.8, 171.6, 171.5, 157.8, 134.4, 132.2, 130.3, 130.2, 128.6, 118.9, 116.9, 
114.5, 79.8, 67.0, 55.6, 52.2, 51.8, 51.5, 41.1, 37.2, 36.3, 36.2, 33.6, 28.2, 24.4, 22.8, 22.2. 
 
HRMS (ES) 560.3346 (MH+). C30H45N3O7 requires 560.3336 
 
 
 
Experimental for chapter 4  216 
  
 
 
216
 
(E/Z)-(8S,11S,14S)-14-tertButoxycarbonylamino-11-isobutyl-10,13-dioxo-2-oxa-9,12-diazabicyclo-
[14.2.2]icosa-1(19),5,16(20),17-tetraene-8-carboxylic acid methyl ester (4.41) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
 
Diene 4.40 (2.20g, 3.57 mmol) was reacted with Grubbs second generation catalyst using General Procedure E2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 2.09g, 100%.  A 1:1.9 ratio of geometric isomers was obtained.  Rf = 0.42 and 0.43 
(1/1 (EtOAc / (50/70) Pet ether)). 
 
1H-NMR for major isomer from mixture (500 MHz in CDCl3) 7.09 (2H, d J=8.1Hz, Ar-H), 6.75 (2H, d J=8.1Hz, 
Ar-H), 6.02 (1H, d J=7.8 Hz, NH Leu), 5.96 (1H, d J=8.0Hz, NH Gly), 5.40-5.65 (2H, m, OCH2CHCHCH2CH2 
and OCH2CHCHCH2CH2), 5.24 (1H, d J=8.3Hz, NH Tyr), 4.93 (1H, ddd J=1.2Hz, J=6.2Hz, J=13.3Hz, 
OCH2CHCHCH2CH2), 4.58-4.77 (1H, m, OCH2CHCHCH2CH2), 4.45 (1H, ddd J=3.4Hz, J=8.6Hz, J=8.8Hz, 
CHCO2CH3), 4.10-4.32 (2H, m, CHCH2Ph, CHCH2CH(CH3)2), 3.74 (3H, s, CHCO2CH3), 3.01 (1H, dd 
J=4.6Hz, J=12.8Hz, CHCH2Ph), 2.82-2.86 (1H, m, CHCH2Ph), 2.37-2.48 (2H, m, OCH2CHCHCH2CH2), 2.20-
2.36 (2H, m,  OCH2CHCHCH2CH2), 1.47-1.60 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.45 (9H, s, 
C(CH3)3), 0.84-0.90 (6H, m, CHCH2CH(CH3)2) 
 
Selected 1H-NMR for minor isomer from mixture: 7.12 (2H, d J=8.4Hz, Ar-H), 6.79 (2H, d J=8.4Hz, Ar-H), 
6.20 (1H, d J=7.4Hz, NH Leu), 6.15 (1H, d J=8.6Hz, NH Gly), 5.73 (1H, d J=7.6Hz, NH Tyr) 
 
HRMS (ES) 532.3034 (MH+). C28H41N3O7 requires 532.3023 
 
(8S,11S,14S)-14-tertButoxycarbonylamino-11-isobutyl-10,13-dioxo-2-oxa-9,12-diazabicyclo-[14.2.2]icosa-
1(19),16(20),17-triene-8-carboxylic acid methyl ester (4.42) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
The unsaturated macrocycle 4.41 (2.30g, 4.33 mmol) was hydrogenated in 50 mL of methanol using General 
Procedure G3 to afford a brown solid, 0.600g, 26% 
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1H NMR ppm (500 MHz in CD3OD) 8.13 (1H, d J=7.6Hz, NH Leu), 7.44 (1H d J=8.3Hz, NH Gly), 7.04 (2H, d 
J=8.5Hz, Ar-H), 6.73 (2H, d J=8.5Hz, Ar-H), 4.20-4.27 (2H, m, CHCO2CH3 and CHCH2CH(CH3)2), 4.11-4.20 
(2H, m, OCH2CH2CH2CH2CH2 and CHCH2Ph), 3.94-3.99 (1H, m, OCH2CH2CH2CH2CH2), 3.65 (3H, s, 
CHCO2CH3), 2.93 (1H, dd J=4.9Hz, J=12.6Hz, CHCH2Ph), 2.71 (1H, dd J=11.8Hz, J=12.6Hz, CHCH2Ph), 
1.63-1.74 (3H, m, OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2), 1.51-1.60 (3H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 1.43 (9H, s, C(CH3)3), 1.21-1.37 (5H, m, OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2 
and OCH2CH2CH2CH2CH2), 0.86 (6H, d J=6.4Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CD3OD) 172.7, 172.1, 171.4, 157.4, 156.0, 130.0, 128.1, 114.8, 79.2, 66.3, 56.3, 
51.4, 51.3, 42.6, 37.0, 31.2, 27.4, 27.3, 24.1, 23.9, 22.1, 21.6   
 
HRMS (ES) 534.3107 (MH+). C28H43N3O7 requires 534.3179 
 
FTIR (KBr) 3302, 2929, 1944, 1747, 1741, 1685, 1647, 1541, 1508, 1248 
 
1-Aminocyclohexanecarboxylic acid methyl ester hydrochloride (4.44) Lit5 
HCl.H2N CO2Me  
 
1-Amino-cyclohexanecarboxylic acid 4.43 (5.00g, 34.9 mmol) was suspended in methanol (100 mL). This was 
esterified using General procedure F1 to afford a white solid. 6.76g, 100%.  
 
1H NMR ppm (500 MHz in CD3OD) 3.74 (3H, s, CO2CH3), 1.97-2.03 (2H, m, CH2CH2CH2CH2CH2), 1.61-1.71 
(4H, m, CH2CH2CH2CH2CH2), 1.41-1.56 (4H, m, CH2CH2CH2CH2CH2) 
 
LRMS (ES) 158.1 (MH+). C8H15NO2 requires 158.1 
 
(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tertbutoxycarbonylaminopropionylamino]-4-methyl-pentanoic acid 
methyl ester (4.45)  
BOCHN
N
H
O
O
CO2Me
 
 
N-BOC-O-allyl-Tyr-H (19.7g, 64.1 mmol) was reacted with Leu-OMe using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 23.7g, 80%.  Rf = 0.31 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.08 (2H, d J=8.5Hz, Ar-H), 6.79 (2H, d, J=8.5Hz, Ar-H), 6.43 (1H, d, 
J=7.6Hz, NH Leu), 6.04 (1H, tdd J=5.3Hz, J=5.3Hz, J=10.5, J=17.1Hz, CH2CHCH2), 5.26-5.42 (2H, m, 
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CH2CHCH2), 5.09 (1H, d, J=6.6Hz, NH Tyr), 4.54-4.57 (1H, m, CH Leu), 4.47 (2H, d, J=5.3Hz, CH2CHCH2), 
4.30-4.36 (1H, m, CHCH2Ph),   3.66 (3H, s, CO2CH3), 2.88-3.02 (2H, m, CHCH2Ph), 1.54-1.62 (2H, m, 
CHCH2CH(CH3)2), 1.43-1.51 (1H, m, CHCH2CH(CH3)2) 1.38 (9H, s, (CH3)3), 0.91 (3H, d J=6.6 Hz, 
CHCH2(CH3)2), 0.89 (3H, d J=6.6 Hz, CHCH2(CH3)2). 
 
13C NMR ppm (75 MHz CDCl3). 174.1, 172.8, 171.4, 157.5, 155.5, 133.2, 130.4, 130.3, 128.7, 117.4, 114.7, 
68.7, 54.3, 52.1, 50.7, 41.3, 37.3, 28.2, 24.6, 22.7, 21.8  
 
HRMS (ES) 449.2662 (MH+). C24H36N2O6 requires 449.2651 
 
(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-4-methylpentanoic acid (4.46) 
BOCHN
N
H
O
O
CO2H
 
 
Dipeptide 4.45 (23.6g, 52.6 mmol) was dissolved in THF (100 mL) and hydrolysed using General procedure C1.  
This afforded a white solid, 22.1g, 97% 
 
1H-NMR (500 MHz in CDCl3) 7.10 (2H, d, J=8.5Hz, Ar-H), 6.82 (2H, d J=8.5Hz, Ar-H), 6.58 (1H, d J=7.9Hz, 
NH Leu), 6.03 (1H, tdd J=5.3Hz, J=5.3Hz, J=10.5Hz, J=17.3Hz, CH2CHCH2), 5.25-5.42 (2H, m, CH2CHCH2), 
5.22 (1H, bs, NH Tyr), 4.54-4.58 (1H, m, CHCH2CH(CH3)2), 4.48 (2H, d, J=5.2Hz, CH2CHCH2), 4.34-4.40 
(1H, m, CHCH2Ph), 2.96-3.02 (2H, m, CHCH2Ph), 1.58-1.70 (2H, m, CHCHCH2(CH3)2), 1.50-1.56 (1H, m, 
CHCHCH2(CH3)2), 1.39 (9H, s, C(CH3)3), 0.92 (3H, d J=6.2Hz, CHCHCH2(CH3)2), 0.91 (3H, d J=6.2 Hz, 
CHCHCH2(CH3)2) 
 
LRMS (ES) 435.2 (MH+). C23H34N2O6 requires 435.2  
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-4-methyl pentanoylam-
ino}-pent-4-enoic acid methyl ester (4.47) 
BOCHN
N
H
O
O
O
N
H
CO2Me
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Carboxylic acid 4.46 (10.0g, 23.0 mmol) was reacted with amine 4.14 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 12.2g, 97%.  Rf = 0.46 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H-NMR (500 MHz in CDCl3) 7.09 (2H, d J=8.5Hz, Ar-H), 6.82 (2H, d J=8.5Hz, Ar-H), 6.65 (1H, d J=7.6Hz, 
NH Gly), 6.47 (1H, d J=8.1Hz, NH Leu), 6.04 (1H, tdd J= 5.3Hz, J=5.3Hz, J=10.5Hz, J=17.0Hz, OCH2CHCH2), 
5.62-5.71 (1H, m, CHCH2CHCH2), 5.08-5.44 (4H, m, OCH2CHCH2 and CHCH2CHCH2), 4.99 (1H, d J=7.3Hz, 
NH  Tyr), 4.57-4.63 (1H, m, CHCH2CH(CH3)2), 4.49 (2H, d J=5.2Hz, OCH2CHCH2), 4.41-4.47 (1H, m, 
CHCH2CHCH2), 4.25-4.34 (1H, m, CHCH2Ph), 3.73 (3H, s, CO2CH3), 2.96-3.05 (2H, m, CHCH2Ph), 2.45-2.61 
(2H, m, CHCH2CHCH2), 1.52-1.68 (2H, m, CHCHCH2(CH3)2) 1.43-1.50 (1H, m, CHCHCH2(CH3)2) 1.39 (9H, 
s, C(CH3)3), 0.90 (3H, d J=6.4Hz, CHCHCH2(CH3)2), 0.89 (3H, d J=6.4Hz, CHCHCH2(CH3)2)  
 
13C NMR ppm (75 MHz in CDCl3). 171.8, 171.5, 171.3, 157.5, 155.4, 133.2, 132.2, 132.0, 130.3, 130.1, 128.5, 
119.2, 119.0, 117.6, 114.8, 80.2, 68.7, 55.6, 52.3, 51.7, 40.9, 40.7, 37.0, 36.2, 28.2, 24.4, 22.8, 22.0 
 
HRMS (ES) 546.3180 (MH+). C29H43N3O7 requires 546.3179  
 
(E/Z)-(7S,10S,13S)-13-tertButoxycarbonylamino-10-isobutyl-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (4.48) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
 
Diene 4.47 (2.00g, 3.67 mmol) was reacted with Grubbs second generation catalyst using General Procedure E2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 1.73g, 91%.  A 1:9 ratio of geometric isomers was obtained.  Rf = 0.28 and 0.30 (1/1 
(EtOAc / (50/70) Pet ether)). 
 
1H-NMR for major isomer from mixture (500 MHz in CDCl3) 7.01 (2H, d J=5.4Hz, Ar-H), 6.78 (2H, d J=5.4Hz, 
Ar-H), 5.87 (1H, d J=8.6Hz, NH Gly), 5.81 (1H, d J=7.1Hz, NH Leu), 5.40-5.58 (2H, m, OCH2CHCHCH2 and 
OCH2CHCHCH2), 5.34 (1H, d, J=8.6Hz, NH Tyr), 4.73 (1H, ddd J=3.2Hz, J=8.6Hz, J=9.2Hz, CHCO2CH3), 
4.55-4.68 (2H, m, OCH2CHCHCH2), 4.09-4.20 (2H, m, CHCH2Ph and CHCH2CH(CH3)2), 3.74 (3H, s, 
CO2CH3), 3.08 (1H, dd J=4.9Hz, J=12.6Hz, CHCH2Ph), 2.65-2.74 (1H, m, CHCH2Ph), 2.26-2.34 (2H, m, 
OCH2CHCHCH2), 1.82-1.90 (1H, m, CHCH2CH(CH3)2), 1.52-1.58 (2H, m, CHCH2CH(CH3)2), 1.44 (9H, s, 
(CH3)3), 0.84-0.88 (6H, m, CHCH2CH(CH3)2) 
 
Selected 1H-NMR for minor isomer from mixture: 3.77 (3H, s, CO2CH3), 2.48-2.52 (1H, m, CHCH2Ph), 1.48 
(9H, s, (CH3)3), 0.89-0.94 (6H, m, CH2CH(CH3)2) 
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HRMS (ES) 518.2869 (MH+). C27H39N3O7 requires 518.2866  
 
(7S,10S,13S)-13-tertButoxycarbonylamino-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]-
nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (4.49) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
The unsaturated macrocycle 4.48 (6.90g, 13.3 mmol) was hydrogenated in 100 mL of methanol using General 
Procedure G3 to afford a brown solid, 6.80g, 98% 
 
1H-NMR (500 MHz in CDCl3) 7.05 (2H, d J=7.8Hz, Ar-H), 6.79 (2H, d, J=7.8Hz, Ar-H), 6.08 (1H, d J=6.1Hz 
NH Gly), 5.74 (1H, d, J=8.2Hz, NH Leu), 5.22 (1H, d J=8.8Hz, NH Tyr), 4.38-4.42 (1H, m, CHCH2Ph), 4.31-
4.36 (1H, m, CHCO2CH3), 4.12-4.28 (2H, m, OCH2CH2CH2CH2), 3.96-4.06 (1H, m, CHCH2CH(CH3)2), 3.73 
(3H, s, CO2CH3), 3.11 (1H, dd J=5.3Hz, J=12.2Hz, CHCH2Ph), 2.65 (1H, dd, J=12.2Hz, J=12.2Hz CHCH2Ph), 
1.68-1.74 (2H, m, OCH2CH2CH2CH2), 1.49-1.63 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.45 (9H, s, 
C(CH3)3), 1.20-1.40 (2H, m, OCH2CH2CH2CH2), 0.82-0.85 (6H, m, CHCH2CH(CH3)2)   
 
HRMS (ES) 520.3031 (MH+). C27H41N3O7 requires 520.3023  
 
(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylamino-propionylamino]-3-phenylpropionic acid 
methyl ester (4.50) 
BOCHN
N
H
O
O
CO2Me
Ph
 
 
N-BOC-O-allyl-Tyr-H (5.00g, 16.3 mmol) was reacted with Phe-OMe using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 6.36g, 81%.  Rf = 0.25 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.21-7.24 (3H, m, Ar-H (Phe)), 7.08 (2H, d J=7.7Hz, Ar-H (Tyr)), 6.99 (2H, 
dd J=1.5, J=7.4, Ar-H (Phe)), 6.82 (2H, d J=7.7Hz, Ar-H (Tyr)), 6.38 (1H, d J=7.1Hz, NH Phe), 5.98-6.07 (1H, 
m, OCH2CHCH2), 5.25-5.41 (2H, m, OCH2CHCH2), 5.02 (1H, bs, NH Tyr) 4.74-4.81 (1H, m, CHCO2CH3), 
4.48-4.49 (2H, m, OCH2CHCH2), 4.25-4.34 (1H, m, NHCHC(O)NH), 3.66 (3H, s, CHCO2CH3), 3.02-3.08 (2H, 
m, CHCH2Ph (Phe)), 2.94-3.02 (2H, m, CHCH2Ph (Tyr)), 1.40 (9H, s, C(CH3)3) 
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13C NMR ppm (75 MHz in CDCl3) 171.3, 170.8, 157.5, 135.6, 133.2, 130.3, 129.1, 128.4, 127.0, 117.5, 114.8, 
68.7, 53.2, 52.2, 37.9, 37.3, 28.2 
 
HRMS (ES) 483.2496 (MH+). C27H34N2O6 requires 483.2495 
 
(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-phenylpropionic acid (4.51) 
BOCHN
N
H
O
O
CO2H
Ph
 
Dipeptide 4.50 (6.30g, 13.1 mmol) was dissolved in THF (30 mL) and hydrolysed using General procedure C1.  
This afforded a white solid, 5.69g, 93% 
 
1H NMR ppm (500 MHz in CDCl3) 8.82 (1H, bs, CO2H), 7.19-7.26 (3H, m, Ar-H (Phe)), 7.04-7.08 (4H, m, Ar-
H (Tyr) and Ar-H (Phe)), 6.81 (2H, d J=8.2Hz, Ar-H (Tyr)), 6.67 (1H, d J=7.7Hz, NH Phe), 6.02 (1H, tdd 
J=5.3Hz, J=10.5Hz, J=17.3Hz, OCH2CHCH2), 5.24-5.42 (2H, m, OCH2CHCH2), 5.22 (1H, bs, NH Tyr), 4.76-
4.78 (1H, m, CHCO2CH3), 4.47 (2H, d J=4.8Hz, OCH2CHCH2), 4.37-4.39 (1H, m, NHCHC(O)NH), 3.13 (1H, 
dd J=4.4Hz, J=13.3Hz, CHCH2Ph (Phe)), 2.91-3.01 (3H, m, CHCH2Ph (Phe) and CHCH2Ph (Tyr)), 1.39 (9H, s, 
C(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3) 176.6, 174.5, 171.5, 135.7, 133.3, 130.4, 130.3, 129.4, 128.5, 127.1, 117.6, 
114.8, 68.8, 37.5, 28.3, 20.8 
 
LRMS (ES) 469.2 (MH+). C26H33N2O6 requires 469.2 
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylamino-propionylamino]-3-phenylpropionyl-
amino}-pent-4-enoic acid methyl ester (4.52) 
 
BOCHN
N
H
O
O
O
N
H
CO2Me
Ph
 
 
Carboxylic acid 4.13 (2.00g, 4.27 mmol) was reacted with amine 4.14 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 1.61g, 65%.  Rf = 0.12 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.20-7.27 (3H, m, Ar-H (Phe)), 7.03-7.12 (4H, m, Ar-H (Phe) and Ar-H 
(Tyr)), 6.83 (2H, d J=8.6Hz, Ar-H (Tyr)), 6.51 (1H, d J=6.8Hz, NH Phe), 6.37 (1H, d J=6.1Hz, NH Gly), 6.04 
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(1H, tdd J=5.3Hz, J=10.6Hz, J=17.4Hz, OCH2CHCH2), 5.57 (1H, tdd J=7.2Hz, J=7.2Hz, J=10.3Hz, J=17.3Hz, 
CHCH2CHCH2), 5.26-5.43 (2H, m, OCH2CHCH2), 5.00-5.05 (2H, m, CHCH2CHCH2), 4.87 (1H, d J=7.1Hz, 
NH Tyr), 4.61-4.64 (1H, m, CHCH2Ph (Phe)), 4.49-4.55 (3H, m, OCH2CHCH2 and CHCO2CH3), 4.26-4.30 
(1H, m, CHCH2Ph (Tyr)), 3.70 (3H, s, CHCO2CH3), 3.10 (1H, dd J=5.7Hz, J=13.7Hz, CHCH2Ph (Phe)), 2.92-
2.99 (3H, m, CHCH2Ph (Phe) and CHCH2Ph (Tyr)), 2.50 (1H, ddd J=5.9Hz, J=6.9Hz, J=13.8Hz, 
CHCH2CHCH2), 2.40 (1H, ddd J=5.9Hz, J=5.9Hz, J=13.8Hz, CHCH2CHCH2), 1.37 (9H, s, C(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3) 171.3, 171.1, 170.0, 157.6, 136.2, 133.2, 132.0, 130.2, 129.3, 128.6, 128.3, 
127.0, 119.1, 117.6, 114.9, 68.7, 54.1, 52.3, 51.9, 37.9, 36.1, 28.2 
 
HRMS (ES) 580.3027 (MH+). C32H42N3O7 requires 580.3023 
 
(E/Z)-(7S,10S,13S)-10-Benzyl-13-tertbutoxycarbonylamino-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (4.53) 
BOCHN
N
H
O
O
O
N
H
CO2Me
Ph
 
Diene 4.52 (1.00g, 1.73 mmol) was reacted with Grubbs second generation catalyst using General Procedure E1.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 0.485g, 51%.  A 1:6.25 ratio of geometric isomers was obtained Rf = 0.29 and 0.30 
(2/1 (EtOAc / (50/70) Pet ether)). 
 
1H-NMR for major isomer from mixture (500 MHz in CDCl3) 7.21-7.28 (3H, m, Ar-H (Phe)), 7.03-7.10 (4H, m, 
Ar-H (Phe) and Ar-H (Tyr)), 6.70 (2H, d J=8.3Hz, Ar-H (Tyr)), 6.18 (1H, d J=8.4Hz, NH Gly), 5.85 (1H, d 
J=6.6Hz, NH Phe), 5.58 (1H, d J=8.0Hz, NH Tyr), 5.36-5.46 (2H, m, OCH2CHCHCH2 and  OCH2CHCHCH2), 
4.68-4.70 (1H, m, CHCO2CH3), 4.50-4.61 (2H, m, OCH2CHCHCH2), 4.42-4.46 (1H, m, CHCH2Ph (Phe)), 4.23-
4.27 (1H, m, CHCH2Ph (Tyr)), 3.72 (3H, s, CHCO2CH3), 3.09-3.17 (2H, m, CHCH2Ph (Phe) and CHCH2Ph 
(Tyr)), 2.86 (1H, dd J=7.0Hz, J=13.4Hz, CHCH2Ph (Phe)), 2.59-2.67 (2H, m, CHCH2Ph (Tyr) and 
OCH2CHCHCH2), 2.24-2.31 (1H, m, OCH2CHCHCH2), 1.50 (9H, s, C(CH3)3) 
 
Selected 1H-NMR for minor isomer from mixture: 3.69 (3H, s, CHCO2CH3), 2.32-2.38 (1H, m, 
OCH2CHCHCH2) 
 
13C NMR ppm (75 MHz in CDCl3) 171.6, 170.8, 169.4, 156.0, 155.0, 135.8, 130.3, 129.4, 128.4, 128.1, 127.3, 
126.9, 115.7, 79.8, 66.4, 57.0, 54.2, 52.5, 51.5, 39.3, 35.2, 28.4 
 
HRMS (ES) 552.2699 (MH+). C30H37N3O7 requires 552.2710 
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(7S,10S,13S)-10-Benzyl-13-tertbutoxycarbonylamino-9,12-dioxo-2-oxa-8, 11-diazabicyclo[13.2.2]nonadeca-
1(18),15(19),16-triene-7-carboxylic acid methyl ester (4.54) 
BOCHN
N
H
O
O
O
N
H
CO2Me
Ph
 
The unsaturated macrocycle 4.53 (0.235g, 0.426 mmol) was hydrogenated in 10 mL of methanol using General 
Procedure G1 to afford a brown solid, 0.0590g, 25% 
 
1H NMR ppm (500 MHz in CDCl3) 7.19-7.27 (3H, m, Ar-H (Phe)), 7.10 (2H, d J=7.0Hz, Ar-H (Phe)), 7.04 (2H, 
d J=7.6Hz, Ar-H (Tyr)), 6.76 (2H, d J=7.6Hz, Ar-H (Tyr)), 6.11 (1H, d J=6.5Hz, NH Phe), 5.56 (1H, d J=7.6Hz, 
NH Gly), 5.35 (1H, d J=7.8Hz, NH Tyr), 4.42 (1H, ddd J=3.6Hz, J=7.6Hz, J=7.6Hz, CHCO2CH3), 4.16-4.25 
(2H, m, CHCH2Ph (Tyr) and OCH2CH2CH2CH2), 4.07-4.11 (1H, m, OCH2CH2CH2CH2), 4.02 (1H, ddd, 
J=6.5Hz, J=8.9Hz, J=12.8Hz, CHCH2Ph (Phe)), 3.66 (3H, s, CHCO2CH3), 3.16 (1H, dd J=5.6Hz, J=12.1Hz, 
CHCH2Ph (Tyr)), 3.07 (1H, dd J=3.9Hz, J=12.8Hz, CHCH2Ph (Phe)), 2.78 (1H, dd J=8.9Hz, J=12.8Hz, 
CHCH2Ph (Phe)), 2.63 (1H, dd J=12.1Hz, J=12.1Hz, CHCH2Ph (Tyr)), 1.80-1.89 (1H, m, OCH2CH2CH2CH2), 
1.65-1.73 (1H, m, OCH2CH2CH2CH2), 1.32-1.59 (11H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and 
C(CH3)3), 1.24-1.32 (1H, m, OCH2CH2CH2CH2), 1.12-1.20 (1H, m, OCH2CH2CH2CH2) 
 
13C NMR ppm (75 MHz in CDCl3) 171.3, 170.2, 169.2, 157.4, 136.0, 129.3, 128.4, 126.9, 115.6, 66.6, 57.1, 
54.8, 52.4, 51.4, 39.5, 39.3, 31.2, 28.3, 28.1, 20.5  
 
HRMS (ES) 554.2871 (MH+). C30H39N3O7 requires 554.2866 
 
1-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]cyclohexanecarboxylic acid 
methyl ester (4.55) 
BOCHN
N
H
O
O
CO2Me
 
N-BOC-O-allyl-Tyr-H (5.00g, 16.3 mmol) was reacted with amine 4.44 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 4.42g, 59%.  Rf = 0.41 (1/2 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.17 (2H, d J=8.4Hz, Ar-H), 6.85 (2H, d J=8.4Hz, Ar-H), 6.18 (1H, bs, NH 
Cy), 6.04 (1H, tdd J=5.2Hz, J=10.6Hz, J=16.8Hz, OCH2CHCH2), 5.26-5.43 (2H, m, OCH2CHCH2), 5.08 (1H, d 
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J=7.2Hz, NH Tyr), 4.51 (1H, d J=5.2Hz, OCH2CHCH2), 4.28 (1H, ddd J=6.3Hz, J=7.7Hz, J=14.0Hz, 
CHCH2Ph), 3.68 (3H, s, CO2CH3), 3.04 (1H, dd, J=6.3Hz, J=14.0Hz, CHCH2Ph), 2.97 (1H, dd J=7.7Hz, 
J=14.0Hz, CHCH2Ph), 1.90-1.93 (2H, m, CH2CH2CH2CH2CH2), 1.75-1.78 (2H, m, CH2CH2CH2CH2CH2), 1.50-
1.56 (3H, m, CH2CH2CH2CH2CH2), 1.42 (9H s, C(CH3)3), 1.18-1.27 (3H, m, CH2CH2CH2CH2CH2) 
 
HRMS (ES) 461.2660 (MH+). C25H36N2O6 requires 461.2651 
 
1-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylamino-propionylamino]cyclohexanecarboxylic acid (4.56) 
BOCHN
N
H
O
O
CO2H
 
Dipeptide 4.55 (4.40g, 9.56 mmol) was dissolved in THF (50 mL) and hydrolysed using General procedure C1.  
This afforded a white solid, 4.18g, 98% 
 
1H NMR ppm (500 MHz in CDCl3) 7.15 (2H, d J=8.3Hz, Ar-H), 6.86 (2H, d J=8.3Hz, Ar-H), 6.39 (1H, bs, NH 
Cy), 6.04 (1H, tdd J=5.1Hz, J=9.9Hz, J=15.7Hz, OCH2CHCH2), 5.26-5.43 (2H, m, OCH2CHCH2), 5.21 (1H, d 
J=7.5Hz, NH Tyr), 4.51 (2H, d J=5.1Hz, OCH2CHCH2), 4.29-4.34 (1H, m, CHCH2Ph), 3.00-3.06 (2H, m, 
CHCH2Ph), 1.94-2.05 (2H, m, CH2CH2CH2CH2CH2), 1.75-1.84 (2H, m, CH2CH2CH2CH2CH2), 1.50-1.64 (3H, 
m, CH2CH2CH2CH2CH2), 1.42 (9H s, C(CH3)3), 1.21-1.30 (3H, m, CH2CH2CH2CH2CH2) 
 
LRMS (ES) 447.3 (MH+). C24H34N2O6 requires 447.3 
 
(S)-2-({1-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]cyclohexanecarbonyl}-
amino)pent-4-enoic acid methyl ester (4.57) 
 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
 
Carboxylic acid 4.56 (2.60g, 5.82 mmol) was reacted with amine 4.14 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 2.47g, 76%.  Rf = 0.46 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.35 (1H, d J=7.4Hz, NH Gly), 7.17 (2H, d J=8.5Hz, Ar-H), 6.87 (2H, d 
J=8.5Hz, Ar-H), 6.04 (1H, tdd J=5.3Hz, J=10.5Hz, J=15.9Hz, OCH2CHCH2), 5.71 (1H, dddd, J=6.5Hz, 
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J=6.5Hz, J=10.4Hz, J=17.7Hz, CHCH2CHCH2), 5.26-5.43 (2H, m, OCH2CHCH2), 5.09-5.13 (3H, m, 
CHCH2CHCH2 and NH Cy), 5.00 (1H, bs, NH Tyr), 4.60 (1H, ddd J=6.5Hz, J=6.9Hz, J=7.4Hz, 
CHCH2CHCH2), 4.52 (2H, d J=5.3Hz, OCH2CHCH2), 4.25 (1H, ddd J=7.1Hz, J=7.1Hz, J=7.0Hz, CHCH2Ph), 
3.72 (3H, s, CO2CH3), 2.99-3.08 (2H, m, CHCH2Ph), 2.59 (1H, ddd J=6.5Hz, J=6.5Hz, J=14.1Hz, 
CHCH2CHCH2), 2.48 (1H, ddd J=6.9Hz, J=6.9Hz, J=14.1Hz, CHCH2CHCH2), 1.94-2.08 (2H, m, 
CH2CH2CH2CH2CH2), 1.71-1.85 (2H, m, CH2CH2CH2CH2CH2), 1.46-1.59 (3H, m, CH2CH2CH2CH2CH2) 1.42 
(9H, s, C(CH3)3), 1.14-1.30 (3H, m, CH2CH2CH2CH2CH2) 
 
HRMS (ES) 558.3182 (MH+). C30H43N3O7 requires 558.3179 
 
(E/Z)-(7S, 13S)-10-Cyclohexyl-13-tertbutoxycarbonylamino-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (4.58) 
 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Diene 4.57 (1.00g, 1.79 mmol) was reacted with Grubbs second generation catalyst using General Procedure E2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 0.294g, 31%.  A 1:6.5 ratio of geometric isomers was obtained Rf = 0.28 and 0.29 
(1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm for major isomer from mixture (500 MHz in CDCl3) 7.20 (2H, d J=8.0 Hz, Ar-H), 6.86 (2H, d 
J=8.0Hz, Ar-H), 6.52 (1H, d J=6.5Hz, NH Cy), 6.29 (1H, d J=8.0Hz, NH Gly), 5.44 (1H, d J=8.5Hz, NH Tyr), 
5.19-5.37 (1H, m, OCH2CHCHCH2), 5.09-5.20 (1H, m, and OCH2CHCHCH2), 4.73 (1H, ddd, J=4.5Hz, 
J=4.5Hz, J=8.0Hz, CHCO2CH3), 4.54-4.63 (2H, m, and OCH2CHCHCH2), 4.35 (1H, ddd, J=5.7Hz, J=5.7Hz, 
J=8.5Hz, CHCH2Ph), 3.75 (3H, s, CHCO2CH3), 3.09 (1H, dd J=5.7Hz, J=12.0Hz, CHCH2Ph), 2.87 (1H, dd, 
J=12.0Hz, J=12.0Hz, CHCH2Ph), 2.23-2.65 (4H, m, OCH2CHCHCH2 and CH2CH2CH2CH2CH2), 1.68-1.83 
(2H, m, CH2CH2CH2CH2CH2), 1.53-1.67 (3H, m, CH2CH2CH2CH2CH2), 1.39 (9H, s, C(CH3)3), 1.02-1.18 (3H, 
m, CH2CH2CH2CH2CH2) 
 
Selected 1H-NMR for minor isomer from mixture: 7.15 (2H, d J=8.0Hz, Ar-H), 6.88 (2H, d J=8.0Hz, Ar-H), 4.44 
(1H, ddd J=4.3Hz, J=4.3Hz, J=9.0Hz, CHCH2Ph), 3.68 (3H, s, CHCO2CH3) 
 
HRMS (ES) 530.2869 (MH+). C28H39N3O7 requires 530.2866 
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(S)-3-Amino-hex-5-enoic acid methyl ester hydrochloride (4.59) 
HCl.H2N CO2Me
 
(S)-3-Amino-hex-5-enoic acid (0.500g, 3.87 mmol) was suspended in methanol (15 mL). This was esterified 
using General procedure F1 to afford a white solid. 0.598g, 86%.  
 
1H NMR ppm (500 MHz in CDCl3) 8.41 (2H, bs, NH2), 5.79 (1H, tdd, J=7.2Hz, J=7.2Hz, J=9.5, J=14.5Hz, 
CH2CHCH2), 5.21-5.29 (2H, m, CH2CHCH2), 3.73 (3H, s, CO2CH3), 3.64-3.65 (1H, m, CHCH2CO2CH3), 2.91 
(1H, dd, J=7.2Hz, J=17.2Hz, CHCH2CO2CH3), 2.81 (1H, dd J=5.2, J=17.2Hz, CHCH2CO2CH3) 2.69-2.74 (1H, 
m, CHCH2CHCH2), 2.49-2.55 (1H, m, CHCH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3)  170.9, 131.4, 120.7, 52.3, 48.2, 36.7, 35.6 
 
LRMS (ES) 144.1 (MH+). C7H14NO2 requires 144.1  
 
(S)-3-{(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-methylbutyryl-
amino}-hex-5-enoic acid methyl ester (4.60) 
BOCHN
N
H
O
N
H
O
O
CO2Me
 
 
Carboxylic acid 4.13 (1.28g, 3.04 mmol) was reacted with amine 4.59 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 1.38g, 83%.  Rf = 0.31 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.10 (2H, d J=8.5Hz, Ar-H), 6.83 (2H, d J=8.5Hz, Ar-H), 6.58 (1H, bs, NH), 
6.55 (1H, d J=8.3Hz, NH), 6.03 (1H, tdd J=5.3Hz, J=10.5Hz, J=17.2Hz, OCH2CHCH2), 5.67-5.75 (1H, m, 
CHCH2CHCH2), 5.05-5.41 (4H, m, OCH2CHCH2 and CH2CHCH2), 5.00 (1H, d J=5.8Hz, NH), 4.49-4.50 (2H, d 
J=5.3Hz, OCH2CHCH2), 4.27-4.33 (2H, m, CHCH2CHCH2 and CHCH2Ph), 4.16-4.20 (1H, m, CHCH(CH3)2), 
3.66 (3H, s, CO2CH3), 3.05 (1H, dd J= 6.2Hz, J=14.0Hz, CHCH2Ph), 3.00 (1H, dd J=7.1Hz, J=14.0Hz, 
CHCH2Ph), 2.53 (2H, d J=5.8Hz, CHCH2CHCH2), 2.30 (2H, dd J=6.9Hz, J=6.9Hz CH2CO2CH3), 2.13-2.19 
(1H, m, CHCH(CH3)2), 1.40 (9H, s, C(CH3)3), 0.88 (3H, d J=6.8 Hz, CHCH(CH3)2), 0.83 (3H, d J=6.8 Hz, 
CHCH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3)  171.3, 157.6, 133.7, 133.2, 130.2, 128.5, 188.3, 117.6, 114.9, 80.4, 68.7, 
58.6, 56.0, 51.7, 45.8, 38.4, 37.7, 36.7, 30.3, 28.2, 19.1, 17.5 
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HRMS (ES) 546.3182 (MH+). C29H43N3O7 requires 546.3179  
(E/Z)-(7S,10S,13S)-13-tertButoxycarbonylamino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),4,15(19),16-tetraen-7-yl)-acetic acid methyl ester (4.61) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
Diene 4.60 (0.700g, 1.28 mmol) was reacted with Grubbs second generation catalyst using General Procedure 
E1.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a brown solid, 0.438g, 66%.  A 1:9.1 ratio of geometric isomers was obtained.  Rf = 0.47 and 
0.49 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H-NMR NMR for major isomer from mixture (500 MHz in CDCl3) 7.04 (2H, d J=8.1Hz, Ar-H), 6.75 (2H, d 
J=8.1Hz, Ar-H), 6.06 (1H, d J=6.5Hz, NH Val), 5.95 (1H, d J=9.5Hz, NH Gly), 5.48-5.57 (2H, m, 
OCH2CHCHCH2 and OCH2CHCHCH2), 5.33 (1H, d J=8.3Hz, NH Tyr), 4.54-5.65 (2H, m, OCH2CHCHCH2), 
4.37-4.43 (1H, m, CHCH2CO2CH3), 4.14-4.22 (1H, m, CHCH2Ph), 3.83-3.86 (1H, m, CHCH(CH3)2), 3.68 (3H, 
s, CO2CH3), 3.07 (1H, dd J=4.4Hz, J=12.1Hz, CHCH2Ph), 2.69 (1H, dd J=12.1Hz, J=12.1Hz, CHCH2Ph), 2.43-
2.52 (2H, m, CH2CO2CH3), 2.27-2.29 (2H, m, OCH2CHCHCH2), 1.96-2.02 (1H, m, CHCH(CH3)2) 1.45 (9H, s, 
C(CH3)3),  0.82 (3H, d J=6.8Hz, CHCH(CH3)2), 0.79 (3H, d J=6.8 Hz, CHCH(CH3)2) 
 
Selected 1H-NMR for minor isomer from mixture: 6.80 (2H, d J=8.5Hz, Ar-H), 6.14 (1H, d J=8.4Hz, NH Val), 
6.00 (1H, d J=7.6Hz, NH Gly), 2.37-2.42 (2H, m, CH2CO2CH3) 
 
HRMS (ES) 518.2873 (MH+). C27H39N3O7 requires 518.2866  
 
(7S,10S,13S)-13-tertButoxycarbonylamino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),15(19),16-trien-7-yl)-acetic acid methyl ester (4.62) 
BOCHN
N
H
O
O
O
N
H
CO2Me
 
The unsaturated macrocycle 4.61 (0.440g, 0.850 mmol) was hydrogenated in 20 mL of methanol using General 
Procedure G1 to afford a brown solid, 0.371g, 84% 
 
 
1H NMR ppm (500 MHz in CDCl3) 7.05 (2H, d J=8.3Hz, Ar-H), 6.79 (2H, d J=8.3Hz, Ar-H), 6.31 (1H, d 
J=6.9Hz, NH Val), 5.93 (1H, d J=9.0Hz, NH), 5.26 (1H, d J=7.9Hz, NH), 4.29-4.35 (1H, m, 
OCH2CH2CH2CH2), 4.21-4.26 (2H, m, CHCH2Ph and CHCH2CO2CH3), 4.09 (1H, ddd J=1.1Hz, J=3.0Hz, 
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J=6.6Hz, OCH2CH2CH2CH2), 3.72 (1H, dd J=3.5Hz, J=8.6Hz, CHCH(CH3)2), 3.48 (3H, s, CO2CH3), 3.10 (1H, 
dd J=5.3Hz, J=12.3Hz, CHCH2Ph) 2.65 (1H, dd J=12.3Hz, J=12.3Hz, CHCH2Ph), 2.35-2.48 (2H, m, 
CH2CO2CH3), 1.92-1.97 (1H, m, CHCH(CH3)2), 1.73-1.87 (2H, m, OCH2CH2CH2CH2), 1.44 (9H, s, C(CH3)3), 
1.21-1.29 (4H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 0.82 (3H, d J=6.6Hz, CHCH(CH3)2), 0.79 (3H, d 
J=6.6Hz, CHCH(CH3)2) 
 
HRMS (ES) 520.3023 (MH+). C27H41N3O7 requires 520.3023  
 
(R)-3-Allylsulfanyl-2-tertbutoxycarbonylaminopropionic acid methyl ester (4.63) Lit6 
BOCHN
S
CO2Me
 
N-BOC-Cys-OMe (5.00g, 21.2 mmol) was dissolved in anhydrous DCM (30 mL) under an atmosphere of argon.  
To this triethylamine (3.26 mL, 1.1 equiv) and allyl bromide (2.02 mL, 1.1 equiv) were added.  The mixture was 
stirred at rt for eighteen h before being concentrated in vacuo.  The residue was partitioned between EtOAc and 
1M HCl(aq).  The organic phase was washed with brine, dried (MgSO4), filtered and concentrated in vacuo.  The 
crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to 
yield a white solid, 3.22g, 55%.  Rf = 0.19 (1/5 (EtOAc / (50/70) Pet ether). 
 
1H NMR ppm (500 MHz in CDCl3) 5.65 (1H, tdd J=7.1Hz, J=10.1Hz, J=17.1Hz, CH2CHCH2), 5.34 (1H, d 
J=8.1Hz, NH), 5.03-5.10 (2H, m, CH2CHCH2), 4.41-4.43 (1H, m, CHCO2CH3), 3.76 (3H, s, CHCO2CH3), 3.05-
3.09 (2H, d J=5.7Hz, CH2CHCH2), 2.86 (1H, dd J=4.5Hz, J=14.8Hz, CHCH2S), 2.77 (1H, dd J=8.1Hz, 
J=14.8Hz, CHCH2S), 1.41 (9H, s, C(CH3)3) 
 
LRMS (ES) 276.1 (MH+). C12H21NO4S requires 276.1 
 
(R)-3-Allylsulfanyl-2-aminopropionic acid methyl ester hydrochloride (4.64) Lit6 
HCl.H2N
S
CO2Me
 
N-BOC protected compound 4.63 (3.20g, 11.6 mmol) was reacted using General Procedure I4 to afford a white 
solid 2.46g, 100%.   
 
1H NMR ppm (500 MHz in CD3OD) 5.78 (1H, tdd J=7.2Hz, J=10.0Hz, J=17.1Hz, CH2CHCH2), 5.13-5.21 (2H, 
m, CH2CHCH2), 4.23 (1H, dd J=4.4Hz, J=8.1Hz, CHCO2CH3), 3.75 (3H, s, CHCO2CH3), 3.17-3.21 (2H, d 
J=7.2Hz, CH2CHCH2), 3.07 (1H, dd J=4.4Hz, J=14.8Hz, CHCH2S), 2.89 (1H, dd J=8.1Hz, J=14.8Hz, CHCH2S) 
 
13C NMR ppm (75 MHz in CD3OD) 177.5, 170.2, 133.4, 52.6, 52.0, 34.1, 30.0 
 
LRMS (ES) 176.0 (MH+). C7H13NO2S requires 176.1 
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(R)-2-{(S)-2-[(S)-3-(4-Allyloxy-phenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-methylbutyryl-
amino}-3-allylsulfanyl-propionic acid methyl ester (4.65) 
BOCHN
N
H
O
O
O
N
H
S
CO2Me
 
Carboxylic acid 4.13 (1.50g, 3.57 mmol) was reacted with amine 4.64 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 2.00g, 97%.  Rf = 0.34 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 7.17 (2H, d J=8.4Hz, Ar-H), 6.82 (2H, d J=8.4Hz, Ar-H), 6.05 (1H, tdd 
J=5.3Hz, J=10.6Hz, J=17.4Hz, OCH2CHCH2), 5.73-5.82 (1H, m, SCH2CHCH2), 5.06-5.41 (4H, m, 
OCH2CHCH2 and SCH2CHCH2), 4.54-4.61 (1H, m, CHCO2CH3), 4.49-4.53 (2H, m, OCH2CHCH2), 4.22-4.36 
(2H, m, CHCH2Ph and CHCH(CH3)3), 3.76 (3H, s, CHCO2CH3), 3.15-3.21 (2H, m, SCH2CHCH2), 2.74-3.04 
(4H, m, CHCH2Ph and CHCH2SCH2CHCH2), 2.02-2.09 (1H, m, CHCH(CH3)3), 1.39 (9H, s, C(CH3)3), 0.96 
(3H, d J=6.7Hz, CHCH(CH3)3), 0.94 (3H, d J=6.7Hz, CHCH(CH3)3) 
 
HRMS (ES) 578.2892 (MH+). C29H43N3O7S requires 578.2900 
 
(E/Z)-(9R,12S,15S)-15-tertButoxycarbonylamino-12-isopropyl-11,14-dioxo-2-oxa-7-thia-10,13-diaza-
bicyclo[15.2.2]henicosa-1(20),4,17(21),18-tetraene-9-carboxylic acid methyl ester (4.66) 
BOCHN
N
H
O
O
O
N
H
S
CO2Me
 
Diene 4.65 (1.00g, 1.73 mmol) was reacted with Grubbs second generation catalyst using General Procedure E1.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 0.685g, 72%.  A 1:1.7 ratio of geometric isomers was obtained.  Rf = 0.25 and 0.23 
(1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm for major isomer from mixture (500 MHz in (CD3)OD) 7.03 (2H, d J=8.7Hz, Ar-H), 6.81 (2H, d 
J=8.7Hz, Ar-H), 5.67-5.81 (2H, m, OCH2CHCHCH2) and OCH2CHCHCH2), 4.62-4.70 (2H, m, 
OCH2CH2CH2CH2S), 4.58 (1H, dd J=5.4Hz, J=14.5Hz, CHCO2CH3), 4.44-4.51 (1H, m, CHCH2Ph), 4.18-4.29 
(1H, m, CHCH(CH3)2), 3.69 (3H, s, CHCO2CH3), 3.08-3.22 (2H, m, OCH2CH2CH2CH2S), 3.06-3.11 (1H, m, 
CHCH2Ph), 2.86-2.97 (1H, m, CHCH2Ph), 2.67-2.86 (1H, m, CHCH2S), 2.56-2.64 (1H, m, CHCH2S), 1.81-1.89 
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(1H, m, CHCH(CH3)2), 1.42 (9H, s, C(CH3)3), 0.94 (3H, d J=6.9Hz, CHCH(CH3)2), 0.92 (3H, d J=6.9Hz, 
CHCH(CH3)2) 
 
Selected 1H-NMR for minor isomer from mixture: 7.11 (2H, d J=8.0Hz, Ar-H), 6.75 (2H, d J=8.0Hz, Ar-H), 
0.85 (3H, d J=6.5Hz, CHCH(CH3)2), 0.80 (3H, d J=6.5Hz, CHCH(CH3)2) 
 
HRMS (ES) 550.2599 (MH+). C27H39N3O7S requires 550.2587 
 
(9R,12S,15S)-15-tertButoxycarbonylamino-12-isopropyl-11,14-dioxo-2-oxa-7-thia-10,13-diazabicyclo-
[15.2.2]henicosa-1(20),17(21),18-triene-9-carboxylic acid methyl ester (4.67) 
BOCHN
N
H
O
O
O
N
H
S
CO2Me
 
The unsaturated macrocycle 4.66 (0.700g, 1.27 mmol) was hydrogenated in 50 mL of methanol using General 
Procedure G2 to afford a brown solid, 0.309g, 44% 
 
 
1H NMR ppm (500 MHz in (CD3)OD 7.03 (2H, d J=8.2Hz, Ar-H), 6.76 (2H, d J=8.2Hz, Ar-H), 4.58 (1H, dd 
J=6.0Hz, J=14.4Hz, CHCO2CH3), 4.18-4.31 (3H, m, CHCH2Ph and OCH2CH2CH2CH2S), 3.98-4.02 (2H, m, 
OCH2CH2CH2CH2S and CHCH(CH3)2), 3.84-3.89 (1H, m, OCH2CH2CH2CH2S), 3.70 (3H, s, CHCO2CH3), 
2.84-3.03 (2H, m, CHCH2Ph), 2.71-2.85 (2H, m, CHCH2S), 1.97-2.13 (1H, m, CHCH(CH3)2), 1.80-1.91 (2H, m, 
OCH2CH2CH2CH2S), 1.73-1.79 (2H, m, OCH2CH2CH2CH2S), 1.42 (9H, s, C(CH3)3), 0.94 (3H, d J=6.7Hz, 
CHCH(CH3)2), 0.82 (3H, d J=6.7Hz, CHCH(CH3)2) 
 
HRMS (ES) 552.2739 (MH+). C27H41N3O7S requires 552.2743 
 
(S)-3-Allyloxy-2-tertbutoxycarbonylaminopropionic acid methyl ester (4.68) Lit7 
 
BOCHN
O
CO2Me
 
Allyl alcohol (1.97mL, 29.0 mmol) was dissolved in diethyl ether (20 mL).  This was cooled to 00C and ethyl 
chloroformate (1.1 equiv) and triethylamine (1.1 equiv) were added.  After stirring in ice for twenty min the 
resultant white precipitate was removed by suction filtration.  The filtrate was concentrated in vacuo and the 
residue dissolved in THF (4 mL).  To this a solution of allyl palladium chloride dimer (0.008 equiv) and 
triphenylphosphine (0.035 equiv) in THF (3 mL) was added.  The mixture was stirred at rt for twenty min and 
this was then added to a solution of N-Boc-Ser-OMe (5.00g, 0.080 equiv) in THF (20 mL).  The mixture was 
stirred at rt for eighteen h and then concentrated in vacuo.  The crude material was purified by flash 
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chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a yellow oil, 1.25g, 21%.  Rf = 
0.27 (1/6 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 in CDCl3) 5.64 (1H, tdd J=5.5Hz, J=5.5Hz, J=11.0Hz, J=16.0Hz, OCH2CHCH2), 5.37 (1H, d 
J=8.6Hz, NH), 4.97-5.12 (2H, m, OCH2CHCH2), 4.21-4.24 (1H, m, CHCO2CH3), 3.74-3.80 (2H, m, 
OCH2CHCH2), 3.65 (1H, dd J=3.2Hz, J=9.4Hz, CHCH2OCH2CHCH2), 3.55 (3H, s, CHCO2CH3), 3.46 (1H, dd 
J=3.4Hz, J=9.4Hz, CHCH2OCH2CHCH2), 1.26 (9H, s, C(CH3)3) 
 
13C NMR ppm (75 MHz in CD3OD) 173.3, 171.4, 133.6, 118.6, 66.6, 53.1, 30.5, 26.7 
 
LRMS (ES) 260.2 (MH+). C12H21NO5 requires 260.1 
 
(S)-3-Allyloxy-2-aminopropionic acid methyl ester hydrochloride (4.69) Lit7 
HCl.H2N
O
CO2Me
 
N-BOC protected compound 4.68 (1.00g, 3.86 mmol) was reacted using General Procedure I1 to afford a white 
solid 0.656g, 87%.   
 
1H NMR ppm (500 MHz in CD3OD) 5.84-5.92 (1H, m, OCH2CHCH2), 5.19-5.31 (2H, m, OCH2CHCH2), 4.27 
(1H, dd J=3.2Hz, J=4.6Hz, CHCO2CH3), 3.99-4.09 (2H, m, OCH2CHCH2), 3.85-3.91 (1H, m, CHCH2OCH2), 
3.83 (3H, s, CHCO2CH3), 3.79 (1H, dd J=3.2Hz, J=10.6Hz, CHCH2OCH2) 
 
LRMS (ES) 160.1 (MH+). C7H13NO3 requires 160.1 
 
(S)-3-Allyloxy-2-{(S)-2-[(S)-3-(4-allyloxy-phenyl)-2-tertbutoxycarbonylamino-propionylamino]-3-methyl-
butyrylamino}propionic acid methyl ester (4.70) 
BOCHN
N
H
O
O
O
N
H
CO2Me
O
 
Carboxylic acid 4.13 (1.29g, 3.07 mmol) was reacted with amine 4.69 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 1.07g, 62%.  Rf = 0.46 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 7.12 (2H, d J=8.0 Hz, Ar-H), 6.82 (2H, d J=8.0Hz, Ar-H), 6.04 (1H, tdd 
J=5.3Hz, J=5.3Hz, J=10.4Hz, J=17.1Hz, PhOCH2CHCH2), 5.87 (1H, dddd J=5.5Hz, J=5.6Hz, J=11.0Hz, 
J=16.0Hz, CH2OCH2CHCH2), 5.13-5.40 (4H, m, PhOCH2CHCH2 and CH2OCH2CHCH2,), 4.59 (1H, dd, 
J=3.2Hz, J=4.7Hz, CHCO2CH3), 4.46-4.53 (2H, m, PhOCH2CHCH2), 4.25-4.32 (2H, m, CHCH2Ph and 
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CHCH(CH3)2), 4.02 (1H, dd J=5.5Hz, J=13.0Hz, CH2OCH2CHCH2), 3.97 (1H, dd J=5.6Hz, J=13.0Hz, 
CH2OCH2CHCH2), 3.83 (1H, dd J=4.7Hz, J=9.8Hz, CH2OCH2CHCH2), 3.72 (3H, s, CHCO2CH3), 3.67 (1H, dd 
J=3.8Hz, J=8.7Hz, CH2OCH2CHCH2), 3.02 (1H, dd J=5.5Hz, J=13.9Hz, CHCH2Ph), 2.75 (1H, dd J=8.9Hz, 
J=13.9Hz, CHCH2Ph), 1.95-2.06 (1H, m, CHCH(CH3)2), 1.37 (9H, s, C(CH3)3), 0.98 (3H, d J=6.7 Hz, 
CHCH(CH3)2), 0.94 (3H, d J=6.7 Hz, CHCH(CH3)2) 
 
HRMS (ES) 562.3121 (MH+). C29H43N3O8 requires 562.3128 
 
(E/Z)-(9S,12S,15S)-15-tertButoxycarbonylamino-12-isopropyl-11,14-dioxo-2,7-dioxa-10,13-diazabicyclo-
[15.2.2]henicosa-1(20),4,17(21),18-tetraene-9-carboxylic acid methyl ester (4.71) 
 
BOCHN
N
H
O
O
O
N
H
CO2Me
O
 
Diene 4.70 (1.06g, 1.89 mmol) was reacted with Grubbs second generation catalyst using General Procedure E1.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 0.233g, 23%.  A 1:4.7 ratio of geometric isomers was obtained.  Rf = 0.28  and 0.27 
(1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm for major isomer from mixture (500 MHz in CDCl3) 7.09 (2H, d J=8.4Hz, Ar-H), 6.77 (2H, d 
J=8.4Hz, Ar-H), 6.27 (1H, d J=8.3Hz, NH Val), 6.24 (1H, d J=8.3Hz, NH Ser), 5.73 (1H, ddd  J=6.5Hz, 
J=6.7Hz, J=7.5Hz, PhOCH2CHCHCH2), 5.62 (1H, td J=6.1Hz, J=6.1Hz, J=7.5Hz, PhOCH2CHCHCH2), 5.40 
(1H, d J=8.6Hz, NH Tyr), 4.76 (1H, ddd J=4.0Hz, J=4.3Hz, J=8.3Hz, CHCO2CH3), 4.67-4.61 (2H, m, 
PhOCH2CHCHCH2), 4.36 (1H, ddd J=4.2Hz, J=8.6Hz, J=9.6Hz, CHCH2Ph), 4.13 (1H, dd J=6.7Hz, J=13.6Hz, 
CH2OCH2CHCHCH2), 4.09 (1H, dd J=6.5Hz, J=13.6Hz, CH2OCH2CHCHCH2), 3.80 (1H, dd J=7.7Hz, J=8.3Hz, 
CHCH(CH3)2), 3.78 (3H, s,  CHCO2CH3), 3.58 (1H, dd J=4.3Hz, J=9.1Hz, CH2OCH2CHCHCH2), 3.51 (1H, dd 
J=4.0Hz, J=9.1Hz, CH2OCH2CHCHCH2), 3.07 (1H, dd J=9.6Hz, J=13.7Hz, CHCH2Ph), 2.91 (1H, dd J=4.2Hz, 
J=13.7Hz, CHCH2Ph), 1.99-2.08 (1H, m, CHCH(CH3)2), 1.46 (9H, s, C(CH3)3), 0.88 (3H, d J=6.7Hz, 
CHCH(CH3)2), 0.88 (3H, d J=6.7 Hz, CHCH(CH3)2) 
 
Selected 1H-NMR for minor isomer from mixture: 6.80 (2H, d J=8.5 Hz, Ar-H), 4.33-4.25 (1H, m, CHCH2Ph), 
3.01 (1H, dd J=4.3Hz, J=12.9Hz, CHCH2Ph), 0.85 (3H, d J=6.8Hz, CHCH(CH3)2), 0.82 (3H, d J=6.5Hz, 
CHCH(CH3)2) 
 
HRMS (ES) 534.2820 (MH+). C27H39N3O8 requires 534.2815 
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(9S,12S,15S)-15-tertButoxycarbonylamino-12-isopropyl-11,14-dioxo-2,7-dioxa-10,13-diazabicyclo-
[15.2.2]henicosa-1(20),17(21),18-triene-9-carboxylic acid methyl ester (4.72) 
BOCHN
N
H
O
O
O
N
H
CO2Me
O
 
The unsaturated macrocycle 4.71 (0.200g, 0.375 mmol) was hydrogenated in 20 mL of methanol using General 
Procedure G2 to afford a brown solid, 0.200g, 100% 
 
1H NMR ppm (500 MHz in CD3OD) 7.05 (2H, d J=8.3Hz, Ar-H), 6.75 (2H, d J=8.3Hz, Ar-H), 4.60 (1H, dd 
J=3.9Hz, J=6.3Hz, CHCO2CH3), 4.21-4.36 (2H, m, CHCH2Ph and PhOCH2CH2CH2CH2), 4.02-4.17 (3H, m, 
CHCH(CH3)2 and PhOCH2CH2CH2CH2 and CH2OCH2CH2CH2CH2), 3.86-3.93 (1H, m, 
CH2OCH2CH2CH2CH2), 3.69 (3H, s, CHCO2CH3), 3.47-3.55 (2H, m, CH2OCH2CH2CH2CH2 ), 2.80-2.91 (2H, 
m, CHCH2Ph), 1.92-2.05 (1H, m, CHCH(CH3)2), 1.71-1.90 (1H, m, PhOCH2CH2CH2CH2), 1.55-1.71 (3H, m, 
PhOCH2CH2CH2CH2 and PhOCH2CH2CH2CH2), 1.44 (9H, s, C(CH3)3), 0.87 (3H, d J=6.4 Hz, CHCH(CH3)2), 
0.86 (3H, d J=6.4Hz, CHCH(CH3)2) 
 
HRMS (ES) 536.2979 (MH+). C27H41N3O8 requires 536.2972 
 
(S)-3-(4-Allyloxyphenyl)-2-amino-propionic acid methyl ester hydrochloride (4.73) 
 
HCl.H2N
O
CO2Me
 
N-BOC-O-allyl-Tyr-H (5.00g, 16.3 mmol) was suspended in methanol (30 mL). This was simultaneously 
esterified and N-deprotected using General procedure J to afford a white solid. 4.23g, 96%.  
 
1H NMR ppm (500 MHz in CD3OD) 7.13 (2H, d J=8.6Hz, Ar-H), 6.91 (2H, d J=8.6Hz, Ar-H), 6.03 (1H, tdd, J= 
5.1Hz, J=5.1Hz, J=10.4Hz, J=17.1Hz, OCH2CHCH2), 5.21-5.39 (2H, m, OCH2CHCH2) 4.51-4.53 (2H, m, 
OCH2CHCH2), 4.22-4.25 (1H, m, CHCH2Ph), 3.79 (3H, s, CO2CH3), 3.17 (1H, dd J=5.9Hz, J=14.5Hz, 
CHCH2Ph), 3.07 (1H, dd J=7.5Hz, J=14.5Hz, CHCH2Ph) 
 
13C NMR ppm (75 MHz in CD3OD) 170.5, 159.8, 134.9, 131.6, 127.2, 117.5, 116.4, 69.8, 55.3, 53.6, 36.6  
 
HRMS (ES) 236.1428 (MH+). C13H17NO3 requires 236.1286 
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(S)-3-(4-Allyloxyphenyl)-2-{(S)-2-[(S)-3-(4-allyloxyphenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-
methyl-butyrylamino}propionic acid methyl ester (4.74) 
BOCHN
N
H
O
N
H
O
O
CO2Me
O
 
Carboxylic acid 4.13 (1.50g, 3.57 mmol) was reacted with amine 4.73 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 0.370g, 17%.  Rf = 0.78 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.10 (2H, d J=7.8Hz, Ar-H), 7.00 (2H, d J=7.8Hz, Ar-H), 6.84 (2H, d J=7.3 
Hz, Ar-H), 6.83 (2H, d J=7.3 Hz, Ar-H), 6.46 (1H, d J=8.1Hz, NH), 6.20 (1H, d J=6.9Hz, NH), 5.99-6.08 (2H, 
m, OCH2CHCH2), 5.26-5.41 (4H, m, OCH2CHCH2), 4.92-4.97 (1H, m, CHCO2CH3), 4.74-4.79 (1H, m, 
CHCH2Ph), 4.47-4.50 (1H, m, OCH2CHCH2), 4.24-4.31 (1H, m, CHCH(CH3)2), 3.71 (3H, s, CO2CH3), 2.96-
3.06 (4H, m, CHCH2Ph), 2.06-2.10 (1H, m, CHCH(CH3)2), 1.41 (9H, s, C(CH3)3), 0.86 (3H, d J=6.5Hz, 
CHCH(CH3)2), 0.80 (3H, d J=6.5Hz, CHCH(CH3)2) 
 
HRMS (ES) 638.3447 (MH+). C35H47N3O8 requires 638.3441  
 
(S)-2-tertButoxycarbonylaminopentanedioic acid-1-methyl ester (4.76) Lit8 
 
BOCHN CO2Me
O OH  
Glu-OMe (2.50g, 15.5 mmol) was N-BOC protected using General Procedure K to afford a white solid, 4.05g, 
97%.   
 
1H NMR ppm (500 MHz in CDCl3) 10.41 (1H, bs, CO2H), 5.23 (1H, d J=8.0Hz, NH), 4.32-4.37 (1H, m, 
CHCO2CH3), 3.75 (3H, s, CHCO2CH3), 2.40-2.52 (2H, m, CHCH2CH2), 2.16-2.23 (1H, m, CHCH2CH2), 1.92-
2.00 (1H, m, CHCH2CH2), 1.44 (9H, s, C(CH3)3) 
 
LRMS (ES) 262.1 (MH+). C11H19NO6 requires 262.1 
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(S)-4-Allylcarbamoyl-2-tertbutoxycarbonylaminobutyric acid methyl ester (4.77) 
BOCHN CO2Me
O N
H  
Carboxylic acid 4.76 (4.05g, 15.5 mmol) was reacted with allyl amine using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a colourless oil, 0.652g, 14%.  Rf = 0.39 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 8.06 (1H, bs, NHCH2CHCH2), 6.98 (1H, d J=7.6Hz, NHCHCO2CH3), 
5.78-5.87 (1H, m, NCH2CHCH2), 5.06-5.20 (2H, m, NCH2CHCH2), 4.13 (1H, ddd J=4.8Hz, J=7.6Hz, J=12.4Hz, 
CHCO2CH3), 3.78 (2H, d J=4.3Hz, NCH2CHCH2), 3.71 (3H, s, CO2CH3), 2.30 (2H, dd J=7.4Hz, J=7.4Hz 
CHCH2CH2), 2.08-2.14 (1H, m, CHCH2CH2), 1.85-1.93 (1H, m, CHCH2CH2), 1.43 (9H, s, C(CH3)3) 
 
LRMS (ES) 301.2 (MH+). C14H24N2O5 requires 301.2  
 
 
(S)-4-Allylcarbamoyl-2-aminobutyric acid methyl ester hydrochloride (4.78) 
HCl.H2N CO2Me
O N
H  
N-BOC protected compound 4.77 (0.800g, 2.66 mmol) was reacted using General Procedure I4 to afford a white 
solid, 0.533g, 100% 
 
1H NMR ppm (500 MHz in CD3OD) 5.75-5.83 (1H, m, NCH2CHCH2), 5.04-5.17 (2H, m, NCH2CHCH2), 4.03-
4.09 (1H, m, CHCO2CH3), 3.79 (3H, s, CO2CH3), 3.75 (2H, d J=3.8Hz, CH2CHCH2), 2.44 (2H, dd J=7.8Hz, 
J=15.0Hz, CHCH2CH2), 2.07-2.20 (2H, m, CHCH2CH2) 
 
LRMS (ES) 201.1 (MH+). C9H16N2O3 requires 201.1  
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(S)-4-Allylcarbamoyl-2-{(S)-2-[(S)-3-(4-allyloxy-phenyl)-2-tertbutoxycarbonylaminopropionylamino]-3-
methylbutyrylamino}butyric acid methyl ester (4.79) 
 
BOCHN
N
H
O
N
H
O
O
CO2Me
O N
H
 
Carboxylic acid 4.13 (1.01g, 2.41 mmol) was reacted with amine 4.78 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 0.550g, 38%.  Rf = 0.39 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.08-7.16 (3H, m, Ar-H and NH Gln), 6.84 (2H, d J=8.1Hz, Ar-H), 6.64 
(1H, d J=6.9Hz, NH Val), 6.46 (1H, bs, NHCH2CHCH2), 6.00-6.08 (1H, m, OCH2CHCH2), 5.78-5.86 (1H, m, 
NHCH2CHCH2), 5.10-5.42 (4H, m, NHCH2CHCH2 and OCH2CHCH2), 4.98 (1H, d J=6.9Hz, NH Tyr), 4.50-
4.52 (3H, m, OCH2CHCH2 and CHCO2CH3), 4.29-4.35 (1H, m, CHCH2Ph), 4.19 (1H, dd J=6.9Hz, J=7.6Hz, 
CHCH(CH3)2), 3.84-3.87 (2H, m, NHCH2CHCH2), 3.73 (3H, s, CHCO2CH3), 3.03 (2H, d J=6.0Hz, CHCH2Ph), 
2.21-2.31 (2H, m, CHCH2CH2C(O)NH), 2.06-2.13 (1H, m, CHCH(CH3)2), 1.99 (2H, m, CHCH2CH2C(O)NH), 
1.40 (9H, s, C(CH3)3), 0.92 (3H, d J=6.7Hz, CHCH(CH3)2), 0.88 (3H, d J=6.7Hz, CHCH(CH3)2)  
 
HRMS (ES) 603.3391 (MH+). C31H46N4O8 requires 603.3394  
 
Pent-4-enoic acid but-3-enylamide (4.91) 
N
H
O  
4-pentenoic acid (0.510 mL, 4.99 mmol) was reacted with 4.98 using General Procedure A1.  The crude material 
was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a 
colourless oil, 0.597g, 78%.  Rf = 0.28 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 5.73-5.86 (2H, m, NHCH2CH2CHCH2 and CH2CH2CHCH2) 4.95-5.09 
(4H, m, NHCH2CH2CHCH2 and CH2CH2CHCH2), 3.22 (2H, dt J=3.8Hz, J=6.9Hz, NHCH2CH2CHCH2), 2.32-
2.34 (2H, m, CH2CH2CHCH2), 2.22-2.27 (4H, m, CH2CH2CHCH2 and  NHCH2CH2CHCH2) 
 
13C NMR ppm (75 MHz in CD3OD) 173.9, 136.9, 135.4, 115.7, 114.5, 38.5, 35.1, 33.5, 29.7 
 
LRMS (ES) 154.1 (MH+). C9H15NO requires 154.1 
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Hex-5-enoic acid allylamide (4.93) 
N
H
O  
5-hexenoic acid (0.520 mL, 4.38 mmol) was reacted with allyl amine using General Procedure A1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a colourless oil, 0.503g, 75%.  Rf = 0.29 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 8.05 (1H, bs, NH), 5.73-5.84 (2H, m, NHCH2CHCH2 and 
CH2CH2CH2CHCH2), 4.90-5.16 (4H, m, NHCH2CHCH2 and CH2CH2CH2CHCH2), 3.76 (2H, ddd J=1.2Hz, 
J=5.7Hz, J=5.7Hz, NHCH2CHCH2), 2.15-2.20 (2H, m, CH2CH2CH2CHCH2), 2.07 (2H, dt J=1.1Hz, J=7.7Hz, 
J=7.8Hz, CH2CH2CH2CHCH2), 1.64-1.70 (2H, m, CH2CH2CH2CHCH2) 
 
13C NMR ppm (75 MHz in CD3OD) 174.4, 137.8, 134.3, 14.8, 114.3, 41.4, 35.1, 33.0, 25.0 
 
LRMS (ES) 154.1 (MH+). C9H15NO requires 154.1 
 
(R)-2-But-3-enyl-isoindole-1,3-dione (4.97) Lit9 
N
O
O  
Phthalimide (10.0g, 68.0 mmol) was suspended in ethanol (100 mL) and potassium hydroxide (1 equiv) was 
added.  This was stirred at rt for two h before being concentrated in vacuo.  The residue was suspended in 
anhydrous DMF under an atmosphere of argon and 4-bromo-1-butene (0.66 equiv) was added.  The mixture was 
heated at reflux for seventy two h, cooled, diluted with EtOAc (300 mL) and partitioned with saturated 
NaHCO3(aq).  The organic phase was washed again with saturated NaHCO3(aq) and brine before being dried 
(MgSO4), filtered and concentrated in vacuo.  The crude material was purified by flash chromatography on silica 
using a gradient of EtOAc and (50/70) pet ether to yield a colourless oil, 13.1g, 96%.  Rf = 0.21 (1/7 (EtOAc / 
(50/70) Pet ether)). 
 
1H NMR ppm (500 MHZ in CDCl3) 7.76-7.78 (2H, m, Ar-H), 7.64-7.67 (2H, m, Ar-H), 5.80 (1H, tdd J=6.9Hz, 
J=10.2Hz, J=17.1Hz, CH2CH2CHCH2), 4.94-5.04 (2H, m, CH2CH2CHCH2), 3.72 (2H, t J=7.1Hz, 
CH2CH2CHCH2), 2.45 (2H, ddd J=6.9Hz, J=7.0Hz, J=7.0Hz, CH2CH2CHCH2)  
 
13C NMR ppm (75 MHz in CDCl3) 168.2, 134.4, 133.8, 132.0, 123.1, 117.4, 37.2, 32.7 
 
LRMS (ES) 202.1 (MH+). C12H11NO2 requires 202.1 
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But-3-enylamine hydrochloride (4.98) Lit9 
NH2.HCl  
 
Method 1 
 
Isoindole 4.97 (5.00g, 24.9 mmol) was dissolved in ethanol (100 mL) and heated to 50oC. Hydrazine 
monohydrate (2 equiv) was added and the mixture was stirred at 50oC for a further one h.  1M HCl(aq) (30 mL) 
was added and this was then concentrated in vacuo.  The residue was partitioned between diethyl ether and 1M 
NaOH(aq).  The organic phase was washed with brine, dried (MgSO4) and filtered.  To the filtrate 2M hydrogen 
chloride in diethyl ether (20 mL) was added and this was concentrated in vacuo to afford a white solid, 0.981g, 
37%. 
 
Method 2 
 
1M lithium aluminium hydride in diethyl ether (74.5 mL, 74.5 mmol) was dissolved in diethyl ether (75 mL) 
under an atmosphere of argon.  The mixture was cooled in ice, aluminium trichloride (1 equiv) added 
portionwise and stirred in ice for ten min before allyl cyanide (1 equiv) was added.  The mixture was stirred  in 
ice for one h and then at rt for a further eighteen h.  The reaction was quenched with 1M NaOH(aq) (10 mL) and 
then concentrated in vacuo.  The residue was partitioned between diethyl ether and 1M NaOH(aq).  The aqueous 
phase was extracted three more times with diethyl ether.  The combined organic extracts were washed with brine, 
dried (MgSO4) and filtered.  To the filtrate 4M hydrogen chloride in 1,4-dioxane (10 mL) was added and this 
concentrated in vacuo to afford a white solid, 4.29g, 54%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.47 (2H, bs, NH2), 5.74-5.84 (1H, m, CH2CH2CHCH2), 5.17-5.27 (2H, m, 
CH2CH2CHCH2), 3.10 (2H, ddd J=6.3Hz, J=8.4Hz, J=12.7Hz, CH2CH2CHCH2), 2.46-2.49 (2H, m, 
CH2CH2CHCH2) 
 
 
(S)-4-But-3-enylcarbamoyl-2-tertbutoxycarbonylaminobutyric acid methyl ester (4.99) 
 
BOCNH CO2Me
O N
H  
Carboxylic acid 4.76 (5.70g, 21.8 mmol) was reacted with amine 4.98 using General Procedure B1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 1.23g, 18%.  Rf = 0.12 (1/1 (EtOAc / (50/70) Pet ether)). 
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1H NMR ppm (500 MHz in CDCl3) 6.66 (1H, bs, NHCH2CH2CHCH2), 5.76 (1H, tdd J=6.8Hz, J=10.2Hz, 
J=17.0Hz, CH2CH2CHCH2), 5.52 (1H, d J=6.8Hz, NHCHCO2CH3), 5.05-5.11 (2H, m, CH2CH2CHCH2), 4.11-
4.17 (1H, m, CHCO2CH3), 3.68 (3H, s, CHCO2CH3), 3.27-3.49 (1H, m, NHCH2CH2CHCH2), 3.19-3.25 (1H, m, 
NHCH2CH2CHCH2), 2.37-2.51 (2H, m, CHCH2CH2C(O)), 2.18-2.23 (2H, m, NHCH2CH2CHCH2), 2.10-2.15 
(1H, m, CHCH2CH2C(O)), 1.93 (1H, dt J=7.6Hz, J=14.6Hz, CHCH2CH2C(O)),  1.43 (9H, s, C(CH3)3) 
 
13C NMR ppm (75 MHz in CDCl3) 173.6, 171.4, 155.7, 135.0, 79.8, 53.6, 51.7, 38.5, 33.6, 30.2, 28.2, 28.0 
 
LRMS (ES) 315.2 (MH+). C15H26N2O5 requires 315.2 
 
(S)-2-Amino-4-but-3-enylcarbamoylbutyric acid methyl ester hydrochloride (4.100) 
HCl.H2N CO2Me
O N
H  
N-BOC protected compound 4.99 (1.00g, 3.18 mmol) was reacted using General Procedure I5 to afford a white 
solid, 0.795g, 100% 
 
1H NMR ppm (500 MHz in CDCl3) 8.30 (3H, bs, NH2 and NHCH2CH2CHCH2), 5.78 (1H, tdd J=6.6Hz, 
J=10.2Hz, J=13.3Hz, CH2CH2CHCH2), 5.01-5.12 (2H, m, CH2CH2CHCH2), 4.39-4.45 (1H, m, CHCO2CH3), 
3.67 (3H, s, CHCO2CH3), 3.40-3.47 (1H, m, NHCH2CH2CHCH2), 3.19-3.24 (1H, m, NHCH2CH2CHCH2), 2.56-
2.68 (2H, m, CHCH2CH2C(O)), 2.22-2.38 (4H, m, NHCH2CH2CHCH2 and CHCH2CH2C(O)) 
 
LRMS (ES) 215.1 (MH+). C10H18N2O3 requires 215.1 
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-tertbutoxycarbonylamino-propionylamino]-3-methyl-
butyrylamino}-4-but-3-enylcarbamoylbutyric acid methyl ester (4.101) 
BOCHN
N
H
O
O
N
H
CO2Me
O N
H
O
 
Carboxylic acid 4.13 (1.43g, 3.40 mmol) was reacted with amine 4.100 using General Procedure B2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 1.13g, 54%.  Rf = 0.17 (2/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in (CD3)2SO) 8.03 (1H, d J=8.0Hz, NH Val), 7.89 (1H, dd J=5.6Hz, J=5.6Hz, 
NHCH2CH2CHCH2), 7.75 (1H, d J=8.5Hz, NHCHCO2CH3), 7.15 (2H, d J=8.4Hz, Ar-H), 6.96 (1H, d J=8.4Hz, 
NH Tyr), 6.83 (2H, d J=8.4Hz, Ar-H), 6.02 (1H, tdd J=4.9Hz, J=10.4, J=17.Hz, OCH2CHCH2), 5.74 (1H, tdd 
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J=6.6Hz, J=6.6Hz, J=10.1Hz, J=17.0Hz, NHCH2CH2CHCH2), 5.21-5.41 (2H, m, OCH2CHCH2), 4.96-5.07 (2H, 
m, NHCH2CH2CHCH2), 4.51 (2H, d J=4.9Hz, OCH2CHCH2), 4.22 (2H, m, CHCO2CH3 and CHCH(CH3)2), 
4.12 (1H, ddd J=5.9Hz, J=8.4Hz, J=11.3Hz, CHCH2Ph), 3.56 (3H, s, CHCO2CH3), 3.04-3.18 (2H, m, 
NHCH2CH2CHCH2), 2.87 (1H, dd, J=11.3Hz, J=14.8Hz, CHCH2Ph), 2.67 (1H, dd J=5.9Hz, J=14.8Hz, 
CHCH2Ph), 2.29 (2H, dd J=7.8Hz, J=7.8Hz, CHCH2CH2C(O)), 2.11-2.17 (2H, m, NHCH2CH2CHCH2), 1.85-
2.00 (2H, m, CHCH(CH3)2 and CHCH2CH2C(O)), 1.71-1.82 (1H, m, , CHCH2CH2C(O)), 1.30 (9H, s, C(CH3)3), 
0.85 (3H, d J=7.2Hz, CHCH(CH3)2), 0.83 (3H, d J=7.2Hz, CHCH(CH3)2) 
 
HRMS (ES) 617.3556 (MH+). C32H48N4O8 requires 617.3550 
 
(E/Z)-(12S,15S,18S)-18-tert-Butoxycarbonylamino-15-isopropyl-9,14,17-trioxo-2-oxa-8,13,16-triaza-
bicyclo[18.2.2]tetracosa-1(23),4,20(24),21-tetraene-12-carboxylic acid methyl ester (4.102) 
BOCHN
N
H
O
O
N
H
CO2Me
O NHO
 
Diene 5.92 (1.10g, 1.78 mmol) was reacted with Grubbs second generation catalyst using General Procedure E1.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 0.178g, 17%.  %.  A 1:2 ratio of geometric isomers was obtained.  Rf = 0.12 (2/1 
(EtOAc / (50/70) Pet ether)). 
 
1H-NMR NMR for major isomer from mixture (500 MHz in CD3OD) 7.09 (2H, d J=8.5Hz, Ar-H), 6.78 (2H, d 
J=8.5Hz, Ar-H), 5.69-5.71 (2H, m, OCH2CHCHCH2CH2 and OCH2CHCHCH2CH2), 4.46-4.65 (2H, m, 
OCH2CHCHCH2CH2 and CHCH2Ph), 4.20-4.36 (2H, m, CHCO2CH3), 3.90-3.94 (1H, m, CHCH(CH3)2), 3.69 
(3H, s, CHCO2CH3), 2.97-3.04 (2H, m, OCH2CHCHCH2CH2), 2.91-2.95 (1H, m, CHCH2Ph), 2.77-2.81 (1H, m, 
CHCH2Ph), 2.27-2.33 (2H, m, OCH2CHCHCH2CH2), 2.12-2.17 (2H, m, CHCH2CH2C(O)), 1.99-2.08 (2H, m, 
CHCH(CH3)2 and CHCH2CH2C(O)), 1.86-1.94 (1H, m, CHCH2CH2C(O)), 1.43 (9H, s, C(CH3)3), 0.92 (3H, d 
J=6.8Hz, CHCH(CH3)2 ), 0.88 (3H, d J = 6.8Hz, CHCH(CH3)2) 
 
Selected 1H-NMR NMR for minor isomer from mixture: 6.99 (2H, d J=8.5 Hz, Ar-H), 3.65 (3H, s, CHCO2CH3), 
0.84 (3H, d J=6.4Hz, CHCH(CH3)2), 0.81 (3H, d J=6.4Hz, CHCH(CH3)2) 
 
HRMS (ES) 589.3241 (MH+). C30H44N4O8 requires 589.3237 
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(7S,10S,13S)-13-Amino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]nonadeca-1(18),15(19),16-
triene-7-carboxylic acid methyl ester hydrogen chloride salt (5.7) 
HCl.H2N N
H
O
O
O
N
H
CO2Me
 
N-BOC protected compound 4.18 (1.00g, 1.97 mmol) was reacted using General Procedure I1 to afford a white 
solid, 0.873g, 100% 
 
1H NMR ppm (500 in (CD3)2SO) 8.51 (2H, bs, NH2), 8.16 (1H, d J=7.2Hz, NH Val), 7.90 (1H, d J=6.4Hz, NH 
Gly), 6.98 (2H, d J=6.8Hz, Ar-H) 6.75 (2H, d J=6.8Hz, Ar-H), 4.31-4.36 (2H, m, OCH2CH2CH2CH2), 4.18-4.25 
(1H, m, CHCO2CH3), 4.03-4.08 (1H, m, CHCH2Ph) 3.84 (1H, dd J=5.2Hz, J=7.2Hz, CHCH(CH3)2), 3.60 (3H, s, 
CHCO2CH3), 3.08 (1H, dd J=5.6Hz, J=11.2Hz, CHCH2Ph), 2.60 (1H, dd J=11.2Hz, J=11.2Hz, CHCH2Ph), 
1.96-2.01 (1H, m, CHCH(CH3)2), 1.76-1.83 (1H, m, OCH2CH2CH2CH2), 1.65-1.74 (1H, m, OCH2CH2CH2CH2), 
1.48-1.57 (2H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 1.22-1.36 (2H, m, OCH2CH2CH2CH2), 0.84 (3H, 
d J=6.4Hz, CHCH(CH3)2), 0.77 (3H, d J=6.4Hz, CHCH(CH3)2) 
 
LRMS (ES) 406.3 (MH+). C21H31N3O5 requires 406.2 
 
(7S,10S,13S)-13-(4-Fluoro-benzenesulfonylamino)-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (5.8) 
N
H
N
H
O
O
O
N
H
CO2MeS
O
O
F
 
Amine 5.7 (0.200g, 0.452 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M3.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
per ether to yield a brown solid, 0.0920g, 36%.  Rf = 0.09 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in (CD3OD) 7.51-7.72 (2H, m, Ar-H (4F-Ph)), 7.25-7.29 (1H, m, Ar-H (4F-Ph)), 6.87 
(2H, d J=8.2Hz, Ar-H (Tyr)), 6.74 (2H, d J=8.2Hz, Ar-H (Tyr)), 4.24-4.58 (2H, m, OCH2CH2CH2CH2 and 
CHCO2CH3) 3.94-4.27 (3H, m, OCH2CH2CH2CH2 and CHCH2Ph and CHCH(CH3)2), 3.69 (3H, s, CHCO2CH3), 
2.95-3.05 (1H, m, CHCH2Ph), 2.67 (1H, dd J=9.4Hz, J=9.4Hz, CHCH2Ph), 1.97-2.03 (1H, m, CHCH(CH3)2), 
1.62-1.83 (2H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 1.44-1.58 (2H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2), 1.20-1.33 (2H, m, OCH2CH2CH2CH2), 0.74 (3H, d J=6.9Hz, CHCH(CH3)2), 0.63 (3H, d 
J=6.9Hz, CHCH(CH3)2) 
 
HRMS (ES) 564.2173 (MH+). C27H34FN3O7S requires 564.2180 
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4-Fluoro-N-((7S,10S,13S)-7-formyl-10-isopropyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]nonadeca-
1(18),15(19),16-trien-13-yl)-benzenesulfonamide (5.10) 
N
H
N
H
O
O
O
N
H
S
O
O
F
O
H
 
Methyl ester 5.8 (0.100g, 0.177 mmol) was reduced using General Procedure R.  The crude material was purified 
by flash chromatography on silica using EtOAc to yield a brown solid, 0.0161g, 17%.  Rf = 0.67 (EtOAc). 
 
1H NMR ppm ((500 MHz in (CD3)2SO) 9.29 (1H, s, CHO), 8.13 (1H, d J=8.2HZ, NH Val), 7.91 (1H, d J=6.9Hz, 
NH Gly), 7.48-7.55 (2H, m, Ar-H (4F-Ph)), 7.31-7.37 (2H, m, Ar-H (4F-Ph)), 6.97 (2H, d J=7.6Hz, Ar-H (Tyr)), 
6.89 (2H, d J=7.6Hz, Ar-H (Tyr)), 6.66 (1H, d J=7.1Hz, NH), 4.40-4.49 (3H, m, OCH2CH2CH2CH2 and 
CHCO2CH3), 4.09-4.30 (2H, m, CHCH2Ph and CHCH(CH3)2), 3.01-3.07 (1H, m, CHCH2Ph), 2.64 (1H, dd 
J=11.1Hz, J=11.1Hz, CHCH2Ph), 1.99-2.06 (1H, m, CHCH(CH3)2), 1.40-1.87 (4H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 1.21-1.38 (2H, m, OCH2CH2CH2CH2), 0.59 
(3H, d J=6.8 Hz, CHCH(CH3)2), 0.55 (3H, d J=6.8 Hz, CHCH(CH3)2) 
 
HRMS (ES) 534.2078 (MH+). C26H32FN3O6S requires 534.2074 
 
(7S,10S,13S)-13-Amino-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]nonadeca-1-(18),15(19),16-
triene-7-carboxylic acid methyl ester hydrogen chloride salt (5.11) 
HCl.H2N N
H
O
O
O
N
H
CO2Me
 
 
N-BOC protected compound 4.49 (0.340g, 0.654 mmol) was reacted using General Procedure I1 to afford a 
brown solid, 0.232g, 100% 
 
1H-NMR (500 MHz in (CD3)2SO) 8.46 (2H, bs, NH2), 8.32 (1H, d J=8.7Hz NH Leu), 7.95 (1H, d J=7.8Hz, NH 
Gly), 6.80 (2H, d, J=8.2Hz, Ar-H), 7.02 (2H, d, J=8.2Hz, Ar-H) , 4.22-4.40 (3H, m, CHCH2Ph and 
CHCH2CH(CH3)2 and OCH2CH2CH2CH2), 3.95-4.08 (2H, CHCO2CH3 and OCH2CH2CH2CH2), 3.56 (3H, s, 
CO2CH3), 3.12 (1H, dd, J=5.9Hz, J=12.7Hz, CHCH2Ph), 2.62 (1H, dd J=12.7Hz, J=12.7Hz, CHCH2Ph), 1.60-
1.75 (4H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 1.49-1.58 (2H, m, CHCH2CH(CH3)2) 1.44-1.48 (1H, 
m, CHCH2CH(CH3)2), 1.22-1.41 (2H, m, OCH2CH2CH2CH2), 0.85 (3H, d J=7.3Hz, CHCH2CH(CH3)2), 0.84 ( 
3H, d J=7.3Hz, CHCH2CH(CH3)2) 
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HRMS (ES) 419.2541 (MH+). C23H34N2O5 requires 419.2546 
 
(7S,10S,13S)-13-Benzyloxycarbonylamino-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]-
nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (5.12) 
N
H
N
H
O
O
O
N
H
CO2MeO
O
Ph
 
 
Amine 5.11 (4.00g, 8.78 mmol) was reacted with benzyl chloroformate using General Procedure H1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc/DCM to yield an off-white 
solid, 2.10g, 43%.  Rf = 0.43 (30% EtOAc/DCM).   
 
1H-NMR (500 MHz in CDCl3) 7.31-7.38 (5H, m, Ar-H (CBZ)), 7.06 (2H, d J=7.9Hz, Ar-H (Tyr)), 6.79 (2H, d 
J=7.9Hz, Ar-H (Tyr)), 6.13 (1H, d J=6.9Hz, NH Gly), 5.79 (1H, d J=7.9Hz, NH Leu), 5.53 (1H, d J=8.5Hz, NH 
Tyr), 5.13 (2H, s, OCH2Ph), 4.51-4.57 (1H, m, CHCH2CH(CH3)2), 4.22-4.32 (2H, m, CHCH2Ph and 
OCH2CH2CH2CH2), 4.11 (1H, ddd, J=5.9Hz, J=10.1Hz, J=16.4Hz, OCH2CH2CH2CH2),  3.95 (1H, ddd J=6.5Hz, 
J=6.9Hz, J=13.0Hz, CHCO2CH3), 3.73 (3H, s, CO2CH3), 3.14 (1H, dd J=5.7Hz, J=12.8Hz, CHCH2Ph), 2.67 
(1H, dd, J=12.8Hz, J=12.8Hz, CHCH2Ph), 1.86-1.95 (1H, m, CHCH2CH(CH3)2), 1.74-1.83 (2H, m, 
OCH2CH2CH2CH2), 1.22-1.58 (6H, m, CHCH2CH(CH3)2 and OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 0.88 
(3H, d J=6.0Hz, CHCH2CH(CH3)2), 0.87 (3H, d J=6.0Hz, CHCH2CH(CH3)2). 
 
13C NMR ppm (75 MHz in CDCl3).  172.5, 170.8, 169.7, 157.1, 155.5, 136.3, 130.1, 128.5, 128.2, 128.1, 127.9, 
115.7, 66.8, 66.7, 57.1, 52.5, 51.7, 51.2, 43.3, 39.0, 31.5, 28.0, 24.5, 22.9, 22.4, 21.2 
 
HRMS (ES) 554.2859 (MH+). C30H39N3O7 requires 554.2866  
 
(7S,10S,13S)-7-Hydroxymethyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]-nonadeca-
1(18),15(19),16-trien-13-yl)carbamic acid benzyl ester (5.13) 
N
H
N
H
O
O
O
N
H
O
O
Ph
OH
 
Methyl ester 5.12 (2.30g, 4.15 mmol) was reduced using General Procedure S to afford an off-white solid, 1.81g, 
83%. 
m.p 238-240oC 
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1H-NMR (500 MHz in CD3OD) 7.68 (1H, d J=9.1Hz, NH Gly), 7.22-7.36 (6H, m, Ar-H (CBZ) and NH Leu), 
7.06 (2H, d, J=7.9Hz, Ar-H Tyr), 6.77 (2H, d, J=7.9Hz, Ar-H Tyr), 5.10 (1H, d J=12.5Hz, OCH2Ph), 5.05 (1H, d 
J=12.1 Hz, OCH2Ph), 4.26-4.34 (2H, m, CHCH2Ph and OCH2CH2CH2CH2), 4.06-4.12 (1H, m, 
OCH2CH2CH2CH2), 3.96-4.02 (1H, m, CHCH2CH(CH3)2), 3.74-3.86 (1H, m, CHCH2OH), 3.30-3.33 (2H, m, 
CH2OH), 2.98 (1H, dd J=5.4Hz, J=12.7Hz, CHCH2Ph), 2.67 (1H, dd, J=12.4Hz, J=12.7Hz, CHCH2Ph), 1.75-
1.84 (2H, m, OCH2CH2CH2CH2), 1.46-1.56 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.22-1.44 (4H, 
m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 0.84 (3H, d J=8.8Hz, CHCH2CH(CH3)2), 0.83 (3H, d J=8.8Hz, 
CHCH2CH(CH3)2) 
 
HRMS (ES) 526.2920 (MH+). C29H39N3O6 requires 526.2917  
 
Microanalysis. C, 64.08; H, 7.22; N, 7.23.  C29H39N3O6.H2O requires C, 64.07; H, 7.60; N, 7.73 
 
(7S,10S,13S)-7-Formyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]nonadeca-1(18),15(19),16-
trien-13-yl)carbamic acid benzyl ester (5.14) 
N
H
N
H
O
O
O
N
H
O
O
Ph
H
O
 
 
Alcohol 5.13 (1.71g, 3.25 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) per ether to yield an off white solid, 
0.720g, 42%.  Rf = 0.41 (2/1 (EtOAc / (50/70) Pet ether)). 
m.p 223-225oC 
 
1H-NMR (500 MHz in (CD3)2SO) 9.33 (1H, s, CHO), 8.05 (1H, d J=8.1Hz, NH Leu),  7.55 (1H, d J=6.8Hz, NH 
Tyr), 7.30-7.37 (5H, m, Ar-H CBZ), 7.16 (1H, d, J=8.1Hz, NH Gly), 7.02 (2H, d, J=8.0Hz, Ar-H Tyr), 6.77 
(2H,d J=8.0Hz, Ar-H Tyr), 5.06 (1H, d J=12.3Hz, OCH2Ph), 5.01 (1H, d J=12.3Hz, OCH2Ph), 4.31-4.36 (2H, m, 
CHCH2Ph and OCH2CH2CH2CH2), 4.18-4.25 (1H, m, CHCH2CH(CH3)2), 4.00-4.07 (2H, m, CHCHO and 
OCH2CH2CH2CH2), 2.86 (1H, dd J=5.6Hz, J=12.8Hz CHCH2Ph), 2.63 (1H, dd J=12.8Hz, J=12.8Hz, 
CHCH2Ph)), 1.70-1.77 (2H, m, OCH2CH2CH2CH2), 1.46-1.52 (1H, m, CHCH2CH(CH3)2), 1.22-1.39 (6H, m, 
CHCH2CH(CH3)2 and OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 0.80-0.83 (6H, m, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz CDCl3). 199.1, 171.1, 155.9, 137.7, 136.4, 129.3, 128.6, 128.5, 128.0, 127.9, 126.7, 
66.6, 57.2, 50.2, 40.2, 38.6, 37.7, 24.8, 23.0, 21.8 
 
HRMS (ES) 524.2762 (MH+). C29H37N3O6 requires 524.2760  
 
Microanalysis. C, 64.08; H, 6.95; N, 7.62.  C29H37N3O6.H2O requires C, 64.31; H, 7.26; N, 7.76 
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(7S,10S,13S)-13-(4-Fluoro-benzenesulfonylamino)-10-isobutyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (5.15) 
N
H
N
H
O
O
O
N
H
CO2MeSF
O
O
 
 
Amine 5.11 (0.232g, 0.508 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M3.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
per ether to yield a brown solid, 0.0190g, 7%.  Rf = 0.13 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H-NMR (500 MHz 500 MHz in (CD3)2SO) 8.11-8.15 (2H, m, NH Tyr and NH Gly), 7.91-7.95 (1H, m, NH 
Leu), 7.92-7.96 (2H, m, Ar-H (4-F-Ph)), 7.33-7.37 (2H, m, Ar-H (4-F-Ph)), 6.92-6.97 (2H, m, Ar-H (Tyr)), 6.70 
(2H, d J=7.9Hz, Ar-H (Tyr)), 4.28-4.38 (2H, m, CHCOCH3 and OCH2CH2CH2CH2), 4.11-4.21 (2H, m, 
CHCH2Ph and OCH2CH2CH2CH2), 3.95-4.04 (1H, m, CHCH2CH(CH3)2), 3.52 (3H, s, CO2CH3), 2.69-2.75 (1H, 
m, CHCH2Ph), 2.54 (1H, dd J=7.1Hz, J=12.0Hz, CHCH2Ph), 1.73-1.78 (2H, m, OCH2CH2CH2CH2), 1.20-1.70 
(7H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.73 (3H, d 
J=6.3Hz, CHCH2CH(CH3)2), 0.72 (3H, d J=6.3Hz, CHCH2CH(CH3)2). 
 
HRMS (ES) 578.2337 (MH+). C28H36FN3O7S requires 578.2336  
 
4-Fluoro-N-((7S,10S,13S)-7-hydroxymethyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),15(19),16-trien-13-yl)benzenesulfonamide (5.16) 
N
H
N
H
O
O
O
N
H
SF
O
O
OH
 
 
Methyl ester 5.15 (0.677g, 1.17 mmol) was reduced using General Procedure S to afford a brown solid, 0.550g, 
87%. 
m.p 256-258oC 
 
1H-NMR (500 MHz in CD3OD) 7.95-7.99 (2H, m, Ar-H (4-F-Ph)), 7.67 (1H, d J=8.8Hz, NH Leu), 7.25-7.28 
(2H, m, Ar-H (4-F-Ph)),  7.17 (1H, d J=7.5Hz, NH Gly), 6.97 (2H, d J=8.0Hz, Ar-H (Tyr)), 6.76 (2H, d 
J=8.0Hz, Ar-H (Tyr)), 4.29 (1H, m, OCH2CH2CH2CH2), 4.08 (2H, m, CHCH2Ph and OCH2CH2CH2CH2), 3.85-
3.87 (2H, m, CHCH2OH and CHCH2CH(CH3)2), 3.24-3.33 (2H, m, CH2OH), 2.88 (1H, dd J=5.5Hz, J=12.3Hz, 
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CHCH2Ph), 2.69 (1H, dd J=12.3Hz, J=12.3Hz, CHCH2Ph), 1.72-1.81 (2H m, OCH2CH2CH2CH2), 1.22-1.68 
(7H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.78 (3H, d 
J=6.4Hz, CHCH2CH(CH3)2), 0.76 (3H, d, J=6.4Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CD3OD).  171.6, 169.7, 166.6, 163.3, 157.1, 130.0, 129.8, 129.6, 127.7, 116.1, 115.8, 
66.7, 64.4, 57.9, 51.8, 50.1, 43.2, 39.0, 29.7, 28.3, 24.2, 22.2, 22.1, 21.4. 
 
HRMS (ES)  550.2369 (MH+). C27H36FN3O6S requires 550.2387  
 
4-Fluoro-N-((7S,10S,13S)-7-formyl-10-isobutyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]-nonadeca-
1(18),15(19),16-trien-13-yl)benzenesulfonamide (5.17) 
N
H
N
H
O
O
O
N
H
SF
O
O
H
O
 
 
Alcohol 5.16 (0.570g, 1.04 mmol) was oxidised using General Procedure L.  The crude material was purified by 
flash chromatography on silica using a gradient of EtOAc and (50/70) per ether to yield an off white solid, 
0.238g, 42%.  Rf = 0.41 (2/1 (EtOAc / (50/70) Pet ether)). 
m.p 243-245oC 
 
 
1H-NMR (500 MHz in (CD3)2SO) 9.29 (1H, s,CHO), 8.15 (1H, d J=8.9Hz, NH Tyr), 8.04 (1H, d J=8.3Hz, NH 
Leu), 7.93-7.97 (2H, m, Ar-H (4-F-Ph)), 7.49 (1H, d J=7.8Hz, NH Gly), 7.33-7.38 (2H, m, Ar-H (4-F-Ph)), 6.95 
(2H, d J=7.6Hz, Ar-H (Tyr)), 6.73 (2H, d J=7.6Hz, Ar-H (Tyr)), 4.22-4.37 (2H, m, CHCH2Ph and 
OCH2CH2CH2CH2), 4.17-4.24 (1H, m, CHCH2CH(CH3)2), 3.97-4.04 (1H, m, OCH2CH2CH2CH2), 3.80-3.87 
(1H, m, CHCHO), 2.72 (1H, dd J=5.2Hz, J=12.7Hz, CHCH2Ph), 2.54-2.60 (1H, m, CHCH2Ph), 1.32-1.74 (7H, 
m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and CHCH2CH(CH3)2 and CHCH2CH(CH3)2) 0.70-0.75 (6H, m, 
CHCH2CH(CH3)2). 
 
13C NMR ppm (75 MHz in (CD3)2SO).  201.0, 171.0, 168.4, 155.9, 130.3, 129.8, 129.7, 127.8, 116.1, 115.8, 
115.5,  66.0, 56.5, 56.3, 50.5, 43.2, 26.8, 26.3, 23.8, 23.1, 22.3, 21.4. 
 
HRMS (ES) 548.2226 (MH+). C27H34FN3O6S requires 548.2230  
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(7S,10S,13S)-13-Amino-10-benzyl-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]nonadeca-1(18),15(19),16-
triene-7-carboxylic acid methyl ester hydrogen chloride salt (5.18) 
HCl.H2N N
H
O
O
O
N
H
CO2Me
Ph
 
N-BOC protected compound 4.54 (0.530g, 0.958 mmol) was reacted using General Procedure I1 to afford a 
brown solid, 0.469g, 100%  
 
1H NMR ppm (500 in (CD3)OD) 7.08-7.20 (5H, m, Ar-H), 7.02 (2H, J=8.7Hz, Ar-H), 6.80 (2H, d J=8.7Hz, Ar-
H), 4.28-4.40 (2H, m, OCH2CH2CH2CH2), 4.14 (1H, dd J=6.1Hz, J=11.3Hz, CHCO2CH3), 4.02-4.10 (1H, m, 
CHCH2Ph (Tyr) and CHCH2Ph(Phe)), 3.63 (3H, s, CHCO2CH3), 3.19 (1H, dd J=6.1Hz, J=12.1Hz, CHCH2Ph 
(Tyr)), 2.96-3.00 (2H, m, CHCH2Ph (Tyr) and CHCH2Ph (Phe)), 2.77 (1H, dd J=12.4, J=12.4Hz, CHCH2Ph 
(Phe)), 2.63 (1H, dd J=12.1Hz, J=12.1Hz, CHCH2Ph (Tyr)), )), 1.70-1.80 (1H, m, OCH2CH2CH2CH2), 1.54-1.62 
(1H, m, OCH2CH2CH2CH2), 1.24-1.39 (4H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2)   
LRMS (ES) 454.2 (MH+). C25H31N3O5 requires 454.2 
 
(7S,10S,13S)-10-Benzyl-13-(4-fluoro-benzenesulfonylamino)-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),15(19),16-triene-7-carboxylic acid methyl ester (5.19) 
N
H
N
H
O
O
O
N
H
CO2Me
Ph
SF
O
O
 
 
Amine 5.18 (0.200g, 0.408 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M3.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
per ether to yield a brown solid, 0.0450g, 18%.  Rf = 0.11 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in (CD3OD) 7.52-7.63 (2H, m, Ar-H (4F-Ph)), 7.26-7.31 (2H, m, Ar-H (4F-Ph)), 7.06-
7.22 (5H, m, Ar-H), 6.85 (2H, d J=8.0Hz, Ar-H (Tyr)), 6.76 (2H, d J=8.0Hz, Ar-H (Tyr)), 4.24-4.44 (2H, m, 
OCH2CH2CH2CH2 and CHCO2CH3) 3.98-4.21 (3H, m, OCH2CH2CH2CH2 and CHCH2Ph (Tyr) and 
CHCH2Ph(Phe)), 3.71 (3H, s, CHCO2CH3), 3.14 (1H, dd J=6.2Hz, J=12.1Hz, CHCH2Ph (Tyr)), 2.94-3.02 (2H, 
m, CHCH2Ph (Tyr) and CHCH2Ph (Phe)), 2.74 (1H, dd J=12.5, J=12.5Hz, CHCH2Ph (Phe)), 2.61 (1H, dd 
J=12.1Hz, J=12.1Hz, CHCH2Ph (Tyr)), 1.71-1.82 (1H, m, OCH2CH2CH2CH2), 1.54-1.66 (1H, m, 
OCH2CH2CH2CH2), 1.20-1.44 (4H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2 and OCH2CH2CH2CH2) 
 
LRMS (ES) 612.2 (MH+). C31H34FN3O7S requires 612.2 
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(6S,9S,12S)-12-Amino-9-isopropyl-8,11-dioxo-2-oxa-7,10-diaza-bicyclo[12.2.2]octadeca-1(17),14(18),15-
triene-6-carboxylic acid methyl ester hydrochloride (5.22) 
HCl.H2N N
H
O
O
O
N
H
CO2Me
 
N-BOC protected compound 4.30 (0.250g, 0.509 mmol) was reacted using General Procedure I1 to afford a 
brown solid, 0.217g, 100% 
 
1H NMR ppm (500 MHz in (CD3)2SO) 8.38 (2H, bs, NH2), 8.13 (1H, d J=7.1Hz, NH Gly), 7.79 (1H, d J=8.7Hz, 
NH Val), 7.16 (2H, d J=8.1Hz, Ar-H), 6.71 (2H, d, J=8.1Hz, Ar-H), 4.29-4.41 (2H, m, OCH2CH2CH2), 4.22-
4.28 (1H, m, CHCO2CH3), 4.06-4.17 (1H, m, CHCH2Ph), 3.80 (1H, dd J=8.2Hz, J=8.7Hz, CHCH(CH3)2), 3.57 
(3H, s, CHCO2CH3), 3.14 (1H, dd J=6.0Hz, J=12.1Hz, CHCH2Ph), 2.57 (1H, dd J=12.1Hz, J=12.1Hz, 
CHCH2Ph), 1.91-2.06 (1H, m, CHCH(CH3)2), 1.78-1.90 (1H, m, OCH2CH2CH2), 1.53-1.74 (2H, m, 
OCH2CH2CH2 and OCH2CH2CH2) 1.21-1.42 (1H, m, OCH2CH2CH2), 0.80 (3H, d J=6.9Hz, CHCH(CH3)2), 0.78 
(3H, d J=6.9Hz, CHCH(CH3)2) 
 
HRMS (ES) 392.2179 (MH+). C20H29N3O5 requires 392.2185 
 
(6S,9S,12S)-12-(4-Fluoro-benzenesulfonylamino)-9-isopropyl-8,11-dioxo-2-oxa-7,10-diazabicyclo[12.2.2]-
octadeca-1(17),14(18),15-triene-6-carboxylic acid methyl ester (5.23) 
N
H
N
H
O
O
O
N
H
CO2MeS
O
O
F
 
Amine 5.22 (0.170g, 0.397 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M3.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
per ether to yield a brown solid, 0.0350g, 16%.  Rf = 0.17 (4/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 7.56-7.64 (2H, m, Ar-H (4-F-Ph)), 7.18-7.35 (2H, m, Ar-H (4-F-Ph)), 6.86 
(2H, d, J=8.2Hz, Ar-H), 6.73 (2H, d J=8.2Hz, Ar-H), 4.16-4.27 (2H, m, OCH2CH2CH2), 4.06-4.18 (1H, m, 
CHCO2CH3), 3.91-4.05 (1H, m, CHCH2Ph), 3.82-3.91 (1H, m, CHCH(CH3)2), 3.70 (3H, s, CHCO2CH3), 2.94-
3.02 (1H, m, CHCH2Ph), 2.91 (1H, dd J=6.9Hz, J=13.1Hz, CHCH2Ph), 1.95-2.06 (1H, m, CHCH(CH3)2), 1.70-
1.84 (1H, m, OCH2CH2CH2), 1.24-1.69 (3H, m, OCH2CH2CH2 and OCH2CH2CH2), 0.87 (3H, d J=6.9Hz, 
CHCH(CH3)2), 0.84 (3H, d J=6.9Hz, CHCH(CH3)2) 
 
HRMS (ES) 550.2198 (MH+). C26H32FN3O7S requires 550.2023 
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4-Fluoro-N-((6S,9S,12S)-6-formyl-9-isopropyl-8,11-dioxo-2-oxa-7,10-diaza-bicyclo-[12.2.2]octadeca-
1(17),14(18),15-trien-12-yl)benzenesulfonamide (5.25) 
N
H
N
H
O
O
O
N
H
S
O
O
F
O
H
 
Methyl ester 5.23 (0.0350g, 0.0637 mmol) was reduced using General Procedure R.  The crude material was 
purified by flash chromatography on silica using EtOAc to yield a brown solid, 0.00180g, 5%.  Rf = 0.34 (1/1 
(EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3OD) 7.68-7.71 (2H, m, Ar-H (4-F-Ph)),, 7.58-7.61 (2H, m, Ar-H (4-F-Ph)), 6.79 
(2H, d J=8.0Hz, Ar-H (Tyr)), 6.48 (2H, d J=8.0Hz, Ar-H (Tyr)), 4.16-4.27 (4H, m, OCH2CH2CH2 and 
CHCO2CH3 and CHCH2Ph), 3.84-3.90 (1H, m, CHCH(CH3)2), 2.86-3.01 (2H, m, CHCH2Ph), 1.63-1.71 (1H, m, 
CHCH(CH3)2), 1.28-1.41 (4H, m, OCH2CH2CH2 and OCH2CH2CH2), 0.93 (3H, d J=7.5Hz, CHCH(CH3)2), 0.90 
(3H, d J=7.5Hz, CHCH(CH3)2) 
 
HRMS (ES) 520.1911 (MH+). C25H30FN3O6S requires 520.1917 
 
(8S,11S,14S)-14-Amino-11-isobutyl-10,13-dioxo-2-oxa-9,12-diazabicyclo[14.2.2]icosa-1(19),16(20),17-
triene-8-carboxylic acid methyl ester hydrochloride (5.26) 
HCl.H2N N
H
O
O
O
N
H
CO2Me
 
N-BOC protected compound 4.42 (0.600g, 1.12 mmol) was reacted using General Procedure I1 to afford an off 
white solid, 0.528g, 100% 
 
1H NMR ppm (500 MHz in CD3OD) 7.04 (2H, d J=8.1Hz, Ar-H), 6.79 (2H, d J=8.1Hz, Ar-H), 4.24-4.27 (1H, 
m, CHCO2CH3), 4.11-4.20 (2H, m, OCH2CH2CH2CH2CH2 and CHCH2CH(CH3)2), 4.07 (1H, dd J=4.7Hz, 
J=10.9Hz, CHCH2Ph), 3.96-4.01 (1H, m, OCH2CH2CH2CH2CH2), 3.64 (3H, s, CHCO2CH3), 3.16 (1H, dd 
J=4.7Hz, J=12.5Hz, CHCH2Ph), 2.81 (1H, dd J=10.9Hz, J=12.5Hz, CHCH2Ph), 1.69-1.79 (2H m, 
OCH2CH2CH2CH2CH2), 1.49-1.61 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.34-1.47 (2H, m, 
OCH2CH2CH2CH2CH2), 1.25-1.33 (4H, m, OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2), 0.90 (3H, d 
J=6.4 Hz, CHCH2CH(CH3)2 ), 0.88 (3H, d J=6.4 Hz, CHCH2CH(CH3)2)  
 
13C NMR ppm (75 MHz in CD3OD) 172.7, 171.5, 166.8, 158.1, 130.0, 125.7, 115.1, 66.4, 54.1, 51.9, 51.4, 51.3, 
42.6, 36.3, 31.1, 27.3, 24.1, 24.0, 23.8, 22.0, 21.6 
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HRMS (ES) 456.2444 (MNa+). C23H35N3O5 requires 456.2474 
 
FTIR (KBr) 3327, 2931, 862, 1743, 1681, 1654, 1541, 1508 
 
(8S,11S,14S)-14-Benzyloxycarbonylamino-11-isobutyl-10,13-dioxo-2-oxa-9,12-diaza-bicyclo[14.2.2]icosa-
1(19),16(20),17-triene-8-carboxylic acid methyl ester (5.27) 
N
H
N
H
O
O
O
N
H
CO2MeO
O
Ph
 
 
Amine 5.26 (0.550g, 1.17 mmol) was reacted with benzyl chloroformate using General Procedure H1.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc/DCM to yield an off-white 
solid, 0.460g, 69%.  Rf = 0.32 (30% EtOAc/DCM).   
 
1H NMR ppm (500 MHz in (CD3)2SO) 8.09 (1H, d J=7.5Hz, NH Leu), 7.42 (1H, d J=6.9Hz, NH Tyr), 7.30-7.36 
(6H, m, NH Gly and Ar-H (CBZ)), 7.02 (2H, d J=8.3Hz, Ar-H Tyr), 6.71 (2H, d J=8.3Hz, Ar-H Tyr), 5.06 (1H, 
d J=12.7 Hz, OCH2Ph), 5.01 (1H, d J=12.7Hz, OCH2Ph), 4.32-4.38 (1H, m, CHCH2Ph), 4.06-4.15 (3H, m, 
CHCO2CH3  and CHCH2CH(CH3)2 and OCH2CH2CH2CH2CH2), 3.98 (1H, td J=5.1Hz, J=10.0Hz, 
OCH2CH2CH2CH2CH2), 3.57 (3H, s, CHCO2CH3), 2.86 (1H, dd J=5.2Hz, J=12.1Hz, CHCH2Ph), 2.68 (1H, dd 
J=12.1Hz, J=12.1Hz, CHCH2Ph), 1.61-1.68 (2H, m, OCH2CH2CH2CH2CH2), 1.54-1.60 (1H, m, 
OCH2CH2CH2CH2CH2), 1.40-1.52 (3H, m, CHCH2CH(CH3)2 and  CHCH2CH(CH3)2), 1.16-1.36 (5H, m, 
OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2), 0.82 (3H, d J=6.5 Hz, 
CHCH2CH(CH3)2), 0.80 (3H, d J=6.5 Hz, CHCH2CH(CH3)2) 
  
HRMS (ES) 568.3051 (MH+). C31H41N3O7 requires 568.3023 
 
(8S,11S,14S)-8-Hydroxymethyl-11-isobutyl-10,13-dioxo-2-oxa-9,12-diaza-bicyclo-[14.2.2]icosa-
1(19),16(20),17-trien-14-yl)carbamic acid benzyl ester (5.28) 
N
H
N
H
O
O
O
N
H
OH
O
O
Ph
 
Methyl ester 5.27 (0.300g, 0.528 mmol) was reduced using General Procedure S to afford a brown solid, 0.206g, 
72% 
mp. 208-210oC 
Experimental for chapter 5  252 
  
 
 
252
1H NMR ppm (500 MHz in CD3OD) 7.57 (1H, d J=9.1Hz, NH Gly), 7.35 (1H, d J=7.3Hz, NH Leu), 7.23-7.32 
(5H, m, Ar-H (CBZ)), 7.20 (1H, d J=6.7Hz, NH Tyr), 6.97 (2H, d J=8.2Hz, Ar-H Tyr), 6.67 (2H, d J=8.2Hz, Ar-
H Tyr), 5.08 (1H, d J=12.2 Hz, OCH2Ph), 5.02 (1H, d J=12.6 Hz, OCH2Ph), 4.21 (1H, dd J=6.7Hz, J=12.0Hz, 
CHCH2Ph), 4.03-4.10 (2H, m, OCH2CH2CH2CH2CH2 and CHCH2CH(CH3)2), 3.90-3.97 (1H, m, 
OCH2CH2CH2CH2CH2), 3.56-3.58 (1H, m, CHCH2OH), 3.28 (2H, d J=5.4Hz, CHCH2OH), 2.87 (1H, dd 
J=5.0Hz, J=12.0Hz, CHCH2Ph), 2.68 (1H, dd J=12.0Hz, J=12.0Hz, CHCH2Ph), 1.57-1.70 (2H, m, 
OCH2CH2CH2CH2CH2), 1.32-1.47 (4H, m, OCH2CH2CH2CH2CH2 and CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 1.14 (5H, m, OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2 and 
OCH2CH2CH2CH2CH2), 0.76 (6H, d J=6.6Hz, CHCH2CH(CH3)2) 
 
HRMS (ES) 540.3061 (MH+). C30H41N3O6 requires 540.3073 
 
Microanalysis. C, 65.76; H, 7.33; N, 7.29.  C30H41N3O6.½H2O requires C, 65.67; H, 7.72; N, 7.66 
 
(8S,11S,14S)-8-Formyl-11-isobutyl-10,13-dioxo-2-oxa-9,12-diaza-bicyclo[14.2.2]icosa-1(19),16(20),17-trien-
14-yl)-carbamic acid benzyl ester (5.29) 
N
H
N
H
O
O
O
N
H
H
O
O
O
Ph
 
Alcohol 5.28 (0.300g, 0.554 mmol) was oxidised using General Procedure L to afford an off white solid, 0.269g, 
90%.   
m.p 238-241oC 
 
1H NMR ppm (500 MHz in CDCl3) 9.49 (1H, s, CHO), 7.31-7.39 (5H, m, Ar-H (CBZ)), 7.07 (2H, d J=7.9Hz, 
Ar-H (Tyr)), 6.76 (2H, d J=7.9Hz, Ar-H (Tyr)), 6.23 (1H, d J=7.5Hz, NH Leu), 6.09 (1H, d J=6.8Hz, NH Gly), 
5.64 (1H, d J=8.8Hz, NH Tyr), 5.12 (2H, s, OCH2Ph), 4.39 (1H, ddd J=5.4Hz, J=6.8Hz, J=7.4Hz, CHCHO), 
4.26-4.36 (1H, m, CHCH2Ph), 4.07-4.22 (1H, m, OCH2CH2CH2CH2CH2), 4.03 (1H, ddd J=5.1Hz, J=7.5Hz, 
J=10.2Hz, CHCH2CH(CH3)2), 3.09 (1H, dd J=4.9Hz, J=12.6, CHCH2Ph), 2.77 (1H, dd J=11.2Hz, J=12.6Hz, 
CHCH2Ph), 1.70-1.82 (3H, m, OCH2CH2CH2CH2CH2 and CHCH2CH(CH3)2), 1.39-1.62 (3H, m, 
OCH2CH2CH2CH2CH2 and CHCH2CH(CH3)2), 1.14 (5H, m, OCH2CH2CH2CH2CH2 and OCH2CH2CH2CH2CH2 
and OCH2CH2CH2CH2CH2), 0.88 (3H, d J=5.4Hz, CHCH2CH(CH3)2), 0.86 (3H, d J=5.4Hz, CHCH2CH(CH3)2) 
 
HRMS (ES) 538.2918 (MH+). C30H39N3O6 requires 538.2917 
 
Microanalysis. C, 64.10; H, 7.22; N, 7.17.  C30H39N3O6.1½H2O requires C, 63.81; H, 7.22; N, 7.44 
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(E)-(7S,10S,13S)-13-Amino-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-[13.2.2]nonadeca-
1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (5.34) 
HCl.H2N N
H
O
O
O
N
H
CO2Me
 
 
N-BOC protected compound 4.16 (0.900g, 1.79 mmol) was reacted using General Procedure I1 to afford an off 
white solid, 0.815g, 100% 
 
1H NMR ppm (500 MHz in CD3OD) 8.29 (1H, d J=9.0Hz, NH Gly), 7.58 (1H, d J=7.4Hz, NH Val), 7.00 (2H, d 
J=8.4Hz, Ar-H), 6.73 (2H, d J=8.4Hz, Ar-H), 5.64 (1H, td J=4.0Hz, J=7.5Hz, OCH2CHCHCH2), 5.50-5.56 (1H, 
m, OCH2CHCHCH2), 4.61-4.64 (2H, m, OCH2CHCHCH2), 4.53 (1H, ddd, J=3.0Hz, J=9.0Hz, J=12.2Hz, 
CHCO2CH3), 4.12 (1H, dd J=5.8Hz, J=10.4Hz, CHCH2Ph), 3.93-3.96 (1H, m, CHCH(CH3)2), 3.66 (3H, s, 
CO2CH3), 3.14 (1H, dd J=5.8Hz, J=13.0Hz, CHCH2Ph), 2.82 (1H, dd J=10.4Hz, J=13.0Hz, CHCH2Ph), 2.61-
2.68 (1H, m, OCH2CHCHCH2), 2.27 (1H, ddd J=7.9Hz, J=12.2Hz, J=15.0Hz, OCH2CHCHCH2), 1.96-2.07 (1H, 
m, CHCH(CH3)2), 0.91 (3H, d J=6.9 Hz, CHCH(CH3)2), 0.86 (3H, d J=6.9Hz, CHCH(CH3)2) 
  
HRMS (ES) 404.2192 (MH+). C21H29N3O5 requires 404.2185 
 
(E)-(7S,10S,13S)-13-(4-Fluorobenzenesulfonylamino)-10-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (5.35) 
 
N
H
N
H
O
O
O
N
H
CO2MeSF
O
O
 
Amine 5.34 (0.810g, 1.78 mmol) was reacted with 4-fluorobenzene sulfonyl chloride using General Procedure 
M3.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
per ether to yield a brown solid, 0.329g, 33%.  Rf = 0.23 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CD3(SO)) 8.10-8.13 (2H, m, NH Tyr and NH Gly), 7.93-7.97 (2H, m, Ar-H (4-F-
Ph)), 7.50 (1H, d J=8.5Hz, NH Val), 7.35-7.40 (2H, m, Ar-H (4-F-Ph)), 6.90 (2H, d J=8.2Hz, Ar-H (Tyr)), 6.62 
(2H, d J=8.2Hz, Ar-H (Tyr)) , 5.54-5.59 (1H, m, OCH2CHCHCH2), 5.40-5.46 (1H, m, OCH2CHCHCH2), 4.55-
4.64 (2H, m, OCH2CHCHCH2), 4.31-4.36 (2H, m, CHCO2CH3 and CHCH2Ph), 3.75 (1H, dd J=6.0Hz, J=8.5Hz, 
CHCH(CH3)2), 3.58 (3H, s, CO2CH3), 2.61-2.67 (2H, m, CHCH2Ph), 2.46 (1H, ddd J=4.0Hz, J=5.2Hz, J=6.5Hz, 
OCH2CHCHCH2), 2.15-2.22 (1H, m, OCH2CHCHCH2), 1.52 (1H, m, CHCH(CH3)2), 0.61 (3H, d J=6.9 Hz, 
CHCH(CH3)2), 0.57 (3H, d J=6.9Hz, CHCH(CH3)2) 
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HRMS (ES) 562.2011 (MH+). C27H32FN3O7S requires 562.2023 
 
4-Fluoro-N-((E)-(7S,10S,13S)-7-formyl-10-isopropyl-9,12-dioxo-2-oxa-8,11-diaza-bicyclo[13.2.2]nonadeca-
1(18),4,15(19),16-tetraen-13-yl)benzenesulfonamide (5.36) 
 
N
H
N
H
O
O
O
N
H
SF
O
O
H
O
 
Methyl ester 5.35 (0.0469g, 0.0835 mmol) was reduced using General Procedure R.  The crude material was 
purified by flash chromatography on silica using EtOAc to yield a brown solid, 0.00800g, 18%.  Rf = 0.66 
(EtOAc) 
 
1H NMR ppm (500 MHz in (CD3)2SO)   9.36 (1H, s, CHO), 8.12 (1H, d J=8.6Hz, NH), 7.90-8.00 (2H, m, Ar-H 
(4-F-Ph)),7.56 (1H, d J=8.9Hz, NH), 7.50 (1H, d J=7.4Hz, NH), 7.34-7.42 (1H, m, Ar-H (4-F-Ph)), 6.90 (2H, d 
J=8.4Hz, Ar-H (Tyr)), 6.62 (2H, d J=8.4Hz, Ar-H (Tyr)), 5.53-5.57 (1H, m, OCH2CHCHCH2), 5.42-5.48 (1H, 
m, OCH2CHCHCH2), 4.53-4.67 (2H, m, OCH2CHCHCH2), 4.23-4.41 (2H, m, CHCO2CH3 and CHCH2Ph), 
3.69-3.82 (1H, m, CHCH(CH3)2), 2.63-2.84 (2H, m, CHCH2Ph), 2.26-2.31 (1H, m, OCH2CHCHCH2), 2.15-2.19 
(1H, m, OCH2CHCHCH2), 1.52-1.61 (1H, m, CHCH(CH3)2), 0.64 (3H, d J=7.1Hz, CHCH(CH3)2), 0.57 (3H, d 
J=7.1Hz, CHCH(CH3)2) 
 
HRMS (ES) 564.2172 (MH+ (hemi-acetal). C27H34FN3O7S requires 564.2180 
 
(9R,12S,15S)-15-Amino-12-isopropyl-11,14-dioxo-2-oxa-7-thia-10,13-diaza-bicyclo-[15.2.2]-henicosa-
1(20),17(21),18-triene-9-carboxylic acid methyl ester hydrochloride (5.42) 
HCl.H2N N
H
O
O
O
N
H
S
CO2Me
 
N-BOC protected compound 4.67 (0.300g, 0.544 mmol) was reacted using General Procedure I1 to afford an off 
white solid, 0.265g, 100% 
 
1H NMR ppm (500 MHz in (CD3)2SO) 8.66 (2H, bs, NH2), 8.54 (1H, d J=7.3Hz, NH), 8.18 (1H, d J=8.9Hz, 
NH), 6.98 (2H, d J=8.3Hz, Ar-H), 6.78 (2H, d J=8.3Hz, Ar-H), 4.38-4.42 (1H, m, CHCO2CH3), 4.02-4.28 (4H, 
m, CHCH2Ph and OCH2CH2CH2CH2S and OCH2CH2CH2CH2S), 3.89-3.95 (1H, m, CHCH(CH3)2), 3.84-3.88 
(1H, m, OCH2CH2CH2CH2S), 3.55 (3H, s, CHCO2CH3), 3.06-3.14 (2H, m, CHCH2Ph), 2.71-2.90 (2H,  m, 
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CHCH2S), 1.93-1.98 (1H, m, CHCH(CH3)2), 1.60-1.75 (4H, m, OCH2CH2CH2CH2S and OCH2CH2CH2CH2S), 
0.88 (3H, d J=7.1Hz, CHCH(CH3)2), 0.87 (3H, d J=7.1Hz, CHCH(CH3)2) 
 
LRMS (ES) 452.3 (MH+). C22H33N3O5 requires 452.2 
 
(9R,12S,15S)-15-Benzyloxycarbonylamino-12-isopropyl-11,14-dioxo-2-oxa-7-thia-10,13-diazabicyclo-
[15.2.2]henicosa-1(20),17(21),18-triene-9-carboxylic acid methyl ester (5.45) 
N
H
N
H
O
O
O
N
H
S
CO2MeO
O
Ph
 
Amine 5.42 (0.200g, 0.410 mmol) was reacted with benzyl chloroformate using General Procedure H1.  The 
crude material was purified by flash chromatography on silica using a gradient of EtOAc/DCM to yield an off-
white solid, 0.0430g, 18%.  Rf = 0.44 (30% EtOAc/DCM).   
 
1H NMR ppm (500 MHz in (CD3OD) ) (Compound exists as a mixture of rotamers) 7.17-7.50 (5H, m, Ar-H 
(CBZ)), 6.94-7.18 (2H, m, Ar-H (Tyr)), 6.62-6.84 (2H, m, Ar-H (Tyr)), 5.02 (1H, d J=10.6Hz, OCH2Ph), 4.98 
(1H, d J=10.6Hz, OCH2Ph), 4.32-4.49 (1H, m, CHCO2CH3), 4.14-4.33 (5H, m, CHCH2Ph and 
OCH2CH2CH2CH2S and OCH2CH2CH2CH2S), 3.80-3.94 (1H, m, CHCH(CH3)2), 3.70 (3H, s, CHCO2CH3), 
2.88-3.12 (2H, m, CHCH2Ph), 2.65-2.90 (2H,  m, CHCH2S), 2.02-2.10 (1H, m, CHCH(CH3)2), 1.55-1.65 (4H, 
m, OCH2CH2CH2CH2S and OCH2CH2CH2CH2S), 0.86-0.91 (6H, m, CHCH(CH3)2),  
 
HRMS (ES) 586.2566 (MH+). C30H39N3O7S requires 586.2587 
 
(9R,12S,15S)-9-Formyl-12-isopropyl-11,14-dioxo-2-oxa-7-thia-10,13-diaza-bicyclo-[15.2.2]henicosa-
1(20),17(21),18-trien-15-yl)-carbamic acid benzyl ester (5.46) 
N
H
N
H
O
O
O
N
H
S
H
O
O
O
Ph
 
Methyl ester 5.45 (0.0430g, 0.0734 mmol) was reduced using General Procedure R.  The crude material was 
purified by flash chromatography on silica using EtOAc to yield a brown solid, 0.00660g, 17%.  Rf = 0.51 
(EtOAc) 
 
1H NMR ppm (500 MHz in (CD3)2SO) 9.39  (1H, s, CHO), 7.70 (1 H, d J=9.1Hz, NH Cys), 7.66 (1H, d 
J=8.1Hz, NH Val), 7.12-7.43 (5H, m, Ar-H (CBZ)), 7.05 (2H, d J=7.8Hz, Ar-H (Tyr)), 6.78 (2H, d J=7.8Hz, Ar-
H (Tyr)), 6.62 (1H, d J=8.3Hz, NH), 5.03 (2H, s, OCH2Ph), 4.20-4.32 (3H, m, CHCO2CH3 and 
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OCH2CH2CH2CH2S), 4.05-4.15 (3H, m, CHCH2Ph and OCH2CH2CH2CH2S), 3.85 (1H, dd J=6.5Hz, J=8.1Hz, 
CHCH(CH3)2), 2.78-2.90 (2H, m, CHCH2Ph), 2.54-2.70 (2H,  m, CHCH2S), 1.94-2.00 (1H, m, CHCH(CH3)2), 
1.21-1.71 (4H, m, OCH2CH2CH2CH2S and OCH2CH2CH2CH2S), 0.82-0.88 (6H, m, CHCH(CH3)2),  
 
HRMS (ES) 586.2480 (MH+). C29H37N3O6S requires 556.2481 
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(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-aminopropionylamino]-4-methylpentanoic acid methyl ester hydrogen 
chloride salt (6.1) 
HCl.H2N
O
N
H
O
CO2Me
 
N-BOC protected compound 4.45 (4.00g, 8.92mmol) was reacted using General Procedure I1 to afford a white 
solid, 3.43g, 100%.  
 
1H NMR ppm (500 MHz in CDCl3) 8.28 (2H, bs,NH2),  7.67 (1H, d, J=6.4Hz NH Leu), 7.27 (2H, d J=8.4Hz, 
Ar-H), 6.82 (2H, d J=8.4Hz, Ar-H), 6.00 (1H, tdd J=5.2Hz, J=5.2Hz, J=10.3Hz, J=16.9Hz, CH2CHCH2), 5.22-
5.40 (2H, m, CH2CHCH2), 4.57-4.64 (1H, m, CHCH2Ph), 4.44 (2H, d J=5.2Hz, OCH2CHCH2), 4.28-4.37 (1H, 
m, CHCH2CH(CH3)2), 3.63 (3H, s, CO2CH3), 3.36 (1H, dd J=4.3Hz, J=13.9Hz, CHCH2Ph), 3.20 (1H, dd 
J=8.2Hz, J=13.9Hz, CHCH2Ph), 1.53-1.63 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.83 (3H, d J=6.7 
Hz, CHCH2CH(CH3)2 ), 0.82 (3H, d J=6.7Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 172.4, 168.2, 157.9,  133.1, 131.0, 126.2, 117.5, 114.9, 68.6, 67.0, 54.6, 
52.2, 51.4, 40.1, 36.2, 24.5, 22.5, 21.9. 
 
LRMS (ES) 349.2 (MH+). C19H28N2O6 requires 349.2 
 
(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-(4-fluorobenzenesulfonylamino)-propionylamino]-4-methylpentanoic 
acid methyl ester (6.2) 
N
H
O
SF
O
O
N
H
O
CO2Me
 
Amine 6.1 (3.50g, 9.10 mmol) was reacted with 4-fluoro-benzene sulfonyl chloride using General Procedure M2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a white solid, 2.70g, 65%.  Rf = 0.81 (1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.68-7.71 (2H, m, Ar-H (4-F-Ph)), 7.06-7.11 (2H, m, Ar-H (4-F-Ph)), 6.91 
(2H, d J=8.6Hz, Ar-H (Tyr)), 6.73 (2H, d J=8.6Hz, Ar-H (Tyr)), 6.42 (1H, d J=8.2Hz, NH Leu), 6.05 (1H, tdd 
J=5.3Hz, J=5.3Hz, J=10.5Hz, J=17.2Hz, CH2CHCH2) 5.27-5.44 (2H, m, CH2CHCH2), 4.46-4.51 (3H, m, 
OCH2CHCH2, and CHCH2CH(CH3)2), 3.84-3.88 (1H, m, CHCH2Ph), 3.71 (3H, s, CO2CH3), 2.94 (1H, dd 
J=7.2Hz, J=14.4Hz,  CHCH2Ph), 2.90 (1H, dd J=6.4Hz, J=14.4Hz, CHCH2Ph) 1.52-1.58 (1H, m, 
CHCH2CH(CH3)2) 1.38-1.47 (2H, m, CHCH2CH(CH3)2) 0.88 (6H, d, J=6.2Hz, CHCH2CH(CH3)2) 
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13C NMR ppm (75 MHz in CDCl3). 172.5, 169.6, 157.9, 133.0, 130.2, 129.9, 129.8, 127.0, 117.8, 116.4, 116.1, 
115.0, 68.7, 57.8, 52.3, 50.9, 41.4, 37.8, 24.6, 22.6, 21.8. 
 
LRMS (ES) 507.3 (MH+). C25H31FN2O6S requires 507.2. 
 
(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-(4-fluorobenzenesulfonylamino)propionylamino]-4-methylpentanoic acid 
(6.3) 
N
H
O
SF
O
O
N
H
O
CO2H
 
Dipeptide 6.2 (2.70g, 5.33 mmol) was dissolved in THF (30 mL) and hydrolysed using General Procedure C1 to 
afford a white solid, 2.50g, 95%. 
 
1H NMR ppm (500 MHz in CD3OD) 8.27 (1H, d,  J=8.0Hz, NH Leu), 7.60-7.63 (2H, m, Ar-H (4-F-Ph)), 7.04-
7.08 (2H, m, Ar-H (4-F-Ph)) 7.02 (2H, d J=8.5Hz, Ar-H Tyr) 6.71 (2H, d J=8.5Hz Ar-H Tyr) 6.04 (1H, tdd 
J=5.2Hz, J=5.2Hz, J=10.5Hz, J=17.3Hz, OCH2CHCH2) 5.20-5.40 (2H, m, OCH2CHCH2), 4.49 (2H, d, J=5.2Hz, 
OCH2CHCH2), 4.22-4.27 (1H, m, CHCH2CH(CH3)2), 3.99 (1H, dd, J=4.5Hz, J=9.5Hz, CHCH2Ph), 2.96 (1H, 
dd, J=4.5Hz, J=14.0Hz, CHCH2Ph), 2.65 (1H, dd, J=9.5Hz, J=14.0Hz, CHCH2Ph), 1.45-1.56 (3H, m, 
CHCH2CH(CH3)2and CHCH2CH(CH3)2), 0.90 (3H, d J=5.8 Hz, CHCH2CH(CH3)2), 0.84 (3H, d J=5.8 Hz, 
CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3). 174.2, 172.0, 166.4, 157.6, 137.0, 133.7, 130.8, 130.1, 129.6, 129.4, 128.7, 
116.1, 115.7, 115.4, 114.1, 68.4, 58.0, 50.6, 40.4, 37.9, 24.5, 22.0, 20.6. 
 
LRMS (ES) 493.2 (MH+). C24H29FN2O6S requires 493.2 
 
(S)-2-{(S)-2-[(S)-3-(4-Allyloxyphenyl)-2-(4-fluorobenzenesulfonylamino)propionylamino]-4-methyl-
pentanoylamino}pent-4-enoic acid methyl ester (6.4) 
N
H
O
SF
O
O
N
H
O
O
N
H
CO2Me
 
Carboxylic acid 6.3 (2.50g, 5.08 mmol) was reacted with amine 4.14 using General Procedure A2.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a white solid, 2.70g, 89%.  Rf = 0.38 (1/1 (EtOAc / (50/70) Pet ether)). 
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1H NMR ppm (500 MHz in CD3OD) 7.61-7.65 (2H, m, Ar-H (4-F-Ph)), 7.06-7.10 (2H, m, Ar-H (4-F-Ph), 6.97 
(2H, d J=8.5Hz, Ar-H Tyr), 6.69 (2H, d J=8.5Hz, Ar-H Tyr), 6.05 (1H, tdd J=5.2Hz, J=5.2Hz, J=10.5Hz, 
J=17.3Hz, OCH2CHCH2), 5.78 (1H, tdd J=7.1Hz, J=10.2Hz, J=17.1Hz, CHCH2CHCH2), 5.04-5.42 (4H, m, 
OCH2CHCH2 and CHCH2CHCH2), 4.48 (2H, d J=5.2Hz, OCH2CHCH2), 4.42 (1H, dd J=5.6Hz, J=8.0Hz, 
CHCO2CH3), 4.32 (1H, dd J=5.0Hz, J=9.4Hz, CHCH2CH(CH3)2), 3.95 (1H, dd J=4.7Hz, J=9.5Hz, CHCH2Ph), 
3.69 (3H, s, CO2CH3), 2.93 (1H, dd J=4.7Hz, J=14.0Hz, CHCH2Ph), 2.63 (1H, dd J=9.5Hz, J=14.0Hz, 
CHCH2Ph), 2.41-2.57 (2H, m, CHCH2CHCH2), 1.50-1.57 (2H, m, CHCH2CH(CH3)2), 1.44-1.48 (1H, m, 
CHCH2CH(CH3)2), 0.92 (3H, d J=6.0Hz, CHCH2CH(CH3)2), 0.87 (3H, d J=6.0Hz, CHCH2CH(CH3)2) 
 
13C NMR ppm (75 MHz in CDCl3) 171.7, 171.5, 170.4, 167.3, 163.7, 157.7, 134.4, 134.3, 133.0, 132.3, 130.2, 
129.9, 129.8, 127.2, 118.9, 117.7, 116.3, 116.0, 114.8, 68.6, 58.4, 52.2, 51.9, 51.9, 41.0, 37.5, 36.1, 24.6, 22.8, 
21.9 
 
LRMS (ES) 604.3 (MH+). C30H38FN3O7S requires 604.2 
 
(E/Z)-(7S,10S,13S)-13-(4-Fluorobenzenesulfonylamino)-10-isobutyl-9,12-dioxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),4,15(19),16-tetraene-7-carboxylic acid methyl ester (6.5) 
N
H
N
H
O
O
O
N
H
CO2MeSF
O
O
 
Diene 6.4 (1.18g, 1.95 mmol) was reacted with Grubbs second generation catalyst using General Procedure E2.  
The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet 
ether to yield a brown solid, 0.700g, 63%.  A 1:6.8 ratio of geometric isomers was obtained.  Rf = 0.17 and 0.18 
(1/1 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm for major isomer from mixture (500 MHz in (CD3)2SO) 8.18 (1H, d J=7.6Hz, NH Tyr), 8.08 (1H, 
d J=8.3Hz, NH Gly), 7.88-7.93 (2H, m, Ar-H (4-F-Ph)), 7.58 (1H, d J=7.5Hz, NH Leu), 7.32-7.38 (2H, m, Ar-H 
(4-F-Ph)), 6.90 (2H, d J=7.7Hz, Ar-H (Tyr)), 6.64 (2H, d J=7.7Hz, Ar-H (Tyr)), 5.52-5.56 (1H, m, 
OCH2CHCHCH2), 5.39-5.46 (1H, m, OCH2CHCHCH2), 4.53-4.67 (2H, m, OCH2CHCHCH2), 4.20-4.30 (2H, 
m, CHCH2Ph and CHCO2CH3), 3.78-3.85 (1H, m, CHCH2CH(CH3)2), 3.54 (3H, s, CO2CH3), 2.58-2.72 (2H, m, 
CHCH2Ph), 2.14-2.25 (2H, m, OCH2CHCHCH2), 1.15-1.25 (2H, m, CHCH2CH(CH3)2), 0.99-1.05 (1H, m, 
CHCH2CH(CH3)2), 0.75 (3H, d J=6.8Hz, CHCH2CH(CH3)2), 0.70 (3H, d J=6.8Hz, CHCH2CH(CH3)2) 
 
Selected 1H NMR ppm for minor isomer from mixture: 7.15-7.22 (2H, m, Ar-H (4-F-Ph)), 7.02-7.06 (2H, m, Ar-
H (Tyr)), 0.73 (3H, d J=6.8Hz, CHCH2CH(CH3)2), 0.69 (3H, d J=6.8Hz, CHCH2CH(CH3)2) 
 
HRMS (ES)  576.2191 (MH+). C28H34FN3O7S requires 576.2180  
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 N-((R)-1-Allylcarbamoyl-1-benzylbut-3-enyl)-benzamide (7.6) 
N
H
O
Ph
Ph
O
N
H
 
Allyl amine (0.283 mL, 3.78 mmol) was dissolved in anhydrous THF (10 mL) under an atmosphere of argon.  
The mixture was cooled to -78oC, nBuLi (1 equiv) was added and stirred at -78oC for five min.  A solution of 
oxazolidinone 7.12 (0.33 equiv) in anhydrous THF (10 mL) was added and stirring continued at -78oC for one h 
and then at rt for a further seventeen h.  The reaction was quenched with saturated NH4Cl(aq) (2 mL) and 
concentrated in vacuo.  The residue was partitioned between EtOAc and saturated NaHCO3(aq).  The organic 
phase was washed with saturated NH4Cl(aq) and brine before being dried (MgSO4), filtered and concentrated in 
vacuo.  The crude material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) 
pet ether to yield a white solid, 0.296g, 91%.  Rf = 0.17 (1/9 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.67 (2H, dd J=3.3Hz, J=5.2Hz, Ar-H), 7.46-7.50 (1H, m, Ar-H), 7.37-7.42 
(2H, m, Ar-H), 7.19-7.21 (3H, m, Ar-H), 7.13 (2H, dd J=2.8Hz, J=6.7Hz, Ar-H), 6.92 (1H, dd J=6.2Hz, 
J=11.2Hz, NHCH2CHCH2), 5.83 (1H, tdd J=5.8Hz, J=5.8Hz, J=10.3Hz, J=17.1Hz, NHCH2CHCH2), 5.68-5.77 
(1H, m, CH2CHCH2), 5.11-5.23 (4H, m, NHCH2CHCH2 and  NHCH2CHCH2), 3.96 (1H, ddd J=5.8Hz, J=5.8Hz, 
J=15.4Hz, NHCH2CHCH2), 3.89 (1H, ddd J=5.7Hz, J=5.7Hz, J=15.5Hz, NHCH2CHCH2), 3.75 (1H, d 
J=13.9Hz, CH2Ph), 3.37 (1H, d J=13.8Hz, CH2Ph), 3.34 (1H, dd J=7.9Hz, J=14.4Hz, CH2CHCH2), 2.79 (1H, dd 
J=6.5Hz, J=14.3Hz, CH2CHCH2) 
  
LRMS (ES) 349.2 (MH+). C22H24N2O2 requires 349.2  
 
(2R,4S)-3-Benzoyl-4-benzyl-2-phenyloxazolidin-5-one (7.9) Lit1 
 
N
O
O
Ph
Ph
O
Ph
 
 
(L)-phenylalanine (10.0g, 60.5 mmol) was suspended in 1M NaOH(aq) (1 equiv).  This was stirred at rt for ten 
min and then the resultant colourless solution was concentrated in vacuo.  The residue was suspended in DCM 
(400 mL), and benzaldehyde (1.5 equiv) added.  This was refluxed for eighteen h during which time water was 
removed azetropically using Dean-Stark apparatus.  The reaction mixture was cooled in ice and benzoyl chloride 
(1 equiv) was added.  This was stirred in ice for four h and then at rt for a further twelve h.  This was partitioned 
with 5% NaHCO3(aq) and the organic phase was washed sequentially with 5% KHSO4(aq), water and brine before 
being dried (MgSO4), filtered and concentrated in vacuo.  The residue was recrystallised from hot methanol to 
afford a white solid, 12.8g, 59% 
 
mp 181-183oc. 
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1H NMR ppm (500 MHz in CDCl3) 7.04-7.38 (15H, m, Ar-H), 5.80 (1H, s, CHPh), 5.21 (1H, bs, CHCH2Ph), 
3.77 (1H, bs, CHCH2Ph), 3.41 (1H, bs, CHCH2Ph) 
 
13C NMR ppm (75 MHz in CDCl3).  171.0, 169.2, 136.2, 135.2, 130.8, 129.8, 128.7, 128.5, 127.7, 126.7, 91.2, 
57.6, 34.9 
 
LRMS (ES) 358.1 (MH+). C23H19NO3 requires 358.1  
 
(2R,4R)-4-Allyl-3-benzoyl-4-benzyl-2-phenyloxazolidin-5-one (7.10) Lit1 
N
O
O
Ph
O
Ph
Ph
 
 
Oxazolidinone 7.9 (1.00g, 2.80 mmol) was dissolved in anhydrous THF (20 mL) under an atmosphere of argon.  
The mixture was cooled to -78oC, a solution of 1M lithium bis(trimethylsilyl)amide in THF (1.1 equiv) added 
and stirring continued at -78oC for three min before allyl bromide (1.5 equiv) was added.  The mixture was 
stirred at -78oC for a further two h and then at rt for a further sixteen h before being concentrated in vacuo.  The 
residue was partitioned between EtOAc and saturated NaHCO3(aq).  The organic phase was washed with saturated 
NH4Cl(aq) and brine before being dried (MgSO4), filtered and concentrated in vacuo to afford a yellow solid, 
1.03g, 93% 
mp 140-142oc. 
 
1H NMR ppm (500 MHz in CDCl3) 7.37-7.46 (5H, m, Ar-H), 7.14 (1H, dd J=0.9Hz, J=7.5Hz, Ar-H), 7.00-7.08 
(2H, m, Ar-H), 6.92-6.99 (1H, m, Ar-H), 6.78 (2H, dd J=0.9Hz, J=7.2Hz, Ar-H), 6.65-6.72 (2H, m, Ar-H), 6.04 
(1H, s, CHPh), 5.91-6.02 (1H, m, CH2CHCH2), 5.46-5.59 (4H, m, CH2CHCH2 and Ar-H),  4.10 (1H, d J=13.5 
Hz, CH2Ph), 3.61 (1H, dd J=9.8Hz, J=13.8Hz, CH2CHCH2), 3.46 (1H, d J=13.4 Hz, CH2Ph), 2.83 (1H, dd 
J=5.2Hz, J=13.7Hz, CH2CHCH2) 
  
13C NMR ppm (75 MHz in CDCl3). 173.1, 169.8, 136.6, 136.3, 135.0, 131.2, 130.8, 129.1, 129.0, 128.2, 127.7, 
127.6, 127.4, 125.2, 122.1, 91.0, 70.0, 41.6, 39.7 
 
LRMS (ES) 398.2 (MH+). C26H23NO3 requires 398.2  
 
(R)-2-Benzoylamino-2-benzyl-pent-4-enoic acid (7.11) 
N
H
O
Ph
Ph
CO2H
 
Oxazolidinone 7.10 (0.900g, 2.26 mmol) was dissolved in a 4:1 methanol/water mixture (25 mL) a and sodium 
hydroxide (2 equiv) was added.  The mixture was refluxed for two h and then concentrated in vacuo.  The 
residue was partitioned between EtOAc and 1M HCl(aq).  The aqueous phase was extracted twice more with 
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EtOAc.  The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in-
vacuo to afford a white solid, 0.496g, 100% 
 
1H NMR ppm (500 MHz in CDCl3) 7.68 (2H, dd J=3.0Hz, J=10.6Hz, Ar-H), 7.40-7.53 (3H, m, Ar-H), 7.18-7.27 
(5H, m, Ar-H), 5.66 (1H, tdd J=7.4Hz, J=7.4Hz, J=10.0Hz, J=14.6Hz, CH2CHCH2), 5.04-5.21 (2H, m, 
CH2CHCH2), 3.86 (1H, d J=12.1Hz, CH2Ph), 3.43 (1H, dd J=7.6Hz, J=13.1Hz, CH2CHCH2), 3.35 (1H, d 
J=13.0Hz,  CH2Ph), 2.81 (1H, dd J=8.3Hz, J=13.5Hz, CH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3). 176.8 , 154.4, 136.5, 135.7 , 131.7 , 129.8, 128.4, 128.2, 128.1, 126.9, 119.5, 
66.4, 64.8, 40.4, 39.8  
  
LRMS (ES) 310.2 (MH+). C19H19NO3 requires 310.1  
 
(R)-4-Allyl-4-benzyl-2-phenyl-4H-oxazol-5-one (7.12) 
N
O
O
Ph
Ph
 
Carboxylic acid 7.11 (0.115g, 0.372 mmol) was dissolved in anhydrous DCM under an atmosphere of argon.  
The mixture was cooled to -20oC, anhydrous pyridine (1 equiv) and cyanuric fluoride (5 equiv) were added.  The 
mixture was stirred at -20oC for one h and at rt for a further seventeen h.  The resultant white precipitate was 
removed by suction filtration.  The residue was washed with DCM and the filtrate was partitioned with water.  
The organic phase was dried (MgSO4), filtered and concentrated in vacuo to afford a yellow oil, 0.108g, 100% 
 
1H NMR ppm (500 MHz in CDCl3) 7.84 (2H, dd J=1.4Hz, J=7.6Hz, Ar-H), 7.50-7.55 (1H, m, Ar-H), 7.44-7.49 
(2H, m, Ar-H), 7.17-7.19 (5H, m, Ar-H), 5.69-5.79 (1H, m, CH2CHCH2), 5.15-5.30 (2H, m, CH2CHCH2), 3.31 
(1H, d J=13.5Hz, CH2Ph), 3.23 (1H, d J=13.5Hz, CH2Ph), 2.78 (1H, dd J=6.9Hz, J=13.7Hz, CH2CHCH2), 2.72 
(1H, dd J=8.0Hz, J=13.5Hz, CH2CHCH2) 
 
LRMS (ES) 292.1332 (MH+). C19H17NO2 requires 292.1337  
 
Allylamino-acetic acid ethyl ester hydrochloride (7.13) Lit2 
HCl.HN CO2Et  
Allyl amine (3.72 mL, 49.6 mmol) was dissolved in anhydrous THF (105 mL).  The mixture was cooled in ice 
and a solution of ethyl bromoacetate (0.5 equiv) in THF (40 mL) was added dropwise over forty five min.  
Stirred was continued in ice for one h and then at rt for a further ninety min.  The reaction mixture was 
concentrated in vacuo and the residue suspended in diethyl ether (75 mL).  This was stirred at rt for ten min and 
then filtered under vacuum.  The filtrate was concentrated in vacuo to afford a yellow oil, 2.59g, 73%. 
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1H NMR ppm (300 MHz in CDCl3) 5.85 (tdd J=6.1HZ, J=6.1Hz, J=10.2, J=17.2Hz, CH2CHCH2), 5.07-5.22 
(2H, m, CH2CHCH2), 4.18 (2H, q J=7.2Hz, CO2CH2CH3), 3.38 (2H, s, CH2CO2Et), 3.26 (1H, dd J=1.4Hz, 
J=1.4Hz, CH2CHCH2), 3.24 (1H, dd J=1.3Hz, J=1.3Hz, CH2CHCH2), 1.26 (3H, t J=7.2Hz, CO2CH2CH3) 
 
LRMS (ES) 144.1 (MH+). C7H13NO2 requires 144.1  
 
N-((R)-3-Benzyl-2-oxo-1,2,3,4-tetrahydro-pyridin-3-yl)benzamide (7.14) 
NH
N
H
O
Ph
O
Ph
 
Diene 7.6 (0.0480g, 0.138 mmol) was dissolved in benzene (10 mL), TFA (1 mL) and Grubbs second generation 
catalyst (0.1 equiv) were added.  The mixture was refluxed for eighteen h and then concentrated in-vacuo.  The 
crude material was purified by flash chromatography on silica using a gradient of methanol and DCM to yield a 
brown solid, 0.0141g, 32%.  Rf = 0.09 (2% MeOH/DCM). 
 
1H NMR ppm (500 MHz in CDCl3) 7.63 (2H, d J=7.1Hz, Ar-H), 7.32-7.45 (3H, m, Ar-H), 7.15-7.18 (3H, m, Ar-
H), 7.09-7.11 (2H, m, Ar-H), 5.62-5.73 (2H, m, NHCHCHCH2 and NHCHCHCH2), 5.11 (1H, d J=8.0Hz, 
NHCHCHCH2), 4.97 (1H, d J=8.9Hz, NHC(O)Ph), 3.83 (1H, dd J=10.5Hz, J=16.2Hz, NHCHCHCH2), 3.42-
3.50 (1H, m, NHCHCHCH2), 3.28 (1H, d, J=12.5Hz, CH2Ph), 2.76 (1H, d J=12.5Hz, CH2Ph) 
 
LRMS (ES) 307.1 (MH+). C19H18N2O2 requires 307.2  
 
 (2S,4S)-4-Benzyl-5-oxo-2-phenyloxazolidine-3-carboxylic acid benzyl ester (7.16) Lit3 
N
O
O
Ph
Ph
O
OPh
 
(L)-N-CBZ-Phe (4.00g, 13.4 mmol) was dissolved in anhydrous diethyl ether (70 mL) under an atmosphere of 
argon.  The mixture was cooled to -78oC and benzaldehyde dimethylacetyl (0.96 equiv) and boron trifluoride 
etherate (4.9 equiv) were added.  Stirring was continued at -78oC for one h and then at rt for a further seventeen 
h.  The reaction was quenched with saturated NaHCO3(aq) (50 mL) and the mixture was allowed to partition.  The 
aqueous phase was extracted twice more with diethyl ether and the combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo.  The crude material was purified by flash chromatography on silica 
using a gradient of diethyl ether, EtOAc and (50/70) pet ether to yield a white solid, 1.60g, 31%.  Rf = 0.24 
(5/1/20 (diethyl ether/EtOAc/(50/70) pet ether)). 
mp 122-124oc. 
 
1H NMR ppm (500 MHz in CDCl3) 7.05-7.45 (13H, m, Ar-H), 6.42-6.60 (2H, bm, Ar-H), 5.21 (1H, d J=12.2 
Hz, OCH2Ph), 5.10 (1H, d J=12.2 Hz, OCH2Ph), 4.70 (1H, s, NCHO), 3.30-3.41 (2H, m, CH2Ph) 
 
LRMS (ES) 388.2 (MH+). C24H21NO4 requires 388.2  
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 (2S,4S)-4-Allyl-4-benzyl-5-oxo-2-phenyloxazolidine-3-carboxylic acid benzyl ester (7.17) 
CBZN
O
O
Ph
Ph
 
Oxazolidinone 7.16 (0.500g, 1.29 mmol) was dissolved in anhydrous THF (10 mL) under an atmosphere of 
argon.  The mixture was cooled to -78oC and a solution of 1M lithium bis(trimethylsilyl)amide in THF (1.1 
equiv) was added.  Stirring was continued at -78oC for three min and then allyl bromide (1.5 equiv) was added.  
The mixture was stirred at -78oC for two h and then at rt for a further sixteen h before being concentrated in 
vacuo.  The residue was partitioned between EtOAc and saturated NaHCO3(aq).  The organic phase was washed 
with saturated NH4Cl(aq) and brine before being dried (MgSO4), filtered and concentrated in vacuo.  The crude 
material was purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield 
a yellow solid, 0.275g, 50%.  Rf = 0.26 (1/9 (EtOAc / (50/70) pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) was obtained which shows the presence of two rotamers about the carbamate 
bond in a ratio of 3:1 (Lit4) 
7.12-7.48 (12H, m, Ar-H), 6.95-7.04 (2H, m, Ar-H), 6.77 (1H, d J=7.1 Hz, Ar-H), 6.12 and 6.28 (1H, d J=7.1Hz, 
Ar-H), 6.05 (1H, s, NCHO), 5.69-5.88 (1H, m, CH2CHCH2), 5.21-5.37 (2H, m, CH2CHCH2), 5.08 (1H, d 
J=12.2Hz, OCH2Ph), 4.88 (1H, d J=12.1Hz, OCH2Ph), 3.66 (1H, d J=13.6Hz, CH2Ph), 3.29-3.39 (1H, m, CH2Ph 
and CH2CHCH2), 2.68 (1H, dd J=6.1Hz, J=13.6Hz, CH2CHCH2)  
 
LRMS (ES) 428.2 (MH+). C27H25NO4 requires 428.2  
 
(S)-2-Benzyl-2-benzyloxycarbonylaminopent-4-enoic acid methyl ester (7.18) 
CBZHN
Ph
CO2H  
Oxazolidinone 7.17 (0.275g, 0.643 mmol) was dissolved in THF (20 mL) and hydrolysed using General 
Procedure C1.  This afforded a white solid, 0.205g, 94% 
 
1H NMR ppm (500 MHz in CDCl3) 8.95 (1H, bs, CO2H), 7.35-7.38 (5H, m, Ar-H), 7.14-7.20 (3H, m, Ar-H), 
7.01 (2H, d J=7.0Hz, Ar-H), 5.66 (tdd, J=7.4Hz, J=7.4Hz, J=10.0Hz, J=15.1Hz, CH2CHCH2), 5.56 (1H, bs, 
NH), 5.05-5.20 (4H, m, CH2CHCH2 and OCH2Ph), 3.59 (1H, d J=13.6Hz, CH2Ph), 3.21 (1H, dd J=7.5Hz, 
J=13.9Hz, CH2CHCH2), 3.17 (1H, d J=13.6Hz, CH2Ph), 2.65 (1H, dd J=7.2Hz, J=13.9Hz, CH2CHCH2) 
 
13C NMR ppm (75 MHz in CDCl3) 176.8, 154.4, 144.2, 136.5, 135.7, 131.7, 130.7, 129.8, 129.0, 128.4, 128.2, 
128.1, 126.9, 119.5, 66.4, 64.8, 40.4, 39.8 
 
LRMS (ES) 340.1 (MH+). C20H21NO4 requires 340.2  
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[Allyl-((S)-2-benzyl-2-benzyloxycarbonylaminopent-4-enoyl)-amino]-acetic acid ethyl ester (7.19) 
CBZHN
Ph
N
O
CO2Et
 
Carboxylic acid 7.18 (0.0500g, 0.147 mmol), amine 7.13 (1.7 equiv) and PyAOP (1.3 equiv) were dissolved in 
anhydrous DMF.  DIPEA (2.7 equiv) was added and the reaction mixture stirred at rt for 18 h.  This was 
partitioned between EtOAc and 1M HCl(aq).  The organic phase was washed sequentially with 1M HCl(aq) and 
brine before being dried (MgSO4), filtered and concentrated in-vacuo.  The crude material was purified by flash 
chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield an orange oil, 0.0123g, 18%.  
Rf = 0.43 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.33-7.41 (5H, m, Ar-H), 7.26-7.31 (3H, m, Ar-H), 7.13-7.18 (2H, m, Ar-
H), 6.04-6.13 (1H, m, NCH2CHCH2), 5.63-5.78 (1H, m, CH2CHCH2), 5.04-5.39 (6H, m, NCH2CHCH2 and 
CH2CHCH2 and OCH2Ph), 4.12 (2H, q J=7.1Hz, CO2CH2CH3), 3.70 (1H, d J=14.0Hz, NCH2CHCH2), 3.60 (1H, 
d J=13.9Hz, NCH2CHCH2), 3.11-3.15 (3H, m, CH2CO2Et and CH2Ph), 3.01 (1H, d J=14.0, CH2Ph), 2.80 (1H, 
dd J=5.5Hz, J=5.5Hz, CH2CHCH2), 2.69 (1H, dd J=7.4Hz, J=14.0Hz, CH2CHCH2), 2.58 (1H, dd J=7.2Hz, 
J=14.0Hz, CH2CHCH2), 1.26 (3H, t J=7.1Hz, CO2CH2CH3) 
 
HRMS (ES) 487.2201 (MH+). C27H32N2O5Na requires 487.2209  
 
(S)-3-Benzyloxycarbonylamino-4-phenylbutyric acid methyl ester (7.25) 
N
H
Ph
CO2Me
O
O
Ph
 
N-CBZ-Phe-H (5.00g, 16.7 mmol) was homologated using General Procedure P.  The crude material was 
purified by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a colourless 
oil, 2.62g, 48%.  Rf = 0.48 (1/3 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.08-7.34 (10H, m, Ar-H), 5.41 (1H, d J=8.6Hz, NH), 5.05 (2H, s, 
OCH2Ph), 4.15-4.28 (1H, m, CHCH2Ph), 3.63 (3H, s, CO2CH3), 2.94 (1H, dd J=6.5Hz, J=13.6Hz, CHCH2Ph), 
2.81 (1H, dd J=7.6Hz, J=13.3Hz, CHCH2Ph), 2.49 (2H, t J=5.3Hz, CH2CO2CH3)  
 
13C NMR ppm (75 MHz in CDCl3). 172.0, 155.7, 137.5, 136.5, 135.7, 133.2, 129.3, 128.5, 128.5, 128.1, 128.0, 
126.7, 66.6, 51.7, 49.4, 40.2, 37.4 
  
LRMS (ES) 328.1 (MH+). C19H21NO4 requires 328.2 
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(S)-2-((S)-1-tertButoxycarbonylamino-2-phenylethyl)pent-4-enoic acid methyl ester (7.26) 
N
H
Ph
CO2Me
O
O
Ph
 
Methyl ester 7.25 (1.00g, 3.05 mmol) was allylated using General Procedure Q.  The crude material was purified 
by flash chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield an orange solid, 
0.730g, 65%.  Rf = 0.42 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.18-7.40 (10H, m, Ar-H), 5.84 (1H, d J=9.6Hz, NH), 5.62-5.72 (1H, m, 
CHCH2CHCH2), 4.94-5.17 (2H, m, CHCH2CHCH2), 4.06-4.17 (1H, m, CHCH2Ph), 3.71 (1H, s, CO2CH3), 2.92 
(1H, dd J=6.3Hz, J=13.6Hz, CHCH2Ph), 2.70 (1H, dd J=8.5Hz, J=13.5Hz, CHCH2Ph), 2.60-2.66 (1H, m, 
CHCH2CHCH2), 2.38-2.47 (1H, m, CHCH2CHCH2), 2.30 (1H, td J=6.9HZ, J=6.9Hz, J=13.8Hz, CHCO2CH3) 
 
13C NMR ppm (75 MHz in CDCl3). 174.7, 155.9, 137.4, 136.6, 134.3, 129.2, 128.4,  127.9, 127.9, 126.5, 117.4, 
66.5, 53.1, 51.6, 46.4, 40.5, 34.3  
 
LRMS (ES) 368.2 (MH+). C22H25NO4 requires 368.2  
 
(S)-2-((S)-1-tertButoxycarbonylamino-2-phenylethyl)pent-4-enoic acid (7.27) 
N
H
Ph
CO2H
O
O
Ph
 
Methyl ester 7.26 (0.201g, 0.547 mmol) was hydrolysed using General Procedure C1 to afford an yellow solid, 
0.160g, 83%. 
 
1H NMR ppm (500 MHz in CDCl3) 7.05-7.32 (10H, m, Ar-H), 5.53-5.71 (1H, m, CHCH2CHCH2), 4.81-5.16 
(4H, m, CHCH2CHCH2 and CHCH2Ph), 3.98-4.12 (1 H, m, CHCH2Ph), 2.88 (1H, dd J=6.5HZ, J=13.6Hz, 
CHCH2Ph), 2.70 (1H, dd J=8.6Hz, J=13.7Hz, CHCH2Ph), 2.51-2.62 (1H, m, CHCH2CHCH2), 2.35-2.41 (1H, m, 
CHCH2CHCH2), 2.26 (1H, td, J= 7.2Hz, J=7.2Hz, J=14.6Hz, CHCO2CH3) 
 
13C NMR ppm (75 MHz in CDCl3). 178.9, 156.1, 137.4, 136.3, 134.1, 129.2, 128.4, 128.0, 126.5, 117.7, 66.7 , 
52.9, 46.4, 40.5, 34.1  
  
LRMS (ES) 354.2 (MH+). C21H23NO4 requires 354.2  
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{Allyl-[(S)-2-((S)-1-benzyloxycarbonylamino-2-phenylethyl)pent-4-enoyl]amino}acetic acid ethyl ester 
(7.28) 
N
O
CBZHN
Ph
CO2Et
 
Carboxylic acid 7.27 (0.0640, 0.181 mmol), amine 7.13 (1.7 equiv) and PyAOP (1.3 equiv) were dissolved in 
anhydrous DMF. DIPEA was added (2.7 equiv) and the reaction mixture stirred at rt for 18 h.  This was 
partitioned between EtOAc and 1M HCl(aq).  The organic phase was washed sequentially with 1M HCl(aq) and 
brine before being dried (MgSO4), filtered and concentrated in-vacuo.  The crude material was purified by flash 
chromatography on silica using a gradient of MeOH and DCM to yield a yellow oil, 0.0250g, 29%.  Rf = 0.21 
(2% MeOH / DCM). 
 
1H NMR ppm (500 MHz in CDCl3) 7.12-7.38 (10H, m, Ar-H), 6.67 (1H, d J=9.5Hz, NH), 5.60-5.80 (2H, m, 
CHCH2CHCH2 and NCH2CHCH2), 4.96-5.24 (6H, m, CHCH2CHCH2 and NCH2CHCH2 and OCH2Ph), 4.22 
(2H, q J=7.1Hz, OCH2CH3), 4.14-4.19 (1H, m, CHCH2Ph), 4.13 (1H, d J=17.6Hz, CH2CO2CH2CH3), 3.90 (1H, 
d J=17.1Hz, CH2CO2CH2CH3), 3.79 (1H, d J=5.6Hz, NCH2CHCH2), 2.97 (1H, dd, J=6.7, J=13.6Hz, CHCH2Ph), 
2.76-2.82 (1H, m, CHCHCO), 2.71 (1H, dd J=9.1Hz, J=13.6 Hz, CHCH2Ph), 2.28-2.42 (2H, m, 
CHCH2CHCH2), 1.29 (3H, t J=7.1Hz, OCH2CH3). 
 
13C NMR ppm (75 MHz in CDCl3). 175.3, 169.0, 156.2, 138.2, 136.8, 134.5, 132.4, 129.1, 128.4, 128.3, 127.8, 
127.7, 126.4, 118.5, 117.7, 66.2, 61.2, 53.3, 51.9, 47.0, 41.36, 40.0, 34.4, 14.1. 
HRMS (ES) 479.2542 (MH+). C28H35N2O5 requires 479.2546 
 
FTIR CM-1 (KBr) 3402, 2945, 1747, 1717, 1635 
 
[(S)-3-((S)-1-Benzyloxycarbonylamino-2-phenyl-ethyl)-2-oxo-2,3,4,7-tetrahydro-azepin-1-yl]acetic acid et-
hyl ester (7.29) 
O
CBZHN
Ph
N CO2Et
 
Diene 7.28 (0.0210g, 0.00438 mmol) was dissolved in anhydrous DCM (3 mL) under an atmosphere of argon 
and Grubbs second generation catalyst (0.1 equiv) was added.  This was refluxed for eighteen h and then 
concentrated in vacuo.  The crude material was purified by flash chromatography on silica using a gradient of 
EtOAc and (50/70) pet ether to yield a brown solid, 0.00430g, 22%.  Rf = 0.31 (1/4 (EtOAc / (50/70) Pet ether)). 
 
1H NMR ppm (500 MHz in CDCl3) 7.16-7.38 (10H, m, Ar-H), 6.62 (1H, d J=9.9Hz, NH), 5.68-5.74 (1H, m, 
CHCH2CHCHCH2N), 5.58-5.64 (1H, m, CHCH2CHCHCH2N), 5.10 (1H, d J=12.3Hz, OCH2Ph), 5.07 (1H, d J= 
12.3Hz, OCH2Ph), 4.52 (1H, d J=17.1Hz, CH2CO2CH2CH3), 4.24 (2H, q J=7.1Hz, OCH2CH3), 4.18-4.28 (1H, 
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m, CHCH2CHCHCH2N), 3.95 (1H, dddd J=2.8Hz, J=5.9Hz, J=8.7Hz, J=10.1Hz, CHCH2CHCHCH2N), 3.86 
(1H, d J= 17.1 Hz, CH2CO2CH2CH3), 3.23 (1H, dd, J=5.9Hz, J=17.4Hz, CHCH2CHCHCH2N), 3.09 (1H, dt J= 
2.8, J=13.1Hz, CHCH2CHCHCH2N), 3.03 (1H, dd J=5.5Hz, J=13.1Hz, CHCH2Ph), 2.92 (1H dd J=9.9Hz, 
J=13.1Hz, CHCH2Ph), 2.42-2.52 (1H, m, CHCH2CHCHCH2N), 2.10-2.20 (1H, m, CHCH2CHCHCH2N), 1.30 
(3H, t J=7.1Hz, OCH2CH3). 
 
13C NMR ppm (75 MHz in CDCl3). 175.4, 169.1, 156.6, 138.7, 136.8, 131.2, 129.3, 128.6, 128.4, 127.8, 127.7, 
126.4, 123.3, 66.4, 61.3, 55.9, 49.8, 47.3, 40.6, 39.9, 30.0, 14.2. 
 
HRMS (ES) 451.2252 (MH+). C26H31N2O5 requires 451.2233 
 
FTIR CM-1 (KBr) 3410, 2981, 1744, 1717, 1647  
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Appendix 1: Calpain inhibition assay 
 
The biological activity of calpain inhibitors synthesised in this thesis was determined by Dr 
Matthew Jones and Janna Nikkel using established protocols1 to determine their inhibition 
constants (IC50).  IC50 indicates the concentration of inhibitor required to decrease the activity 
of the protease by 50%.  This data was calculated using protease substrate casein labelled with 
fluorophore 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid 
(BODIPY).  
 
As shown schematically in Figure A1, without proteolysis no fluorescence is observed as 
auto-quenching of adjacent fluorophores occurs.  When calpain is activated, proteolysis of the 
substrate occurs and fluorescence is detected.    
 
Figure A1: Schematic illustration of calpain IC50 assay 
 
Calculating the IC50 
 
Assays were performed using calpain II, partially purified from sheep lung by ion-exchange 
chromatography, diluted to give a linear response over the course of the assay.  The substrate 
Calpain 
Auto quenching Fluorescence 
BODIPY 
hυ 
Casein 
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solution (0.0005% BODIPY-FL casein in 10 mM tris-HCl, pH 7.5 containing 10 mM CaCl2, 
0.1 mM NaN3, and 0.1% mercaptoethanol) was prepared fresh each day.   
The assays were performed in 96-well black ELISA plates.  Calpain control assays contained 
50 µL calpain II in sample buffer (20 mM tris-HCl, pH 7.5 containing 1 mM EDTA, 1 mM 
EGTA, and 2 mM dithiothreitol).  Fifty µL of substrate solution was used to start the reaction.  
The progress of the reaction at 25°C was followed for 10 min in a BMG Fluorostar with 
excitation of 485 nm and emission of 530 nm.  For the inhibitor assays the sample buffer was 
replaced by 50 µL of inhibitor diluted in the sample buffer.  The percentage inhibition was 
determined as 100 times the activity with inhibitor present divided by the activity of the 
control assay. 
 
Assays were performed in triplicate with serial dilutions of inhibitor concentrations from 250 
µM to 50 nM.   
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Appendix 2.1: 2.13 Eye drop formulation 
 
Dialdehyde 2.13 was formulated into an eye drop of the following composition. 
 
• 0.1% (w/w) compound 2.13 
• 14% EtOH 
• 0.9% sodium chloride 
• 0.3% hydroxypropyl methyl cellulose 
• 0.05% disodium EDTA 
• 0.01% benzalkonium chloride 
• 84.65% MilliQ purified water 
 
Sodium chloride, hydroxypropyl methyl cellulose, disodium EDTA and benzalkonium 
chloride were dissolved in a 14% EtOH aqueous solution.  Compound 2.13 was added and 
stirred at rt until a homogenous solution was obtained. 
 
Appendix 2.2: 2.13 intravitreal injection formulation 
 
Dialdehyde 2.13 was dissolved in a 10% ethanol aqueous solution.   
 
 
Appendix 2.3: 2.13 ointment formulation 
 
 
Dialdehyde 2.13 was formulated into an ointment of the following composition; 
• 1%  compound 2.13  
• 25% cetyl stearyl alcohol 
• 35% lanolin 
• 39% paraffin oil. 
The cetyl stearyl alcohol, lanolin and paraffin oil were melted at 50oC to give a light orange 
solution.  Compound 2.13 was added and the mixture stirred at 50oC until a homogenous 
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solution was obtained.  This was cooled to room temperature and measured into the 
application syringes. 
Appendix 2.4: 5.14 ointment formulation 
 
Aldehyde 5.14 was formulated into an ointment of the following composition; 
 
• 1%  compound 5.14  
• 25% cetyl stearyl alcohol 
• 35% lanolin 
• 39% paraffin oil 
 
Compound 5.14 was dissolved in cetyl stearyl alcohol at 50oC.  Lanolin and paraffin oil were 
then added.  The mixture was stirred at 50oC until a homogenous solution was obtained.  This 
was cooled to room temperature and measured into the application syringes. 
 
